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Abstract  
 
Streptococcus pneumoniae (pneumococcus) is a leading cause of childhood morbidity 
and mortality worldwide. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) 
was introduced in the Malawian infant immunisation programme in November 2011. 
PCV-13 is currently given at a “3+0” schedule: doses are given at 6, 10 and 14 weeks 
and no booster dose is currently implemented. The aim of this thesis was to study 
pneumococcal carriage and transmission in Karonga District, Malawi, before and after 
introduction of PCV-13, in order to review the effect of the current pneumococcal 
vaccination programme on carriage, and to give recommendations on the 
implementation of different vaccination strategies in Malawi.  	
Pneumococcal carriage studies were conducted in Karonga between 2008 and 2014, 
with a focus on infants born to an HIV-positive mother, and HIV-positive adults, both of 
whom are at high risk of invasive pneumococcal disease. We found no difference in 
pneumococcal acquisition in infants by maternal HIV-status. A greater proportion of 
infant pneumococcal acquisition was attributable to carriage in other children <5 years 
in the household than to maternal carriage. Pneumococcal carriage in HIV-positive 
adults in Malawi remained high despite up to two years of antiretroviral treatment, 
indicating a failure of reconstitution of respiratory mucosal immune response.  
 
An analysis on the uptake and timeliness of PCV-13 vaccination showed that despite 
high vaccination coverage in this setting, delays in vaccination were common. Infants 
born to lower educated or farming mothers and those living more remotely were at 
greater risk of being not fully vaccinated and being vaccinated late.  
 
Carriage studies conducted in 2014, two years post PCV-13 introduction, showed that 
carriage of vaccine type (VT) pneumococci had decreased in vaccinated children and 
unvaccinated older age groups, but that a reservoir of VT carriage was still present. VT 
carriage had not decreased in unvaccinated children <5 years. Carriage of non-vaccine 
type pneumococci (NVT) had increased in vaccinated children. Our results suggest 
that a herd immunity effect is taking place albeit slowly in comparison to other 
countries. Waning immunity seemed to occur in vaccinated children 1-4 years.  
 
Our mathematical modelling studies provided further evidence for waning immunity. An 
immunity half-life between 6 months and 1 year was found to fit best with the observed 
post-vaccination carriage prevalence. If the immunity half-life were to be increased to 2 
years, this would have a large impact on VT carriage decline in vaccinated and 
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unvaccinated age groups. In the stochastic individual-based transmission models, 
which included explicit household transmission, an indirect vaccine effect was 
observed immediately after introduction of PCV-13. Adding a booster dose to the 
current three-dose schedule (3+1 schedule) would be beneficial for vaccinated and 
unvaccinated groups. Replacing the current 3+0 schedule with a 2+1 schedule 
(booster dose at 9 months) initially resulted in slower VT decline, but seemed to be 
associated with a longer-term gain in lower VT carriage in 1-4 year olds. Maternal 
vaccination did not result in additional VT carriage reduction in the infant.  
 
Ongoing surveillance is required to assess VT carriage in this population and monitor 
waning immunity and serotype replacement in vaccination individuals. A review of the 
vaccination schedule may be required to optimise total population impact in this high 
carriage setting. There is need for cheaper, more effective, serotype-independent 
pneumococcal vaccines. Potentially cheaper PCVs produced in India are in the 
pipeline, as well as a couple of new generation vaccines that are currently in phase 2 
clinical trials. The next decade is promising to be an exciting time for pneumococcal 
researchers and policy makers worldwide, as new vaccines will pose interesting 
possibilities to further decrease pneumococcal carriage and disease worldwide.  
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1. Introduction 
1.1 Streptococcus pneumoniae 
 
Streptococcus pneumoniae (pneumococcus) is a leading cause of childhood morbidity 
and mortality worldwide. As the major cause of bacterial pneumonia, meningitis and 
sepsis, the pneumococcus was estimated in 2000 to cause 11% of all-cause mortality 
in children 1-59 months worldwide (1). In 2013, pneumococcal pneumonia accounted 
for the largest proportion of lower respiratory infection deaths and was estimated to 
cause 264.000 deaths in children younger than 5 years worldwide (2). Pneumococcal 
meningitis was estimated to cause an additional 79,100 deaths in under-fives 
worldwide (2). In addition, pneumococci are estimated to cause 30-50% of all episodes 
of otitis media, a vast, but poorly defined disease burden worldwide (3). 
 
Currently, more than 90 different serotypes of pneumococci are known, classified by 
differences in the polysaccharide capsule. The polysaccharide capsule protects the 
bacteria from phagocytosis and is the most important virulence factor (4). The natural 
reservoir of the pneumococcus is the human nasopharynx. Although colonisation with 
pneumococci is mostly asymptomatic, nasopharyngeal carriage is thought to be a pre-
requisite for disease (5). The pneumococcus interacts with the human immune system 
in a balance between carriage in the nasopharynx, evading the host’s immune 
response, and causing non-invasive and invasive disease. Virulence and carriage 
characteristics differ amongst serotypes, with less than 10 serotypes estimated to be 
responsible for more than 75% of all episodes of invasive pneumococcal disease (IPD) 
(3). Some invasive serotypes are frequently carried but have a low carrier-case ratio 
(serotype 6B, 19F, 23F), whereas other serotypes have high IPD rates and can cause 
outbreaks in all age groups but are rarely found in carriage (serotype 1, 5) (3, 6).  
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Carriage in the nasopharynx also acts as the main reservoir for pneumococcal 
transmission, with person-to-person spread occurring in close contact (5). 
Pneumococcal carriage acquisition occurs very early in life in low-income countries, 
with an observed median time to acquisition of only 38.5 days, 45.5 days or 8 weeks 
reported from studies in Kenya, Thailand-Myanmar and Bangladesh respectively (7-9). 
This early and intense exposure in infancy is likely to play a role in the high disease 
incidence also experienced in these settings. 
 
1.2 Pneumococcal vaccines 
 
A 23-valent polysaccharide vaccine (PPV-23), containing polysaccharides from the 
capsular antigens of 23 different serotypes has been available since 1983. PPV-23 is 
only licensed for use in individuals aged >2 years, due to poor T-cell independent 
immunogenicity in the younger age group.  
 
A 7-valent pneumococcal conjugate vaccine (PCV-7) containing serotypes 4, 6B, 9V, 
14, 18C, 19F and 23F, has been licensed since 2000 (7). Since then, two new 
conjugate vaccines have been introduced: a 10-valent vaccine (PCV-10) containing 
additional serotypes 1,5 and 7F, and a 13-valent vaccine (PCV-13) containing 
additional serotypes 3, 6A and 19A (Figure 1). PCVs contain polysaccharides of the 
capsular antigens linked a non-toxoid bacterial carrier protein (diphtheria CRM197 
protein in PCV-7 and PCV-13; non-typeable Haemophilus Influenza protein D and 
tetanus and diphtheria toxoids in PCV-10) (10, 11). The presence of the carrier 
proteins elicits a T-cell dependent antibody response to the polysaccharide capsular 
antigens, thereby providing protection against vaccine-type (VT) disease, also in young 
infants (10, 11).  
 
PCV-7 diphtheria 
CRM197  
4 6B 9V 14 18C 19F 23F       
PCV-10 ntHi protein D 
  
4 6B 9V 14 18C 19F 23F 1 5 7F    
PCV-13 diphtheria 
CRM197 
4 6B 9V 14 18C 19F 23F 1 5 7F 3 6A 19A 
Figure 1.1 Serotypes included in 7-valent, 10-valent and 13-valent pneumococcal 
conjugate vaccines.  
ntHi: non-typeable Haemophilus Influenza 
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PCV has been introduced in the infant vaccination schedule of numerous high-income 
countries and is being rolled out in middle- and low-income countries with the support 
of the Global Alliance for Vaccines and Immunisations (GAVI). The World Health 
Organisation (WHO) recommends a vaccination schedule of three primary doses 
(“3+0”) given at 6, 10, 14 weeks or 2, 4, 6 months, or a schedule of two primary doses 
plus a booster (“2+1”) given between 9 and 15 months (12). An early schedule (6, 10, 
14 weeks) is favoured in low-income countries where incidence of pneumococcal 
disease in the first year of life is high. Low uptake of measles vaccination, given 
routinely in low-income countries at 9 months, can be another reason for preference of 
a 3+0 versus a 2+1 schedule. Use of a 2+1 schedule may be preferred in settings 
where duration of protection may be a concern, although it has not been confirmed yet 
how much longer the duration of protection is with a schedule including a booster dose 
(13).  
 
PCV have been shown effective against IPD caused by VT (14-16). An important 
feature of PCV is its ability to reduce nasopharyngeal carriage in vaccinated individuals 
(17). A herd effect, whereby disease incidence is also decreased in non-vaccinated 
individuals as a result of reduced transmission from vaccinated children, has been 
observed in various settings (18-20). Many studies performed in high-income countries 
have shown a decline in pneumococcal disease in unvaccinated individuals after the 
introduction of PCV (21-23). Limited results are available for the more recent 
introduction of PCV in low-income countries. A randomised controlled trial in The 
Gambia reported PCV-9 vaccine efficacy of 77% (95% CI 51-90) for VT IPD, and 50% 
(95% CI 21-69) for IPD caused by all serotypes, when administered to children 6-51 
weeks of age (16). In South Africa, where PCV-7 was introduced in 2009, substantial 
declines in VT IPD were observed in both children and adults, suggesting a herd effect 
(24).  
 
To accelerate the development of herd protection, a catch-up campaign can be offered 
on introduction of PCV, whereby PCV is offered to children too old to be vaccinated in 
the routine immunisation schedule (12). In Kenya, a catch-up campaign was held for all 
children <5 years living in Kilifi County but not the rest of the country (25). Targeting 
those age groups most involved in transmission is expected to obtain the largest herd 
effect, although a systematic evaluation of the added benefit of catch-up campaigns on 
the establishment of herd protection has not yet been done (13). Catch-up campaigns 
also provide direct protection for vaccinated children. Catch-up campaigns were held 
on introduction of PCV in the UK (26) and the US (27) for children <2 years to reduce 
the high rates of IPD in children <2 years in these countries. No catch-up campaign 
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was held in South Africa where the main burden of pneumococcal disease is in infants 
<1 year (28).    
 
A concern regarding the introduction of PCV is that vaccination against a selected 
number of VT is likely to result in an increase in IPD caused by non vaccine types 
(NVT), diminishing the advantage of vaccination (29). Several studies performed in 
high-income countries showed an increase in disease caused by NVT IPD after PCV-7 
introduction (30). Introduction of PCV in low-income countries can be expected to 
result in a higher rate of serotype replacement due to high background rate of 
pneumococcal carriage. Also the burden of human immunodeficiency virus (HIV) in 
many countries could have an effect on the rate by which serotype replacement will 
occur after vaccine introduction. To decrease the extent of serotype replacement, 
pneumococcal conjugate vaccines covering a wider range of serotypes, PCV-10 and 
PCV-13, are currently recommended by the World Health Organisation (WHO) (31). 
 
1.3 Pneumococcal carriage and transmission 
 
Worldwide surveillance on the spread and serotype distribution of pneumococci is 
required to study the impact of vaccination and the extent of serotype replacement. 
Understanding the drivers of pneumococcal transmission in different settings is vital to 
understand and predict VT and NVT incidence in vaccinated and unvaccinated 
individuals and thus to inform vaccination policies. Given the impressive impact of 
PCVs on disease burden in high-income settings, there is an expectation that this will 
also manifest in low-income country settings. If pneumococcal transmission is similar 
then there will be every possibility of the successes seen in the US and Europe. But if 
as seems likely transmission varies under different demographic circumstances then 
understanding these differences will allow consideration of alternate vaccine schedules 
and uses to deliver herd protection. 
 
The exact mechanisms whereby PCV influences carriage are unclear (32). Vaccination 
may reduce an individual’s susceptibility to pneumococcal carriage acquisition. It is 
also possible that vaccination increases clearance of pneumococci from the 
nasopharynx, thereby reducing the duration of carriage. Lastly, vaccination may 
influence the density of carriage, the quantitative bacterial load in the nasopharynx.  
 
Because of its importance for indirect vaccine effects, pneumococcal carriage is 
currently being introduced as an endpoint in vaccine licensing (32). Additional 
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advantages of using carriage as well as disease or immunological assays as an 
endpoint are the easy detection of carriage and its common occurrence, allowing for 
smaller sample sizes. The main drawback of using carriage as an endpoint in clinical 
trials is its poor prediction as a surrogate of disease: some serotypes that frequently 
cause disease are rarely found in carriage (e.g. serotypes 1 and 5), and many 
serotypes frequently carried are rarely causing invasive disease.   
 
1.4 Pneumococcal carriage and disease and HIV/AIDS 
 
HIV-positive adults and children are at 20-100 fold higher risk of IPD (33-35). In sub-
Saharan Africa, IPD in adults is strongly associated with HIV infection and has a high 
mortality rate (36-39). Antiretroviral therapy (ART) reduces the incidence of IPD in HIV-
positive adults (33) and there is a strong temporal relationship between large-scale 
ART introduction and declines in IPD in Malawi (40, 41). This population impact will be 
driven by immune reconstitution and/or immune maintenance at the individual level. 
However, HIV-positive individuals established on ART remain at much higher risk of 
IPD as compared to HIV-uninfected individuals (42). This suggests immune 
reconstitution is incomplete; a finding supported by earlier work in Malawi suggesting 
that ART did not alter the risk of recurrent IPD events (43).  
 
Many high-income countries including the UK and US recommend vaccination for HIV-
positive adults. UK guidelines recommend a single dose of PCV-13 irrespective of CD4 
cell count, ART use and viral load. An additional single dose of PPV-23 is 
recommended for HIV-positive adults who meet the indications for PPV-23 vaccination 
(aged >65 years or with co-morbidity other than HIV) (44). US guidelines recommend a 
single dose of PCV-13 followed by a dose of PPV-23 for all adults with 
immunocompromising conditions (45). A booster dose of PPV-23 is recommended 
after five years. Vaccination of HIV-positive adults is uncommon in low-income 
countries. A randomized, controlled trial conducted in Malawi showed that PCV would 
be beneficial for HIV-positive adults: PCV-7 was found to protect HIV-positive adults 
from recurrent vaccine-type pneumococcal disease (43). An earlier trial in Uganda 
showed that PPV-23 was ineffective in HIV-positive adults and even found higher rates 
of disease in vaccinated individuals (46). 
Pneumococcal carriage is also more common in HIV-positive than HIV-uninfected 
individuals (47-49), which could lead to increased transmission in HIV-affected 
populations. It is possible that HIV-positive individuals represent a large reservoir of S. 
pneumoniae that could have an impact on the effect of the development of herd 
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immunity after introduction of pneumococcal vaccines in infant immunisation schedules 
in HIV-affected countries. 
  
1.5 Situation in Malawi 
 
Malawi is a land-locked country in Southern Africa. It is one of the poorest and most 
underdeveloped countries worldwide (50). Malawi has a high burden of malnutrition, 
HIV/AIDS, malaria, diarrhoea and acute respiratory infections (51). HIV-prevalence 
nationwide was estimated at 10% in adults aged 15-49 years in 2013 (50). Life 
expectancy at birth is 55 years. Under-five mortality has decreased in recent years 
from 245 per 1,000 life births in 1990 to 68 per 1,000 life births in 2013 (50). With this 
decrease Malawi is well on track to meet the fourth Millennium Development Goal of 
reducing child mortality by two-thirds between 1990 and 2015 (52).  
 
The early adoption of PCV-13, introduced in November 2011, has been part of the 
strategy to meet the Millennium Development Goals. PCV-13 is given according to the 
WHO recommended schedule at 6, 10 and 14 weeks, along with Pentavalent vaccine 
(diphtheria, pertussis, tetanus, haemophilus influenza type B and hepatitis B), oral polio 
and oral monovalent rotavirus vaccine (introduced in October 2012). Initial catch-up for 
PCV-13 occurred among children <1 year of age at the time of introduction.  
 
In Malawi, rates of IPD in children under 5 years old were estimated at 62 per 100,000 
child years before introduction of pneumococcal vaccination, among the highest rates 
recorded globally. Pneumococcal meningitis incidence had been declining in all age 
groups prior to introduction of PCV-13, making it difficult to assess whether a direct and 
indirect vaccine impact has taken place. The proportion of pneumococcal meningitis 
attributable to vaccine types has declined in children <5 years two years post 
introduction of PCV-13 (58.3% vs. 29.8%, p=0.003), but not in children 5-14 years 
(61.4% vs. 62.1%, p=0.952) and adults (53.4% vs. 58.7%, p=0.548). These findings 
provide evidence for a direct vaccine effect, but suggest absence of vaccine indirect 
effect (53).  
 
The two groups that would be at most benefit from any herd protection effect in Malawi 
are HIV-positive individuals and infants too young to be fully vaccinated who also suffer 
a high burden of disease. If herd protection is obtained with PCV-13 provided in the 
infant immunisation programme only, this will provide advocacy to continue the 
vaccination programme in Malawi, and for other countries in similar settings to also 
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introduce PCV-13. If insufficient herd protection is currently obtained, other vaccination 
strategies need to be considered, including the vaccination of pregnant women and/or 
HIV-positive adults to protect these vulnerable groups directly from pneumococcal 
disease. Another strategy could be to implement catch-up vaccination campaigns in 
older children to further reduce transmission and thereby increase the potential herd 
protection effect. 
 
This thesis describes pneumococcal carriage and transmission in Karonga District, 
Malawi, before and after introduction of PCV-13. The studies described in this thesis 
can be divided into three parts: studies conducted before introduction of PCV-13 in the 
Malawi infant immunisation schedule (Part I), studies conducted after introduction of 
PCV-13 (Part II) and mathematical modelling studies (Part III). The main focus of this 
thesis is on infants and HIV-positive adults, both high-risk groups for developing IPD.  
 
26 Chapter 2 	
 
 
 
  
Aims and objectives 27 	
 
 
 
2. Aims and objectives 
The overall aims of this thesis were to study pneumococcal carriage and transmission 
in Karonga District, Malawi, before and after introduction of PCV-13, in order to review 
the effect of the current pneumococcal vaccination programme on carriage, and to give 
recommendations on the implementation of different vaccination strategies in Malawi.  
 
Specific objectives were: 
1. To determine what proportion of pneumococcal carriage can be explained as a 
result of transmission from household members or extra-household transmission in 
different geographical settings. 
2. To study pneumococcal carriage in infants and HIV-positive adults, two high-risk 
groups for IPD, in the pre-vaccination period; 
2.1. To compare infant pneumococcal acquisition by maternal HIV-status. 
2.2. To examine serotype-specific associations between infant carriage and 
carriage in their households. 
2.3. To investigate the impact of ART on pneumococcal carriage in Malawian adults 
infected with HIV.  
3. To study pneumococcal carriage in infants and HIV-positive adults, two high-risk 
groups for IPD, in the post-vaccination period; 
3.1. To investigate socio-demographic and programmatic factors affecting 
vaccination uptake and timeliness during the introduction of PCV-13. 
3.2. To measure the direct impact of PCV-13 vaccination on pneumococcal 
carriage in vaccinated individuals. 
3.3. To measure the indirect impact (herd effect) of PCV-13 vaccination on 
pneumococcal carriage in unvaccinated individuals. 
3.4. To examine serotype-specific associations between infant carriage and 
carriage in their households. 
28 Chapter 2 	
 
4. To describe pneumococcal carriage and transmission before and after introduction 
of PCV-13 using a mathematical model. 
4.1. To build a mathematical model on pneumococcal carriage and fit this to the 
Karonga population structure and observed pneumococcal carriage data.  
4.2. To compare household transmission and community transmission of 
pneumococcal carriage.  
4.3. To investigate what level of vaccination coverage in the infant immunisation 
schedule would have to be achieved before a herd effect is observed in 
pneumococcal carriage in unvaccinated individuals.  
4.4. To compare the effect of different waning immunity half-lives after vaccination 
and determine which scenario is most likely given the post-vaccination 
prevalence data. 
4.5. To assess the effect of different vaccination strategies on pneumococcal 
carriage in vaccinated and unvaccinated individuals.  
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3. Methodology 
 
This chapter describes methods used in more than one study. Methods specific to 
individual studies are described in their respective chapters. 
 
3.1 Overview of included studies 
 
Table 3.1 provides an overview of studies included in this thesis. The studies’ main 
focus is on infants and HIV-positive adults, both high-risk groups for developing IPD. In 
the infant studies, samples were also collected from mothers and other household 
members, allowing for epidemiological analyses of household transmission and 
mathematical modelling of household and community-wide transmission. 
 
3.2 Study location and population 
 
All studies were conducted at the Karonga Health and Demographic Surveillance 
System (KHDSS) site in northern Malawi (54). Established in 2002, the KHDSS covers 
an area of 135km² where the population is under continuous surveillance through 
which all births, deaths and migrations are recorded (54, 55). The area has an annual 
birth cohort of about 1350. Population growth is approximately 2.5% per year: the 
population increased from 34,111 people on 1st January 2009 (start of the 
pneumococcal household study) to 39,786 people on 11th September 2015 (end of 
data used for mathematical modelling study).  
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Table 3.1 Overview of studies included in this thesis 
Chapter Study name Before / after 
introduction PCV-
13 (data collection 
period) 
Study 
participants 
Longitudinal / cross-
sectional / modelling 
study 
Data collection Aims of study 
4 Systematic literature 
review 
Both NA Literature review NA • To determine what proportion of 
pneumococcal carriage can be 
explained as a result of transmission 
from household members or extra-
household transmission in different 
geographical settings. 
5 Pneumococcal 
carriage and vaccine 
study – before PCV-13 
introduction 
Before (2009-2011) 
 
Infants  
Mothers 
Household 
members 
Longitudinal Nasopharyngeal 
samples 
• To compare infant pneumococcal 
acquisition by maternal HIV-status. 
• To examine serotype-specific 
associations between infant carriage 
and carriage in their households. 
8 Pneumococcal 
carriage and vaccine 
study – after PCV-13 
introduction 
After (2014) Infants 
Mothers 
Household 
members 
Longitudinal & cross-
sectional 
Nasopharyngeal 
samples 
• To measure the direct impact of PCV-
13 vaccination on pneumococcal 
carriage in vaccinated individuals. 
• To measure the indirect impact (herd 
effect) of PCV-13 vaccination on 
pneumococcal carriage in 
unvaccinated individuals. 
• To examine serotype-specific 
associations between infant carriage 
and carriage in their household 
 
6 ART cohort study Before (2008-2010) HIV-positive 
adults in ART 
clinic 
Longitudinal Nasopharyngeal 
samples 
• To investigate the impact of ART on 
pneumococcal carriage in Malawian 
adults infected with HIV.  
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Table 3.1 Overview of studies included in this thesis 
Chapter Study name Before / after 
introduction PCV-
13 (data collection 
period) 
Study 
participants 
Longitudinal / cross-
sectional / modelling 
study 
Data collection Aims of study 
8 Pneumococcal 
carriage and vaccine 
study – ART arm 
After (2014) HIV-positive 
adults in ART 
clinic 
Cross-sectional Nasopharyngeal 
samples 
• To measure the indirect impact (herd 
effect) of PCV-13 vaccination on 
pneumococcal carriage in 
unvaccinated individuals. 
7 Vaccine uptake study After (2011-2014) Vaccine age-
eligible 
children 
Longitudinal  Vaccine records  
Socio-
demographic 
indicators 
• To investigate socio-demographic and 
programmatic factors affecting 
vaccination uptake and timeliness 
during the introduction of PCV-13. 
9 Mathematical 
modelling study 
Before  Whole 
population 
Modelling Model fitted to 
prevalence 
estimations from 
all available 
studies 
• To describe pneumococcal carriage 
and transmission before and after 
introduction of PCV-13 using a 
mathematical model.  
• To compare household transmission 
and community transmission of 
pneumococcal carriage. 
 
 
 
10 Mathematical 
modelling study 
After Whole 
population 
Modelling Model fitted to 
prevalence 
estimations from 
all available 
• To investigate what level of 
vaccination coverage in the infant 
immunisation schedule would have to 
be achieved before a herd effect is 
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Table 3.1 Overview of studies included in this thesis 
Chapter Study name Before / after 
introduction PCV-
13 (data collection 
period) 
Study 
participants 
Longitudinal / cross-
sectional / modelling 
study 
Data collection Aims of study 
studies observed in pneumococcal carriage in 
unvaccinated individuals.  
• To investigate what the effect would 
be of different vaccination strategies 
on pneumococcal carriage in 
vaccinated and unvaccinated 
individuals.  
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The population growth is the result of a net difference between the annual birth rate 
(37.3/1000 in 2010) and death rate (6.1/1000 in 2010). Population dynamics are further 
influenced by the in-migration (73.2/1000 per year) and out-migration rates (76.7/1000 
per year). Life expectancy at birth was 69.4 years in 2010. Infant and under-five 
mortality rates were 35.0 and 59.1 per 1000 live births in 2010, respectively (54).   
  
The population pyramid of the KHDSS area shows a highly triangular shape, reflecting 
the high childhood mortality, mortality in adults as a result of the HIV epidemic and out-
migration of young adults from this rural area (Fig 3.1) (54).  
 
 
 
Figure 3.1 Population pyramid for Karonga Health and Demographic Surveillance 
System  
Obtained from census data from 01/01/2010. 
 
HIV prevalence in the area was estimated at 7.1% in men and 9.2% in women in 
2008/2009 (56). HIV-prevalence in women of childbearing age ranged between 3% in 
women 15-24 years and 16% in women 30-39 years (56). ART has been available in 
the clinic located within the study site since 2006. 
 
The Karonga Health and Demographic Surveillance System (KHDSS) site is bordered 
by the hills of the Nyika national park in the west and by Lake Malawi in the east (Fig 
3.2). The surveillance area includes one rural hospital, five health centres and 23 
outreach vaccination clinics. The area has three distinct seasons: rainy from December 
to April, cool and dry from May to August and hot and dry from September to 
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November. Main sources of income in the KHDSS area are subsistence farming, 
fishing and small scale trading.  
 
 
Figure 3.2 Map of the Karonga Health and Demographic Surveillance System  
 
3.3 Recruitment and data collection 
 
Recruitment for the studies took place at local hospitals. For the infant studies, 
recruitment took place during antenatal clinics or on the postnatal ward. HIV-positive 
adults were recruited from ART clinics. See the methods sections in individual chapters 
for more details on recruitment criteria. 
 
Pneumococcal carriage was detected using nasopharyngeal samples. Trained nurses 
and field workers collected samples at the household for the infant studies, or at the 
ART clinic for the studies on HIV-positive adults.  
Data on household characteristics, socio-demographics and vaccination status were 
retrieved from the KHDSS records. Data were collected during the KHDSS annual 
census at which all households are visited and individual and household socio-
demographic data are collected by trained interviewers. Vaccine status and date of 
vaccination were transcribed from parent-held booklets (“health passports”) issued free 
by the government to all children at birth or first clinic visit. Absent vaccine 
documentation, parent/guardian reported vaccination status was recorded. 
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3.4 Laboratory procedures 
 
3.4.1 Description of sample collection, growth and serotyping procedures 
Nasopharyngeal samples were collected and analysed according to standard 
procedures (57). A pernasal swab (Medical Wire & Equipment, Corsham, UK) was 
inserted into the posterior nasopharynx. In 2008-2011 a calcium alginate swab was 
used, in 2014 a flocked swab was used. The swab was transported in skim milk-
tryptone-glucose-glycerol medium. Inoculated vials were stored at -20oC within 6 hours 
of collection, and were frozen at -80oC until tested. Samples were cultured on 
gentamicin (5 µg/mL) sheep blood agar plates and incubated overnight at 37oC with 
5% carbon dioxide. Pneumococci were identified by morphology and sensitivity for 
optochin.  
 
In studies conducted before introduction of PCV-13, one colony was isolated and 
cultured in Todd-Hewitt broth. Pneumococci were serogrouped using Latex 
agglutination and serotyped by Quellung reaction using standard antisera (Statens 
Serum Institute, Copenhagen, Denmark). Reagents were available to type 48 of the 
potentially 92 serotypes, including the PCV-13 vaccine (VT) serotypes (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F, 23F). 
 
Samples collected after introduction of PCV-13 were analysed using two different 
methods: 1) LytA and serotyping polymerase chain reactions (PCR), and 2) Latex 
agglutination.  
 
For the PCR methods, a sweep of pneumococcal growth was taken of the positive 
primary culture plates using an inoculation loop and placed in 500µl nuclease free 
water. The bacterial suspension was boiled for 10 minutes at 98oC and 5µl of the 
supernatant containing bacterial genomic DNA was used in subsequent real-time 
polymerase chain reactions (qPCR). Pneumococcal DNA was detected using a qPCR 
assay for the autolysin-A-encoding gene (LytA). Cycle threshold (Ct) values, defined as 
the number of cycles required for the fluorescent signal to cross the threshold and 
exceed the background fluorescence level, were used to evaluate density of 
pneumococcal carriage. Isolates were serotyped using seven sequential triplex qPCR 
reactions, designed to detect 37 serotypes, including the PCV-13 serotypes. Samples 
were considered positive for a specific serotype if the serotype-specific Ct-value was 
less than 40. The PCR method did not allow a distinction between VT and NVT 
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serotypes for serogroups 9A/V, 7A/F, and 18A/B/C/F. For these serotypes, additional 
latex agglutination was performed to make the distinction. 
 
For Latex agglutination, a single colony was selected from the primary plate and a 
secondary plate was grown to obtain pure growth. Both the primary and secondary 
plates were tested for optochin sensitivity. In case of an indeterminate or non-
susceptible result, a bile solubility test was used for confirmation. Latex agglutination 
was performed on pure pneumococcal growth with use of a 13-valent Latex kit (Staten 
Serum Institut, Copenhagen, Denmark) (58).   
 
The advantage of PCR methodology is that it allows for detection of multiple serotypes 
per sample and gives an indication of the abundance of specific serotypes in the 
sample. The disadvantage of PCR methodology is that it was a newly installed method 
at the Malawi Liverpool Wellcome Trust Clinical Research Programme Laboratories 
where analysis took place. At time of the study the comparability between serotyping of 
PCR and Quellung/Latex had yet to be evaluated (see section 3.4.3). The advantage of 
serotyping by Latex agglutination is that it is comparable to the Quellung reaction whilst 
being less labour intensive (58). The disadvantage of Latex agglutination is that is has 
the same drawbacks as Quellung serotyping: in practice only one serotype can be 
detected per sample and there is no quantification of the abundance of the serotype. 
Another disadvantage of Latex agglutination with the Statens Serum Institut 13-valent 
latex kit is that only the PCV-13 serotypes and a few non-vaccine serotypes (NVT) can 
be determined. Conventional Quellung would have to be used to differentiate the NVT 
serotypes. The majority of NVT serotypes were reported as “NVT” with no further 
discrimination available. 
3.4.2 Repeated measures of growth data and evaluation of LytA PCR 
Samples collected after introduction of PCV-13 were assessed for pneumococcal 
presence up to five times: 1. Culture for LytA and serotyping PCR, 2. LytA PCR to 
confirm pneumococcal growth, 3. Culture for Latex serotyping to confirm PCR 
ambiguous VT/NVT results, 4. Culture for Latex serotyping, 5. Culture for Quality 
control (QC) testing (Figure 3.3). Optochin sensitivity testing was not systematically 
done when culture was performed for LytA and serotyping PCR (Step 1). Optochin 
sensitivity testing was performed on all samples when culture was performed for Latex 
serotyping (Step 4).  
 
Of 1337 samples, 584 (43.7%) tested positive on culture (Step 1): 554 (95%) of those 
were tested positive on LytA PCR, 24 (4%) tested negative on LytA PCR (Step 2). Of 
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584 samples tested positive on culture (Step 1), 450 (85%) tested positive and 102 
(18%) tested negative when the culture-step was repeated for Latex-serotyping (Step 
4). Quality control testing (Step 5) was done for 37 culture-positive samples and 20 
culture-negative samples: all 37 (100%) positive samples were found to be culture-
positive on repeat testing; 12 out of 20 (60%) negative samples were found to be 
culture-negative on repeat testing.  
 
Pneumococcal growth on culture was found to have inconsistent results on repeat 
testing. Only 85% of samples initially identified with pneumococcal growth and positive 
on LytA PCR were found to have pneumococcal growth on re-culturing for the Latex 
analysis. It is possible that these results are a result of the different use of optochin 
susceptibility testing in both steps. Optochin susceptibility testing was not performed on 
all samples initially: it is likely that samples containing alpha-haemolytic streptococci 
other than Streptococcus pneumoniae were incorrectly assigned to be culture-positive. 
Although LytA PCR should have only identified Streptococcus pneumoniae, there are 
concerns over the specificity of LytA PCR and the possibility that it may not 
discriminate between Streptococcus pneumoniae and viridans streptococci, resulting in 
false positive results (59, 60). LytA PCR has high sensitivity and specificity for the 
detection of Streptococcus pneumoniae from clinical isolates (61), but specificity is 
lower comparing the detection of pneumococcal carriage with culture: 76% in an 
experimental human pneumococcal carriage trial conducted on adults in the UK (59), 
and 46%, 46% and 19% in samples from children <5 years, HIV-positive and HIV-
negative adults in Kenya (60). Apart from the concern of cross-reactivity with other 
streptococci, lower specificity can be the result of the inability of PCR to distinguish 
between live and dead bacteria, and the ability of PCR to detect low-density culture 
which can be missed on culture (59). It is likely that at least part of our negative culture 
results can be explained by the different use of optochin and suboptimal specificity of 
LytA PCR, but we cannot rule out that the pneumococci collected in our study had lost 
viability on repeat testing. Samples containing Streptococcus pneumoniae from throat 
swabs collected from children in Tanzania were found to be viable after four freeze-
thaw cycles when stored in STGG at -70C (62), providing reassurance for the viability 
of our samples which were stored under the same conditions (62). 
 
3.4.3 Comparison between PCR and Latex agglutination serotyping methods 
We compared the serotyping results of the PCR and Latex agglutination methods. We 
compared the Latex serotyping results to all PCR results (detection of multiple 
serotypes), and to the most abundant serotype detected on PCR. The most abundant 
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serotype was defined as the serotype with the lowest CT-value. However, if the CT-
values of the LytA PCR (detecting total pneumococcal DNA) and the most abundant 
serotype PCR differed by 9.9 or more (equivalent to a 1000x concentration difference), 
we hypothesised that there was another serotype present that was undetectable on the 
serotyping PCR. We summarize our analyses for the most abundant serotype on PCR 
before and after adjustment of this difference in CT-value. 
 
In total, 473 samples were serotyped using PCR and Latex agglutination methods. 
Tables 3.2 shows the sensitivity and specificity of PCR serotyping to identify VT 
serotypes: using all PCR results (A), only the most abundant PCR results (B) or using 
only the most abundant PCR results and adjusting for a difference in PCR and 
serotyping CT-value (C). In this analysis, Latex agglutination is assumed to be the gold 
standard for serotyping.  
 
Sensitivity to identify a VT serotype was 66% when including all PCR results, 62% 
when only including the most abundant PCR result and 50% when adjusting the PCR 
result for a difference in CT-value. The specificity of PCR to correctly identify an NVT 
serotype as most abundant was 87%, or 96% after adjustment for CT value.  
 
Table 3.3 shows the results of table 3.2b by serotype. Amongst the 64 samples that 
were identified as having a most abundant VT serotype on PCR and Latex, the same 
serotype was identified on both methods for 60 samples (94%). Serotype-specific 
sensitivity was particularly low for serotypes 19F (6/21, 29%), 23F (2/7, 29%) and 19A 
(6/13, 46%). Of seven samples identified as 9V on Latex serotyping, 6 were identified 
as “9VA” on PCR, but only one was subsequently identified as 9V when the factortype 
was confirmed by Latex.  
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Figure 3.3 Flowchart with culture and LytA PCR results performed for the post-vaccination studies 
* Optochin testing not systematically done for first culture tests 
** LytA not done for 6 samples 
*** Culture not done for 2 samples 
12/20 (60%) culture-
negative on QC 
1337 samples 
24 (4%) LytA 
negative**  
554 (95%)  
LytA positive 
37/37 (100%) culture-
positive on QC 
450 (82%) culture-
positive 
1. Culture for PCR 
2.  LytA PCR 
3. Culture to re-test 
samples with ambiguous 
VT/NVT PCR results 
4. Culture for Latex 
serotyping 
5. Culture for Quality 
Control Latex serotyping 
584 (43.7%)  
culture-positive* 
56/63 (89%) culture-
positive 
102 (18%) culture-
negative*** 
19 (79%) culture-
positive 
5 (21%) culture 
negative 
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Table 3.2a Comparison between PCR and Latex serotyping methods including 
all PCR results 
 Latex 
+ (VT) - (NVT) Total 
 
PCR  
 
+ (VT) 68 79 147 
- (No VT) 35 291 326 
Total 103 370 473 
Sensitivity: 68/103 = 66% 
Not possible to calculate specificity from this table: NVT on Latex and VT result on PCR are 
not necessary inconsistent results as PCR result could be a lesser abundant serotype. 
 
Table 3.2b Comparison between PCR and Latex serotyping methods including 
only most abundant PCR result (not corrected for CT value difference) 
 
 
Latex 
+ (VT) - (NVT) Total 
PCR 
(most 
abundant 
result) 
+ (VT) 64 48 112 
- (NVT) 39 322 361 
Total 103 370 473 
Sensitivity: 64/103 = 62% 
Specificity: 322/370 = 87% 
 
Table 3.2c Comparison between PCR and Latex serotyping methods including 
the only most abundant PCR result (adjusted for CT value difference) 
 
 
Latex 
+ (VT) - (NVT) Total 
PCR 
(most 
abundant 
result) 
+ (VT) 51 16 67 
- (NVT) 52 354 406 
Total 103 370 473 
Sensitivity: 51/103 = 50% 
Specificity: 354/370 = 96% 
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Table 3.3 Comparison of serotypes detected by Latex / PCR serotyping methods 
 Latex 
PCR 
 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F NVT 
1 0              
3  6            3 
4   0         1   
5    1          3 
6AB     12 19     2   16 
7F       0        
9V        1       
14         5    1 12 
18C          2    1 
19A           6   8 
19F            6  5 
23F             2  
NVT     5 4  6* 1  5 14 4 322 
* 5/6 samples were identified as 9VA on PCR, but latex confirmed as 9A.
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3.4.4 Quality Control of PCR and Latex agglutination serotyping methods  
Quality control (QC) testing was performed by repeat testing of samples using the 
same serotyping method. Lab technicians performing the repeat testing were blinded to 
the original test results. QC testing of PCR was performed on 40 samples with 
pneumococcal growth. PCR results on repeat testing were the same for 26 of 40 
samples (65%). QC testing of Latex agglutination serotyping was performed on 34 
samples with pneumococcal growth. Concordance for VT/NVT results was 85% (29/34 
concordantly identified as VT/NVT). Four out of five discordant VT/NVT results were a 
result of a difference in factor type (e.g. 19F vs. 19B/19C). Of 10 samples with VT 
serotypes on both the original testing and the QC, 9 had identical serotypes on both 
occasions (90%), 1 sample (10%) had a different factor type on QC (6A vs. 6B). Of 19 
samples with NVT serotypes on both the original testing and the QC, 16 had identical 
serotyping results (84%), 1 had different serotype results, and two were non-typeable 
“NVT” on the original test, but had a typeable NVT serotype on QC. 
 
3.4.5 Conclusion on pneumococcal serotyping methods 
The sensitivity of the PCR serotyping method to identify a VT pneumococcus was 
found to be too low (66% when including all PCR results) to allow for an accurate 
comparison of the post-vaccination data to the pre-vaccination data. Also QC testing 
provided better results for Latex serotyping than for PCR serotyping. Validation of the 
PCR method is ongoing at the Malawi Liverpool Wellcome Trust Clinical Research 
Programme Laboratories, but optimisation had not yet been completed at the time of 
this PhD thesis. Based on the results presented in this section, we decided to use the 
culture results where optochin testing was done consistently (Step 4 in Fig 3.3) and the 
Latex serotyping results to report findings of the post-vaccination data (Chapter 8).  
 
3.5 Statistical analysis 
 
Statistical analyses were performed using R 3.0.1 (R Foundation for Statistical 
Computing, Vienna) and Stata 12.1 (Statacorp, Texas). Comparisons between 
categorical data, including proportions of pneumococcal carriage, were made using the 
Pearson’s Chi-square test and Fisher exact test as appropriate. Log-binomial 
regression or Poisson regression with robust standard errors was used to report rate 
ratios (RR) for risk factors of pneumococcal carriage (Chapters 4,5,7) and vaccine 
uptake (Chapter 6). Cox proportional hazard regression was used to examine time to 
first carriage in infants (Chapter 4) and vaccine timeliness (Chapter 6). Multivariable 
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models included initially only covariates achieving p-value <0.2 in univariable analysis. 
We retained in the final multivariable model those covariates achieving a likelihood 
ratio test p-value <0.05. Mixed-effect models (Chapter 4) and generalized estimated 
equations models (Chapter 5) were used to study within-person clustering of the data.  
 
Seasonality was studied in the carriage studies conducted prior to vaccine introduction 
(Chapter 4, 5). For seasonality, parametric functions with different numbers of sin-
cosine waves were examined. For instance, a model with two sin-cosine waves was 
specified as:  !!,! = ! +  !! sin 2!"365 +  !!cos 2!"365 + !! sin 4!"365 +  !! cos 4!"365 +  !! !"#$%&$'()!,!  
 where !!,! is the carriage in individual ! on day of the year !, !!!! terms are regression 
coefficients for each sine and cosine function, and covariates are other factors studied. 
 
3.6 Ethics 
 
Informed written consent was obtained from participants of the studies. In the infant 
carriage studies, informed written consent was obtained from mothers and/or heads of 
participating households. Ethical approval was granted by the National Health 
Sciences Research Committee in Malawi and the London School of Hygiene and 
Tropical Medicine or University of Liverpool ethics committee. 
  
44 Chapter 3 	
 
  
Systematic literature review 45 	
 
 
 
 
4. Transmission of Streptococcus pneumoniae to 
and from children under five years of age: a 
systematic literature review  
 
4.1 Introduction 
Worldwide surveillance on the spread and serotype distribution of pneumococci is 
required to study the impact of vaccination and the extent of serotype replacement. 
Understanding the drivers of pneumococcal transmission in different settings is vital to 
understand and predict VT and NVT incidence and herd protection and thus to inform 
vaccination policies. Given the impressive impact of PCVs on disease burden in 
developed world settings, there is expectation that this will also manifest in developing 
country settings. If pneumococcal transmission is similar then there will be every 
possibility of the successes seen in the US and Europe. But if transmission varies 
under different demographic circumstances then the extent of herd protection may be 
lower than observed in western societies. Understanding differences in transmission 
dynamics will allow consideration of alternate vaccine schedules and uses to deliver 
herd protection.  
 
This chapter reviews the available data on pneumococcal transmission in developed 
and developing countries. This literature research focuses on transmission of 
pneumococci to and from children under five years of age, the age group targeted for 
routine vaccination, and where the largest burden of IPD and otitis media can be found. 
Understanding transmission to and from this age group will be essential to understand 
the success of PCV-13 introduction in Malawi. Besides reviewing literature on 
pneumococcal transmission dynamics, the different study designs and definitions used 
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to study pneumococcal transmission will be reviewed, with the aim of informing the 
study design and analysis for our setting in rural Malawi.     
 
4.2 Research questions 
Research questions related to pneumococcal transmission 
1. What are the pneumococcal transmission dynamics to and from children under five? 
1.1 What is the evidence for pneumococcal transmission to and from children under 
five within the household?  
1.2 What is the evidence for pneumococcal transmission to and from children under 
five outside the household?  
1.3 Is there any evidence that pneumococcal transmission dynamics differ by 
geographical and cultural setting? 
1.4 Is there any evidence that pneumococcal transmission dynamics differ by 
serotype? 
1.5 What is the evidence for altered pneumococcal transmission dynamics post 
introduction of pneumococcal conjugate vaccination? 
 
Research questions related to study designs 
2. Which study designs are used to study pneumococcal transmission dynamics? 
2.1 What are the strengths and weaknesses of each study design? 
2.2 In which settings has pneumococcal transmission to and from children under five 
years of age been studied?  
2.3 What definitions are used to extrapolate pneumococcal transmission from 
epidemiological data? 
 
4.3 Methodology 
A systematic search of English literature published up to February 2015 was performed 
on the following databases: Scopus, Medline (PubMed), Web of Knowledge, World 
Health Organization Library (WHOLIS). We searched the databases on the following 
keywords in any field of the articles: (pneumococc* OR "strep* pneumo*" OR "s. 
pneumo*") AND (child* OR infant* OR preschool OR newborn* OR "under five*" OR 
family OR families OR household* OR "day care" OR mother* OR parent*) AND 
(transmission OR cluster* OR transmit* OR spread* OR longitudinal OR "cross-
sectional") AND (epidemiology OR "carrier state" OR "time factors" OR model*). To 
account for unpublished research, we searched the abstract books of the 2012 and 
2014 ‘International Symposium on Pneumococci and Pneumococcal Diseases’. 
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Firstly, abstracts were screened and excluded from further assessment if they only 
included results from non-human samples or laboratory studies, or if they did not 
include any results on Streptococcus pneumoniae. Secondly, articles were assessed 
for eligibility: articles were included if they discussed human-to-human transmission of 
Streptococcus pneumoniae. Outbreak investigations, cross-sectional studies, case-
control studies, longitudinal studies and modelling papers were included. A study was 
defined as longitudinal if there were at least two samples collected from the same 
study population with a sample interval of less than three months. Studies were 
included only if they reported Streptococcus pneumoniae culture results. Modelling 
studies were included only if they studied person-to-person transmission specifically. 
Outbreak investigations were included if they reported on contact tracing amongst 
asymptomatic contacts of the index case(s).  
 
4.4 Literature search results 
A total number of 2948 records were retrieved through database searches (figure 1). 
Searches through unpublished sources yielded 34 conference abstracts. After 
duplicates were removed, 1081 abstracts were screened. We assessed 250 records 
for eligibility. We excluded 145 records, mostly because results on transmission were 
not reported (n=113 for cross-sectional and longitudinal studies, n=12 for mathematical 
models). One conference abstract was excluded because the study used the same 
results as reported in chapter 5 of this PhD thesis. Finally, we included 103 records, 
from 34 cross-sectional studies (22, 63-95), 20 outbreak reports (96-115), 1 case-
control study (116), 30 longitudinal studies (7, 8, 117-144) and 18 mathematical 
modelling papers (145-162).  
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Figure 4.1 Search results and selection of included studies 
Published sources:  
2948 records retrieved 
through database searches 
Unpublished sources: 
34 conference abstracts 
1651 duplicates excluded 
1331 records screened 
1081 records excluded 
250 records assessed for 
eligibility   
145 records excluded: 
- 113 results on transmission not 
reported/no culture results reported 
- 12 mathematical models with no 
transmission parameters reported 
for children under five  
- 11 no results for children under five 
- 5 outbreak reports without contact 
tracing  
- 2 not published in English, no 
translation available 
- 4 reviews 
103 records included (101 full text, 2 
conference abstracts) 
- 34 cross-sectional studies 
- 20 outbreak investigations 
- 1 case-control study 
- 30 longitudinal studies 
- 18 mathematical modelling 
studies 
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4.5 Cross-sectional studies and outbreak investigations 
 
Settings 
In total, 54 studies were included: 34 cross-sectional studies and 20 outbreak 
investigations. The cross-sectional studies investigated pneumococcal transmission in 
day care centres (DCCs) (n=17) (63-67, 69, 71, 73, 75-77, 87, 88, 91-94), households 
(n=10) (22, 68, 72, 74, 78, 82-84, 86, 89), ethnic communities (n=5) (70, 79, 81, 85, 
90), a post-tsunami camp (n=1) (95), or various settings (n=1) (80). In seventeen out of 
the twenty outbreak investigations, contacts at the DCC or school of the index children 
were screened (97-113). Two investigations involved screening of mothers after 
diagnosis of IPD in neonates (96, 114). The last outbreak investigation combined an 
outbreak report of serotype 12F with information from carriage surveillance studies in 
the same area (115). 
 
More than half of the studies were based in the USA or Canada (n=9) (22, 65, 73, 89, 
97-99, 112, 115) or in European countries (n=23, of which 8 from Sweden) (63, 64, 69, 
71, 75, 77, 80, 87, 88, 91-94, 100-104, 108-111, 114). Seven studies took places in 
Middle-Eastern countries (66, 76, 79, 81-83, 113), four in Asia (67, 72, 95, 107), four in 
Africa (68, 74, 86, 105), four in South-America (84, 85, 96, 106) and three in Australia 
and Papua New Guinea (70, 78, 90).  
 
Study design 
Many cross-sectional studies had a large sample size, resulting in a median sample 
size of 380 children under five (range 29-83301). Individual outbreak investigations 
involved contact tracing in up to 372 contacts (median 70, range 6-372).  
 
Twenty-six (76%) cross-sectional studies used molecular typing methods to determine 
clusters of pneumococci, with pulsed-field gel electrophoresis (PFGE) (n=25) used by 
most studies (64-67, 69, 72, 74-77, 79-91, 94, 95). Other methods included multilocus 
sequence typing (MLST) (n=7), (63, 75, 79, 81, 84, 90, 94), polymerase chain reaction 
(PCR) (n=4) (72, 79, 81, 84, 90), restriction fragment end labeling (RFEL) (n=2) (64, 
85) and hybridization methods (n=2) (88, 89). Four studies did not use molecular typing 
methods, but used antibiotic resistance patterns to infer pneumococcal clustering (71, 
73, 92, 93). Molecular typing methods were also used in eleven (55%) of the twenty 
                                                
1 Maximum estimate (8330) combines multiple studies reported in one publication that were not 
reported separately. One study with 12,793 hospital samples excluded. 
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outbreak investigations (96, 99, 103-108, 111, 113, 115). Six studies did not use typing 
methods, but inferred pneumococcal clustering from antibiotic resistance patterns (98, 
100, 101, 109, 110, 112).   
 
Findings – cross-sectional studies in DCCs 
There were sixteen cross-sectional studies conducted in DCCs (Table 4.1). Carriage 
prevalence differed widely between the different studies conducted in different 
geographical settings (range 5%-78%). Thirteen (81%) studies reported pneumococcal 
transmission within DCCs (63-67, 69, 73, 87, 88, 91-94). An average cluster size of 
approximately 3.5 (range 2-13) individuals was reported. The remaining three studies 
reported no or very little evidence of within DCC transmission (76, 77, 163). 
 
Different conclusions were drawn on whether spread between DCCs and/or within the 
community is likely to have occurred. Eight studies report that different DCCs had 
different PFGE profiles (65, 69, 88, 91, 94), or that specific serotypes or antibiotic 
resistance profiles tended to be overrepresented in certain DCCs (66, 71, 93), 
supporting the hypothesis that each DCC is an “autonomous epidemiological unit” (88). 
Six studies reported that pneumococci with identical PFGE clones or antibiotic 
resistance profiles were found in several DCCs (73, 75, 87, 91-93). Two studies 
identified isolates obtained from DCCs to be representative of internationally 
recognized strains (63, 87).   
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Table 4.1 Cross-sectional studies on pneumococcal transmission in DCCs  
Author, year (ref) Country Study population / samples Molecular 
method* 
Key findings 
Almeida, 2013 (63) Portugal Retrospective study on carriage samples of 
serotypes 1 (n=21), 5 (n=7), 7(n=42) in DCCs  
MLST Although serotypes 1, 5 and 7 were detected sporadically, 
there was evidence of cross-transmission in some DCCs. 
Isolates were associated with international clones. 
Bogaert, 2001 (64)  The 
Netherlands 
Isolates from 244 children in DCC and 61 not 
in DCC  
RFEL Higher risk for horizontal spread of pneumococci in DCCs 
than in the general population 
Boken, 1995 (65) USA Carriage in 32/54 (59%) children in one DCC PFGE Single predominant strain in each of the five DCC rooms 
Borer, 2001 (66) Israel Carriage in 29/50 (58%) children in six DCCs PFGE Pneumococci more frequently acquired from DCC 
attendees than from family members.  
Chen, 2007 (67) Taiwan Carriage in 25/94 (27%) children in 6 classes 
at one DCC 
PFGE Evidence for intraclass transmission 
Gudnason, 2014 (71) Iceland Before/after study on hygiene intervention in 
2399 children in 15 intervention and 15 control 
DCCs   
- Hygiene intervention associated with reduced risk of 
carriage. Pneumococcal carriage differed significantly 
between DCCs 
de Lencastre, 1999 
(69) 
Portugal 277/586 (47%) children in 7 DCCs PFGE Each DCC had a unique microbiological profile 
Kellner, 1999 (73) Canada 586/1322 (44%) children in 39 DCCs - Overall prevalence of antibiotic resistance and specific 
serotypes was not significantly different between DCCs 
Nunes, 2008 (75) Portugal 1973/2888 (68%) children attending DCCs PFGE, 
MLST 
Cross-transmission of serotype 1 in one DCC, but same 
clone also in four other DCCs. 
Percin, 2011 (76) Turkey 11/212 (5%) children in 3 DCCs PFGE No evidence for spread in DCC 
Petrosillo, 2002 (77) Italy 91/610 (15%) children in 19 DCCs PFGE Clonal relationship only in three pairs of strains: one within 
one DCC, two in different DCCs 
Sa-Leao, 2000 (87) 
(88) 
Portugal 1096/2111 (52%) children in 16 DCCs 
 
PFGE 45 of 57 PFGE types each in a single DCC. 8 PFGE types 
in several DCCs, and in international samples 
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Table 4.1 Cross-sectional studies on pneumococcal transmission in DCCs  
Author, year (ref) Country Study population / samples Molecular 
method* 
Key findings 
Souli, 2007 (91) Greece 461/1451 (32%) children in 49 DCCs: 74 
samples PFGE  
PFGE Extensive spread within and amongst DCCs. 
Syrogiannopoulos, 
1997 (92) 
Greece 132/338 (39%) children in 7 DCCs - Strains with common serotypes, resistance patterns, and 
penicillin MICs were noted in up to 4 DCCs 
Tsolia, 1999 (93) Greece 136/382 (36.5%) in 8 DCCs - Strains of the same serogroup/serotype and identical 
susceptibility patterns appeared to cluster in DCCs 
Vestrheim, 2008 (94) Norway 449/573 children (78.4%) in 29 DDCs MLST Clonal distribution of pneumococci was unique for each 
DCC 
* MLST: multi-locus sequence typing, PFGE: pulsed-field gel electrophoresis, RFEL: restriction fragment end labelling,
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Findings – cross-sectional studies in households 
No consistent evidence was found for the importance of within-household transmission 
in ten cross-sectional studies (Table 4.2). In a study performed in Japan, sixteen out of 
29 children with IPD and their parents carried identical pneumococcal strains, leading 
to the conclusion that a high rate of transmission occurred between children and their 
parents (72). In Papua New Guinea, 12 out of 61 mother/infant pairs carried the same 
serotype (78). No evidence for simultaneous carriage of the parent being a risk factor 
for pneumococcal acquisition was found in a study in the Gaza strip aOR = 1.31 
(95%CI 0.59–2.94), whereas a positive association was found for DCC attendance 
aOR = 3.72 (95% CI (0.98–14.17), leading to the conclusion that spread in DCCs is 
more important than intrafamilial spread (82). The same conclusion was drawn from 
another study in Israel by the same authors: of 151 child/parent pairs, only one carried 
an identical strain. Having siblings <6 years was found to be positively associated with 
carriage of pneumococci (any strain) (OR, 2.3; 95% CI, 0.95–5.6; p=0.06), but only four 
out of 32 sibling pairs (12.5%) carried identical strains. A highly positive association 
was found for DCC attendance (OR, 4.7, 95% CI, 2.5–8.6; P <0.001) (83). There is one 
other study which reported one child/parent pair and one sibling pair with identical 
pneumococcal strains, but no conclusions can be drawn from this result since no 
denominator was reported (74). 
 
Evidence for intra-sibling spread was found in a study performed in Utah, USA, both for 
any (aOR 3.3, 95%CI 2.2–5.0) and resistant (aOR 7.5, 95%OR 2.7–20.7) 
pneumococcal carriage. The results for resistant pneumococci were confirmed by 
molecular analysis: in all eight sibling pairs, identical strains were found (89). DCC 
attendance was found to be positively associated with any pneumococcal carriage 
(aOR 2.4, 95%CI 1.6-5.0), but not with carriage of resistant strains 0.5 (0.1–2.1) (89), 
possibly a result of a small number of children attending DCC in this community.  
 
If spread to younger siblings is important, an indirect effect of vaccination would be 
expected to occur: pneumococcal carriage of VT would be expected to drop not only in 
PCV-vaccinated children, but also in their younger unvaccinated siblings as a result of 
reduced spread (herd effect). This is exactly what was observed in a randomized-
controlled trail in the USA: VT carriage was lower amongst non-vaccinated siblings in 
PCV-7 randomized households (OR, 0.57; 95% CI, 0.26–0.98) (22). However, no 
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differences in VT carriage were seen amongst non-vaccinated siblings in PCV-7 
randomized households in The Gambia. This is likely to have been a result of the 
observed high transmission and widespread carriage across age groups, and suggests 
that indirect effects as seen in the USA may not be as profound in settings with 
different transmission dynamics (68). 
 
Simultaneous pneumococcal carriage of children under five and older children (5-
17yrs) or adult household members was found in 11.9% and 31.6% in a slum 
community in Brazil. No positive association for household carriage was found when 
the results of all household members were combined (OR 1.2, 95%CI 0.5-3.1). DCC 
attendance was not associated with carriage (OR 1.3, 95%CI 0.3-5.3), probably due to 
low attendance in this community. School attendance was found to be associated with 
carriage (aOR 2.7, 95%CI 1.2-6.0). 
 
Also no convincing evidence for the importance of the size of household was found. 
One study found that the risk of pneumococcal carriage did increase with the number 
of members in the household (aOR 1.08 per member (95%CI 1.01–1.14) (82), whereas 
another study did not find an association with the size of household (84). 
 
Only one study looked at the association between pneumococcal carriage and HIV-
exposure by the mother in 207 mother-infant pairs. No differences in colonization rates 
were found between HIV-positive, uninfected but HIV-exposed and HIV-unexposed 
children when the children were asymptomatic. A significant different in carriage rates 
between the HIV-positive and HIV-exposed children and the controls was found when 
the children had respiratory symptoms (86).  
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Table 4.2 Cross-sectional studies on pneumococcal transmission in households  
Author, year (ref) Country Study population / samples Molecular 
method* 
Key findings 
Cheung, 2009 (68) The Gambia 2342 children (9-27 mo) participating in a 
randomized controlled trial PCV-9, 675 non-
vaccinated younger siblings (median 3 mo) 
- No significant differences in the patterns of carriage of VT 
or NVT were seen among the younger siblings of the trial 
participants who had received PCV-9 or placebo. 
Hoshino, 2002 (72) Japan 29 children (mean 1.7 yrs) with IPD and their 
parents 
PFGE, 
PCR 
18 (62%) pairs with identical serotypes, suggesting high 
rate of transmission between children and their parents 
Medina, 2005 (74) Kenya 104 HIV-positive adults and 46 children <5yrs PFGE Intrafamilial spread in two families (no denominator) 
Millar, 2008 (22) USA Randomized controlled PCV-7 trial in children 
<5. 241 unvaccinated siblings in PCV group, 
99 unvaccinated siblings in control group 
- VT pneumococcal carriage was lower among adults and 
unvaccinated children living with a PCV-7 vaccinee. 
Pickering, 1988 (78) Papua New 
Guinea 
61 mother/infant pairs and 12 older siblings - 12 of 61 mothers carried the same serotype as their infant. 
From 14 sibling/infant pairs, 6 carried the same serotype. 
Regev-Yochay, 2012 
(82) 
Gaza strip 379 children (3wks-5.5yrs) and one of their 
parents 
 
- No evidence for simultaneous carriage of parent being a 
risk factor for pneumococcal acquisition aOR = 1.31 
(95%CI 0.59–2.94), positive association for DCC 
attendance aOR = 3.72 (95% CI (.98–14.17), 
Regev-Yochay, 2004 
(83) 
Israel 404 children (3wks-6yrs, median 2 yrs), 32 
siblings and 151 parents 
PFGE Only 1 child-parent pair carrying an identical strain. Only 4 
(12.5%) of sibling pairs carried identical strains 
Reis, 2008 (84) Brazil 39 households, including 50 children <5 yrs PCR, 
PFGE, 
MLST 
13 (33%) households and 9 housholds (23%) had more 
than one member who was colonized with pneumococci of 
the same serotype and clonal group, respectively 
Rusen, 1997 (86) Kenya 207 children <5 yrs born to 122 HIV positive 
and 85 HIV negative mothers 
- No differences in colonization rates found between HIV-
positive, uninfected but HIV-exposed and HIV-unexposed 
children when the children were asymptomatic. 
Samore, 2001 (89) USA 351 children <5 yrs in two communities PFGE Transmission within households suggested by risk factor 
analysis (aOR 3.3 (2.2–5.0) for siblings with simultaneous 
carriage and molecular analysis of isolates from pairs of 
siblings (8 identical strains found in sibling pairs). 
* MLST: multi-locus sequence typing, PCR: polymerase chain reaction, PFGE: pulsed-field gel electrophoresis, RFEL: restriction fragment end labelling,
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Findings – cross-sectional studies in other settings 
Table 4.3 lists the included cross-sectional studies conducted in other settings. Two 
studies showed that when two geographical close, but distinct communities were 
compared, differences in serotypes (70) or clonal distributions (79, 81) could be found, 
possibly as a result of low contact patterns between the communities. Two other 
studies compared a larger number of indigenous communities in Venezuela (9 
communities) (85) and Australia (3-19 communities) (90) and found that transmission 
occurred across the communities. The Australian study reports on widespread 
circulation of serotype 1, a potentially highly invasive serotype which is rarely reported 
in carriage from other settings (90). Some transmission was also detected in a post-
tsunami camp in Sri Lanka. A maximum cluster size of 3 was reported (95).  
 
One study in Romania compared pneumococcal strains across children living in an 
institution and children presenting to the hospital for pneumococcal infection or for 
elective surgery. An identical PFGE type was recovered from 24% of children with 
pneumococcal infections and 25% from children living in an institution. The same type 
was not recovered from healthy children admitted for elective surgery (80). 
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Table 4.3 Cross-sectional studies on pneumococcal transmission in other settings  
Author, year (ref) Setting, Country Study population / samples Molecular 
method* 
Key findings 
Gratten, 1981 (70) Villages, Papua New 
Guinea 
25 adults and 37 children (<15 yrs) 
from 9 households in 8 hamlets 
- Significant clustering of the serotypes by hamlets 
Porat, 2000 (80) Children living in an 
institution, Romania 
574 children (1-156 mo): 193 closed 
community; 209 hospital-elective 
surgery; 84 hospital-pneumococcal 
infection; 88 orphanage (HIVpositive) 
PFGE Large fraction of strains recovered from children with 
pneumococcal infections and from those living in an 
institution (24% and 25%, respectively) were represented 
by a single PFGE type, which was absent from healthy 
children admitted for elective surgery 
Porat, 2010 (79, 81) Hospital, Israel Middle ear fluid cultures obtained from 
12,793 children <5 yrs (Jewish and 
Bedouin) with acute otitis media 
PFGE, 
PCR, 
MLST 
Clonal distributions between Jewish and Bedouin children 
were different due to the rarity of contact between them. 
Rivera-Olivero, 2007 
(85) 
Indigenous 
communities in 
Venezuela 
356 Warao children <6 yrs from 9 
communities 
 
RFEL  
 
High degree of horizontal transfer between the Warao 
children 
 
Smith-Vaughan, 2009 
(90) 
Indigenous 
communities in 
Australia 
Various studies.  
 
PCR, 
MLST 
Detected serotype 1 strains circulating in carriage in 
indigenous children living in remote communities 
Watanabe, 2007 (95) Post-tsunami camp 
in Sri Lanka 
324 people, including 48 children <5 
yrs in 3 camps 
PFGE Potential person-to-person transmission with a maximum 
cluster size of 3.  
* MLST: multi-locus sequence typing, PCR: polymerase chain reaction, PFGE: pulsed-field gel electrophoresis, RFEL: restriction fragment end labelling
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Findings – outbreak investigations 
Table 4.4 lists the outbreak investigations included in this literature review. Much of 
what we know about the spread of penicillin-non-susceptible pneumococci (PNSP) is 
due to the South Swedish Pneumococcal Intervention Project, an intervention 
introduced in Southern Sweden in the 1995 to control the spread of PNSP (100, 101, 
103, 104, 108-111). After an increase in PNSP was noticed the early 1990s, infection 
and carriage with PNSP was made notifiable in Southern Sweden. Whenever a person 
with PNSP was notified, extensive contact tracing was performed amongst family 
members and close contacts. If an index case was found to attend DCC, swabs were 
obtained from all children and staff in the same group. PNSP carrying children were 
restricted from attending DCC until they were found to be PNSP-negative (109). An 
overview paper on 2269 PNSP cases (40% index, 60% contact) reported that the 
average number of PNSP-positive contact cases per index case 0-6 years old was 1.6, 
but that this was 3.46 within the DCCs. The number of positive contacts in DCCs 
ranged between 0 (24% DCCs) and 25, with a median of 2 DCC positive contacts per 
index child. Only 20 DCC staff at 227 screened DCCs were found positive (109). One 
internationally recognized stable 9V clone was identified in 26 geographically dispersed 
areas (108). Apparently continuous spread of the 9V clone was identified from one 
area to the neighbouring one, with the clone disappearing and reappearing in the same 
community within a couple of months (108). In contrast, various DNA types and 
resistance patterns were found amongst other serotypes. Most variants (73%) were 
found only in a single DCC, supporting the hypothesis that DCCs are unique 
microenvironments (111). One study compared the incidence of PNSP in an area 
where the South Swedish Pneumococcal Intervention Project was implemented and 
PNSP-carries were excluded from DCC with an area where this had not occurred. At 
the end of the intervention period, the incidence of PNSP was 2.9% in the intervention 
area, and 18.4% in the non-intervention area (RR 6.4, 95%CI 2.0-20.7). Eighty-four 
percent (95%CI 49-95%) of cases occurring in the non-intervention area were 
estimated to be attributed to the lack of intervention. Twenty-one cases were estimated 
to have been averted in the intervention area. Each prevented case was estimated to 
have demanded the exclusion of two PNSP-carriers from DCC for approximately 4 
weeks each.  
 
Within-DCC spread of the outbreak strain was also reported in all outbreaks reported in 
other countries were the index case(s) attended DCC (97-99, 102, 105-107, 112, 113). 
Reported attack rates within the DCC (including index case(s), excluding staff) were 
between 5% (4/75) (97) and 100% (6/6) (99) (median 21%), with a cluster size 
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between 4 (97), and 53 (112) (median 6). Intrafamilial spread was reported in three of 
six outbreaks including contract tracing of family members.  
 
Two studies reported on cases of neonatal sepsis with evidence of vertical 
transmission (96, 114).  
 
One community outbreak investigation in Alaska, USA, used information from repeated 
carriage studies in the outbreak area to investigate spread of serotype 12F through the 
population. The study suggested that outbreaks in rural Alaska occur in the following 
steps: (1) introduction of the organism into an immunologically naïve population, (2) 
widespread transmission of the organism, with the appearance of IPD cases, (3) rapid 
development of widespread mucosal immunity, with the elimination of carriage and 
transmission, and then the disappearance of IPD, and (4) regrowth, through incoming 
birth cohorts, of an immunologically naïve population, which sets the stage for re-
initiation of the cycle with the next introduction of 12F, most likely from larger 
populations in which its circulation was sustained (115). In between outbreaks, carriage 
was found mostly in adult populations in the main city in the area, suggesting adult 
carriage can act as a reservoir (115). 
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Table 4.4 Outbreak investigations on pneumococcal transmission  
Author, year (ref) Country Setting Molecular 
method* 
Key findings  
South Swedish Pneumococcal Intervention Project 
Christenson, 1998 
(100) 
Sweden DCCs, family - 25 index cases of which 13 in DCCs. Same drug resistant serogroup in 12/424 DCC attendees, 
0/128 DCC staff, 5 family members. 
Ekdahl, 1998 
(101) 
Sweden Community - 429 index cases (all ages) with PRP, 609 contact cases (no denominators reported) 
Henriqus Normak, 
2003 (103) 
Sweden DCCs PFGE, 
MLST 
36 index cases, of which 16 in DCC. Within DCC spread recorded in 5/16 DCCs in 13/611 children. 
Högberg, 2004 
(104) 
Sweden DCCs PFGE Intervention study in 2 areas where index children carrying PNSP were (area A) or were not (area B) 
excluded from DCCs until negative. Incidence from 9% (26/292) to 2.9% (4/139) in area A, 15% 
(10/67) to 18.4% (7/38) in study area B. Same clonal type as index case found in 11/20 DCCs in 
area A, 3/5 DCCs in area B. 
Melander 1998, 
(108) 
Sweden Community PCR 22/26 geographically dispersed drug resistant 9V isolates were identical, suggesting community 
spread. 
Melander, 1998 
(110) 
Sweden DCCs - 30 DCCs with index child: drug resistant pneumococci in 2%- 42% (median 8.9%) of DCCs 
attendees  
Melander, 2004 
(109) 
Sweden DCCs - Average 1.6 contact cases per index case 1-6 yrs old, 3.46 in DCCs. Number of contacts in DCC 
between 0 (24% DCCs) and 25 (median 2).  
Nilsson, 2001 
(111) 
Sweden DCCs PCR Internationally recognized 9V clone found very stable. Other serogroups had diverse DNA types and 
resistance patterns, supporting the hypothesis that DCCs have a unique microenvironment 
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Table 4.4 Outbreak investigations on pneumococcal transmission  
Author, year (ref) Country Setting Molecular 
method* 
Key findings  
Other outbreak investigations 
Cane, 2014 (96) Argentina Neonatal 
care 
PFGE Report of two cases of neonatal sepsis with genetically identical pneumococci identified from the 
mother’s genital tract. 
CDC, 1995 (97) USA DCC - Two index children (4-7mo) in DCC. Same serogroup 19 in 3/38 DCC attendees. 
CDC, 2002 (98) USA DCC - Index child (11mo) in DCC. Same serogroup 14 in 10/22 DCC attendees. 
Cherian, 1994 
(99) 
USA DCC, family ribotyping Four index children (8-19mo). Identical 12F strain in 2/2 DCC attendees, 0/9 family members. 
Gupta, 2008 (102) UK School, 
family 
- Five index childen (4-5 yrs) in school with serotype 1. Serotype 1 found in 1/81 contacts 
Klugman, 1994 
(105) 
South 
Africa 
DCC, family MLEE Index child (3yrs) in DCC. Identical 23F isolates in sibling, mother, 2/28 DCC attendees and their 2 
siblings. 
Lamaro-Cardoso, 
2012 (106) 
Brazil School, 
DCC, family 
MLST Index child (10yrs) linked to younger brothers DCC. Identical 22F/A strain in 8/111 DCC attendees. 
Lauderdale, 2005 
(107) 
Taiwan Kindergarten, 
family 
PFGE Index child (5 yrs) in DCC. Identical 19F strain in 10/78 DCC attendees, not found in family of index 
case. 
Reichler, 1992 
(112) 
USA DCC, family - Index child (17mo) in DCC. Identical MDR 23F strain in 52/250 DCC attendees and 17/119 family 
members of DCC attendees. No carriers found in 121 children in two nearby DCCs.  
Shouval, 2010 
(113) 
Israel DCC PFGE Index child (20mo) in DCC. Identical 19A clone in 3/5 DCC attendees. 
Simpson, 1995 
(114) 
UK Neonatal 
care 
- 11 neonatal cases in 11 years. Evidence of vertical transmission from 6/7 mothers sampled. 
62 | Chapter 4 
 
 
Table 4.4 Outbreak investigations on pneumococcal transmission  
Author, year (ref) Country Setting Molecular 
method* 
Key findings  
Zulz, 2013 (115) USA Community PFGE, 
MLST 
Outbreak of 12F in two neighbouring rural Alaska regions. Different 12F clones appear to have been 
introduced episodically into rural populations, spread widely in young, immunologically naïve 
populations and then disappeared rapidly from the population. After initial introduction in children, 
carriage was predominantly in adults.  
 
* MLEE: multi-locus enzyme electrophoresis, MLST: multi-locus sequence typing, PFGE: pulsed-field gel electrophoresis
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4.6 Longitudinal studies and case-control study 
 
Settings 
Thirty longitudinal studies were included (29 full text, 1 conference abstract), which 
studied pneumococcal carriage and transmission in DCCs (n=7) (117, 123, 136, 138, 
139, 143, 144), households (n=21) (7, 8, 116, 118-122, 125-129, 131-135, 140-142), 
orphanages (n=1) (137), or a combination of these settings (n=2) (124, 130). Amongst 
the household studies, eight studies (119, 121, 122, 131, 133, 134, 141, 142) looked at 
mother-infant pairs specifically, of which two studies (122, 133) looked at the difference 
between HIV-exposed and HIV-unexposed infants. The only case-control study (116) 
compared serotype distributions between children with IPD and healthy age-matched 
controls. Family exposure was only studied for the children with IPD and included a 
baseline and one month follow-up visit; this study will therefore be discussed alongside 
the longitudinal studies for the rest of this chapter. 
 
The included studies used data from a wide range of geographical locations. About half 
of the studies used data from a European country (n=8) (128-130, 135-139) or the USA 
(n=7) (117, 118, 120, 123, 126, 132, 140). Eight studies were conducted in African 
countries (8, 116, 119, 122, 127, 131, 133, 134). Other countries studied included 
Israel (124, 143), Bangladesh (7, 125), Papua New Guinea (121), Japan (144), Costa-
Rica (142) and the Thailand-Myanmar border (141).  
 
Study design 
The study interval ranged between twice weekly and trimonthly swabs. There were 
eight studies with a study interval of less than four weeks (8, 120, 121, 126, 127, 134, 
143, 144), 18 studies with a study interval of four weeks or more (116-119, 122, 124, 
128-133, 135, 136, 138-141), and five study which combined both study intervals over 
the total study time (7, 8, 125, 137, 142). The total follow-up period ranged between 
one month and 6.5 years. 
 
All studies collected nasopharyngeal samples. Other sample types included 
pharyngeal samples (120, 126) and saline nasal lavage (117). Serogroup data was 
available for five studies (116, 120, 126, 129, 138), serotype information was available 
for twenty studies (7, 8, 117, 119, 122-125, 127, 128, 130, 132-134, 136, 137, 139-141, 
143). Six studies did not use serogroup or serotype data to study transmission (118, 
121, 131, 135, 142, 144). Ten studies performed one or more additional microbiological 
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analyses on the collected samples, including PFGE (117, 118, 124, 137, 139, 144), 
ribotyping (123, 143), electrophoresis (117, 136), MLST (127) and PCR (143).  
 
The study size ranged between 6 and 1358 children under five years of age, with a 
mean of 217 and median of 134 children. On average, studies conducted in household 
settings (including on mother-infant pairs) were larger than studies conducted in DCCs 
or orphanages, or studies combining both settings (median size 171, 81.5, 72 
respectively).  
 
All but one study (133) on mother-infant pairs recruited the infants at birth. Also four of 
the thirteen other household studies started at birth of the index child (7, 8, 125, 129). 
First samples from infants were taken at birth (119, 134), within the first week (7, 8, 
121, 125), 6 weeks (122, 131), 1 month (141, 142), 2 months (129) or 4 months (133). 
The other household studies had an enrolment age between 4 months and 17 years. 
Age on enrolment was between birth and 4 years in the DCC, orphanage or mixed 
settings.   
 
Two studies were conducted post-introduction of pneumococcal conjugate vaccination 
(132, 140), the remainder of the studies involved vaccine-naïve children. 
 
Exposure definitions 
The included studies used different methods to define pneumococcal transmission or 
exposure. Eight studies defined transmission on molecular typing results, mostly by 
PFGE (117, 118, 123, 136, 137, 139, 143, 144): they defined transmission as occurring 
when two or more identical strains were isolated from the same DCC or household. 
The remainder of studies base their conclusions on serogrouping or serotyping results. 
Definitions using different timings for exposure have been used. Six studies defined 
pneumococcal exposure as occurring when household or DCC members carry the 
same serotype at the same sample time (127-129, 133, 134, 142). A disadvantage of 
this definition is that the direction of transmission cannot be identified: it is unclear 
whether transmission occurred from the household member to the index child or from 
the index child to the household member. Also simultaneous acquisition from a third 
person is possible. To overcome this problem, six studies only consider previous 
carriage as exposure: carriage with the same serogroup/serotype in the previous 30 
days (8, 130, 132), one or two months (125), 3 months (138) or 12 weeks (120). Two 
studies compared carriage of any serotype: in the previous month (135) or at time of 
delivery in a mother-infant study (121). Three studies combined both definitions, and 
defined exposure as carriage by a DCC or household member on the same or previous 
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sample time (119, 124, 141). There were three studies which considered exposure by 
a DCC or household member, but did not specify which time period was applied (126, 
131, 140).  
 
Findings – DCCs and orphanage 
Several studies indicate that DCCs can play a major role in the spread of pneumococci 
(Table 4.5). In two studies involving multiple DCCs was reported that each DCC had a 
distinct pattern of pneumococcal serotypes (123, 130), suggesting that DCCs are 
“independent microenvironments” (123). On the other hand, no significant differences 
between DDCs could be detected in a study performed in Sweden (138).  
 
Spread of pneumococcal serotypes in DCCs is reported in all studies, reporting 
colonization up to 68-76% (137, 139, 143). The most common serogroups/types 
reported to spread in DCCs were 6/6B (123, 137, 138, 143), 14 (123, 137, 138), 
19/19F (123, 130, 137-139) and 23/23F (123, 136-138, 143). Two studies mention that 
it is also likely that horizontal transmission of genetic information has occurred in the 
studied DCCs (117, 136). Only one study reported that just one episode of child-to-
child transmission was recognized and that clusters of infection could not be 
measured, but this could be a result of the small study size (n=6) (144).  
 
A measure of association for carriage in index child and carriage in the DCC and/or the 
household on the previous time point was only reported by one study: this was 
estimated to be RR 5.3 (95%CI  2.9-10.0) for carriage in both household and DCC and 
RR 5.4 (95%CI 3.6-8.2) for carriage in DCC only (130). 
 
Pneumococci can spread from DCCs into households, and become a risk for young 
siblings: when 262 children from 8 DCCs and their 46 younger sibling were studied in 
Israel, the younger siblings were colonized with an identical strain that was present in 
the older sibling’s DCC in 76% vs. another DCC in 32-63% (RR 1.47, 95%CI: 1.34-
1.62) (124).  
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Table 4.5 Longitudinal studies on pneumococcal transmission in DCCs  
Author, 
year (ref) 
Country Population, 
setting 
Sample 
interval 
Exposure definition Findings (95%CI) 
Barnes, 
1995 (117) 
USA 92 children in 1 
DCC 
Monthly Identical strain on 
electrophoresis, PFGE 
Multi drug resistant clone 23F in 14 children over 20 
months. Horizontal transmission of genetic information 
likely. 
Givon-Lavi, 
1999 (123) 
USA 264 children in 8 
DCCs 
Monthly Identical strain on ribotyping Each day care center had a unique pattern of the carried 
pneumococci. 
Givon-Lavi, 
2002 (124) 
Israel 262 children in 8 
DCCs, 46 
younger siblings  
Monthly, 
bimonthly  
Identical strain on PFGE Identical strain from older sibling in 38%, from older 
sibling’s DCC 76%, from other DCC 32-63%. 
Leino, 2008 
(130) 
Finland 59 children in 3 
DCCs and their 
family  
Monthly Same serotype, previous time 
point(s) 
Each DCC dominated by one serotype. Relative rate 5.3 
(2.9-10.0) for carriage in both family and DCC, 5.4 (3.6-
8.2) for carriage in DCC only. Carriage in family only not 
possible to assess. Index child responsible for 66% of 
new introductions to family.   
Pons, 1996 
(136) 
France 116 children in 
one DCC 
Bimonthly Identical strain on 
electrophoresis 
Evidence of within DCC spread of resistant strains, no 
evidence for susceptible strains. 
Raymond, 
2000 (137) 
France 71 children in 
one orphanage 
Monthly, 
biweekly  
Identical strain on PFGE Clones rapidly spread in the orphanage and were then 
eliminated. Transmission of 4 main clones (serotype 6B, 
14, 19F, 23F). Serotype 23F colonized 76% of the 
children. 
Rosen, 
1984 (138) 
Sweden 405 children in 
66 DCCs 
Monthly  Number of children carrying a 
newly introduced type  
Group 6 isolated in average 3.6 children in the first month 
after initial appearance: 2.6, 2.8, 3.2 for groups 14, 19 and 
23, respectively. No significant differences between 
DCCs. 
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Table 4.5 Longitudinal studies on pneumococcal transmission in DCCs  
Author, 
year (ref) 
Country Population, 
setting 
Sample 
interval 
Exposure definition Findings (95%CI) 
Sa-Leao, 
2008 (139) 
Portugal 47 children in 
one DCC 
3-9 
weekly  
Identical strain on PFGE 21 clones detected. One 19F clone colonised 68% of 
children. 
Yagupsky, 
1998 (143) 
Israel 48 children in 
one DCC 
Biweekly  Identical strain on ribotyping/ 
PCR 
One 23F clone colonised 11 (37%) and 13 (72%) children 
in the two cohorts. One 6B close in 14 (47%) children of 
one cohort and 2 (11%) in other cohort. 
Yano, 2000 
(144) 
Japan 6 children (7mo-
6yrs) in one 
DCC 
Irregular Identical strain on PFGE One episode of child-to-child transmission recognized.  
Clusters of infection could not be measured. Strains 
changed with time in each child. 
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Findings – Mother-infant pairs 
Eight studies (119, 121, 122, 133, 134, 141, 142) looked at pneumococcal acquisition 
in mother-infant pairs (Table 4.6). Two studies discussed the effect of colonisation of 
the mother at time of delivery. One study found that maternal carriage at delivery was a 
risk factor for earlier onset of pneumococcal carriage in the first four weeks of life (aHR 
2.60; 95% CI 1.25-5.39; p=0.01) (121). These results were not repeated in another 
study which looked at earlier onset of pneumococcal carriage in the first 24 months of 
life (aHR 1.19, 95% CI 0.84-1.69) (141).  
 
Three studies report that infants carried different pneumococcal serotypes than their 
mothers. In a study performed in The Gambia, 80.6% of infants had a discordant 
serotype with their mothers (134). Also at the Thailand-Myanmar border, only in 5.9% 
of mother-infant swabs a common serotype was identified. Concordant serotype 
carriage was found to be less common as infant age increased (p=0.02), which could 
indicate that transmission occurred more frequently from the mother in the early 
months of life. (141). In Costa Rica, only 2 out of 30 (7%) infants colonised at 6 months 
and 9 out of 37 (24%) infants colonised at 12 months had simultaneous carriage (any 
type) with their mother. Further microbiological and epidemiological investigations 
suggested that siblings were the main source of pneumococcal acquisition in the 
infants (142).  
 
In a study in The Gambia, carrying a specific serotype if the mother carried this type at 
any previous point was associated with an OR of 9.1 (95% CI 6.4-13.6). Still, the 
population attributable fraction (PAF) of maternal carriage, the contribution of mother-
to-child transmission to infant carriage of a specify serotype was only 9.5% (95% CI 
7.4-11.6%), suggesting that reducing mother-infant transmission would have a minimal 
effect on infant carriage (119). There was no evidence that this effect differed by infant 
age. A smaller effect was found for PCV-13 serotypes (OR=5.4, 95%CI: 3.1-9.6, 
PAF=7.0%, 95% CI: 4.4-9.6%) than for non-PCV-13 serotypes (OR=14.1, 95%CI: 8.4-
23.5, PAF=13.3, 95%CI 9.5-17.3%) (119). Simultaneous maternal pneumococcal 
colonization (aOR 1.54, 95%CI 1.10-2.14) was also associated with pneumococcal 
carriage in the child in a study conducted in South Africa, but in contrast to the 
Gambian study, a larger effect for PCV-13 serotypes was reported (aOR 2.36, 95%CI 
1.55-3.57), with similar results for both HIV-exposed and HIV-unexposed infants (133). 
Weak evidence for maternal carriage at any time point being a risk factor for infant 
carriage at any time point was found in a study in Tanzania (131).  
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Two studies specifically looked at the difference in pneumococcal acquisition between 
infants born to HIV-positive and HIV-negative mothers in Zambia (122) and South 
Africa (133). One study did not find a difference the incidence of new pneumococcal 
acquisition; 272 new events/554 swabs (49.1%) in HIV-exposed vs. 302 new events/ 
581 swabs (52.0%) in HIV-unexposed infants (133), although a difference in 
prevalence of pneumococcal colonization in HIV-exposed children at 4-monhts of age 
was found (65% in HIV-exposed vs. 52% in HIV-unexposed children, p=0.04) (133). 
The other study also found that HIV-exposed infants were more likely to be colonized 
than HIV-unexposed infants (25.3% versus 18.1%, RR: 1.4; 95% CI: 1.0–1.9, p=0.04) 
(122).  
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Table 4.6 Longitudinal studies on pneumococcal transmission in mother/infant pairs 
Author, year 
(ref) 
Country n Sample 
interval 
Exposure definition Findings  
Darboe, 2010 
(119) 
The 
Gambia 
196  Birth, 2,5, 12 
months 
Same serotype, any 
time points 
Ever carrying serotype if mother carried: OR=9.1 (6.4-13.6)  PAF = 9.5% (7.4-
11.6): maternal carriage accounts for small percentage infant carriage. 
Francis, 2009 
(121) 
Papua New 
Guinea 
89  Weekly  Maternal carriage at 
delivery 
Maternal pneumococcal carriage at the time of delivery risk factor for early 
acquisition (HR 1.97; 95%CI 1.01-3.85; p=0.046). 
Gill, 2008 (122) Zambia 260 Trimonthly Difference HIV-exposed 
vs HIV-unexposed 
infants 
HIV-exposed infants colonized more frequently than HIV-unexposed infants (RR: 
1.4; 95% CI: 1.0–1.9, p=0.04) 
Kinabo, 2013 
(131) 
Tanzania 338 3 wks, 3mo, 
6mo (mother 
only once) 
Any type, any time 
point  
OR 2.6 (95%CI 0.9-7.5) for carriage in the infant when the mother carried any type 
pneumococci at any time point  
Nunes, 2013 
(133) 
South 
Africa 
243 4, 7, 9, 12, 16 
months 
Any type, simultaneous 
carriage 
Maternal colonisation associated with pneumococcal acquisition in child (aOR 
1.54). New acquisition of PCV-7 or PCV-13 serotype in mother associated with 
colonization in child (aOR 2.01, aOR 2.04). 
Ogundare, 
2012 (134) 
The 
Gambia 
36  Biweekly  Same type, 
simultaneous carriage 
80.6% of infants had a discordant serotype with their mothers 
Turner, 2012 
(141) 
Thailand/ 
Myanmar 
234  Monthly Simultaneous carriage. 
Mother colonized at 
birth.  
Concordant serotype at same time in 5.9%. Less common as infant age increased 
(p=0.02). Mother colonized at birth associated with infant carriage: aOR 1.19 
(0.84-1.69) 
Vives, 1997 
(142) 
Costa Rica 95 1,3,6,12 
months 
Simultaneous carriage  2 mother-infant pairs colonised at 6 months, 9 pairs colonised at 12 month. Infants 
with siblings had a higher carriage than children without siblings. 
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Findings – Household studies 
The first included longitudinal studies on household spread of pneumococci date back 
to the 1970s (120, 126), with Gwaltney et al. reporting on 25 episodes of spread from 
one family member in a study of fifteen families with children observed for one year 
(126), and Dowling et al. reporting age-specific risks from community and household 
exposure (p<0.001, actual risk estimates not reported) (120). 
 
Four studies concluded that new serotypes were most frequently introduced in the 
household by children (127, 128, 130, 132). In 66% (61/92) of new events the 
pneumococcus was introduced by an index child attending DCC in Finland (130) and in 
76% (81/106) of households in The Gambia carriage was first observed in a child <15 
years (127). Age-specific estimates for introduction were reported in a study in the UK: 
25% of pneumococci types were introduced by children under one year of age, 20% by 
children aged 1 year, 19% by children aged 2 years, 5.5% by 3-4 year-olds and 1% by 
5-17 year-olds (128). A study conducted in the USA after routine introduction of 
pneumococcal conjugate vaccination concluded that the rate of new household 
introduction was 3–5 times higher in children <9 years as compared to adults (132).  
 
Four studies compared the serotype distribution amongst households (127) or amongst 
family members (7, 116, 118). Strong evidence of non-random distribution of serotypes 
among households was found, suggesting that within-household transmission is 
important (127). Two studies conclude that the serotype distribution of the index 
children is most similar to their siblings < 5yrs old, suggesting sibling-to-sibling spread 
(7, 116).  No evidence of intrafamilial spread was found in the study considering 30 
cystic fibrosis patients and their families in the USA (118). 
 
Eight studies report risk estimates for acquisition of carriage in children <5 years by 
family exposure status (8, 125, 127-129, 132, 135, 140) (Table 4.7). Seven studies 
report a positive association between pneumococcal carriage in the index child and 
pneumococcal carriage in other household members (8, 125, 127-129, 132, 135, 140). 
Age-specific results are reported for two studies, with higher estimates reported for 
children ≤ 6 months (OR 3.8, 95%CI: 2.1-6.9), as compared to children >6 months (OR 
0.7, 95%CI: 0.3-2.1) (129), and higher estimates reported for 0-2 year-olds (RR 1.42 
(95%CI: 1.26-1.61) as compared to 3-4 year-olds (RR 1.25, 95%CI: 0.95-1.64) (128).  
  
A study performed in Bangladesh reported profound differences between family 
exposure to the same, or a different serotype in the previous two (biweekly or monthly) 
study visits: a large positive association (HR 7.97, 95% CI: 4.89-13.00) was reported 
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for exposure to homologous serotypes, whereas a protective effect (HR 0.66, 95%CI: 
0.49-0.89) was reported for exposure to heterologous carriage in the household, 
indicating that competitive interaction between serotypes occurred (125).  
 
A large study conducted in Kenya, including 1358 infants and their family members, 
reported that mothers and siblings were equally effective in transmitting pneumococci 
to the infants (hazard rate per 30-day period: 0.27, 95%CI 0.19-0.40 (mother), 0.27, 
95%CI: 0.23-0.32 (sibling)). No difference was observed for the age of siblings 0-9 
years (8).  
 
Carriage by another family member at the previous visit was not associated with 
carriage in the index child in an multivariable analysis performed in the UK (aOR 0.89 
(95% CI: 0.69–1.14). However, in their multilevel model with individual- and family-level 
random effects, the family-level random effect was of similar size to the individual-level 
random effect, indicating that variability not accounted for in the model could be 
explained by family transmission (135). 
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Table 4.7 Longitudinal studies on pneumococcal transmission in households 
Author, 
year (ref) 
Country Child 
population 
Sample 
interval 
Exposure 
definition 
Findings (95%CI) 
Studies reporting measure of association for exposure of household members to acquisition in children <5 years 
Granat, 
2009 (125) 
Bangladesh 99 infants Biweekly, 
monthly  
Same type, 
simultaneous 
Family exposure to carriage of the same serotype: HR 7.97(4.89-13.00) 
Family exposure to carriage of another serotype: HR 0.66 (0.49-0.89)  
Hill, 2010 
(127) 
The 
Gambia 
56 children 
<5 yrs 
Biweekly  Same type, 
simultaneous 
Serotype specific results, ranging between OR 0.7 (0.4-1.2) for serotype 23F and OR 
2.7 (1.3-5.6) for serotype 19A for child carriers in family. Effect adult carriers ranging 
between OR 0.7 (0.3-1.4) for serotype 11 and 5.5 (0.9-33.1) for serotype 23B.  
Hussain, 
2005 (128) 
UK 151 children 
<3 yrs  
Monthly Same type, 
simultaneous 
Family exposure: RR 1.42 (1.26-1.61) for 0-2-year-olds, RR 1.25 (0.95-1.64) for 3-4 
year olds 
Leino, 2001 
(129) 
Finland 100 infants 1-6 monthly Same group, 
simultaneous 
Family exposure: OR 3.8 (2.1-6.9) for children ≤ 6 months, OR 0.7 (0.3-2.1) for children 
>6 months. 
Mosser, 
2014 (132) 
USA 545 children 
<5 yrs 
Monthly Same type, 
previous time 
point 
Exposure by child 2-8 years OR 3.80 (1.66-8.70) for serotype 19A, OR 6.93 (2.16-
22.19) for serotype 22F. Non-significant results for exposure by children <2 years or 
adults 
Pebody, 
2009 (135)  
UK 181 children 
<5 yrs  
Monthly Same type, 
previous time 
point(s) 
Family exposure:  aOR 0.89 (95% CI: 0.69–1.14) 
Scott, 2012 
(140) 
USA 459 children 
<5 years 
Monthly Unclear Exposure to a colonized child aged <9 years: aOR = 3.6 (2.90-4.51) 
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Table 4.7 Longitudinal studies on pneumococcal transmission in households 
Author, 
year (ref) 
Country Child 
population 
Sample 
interval 
Exposure 
definition 
Findings (95%CI) 
Tigoi, 2012 
(8) 
Kenya 1358 
newborns 
Twice 
weekly, 
weekly  
 
Same type, 
previous time 
point(s) 
Family exposure: hazard rate per 30-day period: 0.26 (0.23-0.31), exposure by mother: 
0.27 (0.19-0.40), father: 0.10 (0.03-0.56), siblings: 0.27 (0.23-0.32). No difference for 
age of siblings 0-9 years. Serotype-specific hazard rates per 30-day period, ranging 
between 0.04 (0.01-0.39) for serotype 3 and 0.58 (0.20-1.98) for serotype 19B.    
Studies not reporting measure of association for exposure of household members to acquisition in children <5 years 
Chidekel, 
2000 (118) 
USA 30 CF 
patients 1-17 
yrs 
Three-
monthly 
 
Determined 
by PFGE 
No evidence of intrafamilial spread 
Dowling, 
1971 (120) 
USA 97 children 
<5 years 
Biweekly Same type, 
previous time 
point(s) 
Age-specific risk of acquisition from household and community was significantly 
different from zero for each serotype.  
Granat, 
2007 (7) 
Bangladesh 99 infants Biweekly, 
monthly  
Serotype 
distribution 
Serotype distribution similar in <1 year and 1-4 year-old children but different from 
adults. 
Gwaltney, 
1975 (126) 
USA 18 children 
<5 yrs, 105 
children (age 
unspecified) 
Biweekly, 
weekly  
 
Same type 25 episodes of spread from one family member to another noted.  
 
Systematic literature review      75 	
 
Table 4.7 Longitudinal studies on pneumococcal transmission in households 
Author, 
year (ref) 
Country Child 
population 
Sample 
interval 
Exposure 
definition 
Findings (95%CI) 
LloydEvans 
1996 (116) 
The 
Gambia  
81 children 
with IPD (age 
unspecified) 
Within two 
days of IPD 
diagnosis, 
one month 
later 
Same type 8.5% (initial), 9.4% (follow-up) of family members of index cases carried same 
serotype. 65.3% of carriers same type were siblings <5 yrs, 2.8% mothers.  
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4.7 Mathematical modelling studies 
 
Settings 
Eighteen mathematical modelling studies were included in this review (Table 4.5). Six 
studied the transmission of pneumococci in DCCs (145, 147, 150, 155, 159, 160), two 
in schools (148, 149), six in households (146, 152, 157, 158, 161, 162), three in both 
DCCs or schools and households (152, 154, 156), and one selected their study 
participants from the community (151). Intervention strategies were modelled in two 
studies, looking at the impact of excluding carriers of penicillin-resistant pneumococci 
from DCC (145, 156), reducing DCC group size (156) and reducing the proportion of 
the population attending DCC (156). None of the included studies modelled the impact 
of vaccination on transmission in households, schools or DCCs.  
 
The models included empirical data from, or simulated data based on Scandinavian 
countries (n=9) (145-147, 151, 152, 154, 156, 159, 160), UK (n=2) (157, 158), USA 
(n=2) (155, 161), France (n=3) (148-150), South Africa (n=1) (162) and Bangladesh 
(n=2) (152, 153).  
 
Methods - Model structure 
Most studies adopted a “susceptible-infectious-susceptible” (SIS) structure, assuming 
an individual does not gain immunity from pneumococcal colonisation, and not taking 
into account symptomatic infection by pneumococci (146-160, 162). Only one study 
assumed that some individuals were immune to carriage of the study serotype (161), 
and only one study took infection by pneumococci into account (145). There were eight 
age-structured models, with different parameters for children and adults (152-154, 157, 
158, 162), or age-groups within the child population (146, 151, 156). The studies that 
did not have an age-structure included young children only (145, 147-150, 155, 159-
161).  
 
Most models used a stochastic approach to model pneumococcal transmission, taking 
into account the role of chance in transmission patterns (145, 146, 148, 149, 151, 152, 
154, 156-162). Deterministic models were used by three studies (147, 150, 155). 
Fifteen studies used an individual-based approach, keeping track of individual 
acquisition and clearance of pneumococci (146-149, 151-154, 156-162). Three studies 
used aggregate data in a compartmental model (145, 150, 155).  
 
Systematic literature review       77 	
 
Thirteen models included pneumococcal serotypes in their model structure (146-150, 
152-154, 158-162), including between one (161) and 33 (159) different serotypes. One 
study distinguished between PCV-7 and non-PCV-7 serotypes (149), the remainder of 
studies included the most prevalent serotypes. Five studies did not consider serotype-
specific data in their models (145, 151, 155-157). Only two studies allowed for co-
colonization with multiple serotypes (147, 159).  
 
Methods - Definitions and assumptions made 
All studies had to make several assumptions to simplify reality in a mathematical 
model. Assumptions were for instance made on the possibility of carriage or clearance 
events occurring within a certain order or time span: one study assumed that two 
carriages of different serotypes must be separated by a period of non-carriage (146) 
and one study assumed that maximum one acquisition per susceptible occurred during 
a one month period (149). Two studies using the same dataset broke the data down in 
small time intervals of one day, and assumed that only one household member would 
change status in this period (157, 158).  
 
Assumptions about serotype-specific behaviour were made in all studies including 
serotype-specific results. All but two studies (147, 159) assumed that simultaneous 
carriage of multiple serotypes is not possible. Five studies assumed that acquisition 
and clearance rates are the same for all serotypes studied, for the total study 
population (146, 154, 159, 160), or for adults only (153). One study set parameters for 
within-DCC transmission as serotype-specific, but assumed the same parameter for 
transmission outside the DCC for all serotypes (150). 
 
Methods - Model fitting to data 
Two studies fitted models to simulated data (155, 156), the remainder of model used 
empirical data. Fifteen studies used data from longitudinal studies (145-154, 157, 158, 
160-162), one study used cross-sectional data (159). Goodness of fit was assessed by 
maximum likelihood estimation (145, 150, 151, 157, 158, 161) or Bayesian Markov 
Chain Monte Carlo (MCMC) methods (146-149, 152-154, 160, 162). One study used 
approximate Bayesian computation (ABC), in which summary statistics are used to 
approximate the likelihood (159). 
 
All studies involving empirical longitudinal data encounter the problem of unobserved 
transitions: most longitudinal studies had a monthly sample interval, implicating that the 
exact time of acquisition or clearance of a pneumococcal serotype could not be 
determined. Also, scenarios are plausible, in which a pneumococcal serotype was 
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acquired, and cleared again within the same month, thus never showing in the actual 
samples. Likewise, carried pneumococci could be cleared, and reacquired within the 
same month. To overcome this problem of unobserved transitions, five studies used 
MCMC data augmentation to impute unknown intermediate states (146, 148, 149, 152, 
153).  
 
Methods - Sensitivity analysis and validation 
All mathematical models inherently include some degree of uncertainty about the data, 
the parameters and model structure used. To deal with uncertainty about unobserved 
transitions in the data, MCMC data augmentation was used, as discussed above.  
Sensitivity analysis, in which the effect of different values of the included parameters is 
studied, was used by five studies (148, 155, 156, 158, 162). Six Bayesian studies 
performed a predictive check using simulated data (148, 152-154, 159, 160). Different 
model structures were tested in five studies, looking at density-dependency (146), 
heterogeneity in community-acquisition rates across families (146) or schools (149), 
serotype-specific results (147) or different combinations of regression and association 
models (151).  
 
Findings - Transmission  
Transmission of pneumococci occurred in all three settings investigated in the included 
studies; at DCC, household and community level. Children are most likely to introduce 
pneumococci into the household, especially when they are DCC attendees (154, 157, 
158, 162). In Finnish families, 82% of new serotypes were introduced by DCC 
attendees, and in 71% this acquisition could be traced back to a fellow DCC attendee 
(154). Once a serotype has been introduced, within-household transmission frequently 
occurs, with reported risk ratios for carriage in the family as high as 8.7 for 0-2 yrs and 
4.2 for 2-5 yrs (146). The presence of one carrier in a family of four resulted in a 
conditional acquisition rate roughly 12-fold as compared to a situation with no carriers 
in the family (152, 153).  
 
Surprisingly, one UK modelling study found that within the household, the highest daily 
transmission rate was from adults to children, not amongst siblings (158). This could be 
a result of the small family sizes studied (mostly 3 to 4 members). Indeed, the expected 
prevalence in children increased by 3-10% for each additional child in the household 
(158). In young children in South Africa, child-to-child transmission was found to be 
more important than mother-to-child transmission, accounting for 51-67% versus 4-
17% of all transmissions, respectively (162). Other studies did not report on the relative 
importance of pneumococcal transmission by parents or siblings.  
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One study found no carriage in 40 out of 97 families with newborn infants, concluding 
that transmission within families dominates over transmission from the population 
(146). Yet, other studies dispute this conclusion, and reported that the majority of 
acquisitions in children under five come from outside the household: 50-60% in the UK 
(157), 62% in the USA (161) and 90% in Finland (of which 65% from the child’s DCC 
and 25% from the community) (154). The Finnish study reported slightly higher 
transmission rates for within-DCC as compared to within-household transmission 
(0.53/month (90%CI 0.38-0.71) and 0.37/month (90%CI 0.23-0.52)), but a large 
difference in the average time it takes for a carrying child to infect another DCC or 
family member (1.9 versus 4.5 months).  
 
The relative rate for exposure in DCC was estimated to be 2.7 (95% CI: 1.7, 4.4) in 
Danish DCCs (147). In three Finnish DCCs, a mean number of 7.5 serotypes was 
reported, with an average of 2.7 new serotypes introduced into the DCC per month 
(154). A simulation study based on USA data reported that children attending DCC had 
2.2-2.4 times higher odds to carry pneumococci as compared to children not attending 
DCC (155). Also a profound indirect effect of DCC attendance was reported: children 
not attending DCC but living in an area in which a fraction of children attended DCC 
had 3.7-5.8 higher odds of carrying pneumococci as compared to children in a 
hypothetical community where no DCCs were present. These effects were highly 
dependent on the proportion of attending children and the hours per week spent in 
DCC. Combining both indirect and direct effects, the total OR was 7.3 in a community 
where 44% of children attend DCC.  
 
Comparing DCCs in Finland and Portugal, within-room and community transmission 
were found to be higher in Portugal, resulting in higher pneumococcal carriage 
prevalence (160).  
 
Only one study reported that household contacts with siblings were more important to 
understand pneumococcal transmission than DCC attendance: for index children 
without siblings, DCC attendance increased the odds for carriage almost three times, 
but for children with siblings the effect of day-care was negligible (151). 
 
Findings - Interventions  
Two studies looked at the impact of the South Swedish Pneumococcal Intervention 
Project, in which carriers of penicillin-resistant pneumococci were excluded from DCC 
until a negative swab was obtained (145, 156). This approach was found most effective 
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in larger groups and in the second half of the year, due to seasonal variation with a 
peak in September (145). One of the studies compared this approach to two different 
interventions: reducing DCC group size and reducing the proportion of the population 
attending DCC (156). Reducing DCC group size was found to be most efficient to 
reduce spread of penicillin-resistant pneumococci: reducing the average group size 
from 16.7 to 13.4 was estimated to result in a decline of transmission events by 82%. 
Increasing average group size from 16.7 to 17.2 resulted in a mean increase of 20%. 
The same 82% reduction in transmission events was also reached by excluding 15% of 
penicillin-resistant pneumococci carriers from DCC. This approach was deemed less 
favourable, however, because of the economical and social costs associated with 
having parents staying away from work for an unknown period of time.   
 
Findings - Serotype-specific results 
Four out of five studies which compared transmissibility amongst serotypes reported 
that serotypes differed in transmissibility, either from the community (148, 153), within-
household (157) or within-DCC (150). Serotypes 6A (148, 150, 153, 157), 19A (148, 
150), 19F (high in (148, 153), medium in (157)) and 3 (148, 150) were consistently 
reported to be more transmissible than other serotypes. Serotype 9V was consistently 
reported to be less transmissible than other serotypes (148, 150). Conflicting results 
were reported for serotype 14 (high (148, 157), low in (150)), serotype 6B (high in (148, 
153), low in (157)) and 23F (high in (148), medium in (157), low in (150, 153)). One 
study reported that antibiotic susceptibility can affect the transmissibility of strains 
within some serotype, with susceptible strains reported to be more epidemic than 
resistant strains for serotypes 6A and 19F (150). No difference between the 
transmissibility of serotypes was reported between PCV-7 and non-PCV-7 serotypes 
(149), which could be explained by the serotype-specific results reported above: the 
transmissibility of individual PCV-7 serotypes was reported to be high (19F), low (9V) 
or inconsistent (23F, 6B).  
 
There is evidence for between-serotype competition, with current pneumococcal 
carriage reducing acquisition of other serotypes (153, 154, 159, 160). One study found 
that in particular serotype 6B reduced susceptibility to other serotypes, resulting in 
longer period of carriage (157). One study including multiple carriage showed that in 
individuals carrying multiple serotypes did not clear carriage quicker than single 
carriers (RR 0.81 95%CI 0.48-1.26), indicating that the presence of another serotype 
does not affect clearance (147).  
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Table 4.8 Mathematical modelling studies on pneumococcal transmission  
Author, year (ref) Country Setting Findings (95%CI) 
Andersson, 2005 (145) Sweden DCCs with 
control strategy 
DDC group size important for likelihood and size of an outbreak. Intervention measures have impact, 
mostly in large groups. 
Auranen, 2000 (146) Sweden Households No carriage in 40 of 97 families: carriage is clustered in some families. Association carriage in family 
RR 8.7 for 0-2 yrs, RR 4.2 for 2-5 yrs. Temporal clustering of pneumococcal carriage within families: 
transmission within families dominates transmission from population 
Auranen, 2010(147) Denmark DCCs Exposure in DCC: RR 2.7 (1.7-4.4) 
Cauchemez, 2006 (148) 
(149) 
France Schools No difference between VT and NVT for child-child transmission rate 
De Celles 2011 (150) France DCC Transmissibility differs by serotype: 3, 6A, 19A most epidemic, 23F,9V, 14 least epidemic 
Ekholm, 2002 (151) Finland Community Interaction between siblings/DCC: if the child does not have siblings at home, then the effect of DCC 
increases the odds for carriage by a factor of 3, but if the child has siblings at home, the effect of DCC 
is negligible. 
Erasto 2010 (153) (152) Bangladesh Households Within-family transmission rates similar between different serotypes. Acquisition rate in presence of 
household exposure was roughly 12-fold the community force of infection. Evidence for between-
serotype competition: current pneumococcal carriage reduced acquisition of other serotypes 
Hoti, 2009 (154) Finland DCC and 
households 
Transmission in DCC driving force. Role of families minimal, because small size and lower 
susceptibility of adults 
Huang, 2005 (155) USA DCC Children in communities with higher fractions of DCC attendees have higher prevalence.  
Karlsson, 2008 (156) Sweden DCC, school, 
households 
Reducing DCC group size most efficient intervention to reduce pneumococcal transmission. 
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Table 4.8 Mathematical modelling studies on pneumococcal transmission  
Author, year (ref) Country Setting Findings (95%CI) 
Melegaro, 2004 (158) UK Households Children most likely to introduce pneumococci into household 
Within-household highest daily transmission rate is from adults to children 
Melegaro, 2007 (157) UK Households For all serotypes, acquisition rates from the community significantly higher in preschool children than 
older individuals. 
Numminen, 2013 (159)  Norway DCC Evidence for strong between-strain competition. 
Pessoa, 2013 (160) Portugal, 
Finland 
DCC Significant higher within-room and community acquisition in Portugal as compared to Finland 
Sheehe, 1969 (161) USA Households Of 50 acquisitions among the cohort of pre-school children, 62% came from outside household, 38% 
from within household.  
Shiri, 2013 (162) South Africa Mother-infant 
pairs 
Children infected their mothers more frequently than vice versa. Mothers acquire pneumococci more 
frequently from their children than from the community. 
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4.8 Discussion 
 
Comparison of study designs 
We compared the methodology and results of 103 studies: 34 cross-sectional studies, 
20 outbreak investigations, 1 case-control study, 30 longitudinal studies and 18 
mathematical modelling studies. The different study designs pose different advantages 
and disadvantages. Cross-sectional studies have as advantage that they are generally 
easier to conduct than longitudinal studies, and therefore allow for a larger sample 
size. In the included studies, the cross-sectional studies had a median sample size of 
380, versus a median sample size of 134 children amongst the longitudinal studies.  
 
The main disadvantage of cross-sectional studies is that limited conclusions can be 
made on transmission. Although most studies included in this review assume that 
‘transmission’ occurred when the same pneumococcal serotype or clone was found 
within a DCC or household, it would be more accurate to speak of ‘co-localisation’. 
Assuming that transmission occurs when the same serotype or clone is detected, 
another disadvantage of cross-sectional studies is that the direction of transmission 
cannot be identified. Especially in household studies, it is unclear whether transmission 
occurred from the household member to the index child or from the index child to the 
household member. Even simultaneous acquisition from a third person cannot be ruled 
out. The same problem holds true for longitudinal studies with definitions of exposure 
based on simultaneous carriage. Preferred is a serotype specific definition for exposure 
based on previous time points to allow for conclusions of the direction of transmission.  
 
The study interval used in longitudinal studies has direct implications on the 
conclusions made. If the interval between swabs is long, episodes of carriage can be 
missed, resulting in an underestimation of transmission. Especially in the adult 
population, known to carry pneumococci for shorter periods of time, episodes of 
carriage can be overlooked. To overcome this problem, MCMC data augmentation can 
be used to impute unobserved transitions – an advantage of mathematical modelling 
studies. Another advantage of mathematical modelling studies is that the effect of 
interventions to reduce transmission can be studied.  
 
Stochastic, individual-based SIS mathematical models fitted to empirical longitudinal 
data were most commonly used. It is important to include stochasticity in a 
mathematical model designed to study household or DCC transmission: group sizes 
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are often small, making it more important to acknowledge the role of chance in 
transmission.  
 
Comparison of different settings 
Even though the included studies represent a reasonable geographical cover, with data 
from 30 different countries included, the majority of studies are from high-income 
countries, and the conclusions of this review may therefore represent a non-
representative view. There is a wide variation in social mixing patterns between 
different geographical regions and wide variation in family sizes and structures, which 
will have resulted in differences in pneumococcal carriage. Also differences in 
laboratory capacity and performance could have led to the differences in findings 
observed from different geographical settings.  
 
Most studies took place in DCCs or households or combination of both. Studies 
conducted in DCCs were almost solely from countries in high-income countries. All but 
one of the included African studies focused on household transmission only. With an 
official DCC structure lacking in many low-income societies, it would be interesting to 
see what the proportional attribution is of household versus child-to-child transmission. 
How do children under five interact with each other? How many child contacts does a 
child under five have in a society without a formal day care structure? What impact 
does this have on pneumococcal spread? A mixture of anthropological and 
epidemiological studies may be required to answer these questions, which are 
unfortunately outside the scope of this PhD. 
 
Community transmission is more difficult to study directly than transmission in closed 
settings, such as a DCC or household where contact patterns are better defined. When 
studies report on community transmission, it is usually inferred from pneumococcal 
acquisition that cannot be explained by the transmission in the household or DCC. 
Other evidence for community transmission comes from cross-sectional studies or 
outbreak investigations, which have found the same pneumococcal clone in different 
DCCs or distinct communities. International recognized strains with identical MLST 
types are proving evidence for international spread.  
 
Comparison of typing methods  
The majority of included studies presented serotyping results. Distinguishing between 
different serotypes is important to evaluate the strain’s potential invasiveness, and to 
evaluate the impact of pneumococcal conjugate vaccines, which target only specific 
serotypes. Distinguishing between different isolates of the same serotype can be done 
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with molecular typing methods, such as PFGE and MLST. Molecular typing methods 
were frequently used in the included cross-sectional studies (76%) and outbreak 
investigations (55%), but were less common in the included longitudinal studies (26%). 
None of the included mathematical modelling studies used molecular typing data.  
 
Conclusions 
 
Despite the different study designs, generic conclusions can be made (Table 4.9). Both 
transmission in DCCs and households are important to explain the spread of 
pneumococci. There is strong evidence that DDCs act as an amplifier of pneumococcal 
spread in the community. The average cluster size seems to be 3-4. There is some 
evidence that the cluster size is larger in outbreak situations with known invasive 
serotypes (median 6), but this could also be a result of reporting bias, with larger 
outbreaks being reported more frequently than small outbreaks.  
 
Strong evidence for transmission within households also exists, although on population 
level this seems to have a smaller impact than transmission within DCCs or the wider 
community. Young children most frequently introduce new serotypes into the 
household. Within households, sibling-to-sibling spread is reported more commonly 
than parent-to-child transmission. Child-to-parent transmission is also frequently 
reported. Younger infants seem to be affected most by intrafamilial spread, which is a 
plausible result of increased contact rate with other toddlers at older age, either in a 
DCC in developed countries, or in the neighbourhood in some African countries.  
 
The role of the mother in pneumococcal transmission to the infant remains uncertain. 
Almost all studies report an association between maternal and infant carriage, but the 
relative importance to sibling-to-sibling spread is doubtful. More studies on mother-
infants pairs including results for other siblings in the household are required to get a 
better picture of household transmission to young infants. HIV-exposure by the mother 
does not seem to have an effect on the incidence of new pneumococcal acquisition, 
although differences in prevalence of pneumococci in infants have been reported. 
Contradictory results have been reported for differences in maternal transmission of 
PCV-13 and non-PCV-13 serotypes. 
 
There is evidence for different transmissibility of serotypes, with serotypes 6A, 19F, 3 
consistently being reported as being more transmissible than other serotypes. Some 
caution needs to be taken in this statement, however: serotypes 6A and 19F are 
carried for longer duration as compared to other serotypes; frequent detection of 
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serotypes 6A and 19F in clusters may be a function of their long carriage duration, 
rather than with transmissibility. There is also evidence that competition between 
serotypes occurs: current carriage seems to reduce acquisition of other serotypes 
when exposed.  
 
Based on the results from this literature review, most acquisition in children <5 years is 
explained by transmission from other children <5 years; in DCCs and amongst siblings 
within the household. Within the household, children <5 years transmit to both their 
siblings and parents or other adults. Within household transmission from adults to 
children seems to be less important to explain pneumococcal transmission dynamics, 
even amongst mother-infant pairs. The best strategy to target effective transmitters and 
obtain herd immunity would be to focus on vaccination of all children under the age of 
five. Catch-up campaigns may be required for countries newly introducing the 
vaccination in the childhood immunisation programme, especially in high-incidence 
areas were transmission dynamics are rapid and children seem to be active 
transmitters until a higher age than in developed countries. If only targeting infants 
through childhood immunisation programmes, it could take many years for herd 
protection to be established. Randomised controlled trials in the Gambia seem to 
confirm this concern: no indirect benefits were seen for non-vaccinated siblings in a 
PCV-7 randomised controlled trial (68). In Kilifi District in Kenya, where a catch-up 
campaign was held for children <5 years, two-thirds reductions in VT were observed 
two years after vaccine introduction in children <5 years and unvaccinated older 
individuals, suggesting that a substantial herd effect is taking place in this setting (25). 
Surveillance and evaluation, through various study designs, will remain important to 
study the impact of the newly introduced vaccines, and the impact this has on 
transmission dynamics worldwide.    
 
Systematic literature review 87 	
 
Table 4.9 Summary of systematic literature review findings  
Findings Evidence* 
1.1 What is the evidence for pneumococcal transmission to and from children under five within 
the household?  
Children most frequently introduce serotypes into the household, especially 
when attending DCC. 
strong 
Carriage by another household member is a risk factor for pneumococcal 
acquisition. 
strong 
Intrafamilial spread is responsible for <50% of pneumococcal acquisitions in 
the index child. 
strong 
Younger children are more at risk of intrafamilial spread than older children. strong 
Siblings are important in intrafamilial spread to index children. intermediate 
HIV-exposure by the mother does not influences the rate of pneumococcal 
acquisition in the index child. 
intermediate 
Parents are important in intrafamilial spread to index children. inconsistent 
Mothers are important in spread to young infants. inconsistent 
The risk of pneumococcal acquisition increases within a larger household. inconsistent 
1.2 What is the evidence for pneumococcal transmission to and from children under five outside 
the household?  
DCCs are important amplifiers of pneumococcal spread. strong 
The average cluster size in DCCs is 3-4 individuals. strong 
The cluster size is higher for serotypes in outbreak situations (median 6). strong (bias?) 
DDCs are “autonomous epidemiological units” with different serotypes/clonal 
types circulating.  
intermediate 
The risk of pneumococcal acquisition increases within a larger DCC.   strong 
International spread occurs as can be concluded from internationally 
recognized clones 
strong 
1.3 Is there any evidence that pneumococcal transmission dynamics differ by geographical and 
cultural setting? 
Transmission in high-income countries is largely driven by DCCs. We don’t 
know how important child-to-child contact is in settings with low DCC 
attendance  
incomplete 
Children most commonly introduce new serotypes into the household. Because 
household composition differs worldwide, pneumococcal transmission 
dynamics within-household will differ between different geographical and 
cultural settings.   
incomplete 
1.4 Is there any evidence that pneumococcal transmission dynamics differ by serotype? 
Serotypes differ in transmissibility: 6A, 19F, 3 are more transmissible than 
other serotypes. 
strong 
Competition between serotypes occurs: current carriage reduces acquisition of 
other serotypes. 
strong 
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Table 4.9 Summary of systematic literature review findings  
Findings Evidence* 
1.5 What is the evidence for altered pneumococcal transmission dynamics post introduction of 
pneumococcal conjugate vaccination? 
Children remain the main drivers of NVT pneumococcal transmission within the 
household post introduction of PCV 
strong 
 
* Level of evidence based on proportion of studies reporting on topic in favour of hypothesis: 
strong = >80%, intermediate = 60-80%, inconsistent = 40-60%, no = <40%, incomplete = 1 or 
no studies 
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5. Pneumococcal acquisition in HIV-exposed and 
HIV-unexposed infants 
 
5.1 Background 
 
Our literature review (Chapter 4) provided inconclusive evidence for the role of the 
mother in pneumococcal transmission. Almost all studies reported an association 
between maternal and infant carriage, but the relative importance to sibling-to-sibling 
spread was doubtful. In this chapter we show the results of a study which investigated 
pneumococcal acquisition in HIV-exposed and HIV-unexposed infants, and looked into 
the relative contribution of exposure by the mother and other children in the household.  
A longitudinal study design was adopted, shown in the previous chapter to be most 
effective for the investigation of pneumococcal transmission.  
 
Children born to HIV-positive mothers have been shown to experience higher rates of 
respiratory illness (164). Whilst part of this association is explained by HIV-infection in 
the offspring, HIV-exposed uninfected infants also appear to be at increased risk of 
morbidity and mortality from invasive pneumococcal disease (165). In countries of sub-
Saharan Africa with generalized HIV epidemics, HIV-exposure occurs in up to 25% of 
pregnancies. We hypothesized that infants born to HIV-positive mothers (“HIV-
exposed”) would have higher rates of pneumococcal acquisition than infants born to 
HIV-uninfected mothers (“HIV-unexposed”) and that this may lead to increased rates of 
disease in the HIV-exposed. There are two rationales for this hypothesis: 1) HIV-
positive adults have higher rates of pneumococcal carriage than HIV-uninfected adults, 
resulting in an increased risk of exposure by HIV-positive parents to their infants (133), 
and 2) differences in the immune system of HIV-exposed and HIV-unexposed children, 
in particular altered transplacental and breast milk transfer of antibody may lead to 
different susceptibility to pneumococci (166). We conducted a longitudinal household 
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study to compare pneumococcal acquisition rates between HIV-exposed and HIV-
unexposed infants in Malawi. We examined serotype-specific associations between 
infant carriage and carriage in their mothers and household members <5 years, both 
hypothesized to be key transmitters to infants.  
 
5.2 Methods  
 
5.2.1 Study population and design 
 
Recruitment of HIV-positive pregnant women took place in antenatal clinics in two rural 
hospitals between January 2009 and December 2010. Attendance at antenatal clinics 
was very high: 99.7% among pregnant women in the HDSS area in 2009 and 2010. 
HIV-testing was offered to all women attending antenatal clinic. All HIV-positive 
pregnant women living in the HDSS area were eligible for inclusion. For each HIV-
positive woman, up to three HIV-uninfected pregnant women were recruited from the 
HDSS area, frequency-matched on the number of children <10 years in the household. 
Nasopharyngeal swabs were collected from the infant, mother and other household 
members willing to participate at 6, 10, 14, 18, 22, 26, 30, 34, 40, 46, and 52 weeks of 
the infant’s age. Follow-up ceased if the index infant died, the mother-infant pair moved 
outside the study area, consent was withdrawn or there was a failure to sample on two 
sequential visits. Available data for infants lost to follow up were included in the 
analyses.  
 
HIV-exposed infants were tested for HIV DNA at 6 and 26 weeks and for HIV 
antibodies at 12 months of age or when visiting the local clinic as part of another 
affiliated study. Infants with a positive antibody test at 12 months were followed up to 
confirm HIV-status. HIV-positive mothers and infants were referred for appropriate 
care. Data on antiretroviral therapy and cotrimoxazole prophylaxis were available from 
databases linked to the HDSS. A retrospective questionnaire was used for verification 
and to complete missing data.  
 
5.2.3 Definitions 
 
An episode of carriage was defined as isolation of a pneumococcus from one or more 
consecutive samples. An episode was deemed to terminate if the serotype was not 
detected in two consecutive samples. A new acquisition event was defined as the 
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identification of a serotype when the same serotype was not identified at the previous 
two sampling times. We stratified the analyses by PCV-13 (VT) serotypes and by the 
major serotypes associated with colonization and IPD in children (“pediatric serotypes”; 
4, 6A, 6B, 9V, 14, 18C, 19A, 19F, and 23F). Pneumococcal isolates identified in the 
first sample were regarded as new acquisitions. The date of acquisition was defined as 
the midpoint between the last negative and the first positive result. The date of 
termination was defined as the midpoint between the last positive and the first of two 
negative results. We defined pneumococcal exposure as carriage by another 
household member at any of the previous two sample times. We defined concordance 
in carriage as simultaneous carriage of the same serotype by the infant and household 
members. Negative and non-typeable results were excluded from the concordance 
analyses.  
 
5.2.4 Statistical analysis 
 
Statistical analyses were performed using R 3.0.1 (R Foundation for Statistical 
Computing, Vienna, Austria) (167). Comparisons between categorical data were made 
using the Pearson’s χ2 test and Fisher exact test as appropriate. We used survival 
analysis including Kaplan-Meier plots and log-rank tests to study differences in the 
mean time to first pneumococcal acquisition (168). Crude and adjusted risk ratios (RR 
and aRR) for risk factors associated with pneumococcal acquisition of any serotype 
were obtained by log-binomial regression (169).  
 
Rates of infant pneumococcal acquisition were studied using counting process 
(Anderson-Gill) models. The counting process model is a simple extension of the Cox 
proportional hazards model where a subject is at continuous risk for an event and has 
the same baseline hazards function (170). We considered our study subjects to be at 
continuous risk of acquiring a new serotype because of the possibility of multi serotype 
carriage. Time at risk was calculated as the number of days between sampling dates. If 
an infant was missed on a sampling appointment, we estimated the start of the next 
period at risk as the midpoint between the two samples for which a time in days was 
available. We examined the proportional hazards assumption by testing the correlation 
coefficient between transformed survival time and the scaled Schoenfeld residuals. 
 
The effects of infant age and seasonal and secular trends were studied with fitted 
generalized additive mixed models. Secular trends were further studied by serotype 
using generalized additive models and the χ2 test for trend in proportions. For seasonal 
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trend, parametric functions with different numbers of sin-cosine waves were examined. 
For instance, a model with three sin-cosine waves and fitted splines for infant age in 
days and secular trend (days since study onset) was specified as: 
 
!
yi ,t =α0+α1sin(2πt365)+β2cos(2πt365)+α2sin(4πt365)+
β2cos(4πt365)+α3sin(6πt365)+β3cos(6πt365)+ f (age)+ f (trend)+ui ,t  
 
where yi,t is the carriage in infant i for each day of the year t, α and β terms are the 
regression coefficients for each sine and cosine function, f1 and f2 are smooth 
functions for infant age in days and secular trend (days since study onset), and ui,t is 
the infant-specific random effect. Log-binomial regression was used to report rate 
ratios. In addition, generalized linear and additive mixed models with individuals-level 
random effects were fitted to examine the extent of within-person clustering (171, 172). 
  
Serotype-specific analyses on household exposure were performed for the six 
commonest serotypes for infants, mothers and children <5 years. Acquisition and 
exposure was assessed at each sample with the results pooled to give a summary 
estimate. Crude and adjusted population attributable fractions (PAF and aPAF) of 
exposure from the mother/infants/children <5 years -the proportion of new acquisitions 
in the population that is attributable to exposure- were calculated using the formula: 
PAF = Pe(RR-1) / (1+(Pe(RR-1)), where Pe is the proportion of individuals exposed and 
RR is the risk ratio (risk in exposed/risk in unexposed). The PAF was adjusted using 
the aRR obtained in the multivariable log-binomial model.  
 
Duration of carriage was estimated for infants, mothers and other children <5 years. 
Duration of carriage could not be estimated for other adult household members, 
because the response rate was low. Episodes starting at the end of the follow up 
period were excluded, because duration of carriage could not be accurately 
determined. For mothers and children <5 years also events starting at the first 
observation were excluded, because duration of carriage could not be accurately 
determined. Differences in duration of carriage between infants, mothers, and other 
children <5 years, between serotypes, and between HIV-status of the mother were 
calculated using the Mann-Whitney U test. 
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5.3 Results  
 
5.3.1 Study participants and samples 
 
In total, 54 HIV-exposed infants and 131 HIV-unexposed infants were recruited 
between January 2009 and December 2010. Follow up ceased in November 2011. 
Follow-up was terminated prematurely for 24 infants (13.0%). Nine infants departed 
from the study area, six were lost to follow-up, one was withdrawn from the study and 
one left for other reasons. Four HIV-exposed infants (7.4%) and three HIV-unexposed 
infants (2.3%) died within the first year of life (p=0.22). HIV-results were available for 
44 HIV-exposed infants (81.5%) of which seven (15.9%) tested HIV-positive. 
Information on cotrimoxazole prophylaxis and antiretroviral treatment was available for 
46 HIV-exposed infants (85.2%), of which 18 infants (39.1%) received cotrimoxazole 
and 3 infants (6.5%) received antiretroviral treatment during the study. 
 
At least one pernasal swab was available for 140 of 168 (83.3%) children <5 years, 
198 of 288 (68.8%) children aged between 5-14 years and 95 of 287 (33.3%) adults 
other than the mother. In total, 1721 results (90.2% of scheduled visits) were available 
for index infants, 1763 (92.4%) for mothers, 806 (46.3%) for children <5 years, 718 
(24.1%) for children 5-14 years and 200 (6.8%) for other adult household members.   
 
Data on cotrimoxazole and antiretroviral treatment use was available for 50 HIV-
positive mothers (92.6%): 39 (78.0%) mothers received cotrimoxazole during all (n=31) 
or part (n=8) of the study period and 28 (56.0%) mothers received antiretroviral 
treatment during all (n=24) or part (n=4) of the study period. 
 
5.3.2 Pneumococcal prevalence  
 
Pneumococcal carriage prevalence in the index infants increased from 30.6% at week 
6 to 60.6% at week 18 (p<0.001) and subsequently decreased to 25.0% at week 52 
(p<0.001) (Figure 5.1). Overall pneumococcal carriage prevalence was higher in HIV-
positive mothers than in HIV-uninfected mothers (24.8% vs. 14.5%, p<0.001). 
Pneumococcal carriage prevalence did not significantly differ between HIV-positive 
mothers using antiretroviral treatment or not (26.2% vs. 25.5%, p=0.94) or using 
cotrimoxazole or not (27.1% vs. 23.2%, p=0.42). Overall pneumococcal carriage 
prevalence was 51.2% in children <5 years, 40.3% in children 5-14 years and 17.5% in 
adults. Carriage in other children in the household mirrored the differences by week 
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observed for index infants with higher carriage observed in earlier than later sampling 
weeks (64.7% vs. 27.1%, p<0.001 for children <5 years and 50% vs. 15.2%, p<0.001 
for children 5-14 years at week 14 vs. week 52). Carriage in mothers and other adult 
household members did not significantly differ by sampling week. 
 
 
Figure 5.1 Pneumococcal carriage prevalence by age of index infant in weeks  
Bars represent 95% confidence intervals. 
 
The HIV-status of the mother did not result in different pneumococcal carriage 
prevalence in index infants (44.1% HIV-unexposed vs. 46.2% HIV-exposed, p=0.44) 
and other children (50.7% HIV-unexposed vs. 53.4% HIV-exposed, p=0.60 for children 
<5 years and 41.5% HIV-unexposed vs. 36.9% HIV-exposed, p=0.30 for children 5-14 
years).  
 
5.3.3 Serotype distribution 
 
In total, 46 different serotypes were isolated from the infants. The commonest 
serotypes were 19F, 19A, 6B, 23F, 6A and 15B, together accounting for 47.6% of 
isolates. VT serotypes accounted for 54.7%, 48.4%, 40.8%, 34.4% and 25.7% in index 
infants, children <5 years, children 5-14 years, mothers and other adults respectively. 
Paediatric serotypes accounted for 52.4%, 45.0%, 34.6%, 31.2% and 20.0% in index 
infants, children <5 years, children 5-14 years, mothers and other adults respectively. 
There were no significant differences in the proportion VT or pediatric serotypes 
between HIV-exposed and HIV-unexposed infants or children. HIV-positive mothers 
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carried lower proportions of paediatric serotypes than HIV-uninfected mothers (24.4% 
vs. 35.9%, p=0.04). A large proportion of isolates could not be fully typed with the 
available reagents: 22.6%, 33.7%, 32.5%, 43.2% and 48.6% in index infants, children 
<5 years, children 5-14 years, mothers and other adults respectively.  
 
Concordance between serotypes simultaneously carried by mothers and infants was 
low: only in 39 of 586 (6.7%) instances when the infant carried a typeable 
pneumococcus was the same serotype found in the mother. Concordance with 
maternal carriage was 9.0% (15/165) in infants less than 3 months of age. 
Concordance with infant serotype carriage at any age was 17.4% (49/281) for children 
<5 years, 9.1% (19/209) for children 5-14 years and 4.5% (3/66) for adults.  
 
5.3.4 Pneumococcal acquisition in infants 
 
There were 553 new acquisitions observed in index infants during 59,365 days at risk, 
resulting in an acquisition rate of 0.0093 per day (95%CI 0.0086-0.0101). The 
observed median time to first acquisition was 59 days, with no difference observed 
between HIV-exposed and HIV-unexposed infants (median time 58.5 and 59.0 days, 
p=0.99) (Figure 5.2). Infants living with children <5 years acquired pneumococci faster 
than infants without children <5 years in the household (median time to first acquisition 
56.5 and 83.0 days, p=0.001) (Figure 5.3). 
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Figure 5.2 Kaplan-Meier plot for time to first pneumococcal carriage acquisition 
in infants by human immunodeficiency virus (HIV) exposure status  
 
Figure 5.3 Kaplan-Meier plot for time to first pneumococcal carriage acquisition 
in infants by presence or absence of other children <5 years in the household  
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Table 5.1 presents the univariable and multivariable risk factor analysis for 
pneumococcal carriage acquisition in infants. The individual-level variance was found 
to be negligible for infants (σ2<0.01); hence results from the non-mixed model are 
reported. There was no significant difference in pneumococcal acquisition by maternal 
HIV-status (aRR 1.00, 95%CI: 0.87-1.15) or infant HIV-status (aRR 1.00, 95%CI: 0.71-
1.42). Infant age was not found to be associated with pneumococcal acquisition. There 
was weak evidence that cotrimoxazole prophylaxis reduced pneumococcal carriage 
acquisition amongst HIV-exposed infants (aRR 0.77, 95%CI: 0.59-1.02). Results from 
the Cox proportional hazards model were similar to the log-binomial regression model. 
The proportional hazard assumptions were met by all variables apart from infant age, 
which has been omitted from the model presented in Table 5.1.  
 
5.3.5 Household exposure 
 
In the pooled analysis for the six commonest serotypes, both serotype-specific 
exposure by the mother (aRR 3.09, 95%CI: 1.47-6.50) and exposure by other children 
<5 years (aRR 4.30, 95%CI: 2.80-6.60) were found to be associated with infant 
pneumococcal acquisition (Table 2). The aPAF was low for infant pneumococcal 
acquisition: only 1.9% (95%CI: 0.0-4.3) and 8.8% (95%CI: 4.0-13.4) of acquisitions 
were attributable to exposure by the mother and other children <5 years respectively 
(table 2). Extreme case sensitivity analysis changing all missing exposure data to 
carriage or to non-carriage had limited impact on the calculated PAFs suggesting data 
were missing at random (data not shown). 
 
Our results suggest that pneumococcal transmission occurs between infants, other 
children and mothers in all directions (Table 2). Only the association between 
pneumococcal acquisition in other children <5 years and exposure by the mother could 
not be established. For all groups, exposure by children <5 years resulted in the 
highest aRR and aPAFs, identifying them as main transmitters in the household. 
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Table 5.1 Generalized linear model and Cox proportional hazard model describing maternal HIV status and other risk factors associated 
with infant pneumococcal carriage acquisition  
Risk factor No.  New acquisitions  Generalized linear model Cox proportional hazard model 
n % cRR  95%CI aRR 95%CI cHR 95%CI aHR 95%CI 
Age (weeks)            
  6 183 56  30.6 -  -      
 10 171 65  38.0 1.24  0.93, 1.66 1.24  0.93, 1.64     
 14 168 55  32.7 1.07  0.79, 1.46 1.07  0.79, 1.44     
 18 165 64  38.8 1.27  0.95, 1.69 1.26  0.95, 1.68     
 22 152 47  30.9 1.01  0.73, 1.40 0.99  0.72, 1.37     
 26 157 58  36.9 1.21  0.90, 1.63 1.24  0.92, 1.66     
 30 152 49  32.2 1.05  0.77, 1.45 1.17  0.86, 1.59     
 34 145 33  22.8 0.74  0.51, 1.08 0.82  0.57, 1.18     
 40 144 64  44.4 1.45  1.09, 1.93 1.58  1.18, 2.11     
 46 144 38  26.4 0.86  0.61, 1.22 1.05  0.74, 1.50     
 52 140 24  17.1 0.56  0.37, 0.86 0.74  0.48, 1.14     
Sex            
 Female 824 265  32.2 -  -  -  -  
 Male 897 288  32.1 1.00  0.87, 1.15 0.99  0.87, 1.13 0.99 0.86, 1.12 1.00 0.88, 1.12 
Maternal HIV-status            
 HIV-uninfected 1219 381  31.3 -  -  -  -  
 HIV-positive 502 172  34.3 1.10  0.95, 1.27 1.00  0.87, 1.15 1.10 0.97, 1.24 1.02 0.88, 1.16 
HIV-status childa             
 HIV-uninfected 363    127  35.0 -  -  -  -  
 HIV-positive 69 23  33.3 0.95  0.66, 1.37 1.00  0.71, 1.42 0.94 0.72, 1.16 0.99 0.78, 1.20 
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Table 5.1 Generalized linear model and Cox proportional hazard model describing maternal HIV status and other risk factors associated 
with infant pneumococcal carriage acquisition  
Risk factor No.  New acquisitions  Generalized linear model Cox proportional hazard model 
n % cRR  95%CI aRR 95%CI cHR 95%CI aHR 95%CI 
Cotrimoxazolea            
 No 311   112  36.0 -  -  -  -  
 Yes 152 46  30.3 0.84  0.63, 1.12 0.77  0.59, 1.02 0.80 0.57, 1.03 0.78 0.54, 1.03 
Maternal age            
 <28 807 243  30.1 -  -  -  -  
 ≥28 914 310  33.9 1.13  0.98, 1.29 1.05  0.92, 1.20 1.13 1.00, 1.26 1.04 0.92, 1.17 
Feeding            
Exclusively breastfed 740 255 34.5 -  -  -  -  
Mixed 910 276 30.3 0.88   0.77, 1.01 1.04   0.82, 1.30 0.81 0.53, 1.09 0.85 0.55, 1.14 
Weaned 49 15 30.6 0.89   0.58, 1.37 1.04   0.66, 1.65 0.80 0.30, 1.30 0.82 0.35, 1.29 
Seasonality            
 Rain (Dec-April)  720   170  23.6 -  -  -  -  
 Cold (May-Aug)  574   228  39.7 1.68  1.43, 1.99 1.59  1.35, 1.87 1.78 1.60, 1.95 1.68 1.50, 1.86 
 Hot (Sept-Nov)  427 155  36.3 1.54  1.28, 1.84 1.37  1.13, 1.64 1.57 1.38, 1.77 1.39 1.19, 1.60 
Year            
 2009 631   257  40.7 -  -  -  -  
 2010 810   236  29.1 0.72  0.62, 0.83 0.79  0.68, 0.91 0.71 0.56, 0.86 0.76 0.60, 0.91 
 2011 280 60  21.4 0.53  0.41, 0.67 0.62  0.48, 0.80 0.52 0.29, 0.76 0.59 0.34, 0.83 
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Table 5.1 Generalized linear model and Cox proportional hazard model describing maternal HIV status and other risk factors associated 
with infant pneumococcal carriage acquisition  
Risk factor No.  New acquisitions  Generalized linear model Cox proportional hazard model 
n % cRR  95%CI aRR 95%CI cHR 95%CI aHR 95%CI 
Other household members 
<5 years  
           
 No 515  149  28.9 -  -  -  -  
 Yes 1206 404  33.5 1.16  0.99, 1.35 1.15  0.99, 1.33 1.16 1.00, 1.31 1.15 1.00, 1.29 
Exposure by motherb            
 No 1119 340  30.4 -  -  -  -  
 Yes 410 155  37.8 1.24  1.07, 1.45 1.14  0.98, 1.33 1.20 1.02, 1.37 1.10 0.91, 1.28 
Exposure by other children 
<5 yearsb 
           
 No 762 227  29.8 -  -  -  -  
 Yes 467 172  36.8 1.24  1.05, 1.45 1.07  0.90, 1.26 1.16 0.99, 1.32 1.05 0.87, 1.23 
Abbreviations: aRR, adjusted rate ratio; CI, confidence interval; cRR, crude rate ratio; HIV, human immunodeficiency virus  
a Only including HIV-exposed infants. 
b Exposure to any serotype. Exposure unknown for all week 6 samples.  
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Table 5.2 Serotype-specific acquisition of infants, mothers and other children <5yrs, stratified by exposure to other household 
members  
Acquiring category, Exposing 
category, and Exposurea 
No. with 
events 
No. without 
events 
Total no.b cRR  aRRc 
 
95%CI cPAF (%) aPAFb 
(%) 
95%CI 
Infant          
 Mother          
  Yes 8 69 77 3.95 3.09 1.47, 6.50  2.6 1.9  0.0, 4.3 
  No 225 8335 8560       
Infant          
 Other child          
  Yes 22 173 195 4.70 4.30  2.80, 6.60 9.4 8.8 4.0, 13.4 
  No 162 6593 6755       
Mother          
 Infant          
  Yes 13 474 487 4.83 3.89  1.98, 7.65 15.2 12.9 1.5, 23.1 
  No 55 9894 9949       
Mother          
 Other child          
  Yes 9 236 245 5.75 3.99 1.82, 8.76 13.5 9.0 0.0, 17.6 
  No 46 7154 7300       
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Table 5.2 Serotype-specific acquisition of infants, mothers and other children <5yrs, stratified by exposure to other household 
members  
Acquiring category, Exposing 
category, and Exposurea 
No. with 
events 
No. without 
events 
Total no.b cRR  aRRc 
 
95%CI cPAF (%) aPAFb 
(%) 
95%CI 
Other child          
 Infant          
  Yes 15 228 243 2.22 1.86 1.06, 3.29 6.1 5.1 0.0, 11.2 
  No 121 4227 4348       
Other child          
 Mother          
  Yes 1 52 53 0.65 0.33 0.04, 2.45 0.0 0.0 0.0, 0.4 
  No 113 3777 3890       
Other child          
 Other child          
  Yes 7 57 64 3.99 3.17 1.50, 6.70 4.6 3.7 0.0, 7.9 
  No 108 3835 3943       
 
Abbreviations: aRR, adjusted rate ratio; aPAF, adjusted population attributable fraction; CI, confidence interval; cRR, crude rate ratio; cPAF, crude population 
attributable fraction. 
a Exposure was defined as carriage by another household member at any of the previous two sample times. Analysis was limited to those samples for which 
exposure data for at least one of the two previous sample times was available. b The six most common serotypes (19F, 19A, 6B, 23F, 6A, 15B) were assessed for 
acquisition and exposure at each sample with the results pooled to give a summary estimate. c Adjusted analysis for exposure by index child, exposure by children 
<5 yrs, exposure by mother, seasonality stratified by year and within-person clustering (mother only). Using a generalized linear mixed model, there was negligible 
 individual-level variance for index infants (σ2 < 0.01) and other children <5 years of age (σ2 < 0.01), hence results from a (non-mixed) generalized linear model 
were reported. Using a generalized linear mixed model, the individual-level variance for mothers was 0.51. 
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5.3.6 Seasonal and secular trends 
 
A model with three sin-cosine waves and fitted splines for infant age in days and 
secular trend (days since study onset) was found to provide the best fit. The individual-
level variance was found to be negligible for infants (σ2<0.01); hence results from the 
non-mixed model are reported. 
 
A significant seasonal trend was observed, with the highest incidence in August, 
corresponding with the cold season, and the lowest incidence in March, corresponding 
with the end of the rainy season (p<0.001) (Table 5.3, Figure 5.4). Over the two-year 
study period, pneumococcal incidence showed a decreasing trend (p<0.001) (Table 
5.3, Figure 5.6). Acquisition of NVT carriage showed a greater decrease over the study 
period (p<0.001), whilst no decrease in VT carriage was observed (p=0.82). For 
serotype 19A an increase was observed over the study period (p<0.001). 
 
The generalized additive mixed model provided further evidence that pneumococcal 
acquisition was not associated with infant age (Table 5.3, Figure 5.5). 
 
Table 5.3 Generalized additive mixed model results for pneumococcal incidence in 
infants  
Parametric coefficients 
Coefficient Estimate Standard error z value P-value 
Intercept -1.215486 0.038901 -31.246 < 2e-16 
α1 -0.399873 0.069015 -5.794 6.87e-09 
β1 -0.154872 0.061535 -2.517 0.01184 
α2 0.047957 0.052210 0.919 0.35833 
β2 0.161008 0.052797 3.050 0.00229 
α3 -0.122454 0.049683 -2.465 0.01371 
β3 -0.005179 0.050301 0.103 0.91800 
Smooth terms 
Coefficient edf Ref. df Chi-square P-value 
f1 (infant age in days) 2.068 2.068 3.425 0.189 
f2 (secular trend; days 
since study onset) 
3.751 3.751 27.525 1.5e-05 
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Figure 5.4 Fitted parametric seasonal trend in pneumococcal carriage incidence 
in infants  
Grey area represents 95% confidence interval.  
 
 
 
Figure 5.5 Non-parametric spline fit to infant age and pneumococcal incidence in 
infants  
Grey area represents 95% confidence interval.  
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Figure 5.6 Serotype-specific trends of pneumococcal carriage incidence in 
infants 
A. Non-parametric spline fit to secular trend in pneumococcal carriage incidence in 
infants. Grey area represents 95% confidence interval.  
B. Relative abundance of serotypes. Data summarized by season; rain = December-April, 
cold = May-August, hot = September-November. Data for hot season 2011 omitted because of 
low number of isolates (n=5). Increase in serotype 19A: p<0.001, decrease in nonPCV-13: 
p<0.001 (χ2 test for trend in proportions) 
C. Absolute abundance of serotypes. Data summarized by season: rain = December-April, 
cold = May-August, hot = September-November. Bars depict 95% confidence intervals. Total 
decrease: p<0.001; VT decrease: p=0.82; NVT decrease: p<0.001 (χ2 test for trend in 
proportions) 
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5.3.7 Pneumococcal carriage duration  
 
Table 5.4 shows results for duration of carriage in infants, mothers and other children < 
5 years. Infants carried pneumococci of the studied serotypes (19F, 19A, 6B, 23F, 6A 
and 15B) on average for 52.5 days (median 39.5 days). Duration of pneumococcal 
carriage was shorter in mothers (mean 37.2 days, median 28.5 days, p=0.008) and 
other children <5 years (mean 38.9 days, median 28.5 days, p<0.001). No significant 
differences were found between the duration of carriage of the studied serotypes. 
There were no significant differences in duration of carriage by maternal HIV-status for 
the infant, mother or other children <5 years. 
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Table 5.4 Duration of pneumococcal carriage in infants, mothers and other 
children <5 years  
Serotype Episodes (n) Duration of carriage (days) 
Median Mean 
Infants 
 19F 47 41.0 58.7 
 19A 48 40.3 53.2 
 06B 46 41.5 50.7 
 23F 36 41.3 52.3 
 06A 31 35.0 42.7 
 15B 19 42.0 57.0 
 Total 227 39.5 52.5 
 HIV-exposeda 76 35.0 44.6 
 HIV-unexposed 151 41.5 56.5 
Mothers 
 19F 8 35.5 46.3 
 19A 11 28.0 32.4 
 06B 12 28.3 33.1 
 23F 3 28.0 36.5 
 06A 8 31.3 37.4 
 15B 9 35.5 40.7 
 Totalb 51 28.5 37.2 
 HIV-positivea 18 31.5 40.6 
 HIV-negative 33 28.3 35.4 
Other children <5 years 
 19F 18 28.3 41.7 
 19A 10 28.3 37.0 
 06B 21 30.5 40.8 
 23F 10 28.8 42.6 
 06A 16 28.5 36.0 
 15B 8 27.8 31.4 
 Totalc 83 28.5 38.9 
 HIV-exposeda 17 29.0 40.2 
 HIV-unexposed 66 28.5 38.6 
a No significant differences in duration of carriage by maternal HIV-status for infant, mother or 
other children <5 years  
b Difference duration infants and mothers; p=0.008  
c Difference duration infants and children <5 years; p<0.001  
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5.4 Discussion 
 
We report similar pneumococcal acquisition in HIV-exposed and HIV-unexposed 
infants in Malawi. Infant pneumococcal acquisition was associated more with carriage 
in children <5 years in the household than with maternal carriage, but exposure from 
both mothers and other children <5 years could only be linked to a limited proportion of 
acquisitions in the infants.  
 
There is no evidence that pneumococcal acquisition in infants differs by maternal HIV-
status, even though pneumococcal prevalence was higher in HIV-positive mothers than 
in HIV-uninfected mothers. Similar findings were reported from a South African study 
where no difference in pneumococcal acquisition was found between HIV-unexposed 
and HIV-exposed infants (133). The South African study reported an association 
between colonization of the mother and infant, but was not designed to report the 
direction of spread. A mathematical modelling study on the same data concluded that 
children transmit pneumococci more frequently to their mothers than vice versa (162). 
Our results also suggest that infant-to-mother transmission frequently occurs, 
indicating the importance of defining exposure by previous rather than simultaneous 
carriage.   
 
Although large associations were found for serotype-specific exposure by the mother 
or other children <5 years, the proportion of acquisitions that could be explained by 
these exposures was small: only 1.9% and 8.8% respectively. It is likely that 
methodological limitations are responsible for the small PAFs, as discussed below, but 
the possibility of transmission from other household members, or from outside the 
household cannot be dismissed. Similar results were found in a longitudinal study in 
the Gambia: the probability of an infant ever carrying a particular serotype was much 
increased if their mother ever carried it (OR 9.1, 95%CI: 6.4-13.6), but maternal 
carriage accounted for only 9.5% of infant carriage (95%CI: 7.4-11.6) (119). Infants in 
Malawi and other African countries are frequently carried on their mother’s back: it is 
plausible that their contact with other members of the community resembles the 
contact pattern of their mother, increasing the possibility of pneumococcal acquisition 
from outside the household.  
 
Pneumococcal carriage prevalence was lower in older than in younger infants. 
Although at first hand this seems to be related to infant ageing, further analysis 
suggests this is not the case. Similar carriage prevalence trends were observed in 
older child household members, for whom the ageing hypothesis is less likely. In the 
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multivariable analysis including infant ageing, seasonal and secular trends as 
covariates, infant ageing was found not to be significantly associated with 
pneumococcal carriage acquisition, whereas a significant result was found for secular 
trends. This suggests the decrease in carriage at later sampling points is a result of a 
background drop in pneumococcal carriage. There is no obvious explanation for the 
overall decrease in pneumococcal acquisition over the study period: PCV-13 was not 
introduced in Malawi until November 2011. The observed reducing carriage incidence 
is contemporaneous with decreasing rates of invasive disease in Malawi (40). Other 
possible explanations are long-term ecological trends in pneumococcal disease, on the 
back of improved food security and nutrition in this population. Lastly, it is also possible 
that the decrease in pneumococcal carriage was linked to inadvertent changes in 
sample collection and analysis over time. Older infants are more likely to resist sample 
collection by moving their head, which could have negatively influenced the sample 
taken. The same holds true for older children: it is plausible that they showed more 
resistance to sampling on repeated sampling visits. We observed no changes in the 
method the study nurses used for sample collection, or the laboratory personnel used 
for analysis of the samples, but cannot rule out that ‘study fatigue’ occurred towards 
the end of the study.  
 
Carriage prevalence in infants was highest in the cold season and lowest at the end of 
the rainy season. Several factors could underlie these seasonal patterns. Firstly, 
people spend more time indoors in the cold season, allowing for closer contact 
between household members, which could lead to enhanced transmission of 
pneumococci. Also exposure to indoor air pollution, linked to increased pneumococcal 
carriage (244), is likely to be higher in the cold season when people light more fires for 
warmth. Secondly, the occurrence of other seasonal respiratory infections such as 
influenza could have influenced pneumococcal carriage differences by year. 
Concurrent increases in other respiratory viruses and pneumococcal activity have been 
reported in other countries (242, 243). Lastly, the cold season in Karonga District 
corresponds with the school summer holidays: it is possible that older siblings spend 
more time around the index infants in this period, potentially increasing pneumococcal 
transmission in the household. 
 
There are several limitations to our study design. Firstly, the sampling interval of 4-6 
weeks may not have been short enough to detect all carriage episodes, especially in 
mothers who clear pneumococcal carriage faster than children (127, 152). Secondly, 
coverage of household members was incomplete, particularly among older children 
and adults other than the mother who were often absent during study visits or refused 
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to participate. This precludes analyses on the role of older children and adults in 
household transmission. Thirdly, our laboratory procedures did not allow for detection 
of simultaneous colonization with multiple serotypes. A sub-analysis on 64 samples 
from 16 infants detected multiple serotypes in 51% of the samples (unpublished 
results). The low estimated PAFs for exposure by the mother and children <5 years 
may be a result of this suboptimal detection of carriage. Another limitation of our 
laboratory procedures is that a large proportion of isolates could not be typed with 
available reagents, resulting in fewer serotype results available to study transmission 
within the household. A limitation of our Cox model is that failure to adjust for infant age 
could have led to residual confounding. Another limitation of the Cox proportional 
hazards model is that our sampling interval changed over time from four to six weeks. 
This could have led to an underestimation of hazard rates towards the end of the study 
period. A sub-analysis including only time points with sampling intervals of four weeks 
found similar results, suggesting the change in sample intervals did not affect the 
results found.  
 
In conclusion, maternal HIV-status does not affect pneumococcal acquisition in infants 
in this African population. Infant pneumococcal acquisition is associated with carriage 
in other children and mothers, but this could only explain a limited proportion of 
acquisitions. Our findings suggest that maternal HIV-infection and infant exposure will 
not affect the impact of the introduction of PCV-13 into this population, although the 
extent to which PCV-13 effectiveness will mirror the success of this vaccine in high-
income settings remains to be established. From our study we cannot conclude 
whether the majority of infant pneumococcal acquisitions is transmitted within the 
household or the community. Further understanding of pneumococcal transmission in 
all age groups is merited as it is vital to our understanding of both vaccine protection 
and the evolution of non-vaccine serotype replacement disease in the era of conjugate 
vaccine use. 
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6. Pneumococcal carriage among HIV-positive 
adults receiving antiretroviral therapy 
6.1 Introduction 
 
Besides young infants, the other group at high risk for IPD are HIV-positive adults. This 
chapter describes a cohort study investigating pneumococcal carriage in HIV-positive 
adults in the pre-vaccination period. Antiretroviral therapy (ART) reduces the incidence 
of IPD in HIV-positive adults (33) and there is a strong temporal relationship between 
large-scale ART introduction and declines in IPD in Malawi (40, 41). This population 
impact will be driven by immune reconstitution and/or immune maintenance at the 
individual level. However, HIV-positive individuals established on ART remain at much 
higher risk of IPD as compared to HIV-uninfected individuals (42). This suggests 
immune reconstitution is incomplete; a finding supported by earlier work in Malawi 
suggesting that ART did not alter the risk of recurrent IPD events (43).  
 
There is limited information on the effect of ART on pneumococcal carriage in HIV-
positive adults. Three studies have reported carriage prevalence in ART-treated adults 
with diverging results. In two immunological studies on HIV-positive Malawian adults, 
carriage was highest in those receiving ART for more than 12 months (47, 173). The 
third study in HIV-positive Brazilian adults reported a lower risk of colonization in ART-
treated individuals (174). The major limitation in these three studies was the lack of 
control for potential confounders such as child contacts, whilst the studies in Malawi 
were not powered to investigate carriage epidemiology effectively. Based on the drop 
in IPD since introduction of ART in Malawi and the impact of immune reconstitution, we 
hypothesized that pneumococcal carriage in individuals would decrease when 
established on ART. Using a cohort design and recruiting attendees at a rural HIV 
clinic in northern Malawi we investigated the impact of ART on pneumococcal carriage 
in Malawian adults infected with HIV. The study was undertaken prior to introduction of 
PCV-13 in the infant immunisation schedule in October 2011. 
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6.2 Methods 
6.2.1 Study design 
This study is part of a cohort study on ART eligibility, adherence and outcomes, as 
described elsewhere (175). The study was set in a rural HIV clinic within the area 
covered by the Karonga Health and Demographic Surveillance System (HDSS) in 
northern Malawi (54). HIV prevalence in the area was estimated at 7.1% in men and 
9.2% in women in 2008/2009 (56). ART was available in the study clinic since 2006. At 
the time of the study, individuals were eligible for ART if they had clinical features 
consistent with World Health Organization (WHO) disease stage 3 or 4, or had a CD4 
count of <250 cells⁄mm3, as per government guidelines. All individuals attending ART 
clinic were offered cotrimoxazole prophylactic treatment. Pneumococcal vaccination 
was not provided to HIV-positive adults at the time of the study. All HIV-positive adults 
and adolescents (>15 years) living in the HDSS who newly attended the clinic and 
were not already taking ART were invited to participate in the cohort study from 
January 2008. Detailed clinical data were obtained at baseline and on follow-up visits 
every three months. CD4 counts were recorded at baseline and at six-monthly 
intervals. Viral loads were recorded at baseline and at six months after treatment 
initiation. Individuals not qualifying for ART at baseline were assessed on subsequent 
visits for qualification. Treatment failure was assessed as a CD4 count <100cells/mm3 
or a fall of CD4 count below pre-therapy baseline after at least 12 months on ART 
and/or a viral load >10,000 copies/ml after at least 6 months on ART despite good 
adherence. Poor adherence was defined as missing more than three days of therapy in 
three months. 
This study on the effect of ART on pneumococcal carriage included all individuals 
recruited between February 2008 and May 2010. Nasopharyngeal samples were taken 
at baseline and at six-monthly intervals from individuals returning to the HIV clinic until 
February 2011. We included all individuals with a baseline and at least one follow-up 
result in the analysis.  
The cohort was established with the primary objective of understanding outcomes of 
HIV care delivery in adults resident in the HDSS. We expected to recruit 500 
participants of whom 300 would be commenced on ART. Under these circumstances 
we would have 80% power to detect a fall in nasopharyngeal carriage by 40% or more 
following ART initiation from a baseline prevalence of 25% (two-tailed alpha 0.05).  
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6.2.2 Data analysis 
We compared pneumococcal carriage prevalence between individuals started on ART 
and individuals not started on ART. Individuals starting ART during the follow-up period 
contributed observation time to both non-ART and ART groups. Proportions of 
pneumococcal carriage were tested using the Chi-square or Fisher’s exact test as 
appropriate.  
 
Crude and adjusted risk ratios (RR and aRR) for pneumococcal carriage by ART status 
were obtained by log-binomial regression using generalized estimated equations 
(GEE) models with an exchangeable correlation structure and robust standard errors to 
account for any within-person clustering of the data (176). Other factors considered 
were; sex, age, CD4 count, cotrimoxazole use, WHO-defined clinical disease stage, 
and household composition. For seasonality, parametric functions with different 
numbers of sin-cosine waves were examined. For instance, a model with two sin-
cosine waves was specified as:  !!,! = ! +  !! sin 2!"365 +  !!cos 2!"365+ !! sin 4!"365 +  !! cos 4!"365 +  !! !"#!,! + !! !"#$%&$'()!,!  
  
where !!,! is the carriage in individual ! on day of the year !, !!!! terms are regression 
coefficients for each sine and cosine function, ART is a binomial variable of the 
individuals ART-status and covariates are other factors studied.  
 
6.2.3 Sensitivity analyses 
Missing CD4 count data were estimated for individuals with at least two CD4 counts 
available by simple linear regression on two CD4 counts closest in time to the missing 
data point. Sensitivity analysis was performed excluding individuals with poor 
adherence or treatment failure. A separate sensitivity analysis was performed including 
only those individuals that started ART at some point during follow-up. 
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6.3 Results 
 
6.3.1 Study participants and samples 
In total, 468 individuals newly attended the ART clinic between February 2008 and May 
2010. Seventy-two individuals (15.4%) did not re-visit the ART clinic because they died 
(n=22) or departed from the study area (n=23) within 6 months of recruitment or were 
lost to follow-up for unknown reasons (n=27). At least one follow-up visit was recorded 
for 396 individuals (84.6%). At least two nasopharyngeal specimens (one at baseline, 
one at follow-up) were taken from 363 individuals (91.6%). For 26 individuals (7.2%) 
sample results were not available. One individual was excluded from the analysis 
because of unknown ART start date.  
 
In total, 336 individuals were included in the analysis, of which 233 individuals started 
ART during follow-up (Table 1). Individuals completed on average 15.7 months of ART 
during the follow-up period (range 5-31 months). On average, three nasopharyngeal 
samples were available per person. The average number of samples was slightly 
higher in individuals who started ART during follow-up as compared to those who did 
not (3.1 vs. 2.9 samples, p=0.06). More females (n=207) than males (n=129) attended 
the ART clinic and participated in the study (p<0.001). Poor adherence was observed 
for five individuals (2.2%). Treatment failure was observed for 23 of 209 (11.0%) 
individuals with good adherence and repeated CD4 count and/or viral load results 
available. Cotrimoxazole prophylactic treatment was reported to be taken during part or 
all of the follow-period by 94.8% (221/233) of individuals receiving ART during follow-
up and 81.5% (84/103) of individuals who did not receive ART during follow-up. 
 
Pneumococcal carriage was detected in 232 out of 1027 samples (22.6%). 
Pneumococcal carriage prevalence at baseline was similar in individuals who 
subsequently received ART compared to those who did not (21.0% vs. 21.4%, p=0.99).  
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Table 6.1 Baseline characteristics of HIV-positive adults who started ART during 
the follow-up period or not 
 Started ART during 
follow-up (n=233) 
Not started ART during  
follow-up  (n=103) 
Female sex 131 (56.2%) 76 (73.8%) 
Age (mean, sd) 39.9, sd=10.3 37.8, sd=11.4 
CD4 count (median, IQR)  174 cells/mm3 (86-280) 462 cells/mm3 (365-653) 
WHO clinical disease 
stage  
Stage 1: 31 (13.3%) 
Stage 2: 77 (33.0%) 
Stage 3: 101 (43.3%) 
Stage 4: 24 (10.3%) 
Stage 1: 34 (33.0%) 
Stage 2: 69 (67.0%) 
Stage 3: 0 (0%) 
Stage 4: 0 (0%) 
Pneumococcal carriage  49 (21.0%) - all types 
26 (11.1%) - VT 
23 (9.9%) - NVT  
22 (21.4%) - all types 
10 (9.7%) - VT 
12 (11.7%) - NVT 
 
 
 
6.3.2 Pneumococcal carriage by ART status 
Median CD4 count increased over time in patients started on ART, but no decrease in 
pneumococcal carriage was observed (Figure 1). Individuals started on ART were 
more likely to have pneumococcal carriage than individuals not started on ART at all 
subsequent sampling points (25.6% vs. 17.9%, p=0.03) (Figure 1). Amongst individuals 
on ART, carriage did not differ between those who had undetectable or low (≤400 
copies/ml) viral loads and those who had viral loads >400 copies/ml at 6 months after 
treatment initiation (26.1% vs. 23.3%, p=0.84). In the multivariable analysis including all 
samples, increased carriage was still observed for individuals on ART, but results were 
non-significant (aRR 1.22, 95%CI 0.95-1.56) (Table 2). Similar results were maintained 
when omitting results from individuals with treatment failure or poor adherence (aRR 
1.25, 95%CI 0.96-1.63). In the sensitivity analysis with imputed CD4 count data a 
significant increase in carriage was observed for ART-treated individuals (aRR 1.29, 
95%CI 1.03-1.62). Including only individuals who received ART during the follow-up 
period (n=233) resulted in a weaker association in the same direction (aRR 1.17, 0.86-
1.60). There was no evidence that amongst individuals on ART pneumococcal carriage 
differed by duration of treatment (Table 2, Figure 1).  
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Figure 6.1 Pneumococcal colonization and median CD4 count on baseline and by 
month since ART/month since baseline in patients receiving ART or not.  
 
6.3.3 Serotype distribution 
Most common serotypes isolated were 3 (9.1% of isolates), 19F (6.5%), 6B (5.2%), 11 
(4.7%) and 23F (4.7%) (Figure 2). Sixty-six isolates (28.4%) could not be fully typed 
with the available reagents. There was weak evidence that the diversity of serotypes 
carried was greater in the ART-treated group than in the ART-untreated groups (32 
serotypes in 87 typable isolates vs. 25 serotypes in 79 typable isolates): a comparison 
of bootstrapped Shannon diversity indices gave a simulated p-value of 0.08. In a 
pooled analysis of all time points, VT carriage did not differ between individuals on ART 
or not (9.9% vs. 10.2%, p=0.94), but  NVT carriage was higher in individuals on ART 
(16.1% vs. 9.6% p=0.003). NVT carriage remained significantly higher in the ART-
treated group after adjustment in the multivariable analysis (aRR 1.72, 95%CI 1.13-
2.62) (Table 2). 
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Figure 6.2 Carriage of serotypes including in PCV-13 (A) and not included in 
PCV-13 (B) by ART status.  
* Factor typing not done, ** Not able to establish factor typing 
3
19
F 6B 23
F
19
A 14 4 6A 18
C 9V 5 1
VT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Pr
op
or
tio
n 
of
 is
ola
te
s
A
Individuals not receiving ART
Individuals receiving ART
11
*
15
B
17
F 7*
10
A
23
A
35
*
18
A 9N 20 22
A
19
B
15
C 12
*
33
*
23
B
22
F
19
**
18
B
16
F
15
F
15
A
15
** 9L 6*
*
NVT (excluding untypeable)
0.00
0.02
0.04
0.06
0.08
Individuals not receiving ART
Individuals receiving ART
Pr
op
or
tio
n 
of
 is
ola
te
s
B
120 | Chapter 6 	
 
Table 6.2. Risk ratios and 95% confidence intervals (CI) of risk factors associated with pneumococcal carriage in HIV-positive adults. 
Risk factor n 
Carriage Crude  
RR  
95%CI  P 
Adjusted 
RR 
95%CI  P 
n % 
Antiretroviral treatment (ART)          
Carriage of all serotypes          
 Not on ART 560 111 19.8 -   -   
 On ART 467 121 25.9 1.29 1.02-1.62 0.03 1.22 0.95-1.56 0.12 
VT carriage           
 Not on ART 560 57 10.2 -   -   
 On ART 467 46 9.9 0.96 0.68-1.37 0.84 0.87 0.57-1.33 0.51 
NVT carriage          
 Not on ART 560 54 9.6 -   -   
 On ART 467 75 16.1 1.64 1.19-2.27 0.003 1.72 1.13-2.62 0.01 
Months on ART           
 0 (at start ART) 233 53 22.7 -   -   
 6 153 41 26.8 1.20 0.76-1.91 0.43 1.26 0.88-1.80 0.21 
 12 143 33 23.1 1.06 0.68-1.64 0.80 0.85 0.54-1.33 0.47 
 18 87 19 21.8 0.99 0.57-1.72 0.98 1.03 0.63-1.66 0.92 
 24 68 23 33.8 1.92 1.10-3.34 0.02 1.59 1.09-2.33 0.02 
Sex          
 Male 392 61 15.6 -   -   
 Female 635 171 26.9 1.68 1.25-2.27 <0.001 1.74 1.26-2.40 <0.001 
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Table 6.2. Risk ratios and 95% confidence intervals (CI) of risk factors associated with pneumococcal carriage in HIV-positive adults. 
Risk factor n 
Carriage Crude  
RR  
95%CI  P 
Adjusted 
RR 
95%CI  P 
n % 
Age (years)          
 <31 153 45 29.4 -   -   
 31-40 424 99 23.3 0.80 0.58-1.10 0.18 0.84 0.60-1.17 0.30 
 41-50 262 56 21.4 0.76 0.53-1.08 0.13 0.85 0.60-1.21 0.38 
 >50 188 32 17.0 0.58 0.38-0.89 0.01 0.78 0.48-1.28 0.33 
Cotrimoxazole prophylactic treatment (CPT)          
 Not on CPT 418 84 20.1 -   -   
 On CPT 609 148 24.3 1.22 0.96-1.56 0.11 0.95 0.68-1.34 0.77 
CD4count (cells/mm3)a          
 > 250 549 105 19.1 -   -   
 ≤ 250 320 84 26.3 1.35 1.03-1.77 0.03 1.40 1.08-1.82 0.01 
WHO stage           
 1 563 130 23.1 -   -   
 2 324 71 21.9 0.92 0.71-1.18 0.50 1.13 0.85-1.49 0.40 
 3 112 29 25.9 1.06 0.75-1.50 0.76 1.15 0.80-1.66 0.45 
 4 28 2 7.1 0.34 0.12-0.99 0.05 0.37 0.10-1.45 0.15 
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Table 6.2. Risk ratios and 95% confidence intervals (CI) of risk factors associated with pneumococcal carriage in HIV-positive adults. 
Risk factor n 
Carriage Crude  
RR  
95%CI  P 
Adjusted 
RR 
95%CI  P 
n % 
Children <5 years in householdb          
 No 480 105 21.9 -   -   
 Yes 470 109 23.2 1.03 0.79-1.33 0.85 1.05 0.81-1.37 0.70 
Number of household membersb          
 0-2 248 52 21.0 -   -   
 3-7 611 132 21.6 1.07 0.78-1.47 0.69 1.07 0.77-1.49 0.68 
 8-15 91 30 33.0 1.50 0.93-2.41 0.10 1.52 0.95-2.41 0.08 
Year          
 2008 179 33 18.4 -   -   
 2009 452 95 21.0 1.13 0.81-1.56 0.47 1.03 0.72-1.48 0.87 
 2010 395 103 26.1 1.38 0.98-1.95 0.06 1.29 0.85-1.95 0.23 
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Risk ratios were estimated from log-binomial regression models. Within-person clustering was adjusted for using the generalized 
estimating equations (GEE) method. ART, seasonality (parametric spline fit), CD4 count and sex were included in the multivariable 
analysis. Analysis on all serotypes unless specified otherwise. a. CD4 count missing for 158 observations (15.4%). Estimation by linear 
regression for 137 observations from individuals with at least two CD4 counts available resulted in an aRR for the association of ART with 
pneumococcal carriage of all serotypes of 1.29 (95%CI 1.03-1.62). b. Household information missing for 77 observations (7.5%)
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6.3.4 Risk factors for pneumococcal carriage 
Low CD4 count was associated with higher pneumococcal carriage prevalence (aRR 
1.40, 95%CI 1.08-1.82 for ≤250 vs. >250 cells/mm3). There was no evidence for an 
association between pneumococcal carriage and cotrimoxazole prophylactic treatment 
(aRR 0.95, 95%CI 0.68-1.34). Female sex was associated with higher pneumococcal 
carriage prevalence (aRR 1.74, 95%CI 1.26-2.40). Individuals living in large 
households seemed to be more likely to carry a pneumococcus than individuals living 
in small households (aRR 1.52, 95%CI 0.95-2.41 for 0-2 vs 8-15 household members). 
There was no evidence for an association between pneumococcal carriage and living 
with children <5 years of age (aRR 1.05, 95%CI 0.81-1.37). Pneumococcal carriage 
showed strong seasonality with a model with two sine-cosine pairs providing the best fit 
(Figure 3). Carriage prevalence was higher in the cold (May-August) and hot 
(September-November) seasons as compared to the rainy season (December-April). 
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Figure 6.3. Seasonality of pneumococcal carriage.  
A. Crude carriage prevalence; B. Fitted parametric spline from adjusted generalized 
estimated equations (GEE) model. Grey area represents 95% confidence intervals. 
Black horizontal bars represent months in the rainy season (December-April).  
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6.4 Discussion 
 
This cohort study provides strong evidence that pneumococcal carriage in HIV-positive 
adults remains high during the first two years of ART use, with a tendency to increased 
NVT carriage. Two immunological studies from Malawi have reported consistent 
findings (47, 173), but this is the first cohort study that addresses important 
confounders for pneumococcal carriage and provides robust measures of association.  
 
Several of our risk factors for carriage are well known. We found that females are at 
higher risk of pneumococcal carriage, consistent with their higher contact rates with 
young children in which pneumococcal carriage is greatest. However, household 
contact with children <5 years was not found to be independently associated with 
pneumococcal carriage in HIV-positive adults. A possible explanation for this 
inconsistency is that child contact may be universal amongst women and not 
determined by household contact only. Strong seasonality patterns were observed in 
this study, with lowest carriage observed in the rainy season. This finding is consistent 
with the household cohort study on pneumococcal carriage conducted in 2009-2011 
(Chapter 5). 
 
Our findings are consistent with two immunological studies of HIV-positive adults in 
Malawi, which reported continued high pneumococcal carriage over a period of 12-18 
months on ART (47, 173). Both studies reported failure of mucosal immune responses 
to normalise after initiation of ART. Similar incomplete mucosal CD4 T-cell immune 
reconstitution has frequently been reported in gut-associated lymphoid tissue (177). 
Our findings differ from the two smaller Malawian studies in that we did not find a 
difference in pneumococcal carriage between symptomatic and asymptomatic HIV-
positive adults. We did find evidence for higher NVT carriage, providing further 
evidence for the hypothesis of “loss of control” of pneumococcal carriage amongst 
ART-treated adults that was generated from the immunological studies (47, 173). A 
cross-sectional study from Brazil reported stable ART for one year or more was 
associated with lower odds of pneumococcal carriage (174). This study was highly 
male biased (70% in Brazil vs. 38% in our study) and reported low household contact 
with young children (18% in Brazil vs. 50% in our study), representing different 
demography and risk factors from African HIV-positive populations.  
 
A decrease in IPD has been observed since roll-out of ART in Malawi (40), yet no 
decrease in pneumococcal carriage was observed in individuals established on ART. 
There are several possible explanations for this finding. At an individual level ART-
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mediated immune reconstitution may have a different impact on anti-pneumococcal 
mucosal responses than on systemic responses necessary for the control of IPD. 
Incomplete recovery of both mucosal and systemic response to the pneumococcus 
have been measured (47, 173, 178) and a mechanism for differential recovery 
mediated by Treg cells has been suggested from murine studies (179, 180). Behavioural 
changes as a result of improved well-being on ART may result in increased social 
mixing and thus more exposure to pneumococcal transmission. Extending this further, 
reduced use of antibiotics as a consequence of improved health may lead to less 
clearance of pneumococcal carriage. The latter explanation is unlikely given the lack of 
impact of cotrimoxazole on carriage observed in this study.  
 
Several limitations can be identified for this study. Our two-tailed sample size 
calculations were limited by the geographical boundaries of the cohort and based on 
a hypothesized 40% change in pneumococcal carriage in ART-treated adults. We 
recruited less participants than anticipated: 336 were included in this study of which 
233 started ART instead of an expected number of 500 participants of whom 300 
would commence on ART. Despite this lower sample size than anticipated we can 
confidently refute our initial hypothesis and conclude that pneumococcal carriage does 
not decrease after ART initiation. Our study only included data from the first two years 
of ART initiation. It is possible that different results would be found for a prolonged time 
on ART. Despite adjusting for CD4 count, WHO-defined disease stage and other 
potential confounders, residual confounding must also be considered with individuals 
receiving ART differing from individuals not receiving ART during the study period. A 
self-controlled analysis including only the 233 individuals receiving ART during follow-
up found similar results as reported for the full cohort, suggesting major confounders 
were not missed. Our laboratory procedures did not allow for detection of simultaneous 
colonization with multiple serotypes. This will not have impacted our comparison of 
pneumococcal carriage by ART status but may have affected our conclusions over 
serotype diversity. Six-month sampling intervals are too long to study carriage duration 
and investigate whether our findings can be explained by similar carriage incidence but 
a prolonged carriage in HIV-positive adults on ART. We used a self-reported definition 
for poor adherence. Underreporting of poor adherence as a result of social desirability 
could have led to misclassification of patients. The impact of misclassification will have 
been minimized, however, as patients with unreported poor adherence are likely to 
have been classified under treatment failure, for which the definition relied on CD4 
count and viral load measurements only. In the sensitivity analysis, similar results were 
maintained when omitting results from individuals with treatment failure or poor 
adherence. 
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These findings have implications for HIV care and potentially broader public health. 
The results suggest a continued respiratory mucosal immune defect after up to two 
years of ART and are consistent with the continued increased risk of IPD in this 
population.  How long and why this defect persists merits further investigation through 
follow-up studies. In the meantime it is clear that prophylactic measures to prevent 
pneumococcal disease remain a priority and a better understanding of the burden of 
non-invasive pneumococcal disease is required. Rates of IPD have fallen, but 
pneumonia remains a common and serious problem in the HIV clinic and requires a 
renewed focus of attention.  
 
Pneumococcal conjugate vaccination is known to work in this population. It has not 
been recommended for use on the expectation of HIV-positive adults benefiting from 
herd protection following the introduction of infant pneumococcal vaccination into the 
Malawi EPI schedule. However the observed high rates of carriage in HIV-positive 
adults may have implications for pneumococcal transmission and consequently for the 
scale of herd protection. It is unclear how important HIV-positive adults are in 
pneumococcal transmission, but they represent a large reservoir of S.pneumoniae 
which is not reduced by ART in at least the first two years of treatment. Herd protection 
following infant PCV has to date been demonstrated in developed regions with low 
prevalence pneumococcal carriage in adults (181) and in African centres with low HIV 
prevalence (25, 182, 183). In South Africa, declines in vaccine-type carriage (184) and 
IPD (24) in unvaccinated adults suggest indirect effects of PCV in the context of high 
HIV-burden although it is difficult to distinguish vaccine effects from an ongoing 
background drop in pneumococcal carriage that predates the introduction of PCV. 
Surveillance of pneumococcal carriage as well as disease in HIV-positive adults during 
PCV roll-out would be a prudent measure in Malawi and countries with similar 
generalized HIV epidemics. Vaccination of HIV-positive adults could be considered to 
provide both direct protection and maximize herd protection. 
 
In summary, pneumococcal carriage in HIV-positive adults in Malawi remained high 
despite two years of ART, with evidence of increased NVT carriage. Following PCV 
introduction monitoring of carriage in HIV-positive adults should be undertaken to 
determine whether they continue at risk from vaccine serotype pneumococcal disease 
and whether they constitute a reservoir for persisting vaccine serotype carriage and 
pneumococcal diversity. 
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Part II: Post-vaccination period 
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7. Predictors of uptake and timeliness of newly 
introduced pneumococcal and rotavirus 
vaccines, and of measles vaccine 
7.1 Introduction 
PCV-13 was introduced on 12th November 2011 as part of the infant immunisation 
schedule, with doses given at 6, 10, 14 weeks alongside Pentavalent vaccine 
(diphtheria, pertussis, tetanus, Haemophilus influenza type B and hepatitis B) and oral 
polio. Initial catch-up vaccination for PCV-13 in children <1 year of age was conducted 
at the time of introduction. Currently no PCV booster dose is scheduled.  
 
To understand what effect this introduction has had on pneumococcal carriage and 
transmission, we need to know what level of vaccination coverage was reached in the 
birth and catch-up cohorts and whether any PCV-13 is given according to schedule or 
whether delays occur. High risk groups often achieve poorer coverage than the 
national average (185). Furthermore, vaccine coverage estimates do not reflect 
timeliness of vaccination, which may frequently be delayed (186, 187). Previous work 
in this setting prior to introduction of PCV-13 showed high uptake of vaccines but 
delays in schedule (188). Understanding any socio-demographic predictors for vaccine 
uptake and timeliness will help us understand any differences in pneumococcal 
carriage that may arise post vaccination introduction.  
 
We analysed data from a population-based birth cohort study to investigate factors 
affecting vaccination coverage and timeliness in the KHDSS during the period of 
introduction of PCV-13. We took the opportunity to also examine predictors of 
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monovalent rotavirus vaccine (RV1) and measles vaccine (MV) coverage and 
timeliness. RV1 was introduced on 29th October 2012 and is given alongside PCV-13 
at 6 and 10 weeks. Understanding predictors for RV1 coverage and timeliness will 
place our findings for PCV-13 into a wider perspective. Measles vaccine (MV) is 
currently given as a single dose at 9 months of age, but a number of African countries 
including Malawi are planning introduction of a second dose (189). Nationwide and 
district level MV campaigns are conducted when necessary. In our study site in 
Karonga district there have recently been four MV campaigns among infants <1 year of 
age; one in 2011 and three in 2014. Understanding predictors for MV coverage and 
timeliness is also relevant for PCV-13 vaccination: if Malawi were to change it’s PCV-
13 schedule to a “2+1” or “3+1” schedule, it is likely that the booster dose will be given 
alongside MV to keep the number of visits to the health centre at a minimum. 
 
7.2 Methods 
7.2.1 Study population and design 
In this prospective population-based birth cohort study we followed up all children born 
in the KHDSS on or after: 11th November 2010 (thus eligible for PCV-13 catch-up), 30th 
September 2011 (eligible for routine PCV-13 schedule) and 17th September 2012 
(eligible for RV1). Data were collected during the KDHSS annual census at which all 
households are visited and individual and household socio-demographic data are 
collected by trained interviewers. Individual socio-demographic data including vaccine 
status for children <5 years were available until August 2014. Vaccine status and date 
of vaccination were transcribed from parent-held booklets (“health passports”) issued 
free by the government to all children at birth or first clinic visit. Absent vaccine 
documentation, parent/guardian reported vaccination status was recorded. 
Geographical Positioning System (GPS) coordinates were collected to calculate radial 
distance to nearest tarmac road or main track and to the nearest vaccination centre. 
We included in the analysis all children eligible for PCV-13 or RV1 who were at least 1 
year old at time of interview. We excluded: (1) children who died within the first year of 
life; (2) children who had migrated into the study area after 6 weeks of age from the 
PCV-13/RV1 birth cohort or those migrating after start of the PCV-13 catch-up 
campaign from the catch-up cohort; (3) any child whose date of birth or vaccination 
status could not be verified by written record. Children with documented evidence of 
vaccine receipt but lacking date were included in the coverage analysis, but excluded 
from timeliness analysis. Sensitivity analyses were performed to define risk factors 
associated with lack of written document and to repeat the main analyses including 
children without written documentation. 
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7.2.2 Definitions 
Individual uptake of vaccination was defined by the child’s written record in the health 
passport. Population vaccination coverage was calculated as the number of children 
receiving vaccination by one year of age divided by age-eligible population for each 
respective vaccine. We were unable to distinguish measles vaccination as a result of 
mass campaign from routine doses given off schedule. Timeliness of vaccination for 
birth cohorts was calculated as number of days between the recommended vaccination 
age and the date vaccine was given, regardless of age. Children who never received 
the vaccine were right-truncated at one year of age. Delays in later doses subtracted 
any delays on account of prior doses. Total delay was defined as the number of days 
between completing the schedule for a particular vaccine (third dose for PCV-13, 
second dose for RV1, first dose for MV) and the recommended vaccination age. We 
presumed vaccine non-availability at local clinic when PCV-13 or RV1 were 
administered later than the corresponding dose of Pentavalent vaccine. 
 
7.2.3 Statistical analysis 
Potential individual level predictors of vaccine uptake and clinic level predictors of 
discordant delays (presumed non-availability) were separately examined using 
univariable and multivariable Poisson regression with robust standard errors (190, 
191), and reported as risk ratios (RR) and adjusted RR (aRR) respectively (“risk” being 
probability of receiving a vaccine dose) (176). We report timeliness as median days 
delay (and interquartile range [IQR]). Predictors of vaccine timeliness (total delay in 
vaccination) were examined using univariable and multivariable Cox regression, and 
reported as crude and adjusted hazard ratio (HR and aHR) respectively, where HR<1 
implies delayed vaccination compared with baseline group (“hazard” being probability 
of receiving a vaccine dose at time t). Although our analysis examined numerous 
covariates, we did not perform correction for multiple comparisons in univariable 
analysis (192), but for multivariable models included initially only covariates achieving 
P-value <0.2 in univariable analysis. We retained in the final multivariable model those 
covariates achieving a likelihood ratio test P-value <0.05.  
 
7.3 Results 
We visited 2616 vaccine-eligible children at home who were >1 year at time of 
interview. Of these 51 had no documented birth date, 428 had no written 
documentation to confirm vaccination status and 152 migrated into the study area after 
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vaccine-eligible age, leaving 1985 (75.8%) for analysis. Among these, 768 were 
eligible for PCV-13 catch-up, 820 for PCV-13 by routine schedule prior to RV1 
introduction and 397 for both PCV-13 and RV1 (Figure 7.1). 
 
7.3.1 Vaccination coverage 
PCV-13 coverage in the catch-up cohort for dose 1, 2 and 3 was 70.2% (539/768), 
61.6% (470/763) and 49.8% (378/759), respectively. Among children birth-eligible for 
PCV-13, coverage by one year of age for each of three doses was 95.4% (1161/1217), 
94.4% (1149/1217) and 89.4% (1086/1215), respectively. Among those eligible for 
RV1, 90.2% (358/397) received one dose and 86.9% (344/396) received two doses. 
Coverage for MV by one year, regardless of routine dose or mass campaign, was 
87.7% (1772/2020) (Figure 7.1). 
 
7.3.2 Vaccine ‘non-availability’ 
In the PCV-13 birth cohort there were 276 of 1007 (27.4%) children who received the 
third dose of PCV-13 later than the third dose of Pentavalent vaccine (Table 7.1). Of 
336 children eligible for RV1, 122 (36.3%) children received second dose RV1 later 
than the respective Pentavalent dose (Supplementary Table 7.1). Assumed “vaccine 
non-availability” for PCV-13 decreased with time since national introduction, but 
vaccine non-availability for RV1 remained high and no clear association with time since 
introduction was observed. PCV-13 non-availability was higher in the rainy than in the 
dry season (dose 1: aRR 1.63, CI 1.12-2.37). Non-availability of vaccines was 
associated with further distance from the road for both PCV-13 dose 1 (aRR1.57, 
95%CI 1.07-2.30) and RV1 dose 1 (aRR 2.65, CI 1.68-4.19). Children whose initial 
PCV-13 doses were delayed compared with Pentavalent, were less likely to complete 
their PCV-13 series (aRR 0.82, CI 0.76- 0.89 where dose 1 delayed; aRR 0.86, CI 
0.81- 0.91 where dose 2 delayed) (Table 7.1). 
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Figure 7.1 Flowchart of eligible children included in vaccination coverage and timeliness analyses. 
* There were 35 children for whom written documentation was available for MV but missing for PCV-13/RV1 
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Table 7.1. Robust Poisson regression for factors associated with PCV-13 given at a later date than Pentavalent vaccine: “vaccine non-
availability” 
Variable 
 PCV-13 dose 1  PCV-13 dose 3 
N 
N (%) received 
dose later than 
Pentavalent RR (95% CI) aRR1 (95% CI) N 
N (%) received 
dose later than 
Pentavalent RR (95% CI) aRR2 (95% CI) 
Time since vaccine 
introduction3 
        
0-3 months 214 47 (22.0%) 1 1 190 78 (41.1%) 1 1 
4-6 months 186 32 (17.2%) 0.78 (0.52-1.17) 0.97 (0.63-1.49) 168 65 (38.7%) 0.94 (0.73-1.22) 0.94 (0.73-1.22) 
7-9 months 170 27 (15.9%) 0.72 (0.47-1.11) 1.15 (0.65-2.04) 163 54 (33.1%) 0.81 (0.61-1.06) 0.81 (0.61-1.06) 
> 9 months 517 57 (11.0%) 0.50 (0.35-0.71) 0.61 (0.41-0.90) 486 79 (16.3%) 0.40 (0.30-0.52) 0.40 (0.30-0.52) 
Distance to road (km)         
<1 823 119 (14.5%) 1 1 766 202 (26.4%) 1 1 
1-1.49 146 19 (13.0%) 0.90 (0.57-1.41) 0.89 (0.57-1.41) 138 48 (34.8%) 1.31 (1.02-1.71) 1.29 (1.00-1.66) 
≥ 1.5 118 25 (21.2%) 1.47 (1.00-2.15) 1.57 (1.07-2.30) 103 26 (25.2%) 0.96 (0.67-1.36) 1.13 (0.80-1.59) 
Season4         
Dry 566 71 (12.5%) 1 1 600 174 (29.0%) 1 1 
Rainy 521 92 (17.7%) 1.60 (1.20-2.14) 1.63 (1.12-2.37) 407 102 (25.1%) 0.86 (0.70-1.07) 0.97 (0.75-1.25) 
1Adjusted for distance to the main road, season and time since vaccine introduction 
2Adjusted for time since vaccine introduction 
3Time between vaccine introduction and PCV-13 due date 
4 Season at time of Pentavalent receipt: dry season = May-November, rain season = December-April 
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7.3.3 Predictors of vaccination coverage by catch-up campaign 
Among children in the PCV-13 catch-up cohort, age at onset of campaign was strongly 
associated with uptake of third dose of PCV-13 with 77.5% vaccinated among those <4 
months old versus 9.7% amongst those 10-12 months old at time of campaign onset 
(aRR 0.13, CI 0.08-0.22). Children born to mothers aged ≥30 years were less likely to 
be vaccinated with three doses (aRR 0.77, CI 0.64-0.92). Vaccine coverage with at 
least one dose of PCV-13 was higher amongst males (aRR 1.11, CI 1.02-1.20), but this 
effect was no longer observed for coverage with three doses (aRR 1.05, CI 0.93-1.18) 
(Table 7.2). 
 
7.3.4 Predictors of vaccination coverage by routine schedule 
Time since national introduction was an important predictor of vaccination coverage in 
the PCV-13 birth cohort, with higher coverage >9 months compared to 0-3 months 
since introduction (aRR 1.09, CI 1.05- 1.13; aRR 1.16, CI 1.09-1.23 for first and third 
dose respectively) (Table 7.3). Uptake was lower if vaccination was due in the rainy 
season than in the dry season (aRR 0.97, CI 0.95-1.00 for dose 1). Maternal farming 
was associated with a lower uptake of PCV-13 (aRR 0.96, CI 0.93-0.98 for dose 1, 
aRR 0.93, CI 0.89-0.98 for dose 3). Children from larger households or those with 
more children were more likely to receive PCV-13. Children were less likely to be fully 
vaccinated for the third dose of PCV-13 if distance to the nearest clinic was ≥1.5km 
(aRR 0.89, CI 0.81- 0.98). 
 
For RV1 uptake was higher if the mother was not married (aRR 1.08, CI 1.01-1.15 for 
dose 1) or if maternal age was ≥40 years (aRR 1.10, CI 1.00- 1.21 for dose 2), but 
lower if distance to the nearest road was ≥1.5km (aRR 0.80, CI 0.69- 0.93 dose 1; aRR 
0.75, CI 0.63- 0.90 dose 2). In contrast to the PCV-13 birth cohort, children were less 
likely to be vaccinated with RV1 if they lived in a household with more than three 
children <5 years of age (aRR 0.77, CI 0-59-1.00 dose 2) (Supplementary table 7.2). 
 
Infants were less likely to receive MV if there were other children in the household 
(aRR 0.94, CI 0.91-0.97), if distance to the nearest clinic was ≥1.5km (aRR 0.91, CI 
0.85-0.98) or if their mothers were farmers (aRR 0.92, CI 0.89-0.96). Children were 
more likely to be vaccinated if the mother attended post-primary education (aRR 1.09, 
CI 1.00-1.18) (Supplementary Table 7.3). 
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Table 7.2 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the catch-up campaign cohort 
Variable N 
Predictors of being vaccinated with one dose of PCV-13  
N 
Predictors of being vaccinated with three doses of PCV-13 
Coverage (%) RR (95% CI) a RR1 (95% CI) Coverage (%) RR (95% CI) a RR2 (95% CI) 
Gender         
Female 372 65.9 1 1 367 47.7 1 1 
Male  396 74.2 1.13 (1.03 -1.24) 1.11 (1.02- 1.20) 392 51.8 1.09 (0.94 - 1.25) 1.05 (0.93- 1.18) 
Child’s age at campaign 
onset 
        
<4 months 148 85.8 1 1 147 77.5 1 1 
4-6 months 235 86.0 1.00 (0.92 -1.09) 1.04 (0.57- 1.88) 231 63.6 0.82 (0.72 -0.94) 0.83 (0.73- 0.95) 
7-9 months 238 71.4 0.83 (0.75 - 0.92) 0.42 (0.24- 0.72) 236 43.6 0.56 (0.48 - 0.67) 0.58 (0.49- 0.68) 
10-12 months 147 27.2 0.32 (0.24 -0.42) 0.06 (0.03- 0.11) 145 9.7 0.12 (0.08 - 0.21) 0.13 (0.08- 0.22) 
Mother’s age (yrs)         
<20 125 75.2 1 1 121 63.6 1 1 
20-29 408 71.6 0.95 (0.85- 1.07) 1.00 (0.90- 1.11) 406 50.3 0.79 (0.67- 0.93) 0.87 (0.75- 1.00) 
30-39 209 68.4 0.91 (0.79- 1.04) 0.95 (0.84- 1.07) 205 44.4 0.70 (0.57- 0.86) 0.77 (0.64- 0.92) 
≥ 40 26 38.5 0.51 (0.31- 0.84) 0.65 ( 0.41- 1.03) 27 22.2 0.35 (0.17- 0.72) 0.51 (0.28- 0.93) 
Mother’s education         
<5 years primary 63 65.1 1 1 63 47.6 1 1 
>= 5 years primary 492 67.6 1.04 (0.85- 1.26) 0.97 (0.83- 1.13) 487 47.6 1.00 (0.75- 1.32) 0.82 (0.65- 1.02) 
Secondary / tertiary 212 77.8 1.20 (0.98- 1.45) 1.11 (0.95- 1.30) 208 55.8 1.17 (0.88- 1.56) 0.97 (0.76- 1.23) 
Mother’s marital status         
Married 682 70.1 1 1 674 49.4 1 1 
Unmarried3 84 71.4 1.02 (0.88- 1.18) 1.03 (0.91- 1.16) 84 53.6 1.18 (0.75- 1.86) 1.08 (0.90- 1.30) 
Mother mobile phone         
No 490 71.8 1 1 485 49.5 1 1 
Yes 75 68.0 0.95 (0.80- 1.12) 1.01 (0.87- 1.17) 73 42.5 0.86 (0.65- 1.14) 1.00 (0.76- 1.30) 
Mother’s occupation         
Farming 710 70.0 1 1 701 48.9 1 1 
Other 45 75.6 1.08 (0.91- 1.28) 1.14 (0.95- 1.35) 45 50.1 0.98 (0.72- 1.33) 1.13 (0.82-1.56) 
Orphanhood         
Both parents alive 749 70.4 1 1 740 49.9 1 1 
Father died 12 58.3 0.83 (0.51- 1.34) 0.82 (0.55- 1.23) 12 50.0 1.00 (0.57- 1.77) 1.09 (0.68- 1.74) 
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Table 7.2 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the catch-up campaign cohort 
Variable N 
Predictors of being vaccinated with one dose of PCV-13  
N 
Predictors of being vaccinated with three doses of PCV-13 
Coverage (%) RR (95% CI) a RR1 (95% CI) Coverage (%) RR (95% CI) a RR2 (95% CI) 
Place of birth         
Health centre 668 71.3 1 1 662 50.6 1 1 
Home / TBA / other 70 65.7 0.92 (0.77- 1.10) 0.91 (0.78- 1.07) 68 47.1 0.93 (0.71- 1.21) 0.94 (0.75- 1.19) 
Housing standard         
1 (lowest) 127 68.5 1 1 126 50.0 1 1 
2 280 68.9 1.01 (0.87- 1.16) 1.02 (0.91- 1.15) 275 50.6 1.01 (0.82- 1.25) 1.06 (0.87- 1.27) 
3 151 68.2 1.00 (0.85- 1.17) 0.99 (0.87- 1.14) 150 46.7 0.93 (0.73- 1.19) 0.96 (0.77- 1.20) 
4 (highest) 124 72.6 1.06 (0.90- 1.24) 1.07 (0.93- 1.22) 124 50.0 1.00 (0.78- 1.28) 1.00 (0.80- 1.26) 
Household size         
<4 148 74.3 1 1 145 57.2 1 1 
4-6 396 69.7 0.94 (0.84- 1.05) 1.00 (0.91- 1.11) 393 50.1 0.88 (0.74- 1.04) 1.05 (0.88- 1.25) 
≥ 7 224 68.3 0.92 (0.81- 1.05) 0.96 (0.86- 1.08) 221 44.3 0.77 (0.63- 0.95) 0.95 (0.78- 1.17) 
Number of children <5 
years in household 
        
1 329 70.8 1 1 324 52.5 1 1 
2 394 69.5 0.98 (0.89- 1.08) 0.96 (0.88- 1.05) 391 47.3 0.90 (0.78- 1.04) 0.95 (0.83- 1.09) 
≥ 3 45 71.1 1.00 (0.82- 1.23) 0.96 (0.81- 1.14) 44 49.8 1.00 (0.74- 0.35) 0.99 (0.76- 1.31) 
Distance to road (km)         
<1 579 71.0 1 1 571 49.6 1 1 
1-1.5  125 67.2 0.95 (0.83- 1.08) 0.93 (0.84- 1.04) 124 52.4 1.06 (0.88- 1.28) 1.04 (0.89- 1.21) 
≥ 1.5  64 68.8 0.97 (0.81- 1.15) 0.92 (0.77- 1.10) 64 46.9 0.95 (0.72- 1.24) 0.89 (0.68- 1.16) 
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Table 7.2 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the catch-up campaign cohort 
Variable N 
Predictors of being vaccinated with one dose of PCV-13  
N 
Predictors of being vaccinated with three doses of PCV-13 
Coverage (%) RR (95% CI) a RR1 (95% CI) Coverage (%) RR (95% CI) a RR2 (95% CI) 
Distance to clinic (km)         
<1 514 72.0 1 1 509 50.9 1 1 
1-1.49 176 67.1 0.93 (0.83- 1.05) 0.93 (0.84- 1.03) 174 50.6 0.99 (0.84- 1.18) 0.98 (0.85- 1.13) 
≥ 1.5  78 65.4 0.92 (0.77- 1.07) 0.94 (0.81- 1.08) 76 40.8 0.80 (0.60- 1.07) 0.85 (0.66- 1.09) 
Moved house          
No  742 69.7 1 1 734 49.5 1 1 
Yes  26 84.6 1.21 (1.02- 1.44) 1.14 (0.98- 1.31) 25 60.0 1.21 (0.87- 1.69) 1.10 (0.74- 1.38) 
1 Adjusted for child’s age at onset of catch-up vaccination campaign and sex 
2 Adjusted for child’s age at onset of catch-up vaccination campaign and maternal age 
3 Never married/divorced/widowed 
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Table 7.3 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the birth cohort 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of PCV-
13 
 
 
N 
Predictors of being vaccinated with three doses of 
PCV-13 
Coverage1 
(%) 
Crude RR  
(95% CI) 
Adjusted RR2  
(95% CI) 
Coverage 
(%) 
Crude RR  
(95% CI) 
Adjusted RR3  
(95% CI) 
Gender         
Female 634 95.1 1 1 632 89.7 1 1 
Male  583 95.7 1.01 (0.98- 1.03) 1.00 (0.98- 1.03) 583 89.0 1.00 (0.96- 1.03) 0.99 (0.95- 1.03) 
First dose PCV-13 
given later than 
Pentavalent 
        
No  - - - - 922 96.2 1 1 
Yes - - - - 163 79.1 0.82 (0.76- 0.89) 0.82 (0.76- 0.89) 
Second dose PCV-
13 given later than 
Pentavalent 
        
No - - - - 834 97.6 1 1 
Yes - - - - 243 84.0 0.86 (0.81- 0.91) 0.86 (0.81- 0.91) 
Time since vaccine 
introduction4 
        
0-3 months 268 90.7 1 1 268 81.7 1 1 
4-6 months 220 92.7 1.02 (0.97- 1.08) 1.03 (0.97- 1.08) 220 86.4 1.06 (0.98- 1.14) 1.07 (0.99- 1.15) 
7-9 months 194 94.3 1.04 (0.99- 1.10) 1.02 (0.97- 1.07) 194 89.7 1.10 (1.02- 1.18) 1.10 (1.02- 1.18) 
> 9 months 535 99.3 1.09 (1.05- 1.14) 1.09 (1.05- 1.13) 533 94.4 1.15 (1.09- 1.23) 1.16 (1.09- 1.23) 
Mother’s age         
<20 205 94.2 1 1 205 88.8 1 1 
20-29 662 94.7 1.10 (0.97- 1.05) 0.99 (0.95- 1.03) 661 88.5 1.00 (0.94- 1.05) 0.99 (0.94- 1.05) 
30-39 312 97.4 1.03 (1.00- 1.08) 1.02 (0.98- 1.06) 312 91.0 1.03 (0.97- 1.09) 1.03 (0.97- 1.09) 
≥ 40 
 
36 97.2 1.03 (0.97- 1.10) 1.01 (0.95- 1.08) 35 94.3 1.06 (0.97- 1.17) 1.07 (0.98- 1.17) 
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Table 7.3 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the birth cohort 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of PCV-
13 
 
 
N 
Predictors of being vaccinated with three doses of 
PCV-13 
Coverage1 
(%) 
Crude RR  
(95% CI) 
Adjusted RR2  
(95% CI) 
Coverage 
(%) 
Crude RR  
(95% CI) 
Adjusted RR3  
(95% CI) 
Mother’s education         
<5 years primary 77 96.1 1 1 77 85.7 1 1 
>= 5 years 
primary 
791 95.5 0.99 (0.95- 1.04) 0.99 (0.95- 1.05) 790 89.0 1.04 (0.94- 1.14) 1.04 (0.95- 1.14) 
Secondary / 
tertiary 
348 95.1 0.99 (0.94- 1.04) 0.99 (0.94- 1.04) 347 91.1 1.06 (0.96- 1.17) 1.05 (0.95- 1.16) 
Mother’s marital 
status 
        
Married 1085 95.6 1 1 1083 89.6 1 1 
Unmarried5 130 93.9 0.98 (0.94- 1.03) 0.97 (0.93- 1.02) 130 87.7 0.98 (0.92- 1.05) 0.97 (0.90- 1.03) 
Mother mobile phone 
personal use 
        
No 926 96.1 1 1 962 90.1 1 1 
Yes 155 93.9 0.98 (0.94- 1.02) 0.96 (0.92- 1.00) 165 90.9 1.01 (0.96- 1.06) 0.98 (0.93- 1.04) 
Mother’s occupation         
Farming 1113 95.2 1 1 1111 88.8 1 1 
Other 82 98.8 1.04 (1.01- 1.07) 1.04 (1.02- 1.07) 82 95.1 1.07 (1.02- 1.13) 1.07 (1.02- 1.13) 
Orphanhood         
Both parents alive 1194 95.3 1 1 1192 89.3 1 1 
Father died 11 100 1.05 (1.04- 1.06) 1.05 (1.02- 1.08) 11 90.9 1.02 (0.15- 9.47) 1.02 (0.85- 1.21) 
Mother died 5 100 1.05 (1.04- 1.06 1.01 (0.98- 1.05) 5 100 1.12 (1.09- 1.14) 1.08 (1.03- 1.13) 
Place of birth         
Health centre 1091 95.4 1 1 1089 90.1 1 1 
Home / TBA / 
other 
114 94.7 0.99 (0.95- 1.04) 1.00 (0.96- 1.05) 114 83.3 0.93 (0.85- 1.01) 0.94 (0.87- 1.03) 
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Table 7.3 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the birth cohort 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of PCV-
13 
 
 
N 
Predictors of being vaccinated with three doses of 
PCV-13 
Coverage1 
(%) 
Crude RR  
(95% CI) 
Adjusted RR2  
(95% CI) 
Coverage 
(%) 
Crude RR  
(95% CI) 
Adjusted RR3  
(95% CI) 
Housing standard         
1 (lowest) 158 93.0 1 1 157 82.8 1 1 
2 401 95.5 1.03 (0.98- 1.08) 1.02 (0.97- 1.07) 400 90.0 1.09 (1.00- 1.18) 1.06 (0.98- 1.14) 
3 168 96.4 1.04 (0.98- 1.09) 1.03 (0.97- 1.08) 168 88.7 1.07 (0.98- 1.17) 1.03 (0.95- 1.13) 
4 (highest) 148 93.9 1.01 (0.95- 1.07) 1.00 (0.94- 1.06) 148 89.9 1.09 (0.99- 1.19) 1.04 (0.95- 1.13) 
Household size 
(persons)  
        
<4 256 92.6 1 1 256 85.9 1 1 
4-6 641 96.1 1.04 (1.00- 1.08) 1.04 (1.00- 1.08) 640 90.9 1.06 (1.00- 1.12) 1.05 (1.00- 1.11) 
≥ 7 320 96.3 1.04 (1.00- 1.08) 1.04 (1.00- 1.09) 319 89.0 1.04 (0.97- 1.10) 1.04 (0.98- 1.10) 
Number of children 
<5 years in 
household 
        
1 495 94.1 1 1 495 88.3 1 1 
2 621 96.0 1.02 (0.99- 1.05) 1.00 (0.97- 1.03) 619 89.8 1.02 (0.98- 1.06) 1.02 (0.98- 1.07) 
≥ 3 101 98.0 1.04 (1.00- 1.08) 1.03 (0.99- 1.08) 101 92.1 1.04 (0.98- 1.11) 1.07 (1.00- 1.13) 
Distance to road 
(km) 
        
<1 922 95.3 1 1 921 89.8 1 1 
1-1.49 164 95.1 1.00 (0.96- 1.04) 1.00 (0.96- 1.04) 163 92.0 1.02 (0.97- 1.08) 1.05 (1.00- 1.10) 
≥ 1.5 131 96.2 1.00 (1.05- 1.05) 1.00 (0.96- 1.04) 131 83.2 0.93 (0.86- 1.00) 0.95 (0.87- 1.03) 
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Table 7.3 Univariable and multivariable analysis of predictors of pneumococcal vaccine uptake in the birth cohort 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of PCV-
13 
 
 
N 
Predictors of being vaccinated with three doses of 
PCV-13 
Coverage1 
(%) 
Crude RR  
(95% CI) 
Adjusted RR2  
(95% CI) 
Coverage 
(%) 
Crude RR  
(95% CI) 
Adjusted RR3  
(95% CI) 
Distance to clinic 
(km) 
        
<1 856 96.1 1 1 854 90.8 1 1 
1-1.49 249 94.8 0.99 (0.95- 1.02) 0.98 (0.95- 1.02) 249 88.8 0.98 (0.93- 1.03) 0.98 (0.93- 1.03) 
≥ 1.5 112 91.1 0.95 (0.89- 1.01) 0.95 (0.90- 1.01) 112 80.4 0.86 (0.81- 0.97) 0.89 (0.81- 0.98) 
Moved house         
No 1155 95.7 1 1 1153 89.9 1 1 
Yes 62 90.3 0.94 (0.87- 1.03) 0.96 (0.88- 1.04) 62 80.7 0.90 (0.79- 1.02) 0.91 (0.80- 1.03) 
Season6         
Dry 621 97.1 1 1 619 92.7 1 1 
Rainy 596 93.6 0.96 (0.94- 0.99) 0.97 (0.95- 1.00) 596 85.9 0.97 (0.93- 1.00) 0.97 (0.93- 1.01)  
PCV = Pneumococcal Conjugate Vaccine, TBA = Traditional Birth Attendant 
1 Coverage is percent vaccinated 
2 Adjusted for age at onset of vaccination, number of household members, season and maternal occupation 
3 Adjusted for age at onset of vaccination, distance to the nearest clinic and maternal occupation 
4 Time between vaccine introduction and due date of first dose PCV  
5 Never married/divorced/widowed 
6 Season at due date of PCV: dry season = May-November, rainy season = December-April 
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7.3.5 Timeliness of vaccination 
Figure 7.2 shows the timeliness of vaccination in the eligible birth cohorts. Median time 
delay for each PCV-13 dose was 17 days (IQR 7-36), 7 days (IQR 0-28) and 7 days 
(IQR 0-35) respectively. For RV1 doses, median delay was 19 days (IQR 8-36) and 7 
days (IQR 0-35) respectively. MV median delay was 20 days (IQR 3-46). Total delay in 
vaccination was associated with living further away from the road. Living with more 
under-five children was associated with delays for MV and RV1. Maternal farming and 
non-facility birth were associated with delays in PCV-13 and MV. Lower maternal 
education was associated with delayed MV. PCV-13 delay was associated with moving 
house in the vaccination period and vaccination due in the rainy season, but no such 
associations were observed for RV1 and MV (Table 7.4, Supplementary table 7.4 & 
7.5).
 
 
Figure 7.2 Timeliness of pneumococcal conjugate, rotavirus and measles 
vaccines, among vaccinated children in the Karonga Health and Demographic 
Surveillance Site 
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Table 7.4 Survival analysis of predictors of timeliness of pneumococcal 
vaccination 
 
Variable 
 
N 
Median delay in 
days (IQR) 
Crude hazard ratio 
(95%CI) 
Adjusted hazard 
ratio1 (95%CI) 
Gender     
Female 601 51 (25-102) 1 1 
Male  555 53 (23-110) 0.97 (0.86-1.10) 0.99 (0.87-1.13) 
Mother’s age (yrs)     
<20 186 54 (22-102) 1 1 
20-29 629 57 (25-114) 0.97 (0.82-1.16) 0.96 (0.80-1.15) 
30-39 304 46 (23-97) 1.10 (0.90-1.33) 1.09 (0.89-1.32) 
≥ 40 35 40 (21-99) 1.27 (0.87-1.85) 1.25 (0.85-1.84) 
Mother’s education     
<5 years primary 74 72 (27-143) - - 
>= 5 years primary 751 57 (25-114) 1.19 (0.92-1.54) 1.15 (0.88-1.50)  
Secondary / tertiary 330 41 (19-92) 1.43 (1.09-1.87) 1.27 (0.96-1.68) 
Mother’s marital status     
Married 1028 54 (24-107) 1 1 
Unmarried 2 126 46 (19-119) 1.00 (0.82-1.21) 0.97 (0.79-1.19) 
Mother mobile phone     
No 919 55 (24-105) 1 1 
Yes  159 39 (19-79) 1.21 (1.01, 1.44) 1.08 (0.90-1.30) 
Mother’s occupation     
Farming  1056 55 (24-113) 1 1 
Other 80 32 (18-49) 1.69 (1.33-2.14) 1.80 (1.41-2.28) 
Orphanhood     
Both parents alive 1133 51 (24-109) 1 1 
Father died 11 46 (13-113) 1.03 (0.55-1.92) 1.20 (0.64-2.24) 
Mother died 5 42 (7-69) 1.66 (0.69-4.00) 2.64 (0.98-7.12) 
Place of birth     
Health centre 1040 49 (23-100) 1 1 
Home / TBA / other 104 71 (35-193) 0.71 (0.57-0.88) 0.77 (0.61-0.97) 
Housing standard     
1 (lowest) 146 77 (34-166) 1 1 
2 380 53 (24-112) 1.35 (1.09-1.66) 1.25 (1.00-1.55) 
3 160 55 (24-107) 1.34 (1.05-1.71) 1.22 (0.95-1.57) 
4 (highest) 146 41 (79-91) 1.58 (1.23-2.02) 1.27 (0.97-1.66) 
Household size     
<4 235 52 (23-110) 1 1 
4-6 611 50 (23-101) 1.10 (0.94-1.30) 1.10 (0.93-1.29) 
≥ 7 310 56 (25-115) 1.01 (0.85-1.22) 1.01 (0.84-1.21) 
Number of children <5 
years in household 
    
1 469 46 (21-93) 1 1 
2 593 58 (26-117) 0.91 (0.80-1.03) 0.95 (0.83-1.08) 
≥ 3 94 48 (25-102) 1.01 (0.80-1.28) 1.19 (0.93-1.50) 
Distance to road (km)     
<1 875 46 (22-98) 1 1 
1-1.49 155 56 (31-92) 0.96 (0.81-1.15) 1.02 (0.85-1.22) 
≥ 1.5 126 86 (47-156) 0.65 (0.53-0.79) 0.68 (0.55-0.84) 
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Table 7.4 Survival analysis of predictors of timeliness of pneumococcal 
vaccination 
 
Variable 
 
N 
Median delay in 
days (IQR) 
Crude hazard ratio 
(95%CI) 
Adjusted hazard 
ratio1 (95%CI) 
Distance to clinic (km)     
<1 820 48 (22-99) 1 1 
1-1.49 230 63 (27-111) 0.89 (0.76-1.04) 0.91 (0.78-1.07) 
≥ 1.5 106 57 (30-160) 0.71 (0.57-0.89) 0.80 (0.63-1.01) 
Moved house      
No 1102 49 (23-101) 1 1 
Yes 54 96 (68-199) 0.54 (0.40-0.74) 0.50 (0.37-0.69) 
Season3     
Dry 606 50 (25-99) 1 1 
Rainy 550 55 (22-119) 0.90 (0.79- 1.02) 0.86 (0.76- 0.98) 
TBA = Traditional Birth Attendant 
1 Adjusted for maternal occupation, place of birth, distance from the road, moved house, 
season. 
2 Never married/ divorced/widowed 
3 At due date of vaccination 
 
 
7.3.6 Sensitivity analysis including children without written documentation 
There were 428 children without written documentation of PCV-13 and RV1 vaccine 
status. Verbal report of PCV-13 vaccine status was available for 356 children, provided 
by the mother (44.9%), father (34.3%), a sibling (3.7%), other relative (16.9%) or a 
non-relative (0.3%). Coverage by verbal report amongst children without written 
documentation, excluded from the analyses reported above, was lower for the PCV-13 
catch-up cohort (45.8% (87/190) dose 1, 45.3% (86/190) dose 2, 45.3% (86/190) dose 
3), PCV-13 birth cohort (84.3% (140/166) dose 1, 84.3% (140/166) dose 2, 83.7% 
(139/166) dose 3) and RV1 (78.0% (39/50) dose 1, 76.0% (38/50) dose 2), but higher 
for coverage of MV (99.7% (361/362)). Moving house (aRR 0.89, CI 0.80-1.00) and 
being born to an unmarried mother (aRR 0.93, CI 0.87-1.00) were associated with lack 
of written documentation. Children born to farming mothers were found to be more 
likely to have written documentation available (aRR 1.17, CI 1.07-1.29). Including 
children without written documentation in the primary analyses did not change our main 
findings, although significance was lost for some risk factors, possibly as a result of 
misclassification of verbal report of vaccination status. No new risk factors for vaccine 
uptake were identified in analyses including only children without written 
documentation. 
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7.4 Discussion 
 
Malawi has been proactive in the trialling, introduction and post-roll out evaluation of 
vaccines, and as our data show, has achieved high coverage and good timeliness, 
even in our remote study setting. As with all universal programmes some gaps remain. 
Studies that have examined factors associated with vaccination coverage and 
timeliness of vaccines in sub-Saharan Africa, have found that lower vaccine uptake 
and delayed vaccination were associated with low socioeconomic status, low maternal 
education, non-facility birth, and increased distance to a health facility (186-188, 193-
209) (Supplementary Table 7.6), consistent with the findings of this study. No studies 
were conducted in the context of newly introduced PCV-13 and RV1. In this study, 
despite our communal context of homogenous cultural affiliation and of socioeconomic 
standing and remoteness, we found programmatic and socio-demographic 
characteristics that are associated with vaccination coverage and timeliness among 
individual infants in a rural region of Malawi. The recognition that there exist individual 
vulnerabilities even in an otherwise homogenous setting is important, and we return to 
this point in our recommendations. 
 
We made the assumption that if Pentavalent vaccine was received on time but PCV-13 
was delayed then this was due to local non-availability of the latter. At the time of PCV-
13 introduction in late 2011 Malawi suffered major fuel shortages that impacted on 
distribution of newly introduced vaccines and many other societal functions. Although 
we are unable to verify this assumption, presumed non-availability reduced with time 
since national introduction and was associated with seasonality and distance from the 
road. More remote health centres generally serve a more scattered population residing 
away from dense centres, and often away from sealed roads. Such health centres are 
more difficult to access by the vaccine programme delivery mechanisms; we tried to 
capture this, albeit imperfectly by including in distance to sealed road. Non-availability 
of early doses predicted not only total vaccination delay, but also non-completion of the 
vaccine course. Recognising the challenges in place at the time of PCV-13 
introduction, the Malawi National Immunisation Technical Advisory Group conducted 
several sessions to review lessons learnt from PCV-13 in planning for RV1 
introduction. These reviews included wide representation from ministerial, non-
government and academic health planners with vaccine programme experience, 
epidemiologists, procurement, media, finance and transport specialists. Separately 
conducted coverage estimates from southern Malawi do suggest rapid attainment of 
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RV1 population coverage (210), although in our more remote setting RV1 non-
availability seemed to persist over time. 
 
Despite the decision to provide catch-up vaccination to infants, the country was 
provided with doses adequate only for the birth cohort (211). Coverage achieved 
among infants was moderate, but was low amongst older infants (9.7% for dose 3 
amongst those 10-12 months at time of campaign onset). It is likely that available PCV-
13 doses were prioritised for younger infants, but alternative hypotheses for the lower 
uptake amongst older infants are that mothers were unaware of the programme for 
older infants, or that mothers were reluctant or could not afford to make an additional 
visit to the health centre, but accepted vaccination as part of the routine schedule for 
younger infants. 
 
We identified several socio-demographic predictors of vaccine coverage and 
timeliness. Specific associations varied by vaccine and dose and should be interpreted 
with caution, particularly when results are counterintuitive, conflicting, of borderline 
significance or so small as to be not meaningful for example RV1 uptake being higher 
among unmarried mothers, or crowded households being associated with higher 
uptake of PCV-13 coverage but lower uptake of RV1 and MV. Despite these caveats, 
we did find that infants living further away from the road or clinic were consistently 
more likely to be vaccinated late and less likely to complete vaccination as previously 
found in the same setting (188). Both measures of distance capture slightly different 
challenges in reaching vaccine services. Distance from road is a measure of 
remoteness and in this setting a marker for socioeconomic standard. Distance to clinic 
more directly reflects accessibility. Lower maternal education was consistently 
associated with lower vaccine uptake and more delays, although significance on 
multivariable analysis was only retained for MV. This finding provides further evidence 
for the importance of maternal education in remote rural settings, and of community 
sensitisation methods other than printed media. Infants born to farming mothers were 
more likely to be vaccinated late and less likely to complete vaccination for PCV-13 
and MV. It is plausible that farming mothers have fewer opportunities to bring their child 
to the clinic on time. With regards to the catch-up campaign for PCV-13, greater 
maternal age was associated with lower uptake. For both RV1 and MV living in a 
household with multiple children <5 years was a risk factor for both lower uptake and 
delayed timeliness. Infants born outside of health facilities were vaccinated later for 
PCV-13 and MV. For PCV-13, vaccination due in the rainy season was found to be 
associated with lower uptake and more delays. In rural Malawi health facilities are 
spaced approximately every 10km to make access possible by foot. However, during 
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the rains this is challenging, since torrents frequently wash away bridges and render 
footpaths impassable and farming communities are busy with planting and weeding. 
Noting the factors associated with MV coverage is important because if our coverage 
levels reflect those in the whole population <5 years herd protection against measles 
will not be achieved. 
 
Vaccination timeliness is important for several reasons. Optimising vaccine schedules 
requires balancing benefits of delayed vaccination, such as prolonged immunity, 
against protection at an early age in the context of high force of infection (212, 213). 
Timeliness is also a marker of the functionality of the national vaccine delivery system 
so is of inherent interest to health service planners. 
 
Limitations 
Our study has limitations. Excluding children if written documentation of dates was 
unavailable may lead to an overestimation of vaccine coverage for PCV-13 and RV1 
since reported coverage was lower among children without documentation. Coverage 
estimates for measles may have been underestimated if doses given during district-
wide campaigns were unrecorded, consistent with higher coverage reported by parents 
than documented in health passport. A sensitivity analysis including children without 
written documentation did not alter the main findings of this study. Our data could not 
distinguish whether written documentation was missing because the health passport 
was truly lost, or because the mother, generally in charge of keeping the children’s 
health passports, was not available at time of the interview. The low proportion of 
mothers available at time of interview for children for whom written documentation was 
not available (44.9% vs. 84.3% for children with documentation) suggests that both 
scenarios occur. We included only children surviving to one year of age. We 
hypothesise that children dying in infancy are more likely to be unvaccinated, and this 
is currently being investigated (214); results are anticipated in 2016. Our data come 
from an area under continuous demographic surveillance which may have an 
increased vaccine uptake. Although vaccine uptake may be higher in our Demographic 
Surveillance Site than in other areas, the risk factors we found for low uptake or poor 
timeliness of vaccination are likely to be relevant to other rural African settings not 
under continuous demographic surveillance. A fortiori, if in an area with relatively good 
service provision we identified children whose circumstances adversely affect vaccine 
coverage, then in other rural areas with similar socio-demographics but less functioning 
health systems, such children are very likely to be under-served.  In the absence of 
reliable data on stock-outs, we made the assumption that delay in new vaccines when 
older vaccines were given on time was due to non-availability of new vaccines. The 
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validity of this assumption cannot be confirmed. Our definition would miss non-
availability of all vaccines, however in practice initial post-introduction delivery to clinics 
of PCV-13 and RV1 occurred separately from routine vaccine delivery.  
 
Conclusion 
Although vaccination coverage is moderately high in this rural population of northern 
Malawi, we found that infants born to lower educated mothers or farming mothers and 
those living further away from the road or clinic were at greater risk of being not fully 
vaccinated and being vaccinated late. We also found delays in vaccination to be 
associated with non-facility birth. Vaccine stock-outs which were more likely during the 
rains resulted in both a delay in vaccine timeliness and in fewer infants being fully 
vaccinated. Countries introducing new vaccines should (i) ensure adequate stock and 
resources for planned catch-up campaigns and strengthen system required for rapid 
roll-out and delivery. (ii) Understand who remains most vulnerable so that focussed 
delivery to improve access to immunisation occurs. This is crucial for maximising the 
equitable benefits of universal vaccination programmes. (iii) Ensure culturally 
appropriate and understandable health information about vaccines is widely available 
together with a continued focus on making vaccines as accessible as possible to 
families on the social margins. These suggested recommendations are essential if the 
full benefits of vaccination programmes are to be realized among the most vulnerable.  
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Supplementary tables 
 
Supplementary table 7.1: Robust Poisson regression for factors associated with rotavirus vaccine given at a later date than Pentavalent 
vaccine: “vaccine non-availability” 
Variable 
 RV1 dose 1  RV1 dose 2 
N 
N (%) received 
dose later than 
Pentavalent RR (95% CI) aRR1 (95% CI) N 
N (%) received 
dose later than 
Pentavalent RR (95% CI) aRR2 (95% CI) 
Time since vaccine 
introduction3 
        
0-3 months  79 18 (22.8%) 1 1 77 30 (39.0%) 1 1 
4-6 months 90 23 (25.6%) 1.58 (0.97-2.56) 1.64 (1.02-2.64) 87 33 (37.9%) 1.11 (0.79-1.55) 1.14 (0.82-1.58) 
> 6 months 179 29 (16.2%) 1.41 (0.83-2.38) 1.55 (0.91-2.64) 172 59 (34.3%) 1.14 (0.80-1.61) 1.27 (0.87-1.84) 
Distance to road (km)         
<1 270 44 (16.3%) 1 1 265 86 (32.5%) 1 1 
1-1.49 37 16 (43.2%) 2.65 (1.68-4.19) 2.65 (1.68-4.19) 34 23 (67.7%) 2.08 (1.56-2.79) 2.08 (1.56-2.79) 
≥ 1.5 41 10 (24.4%) 1.50 (0.82-2.74) 1.50 (0.82-2.74) 37 13 (35.1%) 1.08 (0.68-1.73) 1.08 (0.68-1.73) 
Season4         
Dry 154 34 (22.1%) 1 1 137 48 (35.0%) 1 1 
Rainy 194 36 (18.6%) 0.84 (0.55-1.28) 0.86 (0.57-1.30) 199 74 (37.2%) 1.06 (0.79-1.42) 1.02 (0.76-1.37) 
1 Adjusted for distance to the main road and time since vaccine introduction 
1 Adjusted for distance to the main road  
2 Time between vaccine introduction and RV1 due date 
3 Season at time of Pentavalent receipt: dry season = May-November, rain season = December-April 
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Supplementary table 7.2. Univariable and multivariable analysis of predictors of rotavirus vaccine uptake 
 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of  
Rotavirus vaccine 
 
 
N 
Predictors of being vaccinated with two doses of  
Rotavirus vaccine 
Coverage1 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR2 (95% 
CI) 
Coverage 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR3 (95% CI) 
Gender         
Female 201 90.1 1 1 201 86.1 1 1 
Male  196 90.3 1.00 (0.94- 1.07) 1.01 (0.50- 2.04) 195 87.7 1.02 (0.94- 1.10) 1.01 (0.94- 1.09) 
First dose RV1 given 
later than Pentavalent 
        
No  - - - - 278 96.4 1 1 
Yes - - - - 69 94.3 0.99 (0.94- 1.05) 1.00 (0.95- 1.05) 
Time since vaccine 
introduction4 
        
0-3 months 198 91.9 1 1 197 88.3 1 1 
4-6 months 109 83.5 0.91 (0.83- 1.00) 0.92 (0.84- 1.00) 109 80.7 0.91 (0.82- 1.02) 0.93 (0.84- 1.02) 
>7 months 90 94.4 1.03 (0.96- 1.10) 1.03 (0.96- 1.10) 90 91.1 1.03 (0.95- 1.12) 1.03 (0.94- 1.13) 
Mother’s age (years)         
<20 62 93.6 1 1 62 90.3 1 1 
20-29 228 89.5 0.96 (0.88- 1.04) 1.00 (0.92- 1.07) 227 86.3 0.96 (0.87- 1,05) 1.00 (0.91- 1.09) 
30-39 98 88.8 0.95 (0.86- 1.04) 0.98 (0.90- 1.07) 98 84.7 0.94 (0.83- 1.05) 0.97 (0.87- 1.08)  
≥ 40 8 100 1.07 (1.00- 1.14) 1.07 (0.99- 1.16) 8 100 1.11 (1.02- 1.20) 1.10 (1.00- 1.21) 
Mother’s education         
<5 years primary 27 74.1 1 1 27 70.4 1 1 
≥ 5 years primary 260 90.8 1.23 (0.98- 1.54) 1.19 (0.97- 1.45) 259 86.9 1.23 (0.96- 1.58) 1.19 (0.95- 1.49) 
Secondary / tertiary 109 92.7 1.25 (0.99- 1.57) 1.19 (0.97- 1.46) 109 90.8 1.29 (1.00- 1.66) 1.22 (0.97- 1.53) 
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Supplementary table 7.2. Univariable and multivariable analysis of predictors of rotavirus vaccine uptake 
 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of  
Rotavirus vaccine 
 
 
N 
Predictors of being vaccinated with two doses of  
Rotavirus vaccine 
Coverage1 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR2 (95% 
CI) 
Coverage 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR3 (95% CI) 
Mother’s marital status         
Married 354 89.6 1 1 353 86.4 1 1 
Unmarried5 42 95.2 1.06 (0.99- 1.15) 1.08 (1.01- 1.15) 42 90.5 1.05 (0.94- 1.16) 1.05 (0.96- 1.15) 
Mother mobile phone         
No 326 89.6 1 1 325 86.2 1 1 
Yes 65 92.3 1.03 (0.95- 1.12) 1.02 (0.94- 1.10) 65 90.8 1.05 (0.96- 1.15) 1.04 (0.95- 1.13) 
Mother’s occupation         
Farming 365 90.1 1 1 364 86.8 1 1 
Other 27 88.9 0.99 (0.85- 1.13) 0.96 (0.86- 1.07)  27 88.9 1.02 (0.89- 1.18) 0.98 (0.88- 1.10) 
Orphanhood         
Both parents alive 389 90.0 1 1 388 86.7 1 1 
Father died 4 100 1.11 (1.08- 1.15) 1.22 (1.02- 1.46) 4 75.0 0.86 (0.49- 1.52) 0.96 (0.64- 1.45) 
Mother died 2 100 1.11 (1.08- 1.15) 1.12 (0.91- 1.38) 2 100 1.15 (1.11- 1.20) 1.20 (0.96- 1.49) 
Place of birth         
Health centre 367 90.2 1 1 366 87.4 1 1 
Home / TBA / other 25 88.0 0.98 (0.84- 1.13) 0.97 (0.91- 1.03) 25 76.0 0.87 (0.69- 1.09) 0.93 (0.74- 1.15) 
Housing standard         
1 (lowest) 42 86.7 1 1 41 82.9 1 1 
2 127 88.2 1.03 (0.90- 1.18) 0.95 (0.81- 1.10) 127 84.3 1.02 (0.87- 1.19) 0.93 (0.77- 1.11) 
3 54 87.0 1.02 (0.86- 1.19) 0.95 (0.81- 1.12) 54 85.2 1.03 (0.86- 1.23) 0.95 (0.79- 1.14) 
4 (highest) 38 94.7 1.11 (0.96- 1.28) 0.97 (0.83- 1.14) 38 89.5 1.08 (0.90- 1.29) 0.93 (0.76- 1.13) 
Household size 
(persons) 
        
<4 70 92.9 1 1 70 90.0 1 1 
4-6 220 88.6 0.95 (0.88- 1.03) 1.00 (0.91- 1.09) 219 85.8 0.95 (0.87- 1.04) 0.98 (0.89- 1.09) 
≥ 7 107 91.6 0.99 (0.90- 1.08) 1.06 (0.97- 1.16) 107 86.9 0.97 (0.87- 1.08) 1.02 (0.92- 1.14) 
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Supplementary table 7.2. Univariable and multivariable analysis of predictors of rotavirus vaccine uptake 
 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of  
Rotavirus vaccine 
 
 
N 
Predictors of being vaccinated with two doses of  
Rotavirus vaccine 
Coverage1 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR2 (95% 
CI) 
Coverage 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR3 (95% CI) 
Number of children <5 
years in household 
        
1 148 94.6 1 1 148 91.9 1 1 
2 226 88.9 0.94 (0.89- 1.00) 0.97 (0.91- 1.03) 225 85.3 0.93 (0.86- 1.00) 0.96 (0.90- 1.03) 
≥ 3 23 73.9 0.78 (0.61- 1.00) 0.81 (0.63- 1.03) 23 69.6 0.76 (0.58- 1.00) 0.77 (0.59- 1.00) 
Distance to road (km)         
<1 297 93.9 1 1 297 91.6 1 1 
1-1.49 45 84.4 0.90 (0.79- 1.02) 0.90 (0.80- 1.02) 45 77.8 0.85 (0.72- 1.00) 0.85 (0.73- 1.00) 
≥ 1.5 55 74.6 0.79 (0.68- 0.93) 0.80 (0.69- 0.93) 54 68.5 0.75 (0.62- 0.90) 0.75 (0.63- 0.90) 
Distance to clinic (km)         
<1 284 92.3 1 1 283 89.1 1 1 
1-1.49 84 88.1 0.95 (0.88- 1.04) 0.98 (0.91- 1.07) 84 85.7 0.96 (0.87- 1.06) 1.00 (0.91- 1.10) 
≥ 1.5 29 75.9 0.82 (0.67- 1.01) 0.90 (0.73- 1.11) 29 69.0 0.77 (0.60- 0.99) 0.85 (0.65- 1.10) 
 
Moved house         
No 383 90.1 1 1 382 87.2 1 1 
Yes 14 92.9 1.03 (0.89- 1.20) 1.07 (0.90- 1.28) 14 78.6 0.90 (0.68- 1.19) 0.96 (0.74- 1.24) 
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Supplementary table 7.2. Univariable and multivariable analysis of predictors of rotavirus vaccine uptake 
 
Variable 
 
 
N 
Predictors of being vaccinated with one dose of  
Rotavirus vaccine 
 
 
N 
Predictors of being vaccinated with two doses of  
Rotavirus vaccine 
Coverage1 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR2 (95% 
CI) 
Coverage 
(%) 
 
Crude RR (95% CI) 
 
Adjusted RR3 (95% CI) 
Season6         
Dry 178 91.6 1 1 178 89.3 1 1 
Rainy 
 
 
219 89.0 0.97 (0.88- 0.96) 1.01 (0.84- 1.10) 218 84.9 0.95 (0.88- 1.03) 0.95 (0.88- 1.03) 
RV1 = Monovalent Rotavirus Vaccine, TBA = Traditional Birth Attendant 
1 Coverage is percent vaccinated 
2 Adjusted for age at onset of vaccination, distance to the nearest main road and number of children <5 years in the household 
2 Adjusted for distance to the nearest main road and number of children <5 years in the household 
4 Time between vaccine introduction and due date of first dose RV1  
5 Never married/divorced/widowed 
6 Season at due date of RV1 receipt: dry season = May-November, rainy season = December-April 
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Supplementary table 7.3. Univariable and multivariable analysis of measles 
vaccine uptake 
Variable N Coverage (%) RR (95% CI) a RR1 (95% CI) 
Gender     
Female 1025 87.5 1 1 
Male  995 87.9 1.00 (0.97-1.04) 1.00 (0.97-1.04) 
Mother’s age (yrs)     
<20 332 91.0 1 1 
20-29 1093 88.0 0.97 (0.93-1.01) 0.99 (0.95-1.03) 
30-39 530 85.9 0.94 (0.90-0.99) 0.96 (0.92-1.01) 
≥ 40 63 82.5 0.91 (0.81-1.02)  0.91 (0.81-1.03) 
Mother’s education     
<5 years primary 146 80.8 1 1 
>= 5 years primary 1304 87.4 1.08 (0.97-1.17) 1.08 (0.99-1.17) 
Secondary / tertiary 568 90.1 1.12 (1.03-1.21) 1.09 (1.00-1.18) 
Mother’s marital status     
Married 1801 88.0 1 1 
Unmarried2 215 85.6 0.97 (0.92-1.03) 0.95 (0.89-1.00) 
Mother mobile phone     
No 1478 87.1 1 1 
Yes 245 88.2 1.01 (0.96-1.06) 0.99 (0.95-1.05) 
Mother’s occupation     
Farming 1744 87.1 1 1 
Other 130 96.2 1.10 (1.06-1.15) 1.09 (1.05-1.13) 
Orphanhood     
Both parents alive 1976 87.6 1 1 
Father died 23 87.0 0.99 (0.85-1.16) 1.00 (0.86-1.16) 
Mother died 7 100.0 1.14 (1.12-1.16) 1.12 (1.09-1.16) 
Place of birth     
Health centre 1787 88.3 1 1 
Home / TBA / other 191 81.7 0.93 (0.86-0.99) 0.94 (0.88-1.01) 
Housing standard     
1 (lowest) 293 84.0 1 1 
2 694 86.7 1.03 (0.98-1.09) 1.02 (0.96-1.09) 
3  325 88.3 1.05 (0.99-1.12) 1.03 (0.96-1.10) 
4 (highest) 278 91.1 1.08 (1.02-1.15) 1.04 (0.97-1.11) 
Household size (persons)     
<4 409 90.7 1 1 
4-6 1057 88.0 0.97 (0.93-1.00) 1.01 (0.97-1.06) 
≥ 7 554 85.0 0.94 (0.89-0.98) 0.98 (0.93-1.03) 
Number of children <5y in 
household 
    
1 837 91.2 1 1 
2 1035 84.8 0.93 (0.90-0.96) 0.94 (0.91-0.97) 
≥ 3 148 88.5 0.97 (0.91-1.03) 0.99 (0.93-1.05) 
Distance to road (km)     
<1 1526 88.7 1 1 
1-1.49 295 85.8 0.97 (0.92-1.02) 1.00 (0.95-1.05) 
≥ 1.5  199 83.4 0.94 (0.88-1.00) 0.98 (0.92-1.05) 
 
 
    
158 Chapter 7 	
 
Supplementary table 7.3. Univariable and multivariable analysis of measles 
vaccine uptake 
Variable N Coverage (%) RR (95% CI) a RR1 (95% CI) 
Distance to clinic (km) 
<1 1397 89.3 1 1 
1-1.49  431 85.9 0.96 (0.92-1.00) 0.97 (0.93-1.01) 
≥ 1.5  192 80.7 0.90 (0.84-0.97) 0.91 (0.85-0.98) 
Moved house     
No 1931 87.9 1 1 
Yes 89 84.3 0.96 (0.88-1.05) 0.96 (0.88-1.05) 
Season3     
Dry 1158 87.9 1 1 
Rainy 862 87.5 1.00 (0.96- 1.03) 0.99 (0.96- 1.04) 
1 Adjusted for maternal occupation, children <5 years in household, distance to clinic 
2 Never married/divorced/widowed 
3 At time measles vaccine dose due 
 
Supplementary table 7.4 Survival analysis of predictors of timeliness of rotavirus 
vaccination 
 
Variable 
 
N 
Median delay 
in days (IQR) 
Crude hazard ratio 
(95%CI) 
Adjusted hazard 
ratio1 (95%CI) 
Gender     
Female 197 45 (20-101) 1 1 
Male  190 41 (18-116) 1.05 (0.84-1.30) 1.06  (0.85-1.32) 
Mother’s age     
<20 58 33 (16-87) 1 1 
20-29 222 46 (21-100) 0.87 (0.64-1.18) 1.04 (0.75-1.44) 
30-39 98 44 (19-145) 0.81 (0.57-1.14) 0.97 (0.68-1.39) 
≥ 40 8 6 (5-16) 2.91 (1.38-6.14) 3.47 (1.63-7.41) 
Mother’s education     
<5 years primary 27 46 (19-*) 1 1 
>= 5 years primary 255 48 (22-113) 1.34 (0.84-2.14) 1.07 (0.66-1.72) 
Secondary / 
tertiary 
104 30 (11-68) 1.77 (1.08-2.90) 1.36 (0.82-2.24) 
Mother’s marital 
status 
    
Married 345 45 (19-110) 1 1 
Unmarried2 41 31 (13-67) 1.24 (0.88-1.75) 1.22 (0.85-1.74) 
Mother mobile phone 
personal use 
    
No 317 46 (20-113) 1 1 
Yes  65 29 (13-73) 1.32 (0.99-1.75) 1.25 (0.94-1.66) 
Mother’s occupation     
Farming  356 45 (19-104) - - 
Other 27 28 (12-67) 1.23 (0.81-1.86) 1.15 (0.76-1.77) 
Orphanhood     
Both parents alive 379 42 (18-104) 1 1 
Father died 4 61 (13-176) 0.62 (0.20-1.93) 0.71 (0.23-2.23) 
Mother died 2 35 (35-86) 1.09 (0.27-4.37) 1.13 (0.27-4.65) 
Both died -  - - 
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Supplementary table 7.4 Survival analysis of predictors of timeliness of rotavirus 
vaccination 
 
Variable 
 
N 
Median delay 
in days (IQR) 
Crude hazard ratio 
(95%CI) 
Adjusted hazard 
ratio1 (95%CI) 
 
 
Place of birth 
    
Health centre 358 42 (18-101) 1 1 
Home / TBA / other 24 37 (30-215) 0.76 (0.47-1.22) 0.92 (0.57-1.50) 
Housing standard     
1 (lowest) 41 62 (29-169) 1 1 
2 124 49 (22-145) 1.09 (0.74-1.60)  0.86 (0.58-1.29) 
3 52 34 (16-101) 1.28 (0.82-2.01) 1.00 (0.62-1.59) 
4 (highest) 38 26 (12-65) 1.73 (1.07-2.78) 1.22 (0.74-2.01) 
Household size 
(persons) 
    
<4 66 35 (21-81) 1 1 
4-6 215 49 (19-119) 0.85 (0.63-1.13) 1.09 (0.76-1.55) 
≥ 7 106 31 (18-81) 1.01 (0.73-1.41) 1.49 (1.02-2.18) 
Number of children <5 
years in household 
    
1 144 31 (13-73) 1 1 
2 220 47 (23-133) 0.72 (0.57-0.90) 0.80 (0.64-1.00) 
≥ 3 23 64 (19-*) 0.52 (0.31-0.87) 0.55 (0.33-0.92) 
Distance to road (km)     
<1  290 33 (16-77) 1 1 
1-1.49 44 73 (44-215) 0.51 (0.36-0.74) 0.53 (0.37-0.75) 
≥ 1.5  52 72 (36-*) 0.47 (0.33-0.67) 0.50 (0.35-0.71) 
Distance to clinic (km)     
<1 277 44 (18-89) 1 1 
1-1.49 82 38 (22-134) 0.88 (0.67-1.14) 0.95 (0.73-1.25) 
≥ 1.5 28 46 (19-*) 0.61 (0.39-0.98) 0.71 (0.44-1.14) 
Moved house      
No 374 41 (19-104) 1 1 
Yes 13 57 (21-97) 0.80 (0.43-1.52) 0.96 (0.51-1.82) 
Season3      
Dry 138 42 (18-97) 1 1 
Rainy 249 41 (19-113) 0.92 (0.74- 1.15) 0.96 (0.77- 1.20) 
TBA = Traditional Birth Attendant 
1Adjusted for distance to road and number of children <5 in the household 
2 Never married/divorced/widowed 
3 At time of due date of vaccination 
* No 75th percentile delay reported: >25% not vaccinated 
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Supplementary table 7.5 Survival analysis of predictors of timeliness of measles 
vaccination 
Variable N 
Median delay 
in days (IQR) HR (95%CI) aHR1 (95%CI) 
Gender     
Female 898 23 (5-52) 1 1 
Male  900 22 (4-53) 1.03 (0.94, 1.14) 1.00 (0.91, 1.11) 
Mother’s age     
<20 279 22 (3-49) 1 1 
20-29 982 22 (4-50) 0.97 (0.85, 1.11) 1.03 (0.89, 1.19) 
30-39 477 27 (6-60) 0.87 (0.75, 1.02) 0.95 (0.81, 1.12) 
≥ 40 58 29 (10-56) 0.76 (0.56, 1.03) 0.83 (0.61, 1.13) 
Mother’s education     
<5 years primary 126 28 (6-83) 1 1 
>= 5 years primary 1163 23 (5-54) 1.33 (1.09, 1.62) 1.30 (1.06, 1.59) 
Secondary / tertiary 508 20 (4-48)  1.47 (1.19, 1.81) 1.34 (1.08, 1.67) 
Mother’s marital status     
Married 1605 23 (4-52) 1 1 
Unmarried2 190 20 (6-55) 0.98 (0.84, 1.15) 0.91 (0.77, 1.07) 
Mother mobile phone 
personal use 
    
No 1328 24 (5-54) 1 1 
Yes  223 20 (4-54) 1.03 (0.89, 1.19) 0.96 (0.82, 1.12) 
Mother’s occupation     
Farming  1646 23 (5-55) 1 1 
Other 123 16 (2-32) 1.45 (1.21, 1.75) 1.37 (1.12, 1.66) 
Orphanhood     
Both parents alive 1760 23 (4-52) 1 1 
Father died 20 16 (6-57) 1.04 (0.67, 1.62) 1.07 (0.68, 1.69) 
Mother died 5 34 (22-44) 1.25 (0.52, 3.00) 1.18 (0.44, 3.17) 
Both died -  - - 
Place of birth     
Health centre 1604 22 (4-50) 1 1 
Home / TBA / other 160 27 (4-74) 0.77 (0.65, 0.92) 0.82 (0.69, 0.98) 
Housing standard     
1 (lowest) 258 27 (4-62) 1 1 
2 617 26 (5-55) 1.04 (0.90, 1.21) 1.00 (0.86, 1.17) 
3 283 22 (5-59) 1.09 (0.91, 1.30) 1.00 (0.84, 1.20) 
4 (highest) 249 19 (4-45) 1.23 (1.03, 1.47) 1.06 (0.88, 1.29) 
Household size     
<4 354 21 (4-48) 1 1 
4-6 953 22 (4-50) 0.94 (0.83, 1.07) 1.05 (0.90-1.23) 
≥ 7 491 28 (6-61) 0.82 (0.71, 0.94) 0.94 (0.79-1.11) 
Number of children 
<5y in household 
    
1 742 20 (4-48) 1 1 
2 925 25 (5-56) 0.86 (0.78, 0.95) 0.89 (0.80, 0.98) 
≥ 3 131 26 (4-62) 0.82 (0.67, 0.99) 0.83 (0.68, 1.00) 
Distance to road (km)     
<1 1362 21 (4-49) 1 1 
1-1.49 259 23 (6-58) 0.89 (0.78, 1.03) 0.96 (0.83-1.10) 
≥ 1.5  177 32 (11-73) 0.78 (0.66, 0.92) 0.85 (0.71-1.01) 
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Supplementary table 7.5 Survival analysis of predictors of timeliness of measles 
vaccination 
Variable N 
Median delay 
in days (IQR) HR (95%CI) aHR1 (95%CI) 
Distance to clinic (km)     
<1 1251 21 (4-50) 1 1 
1-1.49  375 25 (7-54) 0.92 (0.81, 1.03) 0.95 (0.84, 1.07) 
≥ 1.5  172 27 (4-77) 0.80 (0.67, 0.94) 0.86 (0.72, 1.02) 
Moved house      
No 1723 23 (4-52) 1 1 
Yes 75 27 (6-74) 0.87 (0.68, 1.11) 0.88 (0.69, 1.13) 
Season3     
Dry 1042 22 (4-55) 1 1 
Rainy 756 24 (5-49) 0.97 (0.87- 1.07) 0.96 (0.87- 1.06) 
1 Adjusted for maternal education, maternal occupation, number of children <5 years in the 
household and place of birth. 
2 Never married/divorced/widowed 
3 At due date of measles vaccination 
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Supplementary table 7.6 Literature reporting risk factors for low vaccine uptake and/or late vaccination in sub-Saharan countries 
 
Reference  
 
Data source 
 
Country  
 
Rural/urban  
Risk factors for low vaccine uptake 
and/or late vaccination 
Abadura SA et al, 2015 (193) DHS  Ethiopia Both  
-non-facility birth 
-low maternal education 
-low socio-economic status 
-resident in rural area 
-increasing number of children <5 years in the 
household 
Babalola S, 2008 (194) Household survey  Nigeria Both  
-non-facility birth 
-maternal age <20 years 
-low maternal education 
-low socio-economic status 
Babirye JN et al, 2012 (195) Cross-sectional survey Kampala, Uganda Urban  
-non-facility birth 
-increasing number of children per woman 
-household poverty 
Bosch-Capblanch X et al, 2012 (196) Review of DHS 96 low & middle income 
countries including Malawi 
Both  
-household poverty 
-low education status of caregiver and caregiver’s 
partner 
-caregivers not received tetanus toxoid vaccine 
Canavan ME et al, 2014 (197) Review of DHS in Africa  
Burundi, Ethiopia, Kenya, 
Rwanda, Tanzania, and 
Uganda 
Both -non-facility birth 
 
Fadness LT et al, 2011 (187) 
Secondary analysis data 
from cluster randomised 
controlled trial 
Uganda Both  -low maternal education 
Fadness LT et al, 2011 (198) 
Secondary analysis data 
from cluster randomised 
controlled trial 
South Africa Both  
-low maternal education 
-non-facility birth 
-resident in rural area 
Favin M et al, 2012 (199) Review of grey literature Global (53.9% African) Both  
-long distances to health facilities 
-low socio-economic status 
-low parental educational status 
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Supplementary table 7.6 Literature reporting risk factors for low vaccine uptake and/or late vaccination in sub-Saharan countries 
 
Reference  
 
Data source 
 
Country  
 
Rural/urban  
Risk factors for low vaccine uptake 
and/or late vaccination 
Glatman-Freedman A & Nichols K, 
2012 (200) Review 
Low, middle & high 
income countries 
 
Both 
-low socio-economic status 
-low parental education particularly maternal 
education. 
-long distances to health facilities 
Gram L et al, 2014 (186) 
Secondary analysis of 
HDSS  Ghana Rural  
-resident in rural area 
-low maternal education 
-low socio-economic status 
Jahn A et al, 2008 (188) HDSS  Malawi 
Rural  
 
-non-facility birth 
-low parental education 
-long distances to health facilities 
-low socio-economic status 
Jani JV et al, 2007 (201) Cross-sectional survey Mozambique  Rural  
-long distances to health facilities 
-low maternal education 
-non-facility birth 
Le Polain de Waroux O et al, 2012 
(202) 
Cluster survey Southern Tanzania Rural  
-long distances to health facilities 
-household poverty 
-low maternal education 
-rainy season 
Malawi Demographic and Health 
Survey 2010 (204) 
 
DHS Malawi 
90% of the 
population live 
in rural areas. 
-resident in urban area 
-low maternal education 
-low socio-economic status 
Munthali AA, 2007 (203) DHS 1992, 1996, 2000, 
2004 
Malawi Both  
-low maternal education 
-resident in rural areas 
-increased child birth order 
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Supplementary table 7.6 Literature reporting risk factors for low vaccine uptake and/or late vaccination in sub-Saharan countries 
 
Reference  
 
Data source 
 
Country  
 
Rural/urban  
Risk factors for low vaccine uptake 
and/or late vaccination 
Odutola A et al, 2015 (205) Cross sectional survey Western Gambia Both  
-increased child birth order 
-non-facility birth 
Payne S et al, 2014 (206) HDSS  Gambia Both  
-resident in urban areas 
-ethnicity (Mandinka)  
 
 
Rainey JJ et al, 2011 (207) 
Systematic literature 
review  
Global literature published 
between 1999-2009  
Both  
-low maternal education 
-low socio-economic status 
-long distances to health facilities 
-high costs (direct and indirect) 
-fear of adverse events 
Schoeps A et al, 2013 (208) HDSS  Burkina Faso Both  
-low maternal education 
-low socio-economic status 
-dry season at birth 
-long distances to health facilities 
Wysonge CS et al, 2012 (209) DHS  
24 countries in sub-
Saharan Africa  
Both  
-low maternal education 
-low paternal education 
-low socio-economic status 
-resident in urban areas 
-countries with high fertility rates 
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8. Pneumococcal carriage and transmission in 
the post-vaccination period 
8.1 Background 
In chapter 7 we discussed the introduction of PCV-13 in November 2011 and the levels 
of vaccine coverage and timeliness achieved by August 2014. This section of the 
thesis will discuss the impact of PCV-13 on pneumococcal carriage. With the 
introduction of PCV-13, VT carriage is expected to be reduced in vaccinated children. If 
a herd effect has taken place as a result of reduced transmission from vaccinated 
children, reduced carriage prevalence is also expected to occur in unvaccinated 
individuals.	
 
This chapter includes the findings of a longitudinal and cross-sectional study performed 
in 2014, 2.5 years after introduction of PCV-13. We repeated sample collection of the 
same age groups as were studied in 2008-2011: infants, mothers and their household 
members, and HIV-positive adults attending a local ART clinic.  
 
The objectives of the studies were: 
1) To measure the direct impact and indirect impact of PCV-13 vaccination on 
pneumococcal carriage in households, by measuring changes in VT and NVT 
serotype carriage in vaccinated and unvaccinated individuals in households in 
Karonga District, comparing the pre-vaccination (2009-2011) and post-
vaccination (2014) period. 
2) To measure the indirect impact of PCV-13 vaccination on pneumococcal 
carriage in HIV-positive adults attending antiretroviral therapy (ART) clinic, by 
measuring changes in VT and NVT serotype carriage in HIV-positive adults 
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attending an ART clinic in Karonga District, comparing the pre-vaccination 
(2008-2010) and post-vaccination (2014) period. 
3) To study characteristics of carriage in infants, other household members <5 
years old and mothers using a 2-week study interval (instead of a 4-6 week 
study interval as was used before), to inform the analysis of longitudinal data 
collected in 2009-11.  
8.2 Methods 
8.2.1 Study design 
This analysis combines the results of three related studies: a longitudinal household 
study on mother-infants pairs and any household members <5 years of age; a cross-
sectional study on mother-infant pairs and any household members <15 year; and a 
cross-sectional study on HIV-positive adults attending a local ART clinic. The 
combination of a longitudinal and cross-sectional household study was adopted to 
increase sample size for infants 6 weeks of age, and to include older children. Because 
participation of older children in longitudinal sampling was found unsatisfactory in the 
earlier study conducted in 2009-2011, older children (5-15 years) were only included in 
the cross-sectional component of this study to focus sampling efforts.  
 
Household studies 
Recruitment of mother-infant pairs took place in the postnatal clinics of two rural 
hospitals between April and July 2014. All mother-infant pairs that were discharged 
within one week of delivery and were living within the KHDSS area were eligible for 
inclusion in the study. For the longitudinal study, nasopharyngeal swabs were collected 
at the household from the infant, mother and any other household members <5 years 
at 6, 8, 10, 12, 14, 16, 18 weeks of the index infant’s age (Table 8.1). In addition, a 
sample was taken from the mother and any household members <5 years around the 
first week of the index infant’s age to assess exposure in the first weeks of life. No 
sample from the index child was taken at this point: a pilot study performed in the cold 
(peak) season in 2010 on carriage acquisition in infants showed that all 24 infants 
included were negative for Streptococcus pneumoniae at week 1 (unpublished results). 
In the cross-sectional study, a nasopharyngeal sample was taken at 6 weeks of the 
infant’s age. A nasopharyngeal sample was taken from all household members <15 
years willing to participate. 
 
HIV-status of the mother was transcribed from her health passport. If the health 
passport was unavailable the mother was asked for her HIV-status verbally. HIV-status 
reported verbally was crosschecked with the KHDSS database from the ART clinic. 
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Index infants were offered all routine vaccinations including PCV-13 at 6, 10, and 14 
weeks of age. Vaccination status of other household members <5 years was obtained 
from the KHDSS records.  
 
Table 8.1 Overview of household carriage studies conducted before (2009-2011) 
and after (2014) introduction of PCV-13  
Year Participants Sampling weeks  
1 6 8 10 12 14 16 18 … 52a 
2009-2011 
longitudinal  
Infant, mother, all hh 
members 
 
X  X  X  X X 
2014 
longitudinal 
Infant, mother, children  
<5yrs 
Xb X X X X X X X  
2014 
cross-sectional 
Infant, mother, children 
<15yrs 
 
X        
a Sampling continued at 22, 26, 30, 34, 40, 46, 52 weeks 
b Week 1 sample not collected for infants 
 
HIV-positive adults attending ART clinic 
HIV-positive adults were recruited from the local ART clinic between May and August 
2014. All HIV-positive adults attending the local ART clinic who were living in the 
KHDSS were eligible for participation in the study, regardless of ART status. A 
nasopharyngeal sample was taken at the ART clinic. Household characteristics and 
ART prescription history were obtained from the KHDSS records. Using unique 
identifiers we linked participation in this study to individual records of nasopharyngeal 
swabs taken in the study conducted in 2008-2010 (chapter 6).  
 
8.2.2 Sample size 
Cross-sectional analysis 
Sample size calculations by age group are presented in Table 8.1. Sample size 
calculations were based on the prevalence of VT serotypes measured in 2009-11. We 
hypothesized that a 70% reduction of VT carriage occurred in vaccine-eligible and non-
vaccine-eligible age groups in frequent contact with vaccinated individuals (infants, 
mothers and children 5-14 years). We hypothesized that a 60% reduction of VT 
carriage occurred in HIV-positive adults attending the ART clinic. Sample sizes were 
calculated based on one sample per individual for the children and for HIV-positive 
individuals presenting to the ART clinic. Too few mothers (n=201) were recruited in the 
PVC study in 2009-11 to allow for a comparison based on one sample per individual, 
given the low baseline VT carriage of adults (6.0%) We therefore used all available 
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samples (multiple samples per individual) in the prevalence comparison. We calculated 
the design effect (Deff), the factor by which the sample would need to be inflated to 
adjust for this use of multiple samples per person. For this, we calculated the intraclass 
correlation coefficient (ICC) to determine the correlation between samples of the same 
individual, and between different individuals:  !"" =  !"2!"2+ !"2  with !"! =  between-individual variance and  !"! = within-individual variance !"## =  1 + ! − 1 ∗ !!!  with != number of samples per individual (!=8 in 2014) 
 
Sample and power calculations were performed using the ‘pwr’ and ‘ICC’ packages in 
the statistical software programme R 3.0.1 (R Foundation for Statistical Computing, 
Vienna, Austria) (167, 215, 216). 
 
Table 8.2 presents power calculations for the index infants at 6 weeks of age. 
Recruitment of at least 134 infants was required to allow a detection of 70% reduction 
in VT carriage with 80% power (α=0.05).  
 
Longitudinal analysis 
Table 8.3 shows the power calculations for a survival analysis, comparing VT 
acquisition in infants 2009-2011 (50% of 185 infants acquired a VT serotype at least 
once in 18 weeks) with VT acquisition in infants in 2014. Recruitment of at least 35 
infants was required to allow detection of a 70% reduction in acquisition of VT 
pneumococcus in the first 18 weeks of life. Recruiting 40 mother/infant pairs would 
allow the detection of a 70% reduction with 86% power and a 60% reduction with 77% 
power.  
 
 
 
  
Carriage in the post-vaccination period       169 	
 
 
Table 8.2 Sample size calculations by age group – cross-sectional study 
Age group Prevalence 
VT carriage 
pre-
vaccination 
(2009-11) 
Expected 
reduction 
Expected 
prevalence 
VT carriage 
post-
vaccination 
(2014) 
Number of  
individuals 
(samples)   
2009-11 
Minimum 
sample size  
2014*  
Household study  
6 wks 11.4% 70% 3.4% 185 (185) 134 
18 wks  32.1% 70% 9.6% 165 (165) 29 
1-3 yrs 
(vaccine-
eligible) 
24.1% 70% 7.2% 104 (586) 51 
4-14 yrs 18.3% 70% 5.5% 227 (889) 59 
Mothers  6.0% 70% 1.8% 201 (1858) 276**  
(134 
persons) 
Study at ART clinic 
HIV-positive 
adults  
10.3% 60% 4.1%  544 
(1227) 
171 
* Power calculation for two proportions (different sample sizes), α=0.05, power = 0.80, two-
sided.  
** Using all available samples (n=1858) from 2009-11 ICC  = 0.09, Deff = 1.63. Sample size for 
2009-11 unadjusted = 169 (unadjusted) * 1.63 = 276 (adjusted). 
 
 
Table 8.3 Power calculations for cross-sectional study on 6-week infants  
(Hypothesized scenario highlighted) 
2014 sample size 
(2009-11=185) 
Reduction in VT serotype carriage (two-sided test) 
50% 60% 70%  80% 
100 0.38 0.54 0.72  0.87 
110 0.40 0.57 0.75  0.89 
120 0.42 0.59 0.77  0.91 
130 0.44 0.61 0.79  0.92 
140 0.45 0.63 0.81  0.93 
150 0.47 0.65 0.82  0.94 
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8.2.3 Changes to analysis design post sample size calculations 
Based on the above presented sample size calculations, we aimed to recruit at least 
134 mother-infant pairs, of which at least 35 participated in the longitudinal study. We 
aimed to recruit at least 171 HIV-positive adults attending the ART clinic.  
 
During the analysis phase of this study four changes to the original analysis design 
were made. Firstly, it became evident that matching the pre- and post-vaccination 
period on month of sampling was crucial for the household study: seasonality was 
shown in the pre-vaccination period to be a strong predictor of pneumococcal carriage 
in this population (results in chapters 5). Adjusting all results from both periods on 
sampling month, for instance using sine-cosine waves, proved difficult because 
sampling in the post-vaccination period was only performed during April-August, with 
no estimates available from September-March. It was therefore decided to only use 
samples collected in the same calendar months (April-August) when comparing both 
sampling periods in the household study. In the study on HIV-positive adults attending 
the local ART clinic in 2008-2010, no difference was found between carriage in May-
August (study period 2014) and September-April. Hence, all samples from the pre-
vaccination study were included for this analysis. 
 
Secondly, only a few HIV-positive mothers (n=4) were recruited post-vaccination 
introduction. This is not surprising, given that mothers in the post-vaccination period 
were not selected based on their HIV-status. Because HIV-status was found to be 
associated with carriage amongst mothers in the pre-vaccination period, comparisons 
amongst mothers in the pre- and post-vaccination period included only HIV-negative 
mothers. For infants and other children, all samples were included because maternal 
Table 8.4 Power calculations for longitudinal study infants - survival analysis 
comparing 2009-11 and 2014  
(Hypothesized scenario highlighted) 
2014 sample size 
(2009-11=185) 
Reduction in PCV-13 serotype acquisition (two-sided test) 
50% 60% 70%   80% 
30 0.54 0.67 0.77  0.85 
35 0.59 0.72 0.82  0.89 
40 0.64 0.77 0.86  0.92 
45 0.68 0.81 0.89  0.94 
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HIV-status was not found to be associated with their pneumococcal carriage (chapter 
5).  
 
Thirdly, the above sample size calculations for children 1-14 years and HIV-positive 
adults on ART were based on a single sample per person. Multiple samples per person 
were included in the analysis: within-person clustering was tested for using random 
effect models.  
 
Lastly, the above sample size calculations for children 1-3 years were based on 
vaccine eligibility, not on vaccine receipt. Because information on vaccine receipt was 
available during the analysis, this group was further divided into fully vaccinated and 
non-vaccinated children.  
 
8.2.4 Statistical analysis 
Carriage prevalence ratios (PR) were calculated for the periods before and after 
vaccine introduction. Potential confounders were identified by testing the association 
between variables and the vaccine period: any potential confounding variable with a p-
value of < 0.1 that was a priori thought to be associated with pneumococcal carriage 
was included in the multivariable models. Adjusted prevalence ratios (APR) were 
calculated using log-binomial regression, or Poisson regression with robust standard 
errors if the log-binomial regression failed to converge (169).  
 
Acquisition of first pneumococcal carriage in infants was assessed by survival analysis 
including Kaplan-Meier plots and log-rank tests (168). For the comparison of mean 
time to first acquisition of any or VT carriage between 2009-2011 and 2014, only 
samples from weeks 6, 10, 14 and 18 were used, to allow for direct comparison. All 
available samples were used for analyses including samples collected in 2014 only.  
 
Vaccine effectiveness (VE) against new acquisition of VT carriage was calculated as: !"! = 1 − !!, with RR being the rate ratio of new acquisition of VT carriage in the 
post-vaccination period as compared to the pre-vaccination period. Only samples from 
weeks 6, 10, 14 and 18 collected in 2009-2011 and 2014 were used, to allow for direct 
comparison. A new acquisition event was defined as the identification of a serotype 
when the same serotype was not identified at the previous two sampling times. 
 
Serotype-specific analyses on household exposure and duration of carriage were 
conducted using the same definitions as in chapter 5. Serotyping using latex 
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agglutination did not allow for the distinction between the factortypes of certain NVT, 
e.g. 18A/B or 7A/7B/7C. For the serotype-specific analyses we included those 
serogroups where no further distinction was possible and regarded them to be the 
same serotype. Samples with result “NVT” without further detail available were 
excluded from analysis on carriage duration, but included on the serotype-specific 
analysis on household exposure for mothers and children <5 years, because too few 
typeable isolates were available to exclude “NVT” results in this analysis. 
 
8.3 Results: household study 
8.3.1 Study participants and samples in the post-vaccination period 
There were 156 mother-infant pairs approached to participate in the study (Figure 8.1). 
Two mothers refused to take part in the study, one infant died before participation, and 
one infant was excluded from the study because of a prolonged stay in hospital. Four 
recruited mother-infant pairs were lost to follow-up after recruitment. In total, 148 
mother-infant pairs participated in the study: the first 44 in the longitudinal study, the 
latter 104 in the cross-sectional study. One mother withdrew consent for her own 
participation, but allowed her infant to continue in the longitudinal study. Documented 
HIV test results were available for 88.5% (131/148) mothers. Four (2.7%) mothers 
were HIV-positive (two with documented, two with verbal report): two in the longitudinal 
and two in the cross-sectional study. Of the HIV-negative mothers, 97.9% (141/144) 
reported to have been tested within the last year. In the longitudinal study there were 
23 other household members <5 years; at least one nasopharyngeal sample was 
collected from all of them. In the cross-sectional study there were 54 household 
members <5 years and 121 household members 5-15 years: a nasopharyngeal sample 
was collected from 51 (94.4%) and 89 (73.6%) respectively.  
 
All infants participating in the study received PCV-13. Amongst the 77 household 
members <5 years, 25 (32.5%) were age-eligible for vaccination in the birth cohort: all 
had received full vaccination with PCV-13 at time of the study. Twenty-eight children 
(36.4%) were age-eligible for vaccination in the catch-up cohort; 15 (53.6%) had 
received full vaccination, 4 (14.3%) had received partial vaccination and 9 (32.1%) had 
received no vaccination. Twenty-three children (29.9%) were not age-eligible for PCV-
13 and had not received the vaccine. One child’s birth date and hence vaccine 
eligibility was unknown: this child had not received PCV-13 vaccination. 
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In total, 1140 samples were collected: 792 in the longitudinal and 348 in the cross-
sectional arm of the study. Six samples were lost (3 on initial storage, 3 during 
laboratory analysis), leaving 1334 samples for analysis on pneumococcal carriage.  
 
Figure 8.1 Flowchart of recruitment of mother-infant pairs and other children in 
the household in the post-vaccination period 
 
8.3.2 Comparing characteristics of participants in the pre- and post-vaccination periods 
Table 8.5 shows the characteristics of participants in the pre- and post-vaccination 
periods. For the seasonality-matched analysis, samples from the pre-vaccination 
period were included from 70 infants 6-week old, 71 infants 18-week old, 109 children 
1-4 years, 144 children 5-15 years and 135 HIV-negative mothers. There were seven 
mothers who participated in both the pre- and post-vaccination period. Four children 
were included as index infant in the pre-vaccination and as children 1-4 years in the 
post-vaccination period. Mean age of all children 1-4 years was the same in the pre- 
and post-vaccination period (2.7 years vs. 2.7 years), but differed when considering the 
children’s vaccination status in the post-vaccination years (3.5 years for unvaccinated 
children, 2.1 years for vaccinated children; p<0.001). Participating children in the age 
group 5-15 years were older in the post-vaccination period (mean 7.8 vs. 8.5 years, 
p=0.002). HIV-negative mothers were younger in the post-vaccination period (mean 
26.2 vs. 24.2 years, p<0.001). In the pre-vaccination period, there were more 
households with one or two children <5 years in the household other than the index 
156 mother-infant pairs 
approached  
148 mother-infant pairs 
participated  
2 refusals 
1 died 
1 excluded 
4 lost to follow up 
44 mother-infant pairs in 
longitudinal study 
104 mother-infant pairs in 
cross-sectional study 
348 samples:  
- 104 from mothers (100%) 
- 104 from index infants (100%) 
- 51 from 54 children <5 years (94%) 
- 89 from 121 children 5-15 years (74%) 
792 samples (94% of scheduled visits):  
- 336 from mothers (96%) 
- 299 from index infants (97%) 
- 157 from 23 children <5 years (85%) 
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infant. Participant’s sex did not differ between the two vaccination periods, with the 
exception of children 1-4 years (60.6% vs. 36.5% females, p=0.002). All pneumococcal 
prevalence ratios were adjusted for age and number of children <5 years in the 
household, known to be associated with pneumococcal carriage.  
 
Table 8.5 Characteristics of participants in the pre- and post-vaccination period 
 Pre-vaccination Post-vaccination p-value 
Female sex    
 Infants 6 weeks 
 Infants 18 weeks 
 Children 1-4 years 
  
  
 Children 5-15 years 
 HIV-negative mothers 
35/70 (50.0%) 
33/71 (46.5%) 
66/109 (60.6%) 
 
 
72/144 (50.0%) 
135/135 (100%) 
75/146 (51.4%) 
26/44 (59.1%) 
12/29 (41.4%) (unvaccinated) 
15/38 (39.5%) (vaccinated) 
27/74 (36.5%) (all) 
40/89 (44.9%) 
144/144 (100%) 
0.97 
0.26 
0.10 
0.04 
0.002 
0.54 
- 
Age in years (mean, sd)    
 Children 1-4 years 
 
 
 Children 5-15 years 
 HIV-negative mothers 
2.7, sd = 0.9 
 
 
7.8, sd=2.6  
26.2, sd=6.9  
3.5, sd=0.6 (unvaccinated) 
2.1, sd=0.7 (vaccinated) 
2.7, sd=1.0 (all)  
8.5, sd=3.0  
24.2, sd=6.3 
<0.001 
<0.001 
0.99 
0.002 
<0.001 
Number of children <5 
years other than the index 
infant (households) 
0: 45 (27.1%) 
1: 92 (55.4%) 
2: 29 (17.5%) 
0: 79 (53.4%) 
1: 61 (41.2%) 
2: 8 (5.4%) 
 
<0.001 
sd: standard deviation 
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Figure 8.2 Map of the study area depicting study households in 2009-2011 and 
2014  
Hospital
Health centres
Study households, 2009ï2011
Study households, 2014
Tarmac road
Main tracks
KHDSS area
Lake MalawiNyika National Park
Chilumba 
 Rural Hospital
E
N
W
S
0 2 4 km
176 Chapter 8 	
 
Figure 8.2 shows the geographical spread of households participating in the pre-
vaccination (2009-2011) and post-vaccination (2014) period. In both periods, good 
geographical coverage of the KHDSS area was achieved.   
8.3.3 Pneumococcal carriage prevalence in the pre- and post-vaccination period 
Figure 8.3 shows the prevalence of pneumococcal carriage of any serotype (a), VT 
serotypes (b) and NVT serotypes (c) for each of the age groups in the household study 
by year. Fluctuations in carriage prevalence by year can be observed for all age 
groups. There is no evidence that the decreasing trend in pneumococcal carriage of 
any serotype that was reported for the period 2009-2011 (Chapter 5) continued in 
2014: carriage prevalence in 2014 is as high or higher than carriage prevalence in 
2010 for all age groups. Figure 8.4 shows the proportion of VT isolates amongst 
pneumococcal carriers by age group by year. Estimates for the proportion of VT 
isolates are lower in 2014 than in 2009-2010 for all age groups, with the exception of 6-
week old infants. 
 
In figure 8.5 and 8.6 the same information is summarized for the pre- and post-
vaccination period. Table 8.6 shows the crude and adjusted prevalence ratios for the 
pre- and post-vaccination period. After vaccine introduction, VT carriage decreased 
amongst 18-week old infants (APR 0.24, 95CI% 0.08-0.75) and vaccinated children 1-4 
years (APR 0.54, 95%CI 0.33-0.88). VT carriage also decreased in children 5-15 years 
and mothers: APR 0.37 (95%CI 0.17-0.78) and APR 0.34 (95%CI 0.15-0.79) 
respectively. No decrease in VT carriage was observed for 6-week infants (APR 1.07, 
95% CI 0.38-3.02) and unvaccinated children 1-4 years (APR 0.84, 95%CI 0.53-1.33). 
NVT carriage increased amongst vaccinated children 1-4 years (APR 1.58, 95%CI 
1.21-2.06). No significant increase or decrease in NVT carriage was observed for the 
other age groups. 
 
In the post-vaccination period, the most common VT isolated were 19F, 6B and 6A, 
isolated from 14, 13 and 10 individuals respectively. Other isolated VT were 19A (7 
individuals), 9V (5), 14 (5), 3 (4), 18C (2) and 5(1). Serotypes 1, 4 and 7F were not 
detected in this study population. The most common NVT that we were able to type 
were 19B/19C, 23A/23B and 7A/7B/7C isolated from 19, 14 and 9 individuals 
respectively.  
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A. Carriage prevalence of any serotype 
 
 
B. VT carriage prevalence  
 
 
Figure 8.3 Prevalence of carriage of any serotype (A), VT carriage (B) or NVT 
carriage (C) by age group by year.  
Estimates for pre-vaccination period matched by month of sample collection. No 
samples from infants collected in 2011 
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C. NVT carriage prevalence  
 
Figure 8.3 continued 
Estimates for pre-vaccination period matched by month of sample collection. No 
samples from infants collected in 2011 
Figure 8.4 Proportion of VT isolates amongst pneumococcal carriers by age 
group by year 
Not enough samples collected in 2011 to report proportion of VT isolates. 
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A. Carriage of any serotype 
 
 
B. Carriage of PCV-13 serotypes  
 
Figure 8.5 Prevalence of carriage of any serotype (A) or VT carriage (B) or NVT 
carriage (C) by age group in the pre- and post-vaccination periods.  
Estimates for pre-vaccination period matched by month of sample collection. 
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C. Carriage of NVT serotypes 
 
 
Figure 8.5 continued. Estimates for pre-vaccination period matched by month of 
sample collection. 
 
 
 
Figure 8.6 Proportion of PCV-13 serotype isolates amongst pneumococcal 
carriers by age group in the pre- and post-vaccination periods.  
infants
6wks
infants
18wks
children
1−4yrs
children
5−15yrs
HIV−
mothers
P r
o p
o r
t i o
n  
c a
r r i
a g
e
0.0
0.2
0.4
0.6
0.8
1.0
infants
6wks
infants
18wks
children
1−4yrs
children
5−15yrs
HIV−
mothers
P r
o p
o r
t i o
n  
o f
 i s
o l a
t e
s
0.0
0.2
0.4
0.6
0.8
1.0
pre−vaccination period (2009−2011)
post−vaccination period (2014)
vaccinated children
pre−vaccination period (2009−2011)
post−vaccination period (2014)
vaccinated children
Carriage in the post-vaccination period       181 	
 
Table 8.6 Carriage prevalence and prevalence ratio for pneumococcal carriage by age group 
 Carriage prevalence  
pre-vaccination 
Carriage prevalence post-
vaccination 
Crude prevalence ratio 
(95%CI) 
Adjusted prevalence ratio 
(95%CI)2 
All serotypes 
Infants, 6 wks  27/70 (38.6%) 64/146 (43.8%) 1.14 (0.80-1.61) 0.98 (0.66-1.47) 
Infants, 18 wks 53/71 (74.7%) 22/44 (50.0%) 0.67 (0.48-0.93) 0.60 (0.42-0.86)3 
Children 1-4 yrs    
- unvaccinated 
- vaccinated 
- all1 
 
196/330 (59.4%) 
 
53/83 (63.9%)  
 
1.08 (0.89-1.29) 
 
1.06 (0.86-1.30)3 
72/103 (70.0%) 1.18 (1.01-1.37) 1.08 (0.91-1.28)3 
141/207 (68.1%) 1.15 (1.01-1.30) 1.10 (0.97-1.25)3 
Children 5-15 yrs 161/325 (49.5%) 33/89 (37.1%) 0.75 (0.56-1.00) 0.73 (0.55-0.97)3     
HIV- mothers 100/595 (16.8%) 64/418 (15.3%) 0.92 (0.69-1.22) 0.75 (0.47-1.17) 
PCV-13 serotypes 
Infants, 6 wks  8/70 (11.4%) 19/146 (13.0%) 1.14 (0.52-2.47) 1.07 (0.38-3.02) 
Infants, 18 wks 32/71 (45.1%) 4/44 (9.1%) 0.20 (0.08-0.53) 0.24 (0.08-0.75)3 
Children 1-4 yrs  
- unvaccinated 
- vaccinated 
- all1 
 
93/330 (28.2%) 
 
19/83 (22.9%) 
 
0.81 (0.53-1.25) 
 
0.84 (0.53-1.33)3 
17/103 (16.5%) 0.59 (0.37-0.93) 0.54 (0.33-0.88)3 
37/207 (17.9%) 0.63 (0.45-0.89) 0.63 (0.45-0.90)3 
Children 5-15 yrs 69/325 (21.2%) 7/89 (7.9%) 0.37 (0.18-0.78) 0.37 (0.17-0.78) 
HIV- mothers 39/595 (6.6%) 10/418 (2.4%) 0.37 (0.19-0.73) 0.34 (0.15-0.79) 
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Table 8.6 Carriage prevalence and prevalence ratio for pneumococcal carriage by age group 
 Carriage prevalence  
pre-vaccination 
Carriage prevalence post-
vaccination 
Crude prevalence ratio 
(95%CI) 
Adjusted prevalence ratio 
(95%CI)2 
Non-PCV-13 serotypes 
Infants, 6 wks  19/70 (27.1%) 45/146 (30.8%) 1.14 (0.72-1.79) 0.95 (0.57-1.56) 
Infants, 18 wks 21/71 (29.6%) 18/44 (40.9%) 1.38 (0.83-2.29) 0.91 (0.47-1.77) 
Children 1-4 yrs  
- unvaccinated 
- vaccinated 
- all1 
 
103/330 (31.2%) 
 
34/83 (41.0%) 
 
1.31 (0.97-1.78) 
 
1.24 (0.88-1.74)3 
55/103 (53.4%) 1.71 (1.34-2.18) 1.58 (1.21-2.06)3 
104/207 (50.2%) 1.61 (1.30-1.99) 1.50 (1.22-1.86) 
Children 5-15 yrs 92/325 (28.3%) 26/89 (29.2%) 1.03 (0.72-1.49) 1.03 (0.71-1.49) 
HIV- mothers 61/595 (10.3%) 54/418 (12.9%) 1.27 (0.90-1.79) 0.99 (0.57-1.73) 
 
1Including children with unknown vaccination status 
2Adjusted for month of sample collection, number of children <5 years in the household, age and within-person clustering (mother only). Using a generalized linear 
mixed model, there was negligible individual-level variance for children 1-4 and 5-5 years of age (σ2 < 0.01), hence results from a (non-mixed) generalized linear 
model were reported. Using a generalized linear mixed model, the individual-level variance for mothers was 0.68 (all serotypes) / 1.25 (PCV-13) / 1.03 (non-PCV-
13). 
3Log-binomial regression model data did not to converge so results of a Poisson model with robust standard errors are presented. 
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8.3.4 Pneumococcal acquisition in infants  
Figure 8.7 and 8.8 show the time to first pneumococcal carriage acquisition in the pre- 
and post-vaccination periods for any serotype and VT, respectively. For acquisition of 
pneumococcal carriage of any serotype, no difference was observed between the pre- 
and post-vaccination period (median time 55.5 vs. 56.5 days, p= 0.71).  
 
 
Figure 8.7 Kaplan-Meier plot for time to first pneumococcal carriage acquisition 
in infants pre and post introduction of PCV-13 
Observations in the pre-vaccination period right-truncated at 18 weeks (maximum 
observation period post-vaccination period). Individuals matched on month of birth. 
 
For VT carriage, a difference was observed between the pre- and post-vaccination 
period, with 62.9% (22/35) vs. 27.9% (12/43) of infants acquiring a VT pneumococcus 
at least once within the first 18 weeks of life (p=0.008). The Kaplan-Meier estimates for 
VT acquisition in the pre-vaccination and post-vaccination period diverge after each 
dose of PCV-13 receipt, providing evidence for a direct vaccine effect.  
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Figure 8.8 Kaplan-Meier plot for time to first acquisition of a vaccine type 
pneumococcus in infants pre and post introduction of PCV-13 
Observations in the pre-vaccination period right-truncated at 18 weeks (maximum 
observation period post-vaccination period). Individuals matched on month of birth. 
 
Incidence of VT carriage acquisition in weeks 6-10 among infants was 22.2% (38/171) 
in the pre-vaccination period and 9.3% (4/43) in the post-vaccination period, implying a 
vaccine efficacy (VE) of 58% for one dose of PCV-13. Incidence in weeks 10-14 was 
14.9% (25/168) in the pre-vaccination period and 4.9% (2/41) in the post-vaccination 
period, implying a VE of 67% for two doses of PCV-13. Incidence in weeks 14-18 was 
20.0% (33/165) in the pre-vaccination period and 2.3% (1/44) in the post-vaccination 
period, implying a VE of 89% for three doses of PCV-13. Combining the results for all 
weeks, VE for at least one dose of PCV-13 was 71%. 
 
In the post-vaccination period, infants living with children <5 years acquired 
pneumococci faster than infants without children <5 years in the household, both for 
pneumococci of any type (p=0.03) (Figure 8.9) and for VT pneumococci (p=0.13) 
(Figure 8.10). No evidence was found for a difference in first VT acquisition between 
infants living with vaccinated or unvaccinated children <5 years (p=0.73, results not 
shown).  
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Figure 8.9 Kaplan-Meier plot for time to first pneumococcal carriage acquisition 
in infants by presence or absence of other children <5 years in the household 
 
Figure 8.10 Kaplan-Meier plot for time to first acquisition of a vaccine type 
pneumococcus in infants by presence or absence of other children <5 years in 
the household  
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8.3.5 Duration of pneumococcal carriage  
Table 8.7 shows results for duration of carriage in infants, mothers and other children 
<5 years. There was some evidence that duration of VT carriage was longer than 
duration of NVT carriage for infants (p=0.08) and other children <5 years (p=0.15), 
although the longest carriage episodes observed were for NVT: an infant carried NVT 
“7A/7B/7C” for an estimated 104 days and a vaccinated child <5 years carried NVT 
“23A/23B” for an estimated 88 days. There was no evidence for a difference in carriage 
duration between vaccinated and unvaccinated children <5 years (p=0.54). Carriage 
episodes of a single sample occurred in 11/26 (42.3%) of episodes for infants, 2/5 
(40%) of episodes for mothers and 14/22 (63.6%) of episodes for children <5 years, 
indicating carriage duration of 14 days or less occurred frequently.  
 
Table 8.7 Duration of Pneumococcal Carriage in Infants, Mothers and Other 
Children < 5 Years in Karonga District, Malawi, 2014 
Serotype Episodes 
(n) 
Duration of carriage (days) 
Median Mean Range 
Infants 
 PCV-13 13 36 47 14-97 
 non-PCV-13 13 16 32 14-104 
 Total 26 32 39 14-104 
Mothers 
 Total 5 26 32 14-39.5 
Other children <5 years: fully vaccinated 
 PCV-13 4 37 34 13-52 
 non-PCV-13 6 20 35 13-88 
 Total 10 24 35 13-88 
Other children <5 years: unvaccinated 
 PCV-13 6 32 38 14-86 
 non-PCV-13 5 14 14 13-16 
 Total 11 16 27 13-86 
Excluding episodes of NVT which were not further serotyped. 
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8.3.6 Household exposure 
Concordance between serotypes simultaneously carried by mothers and infants was 
low: only in 5 of 84 (6.0%) instances when an infant in the longitudinal or cross-
sectional study carried a typeable pneumococcus was the same serotype found in the 
mother. Concordance with infant serotype carriage was 28.9% (11/38) for children <5 
years and 28.6% (2/7) for children 5-14 years.   
 
In the pooled analysis for serotype-specific exposure, both exposure by the mother 
(aRR 9.35, 95%CI 4.51, 20.11) and exposure by other children <5 years (aRR 8.24, 
95%CI 4.22, 16.09) were found to be associated with infant pneumococcal acquisition 
(Table 8.8). Exposure by the infant was associated with pneumococcal acquisition in 
the mother (aRR 18.14, 95%CI 7.22-45.58) and other children in the household (aRR 
11.00, 95%CI 4.51-26.80). Only the association between pneumococcal acquisition in 
other children <5 years and exposure by the mother was not significant – the same 
result as was found in the pre-vaccination period (chapter 5). 
 
Of all acquisitions in the infant, 8.8% (95%CI 0.3-16.6) were attributable to exposure by 
the mother and 15.3% (95%CI 4.1-25.2) were attributable to exposure by another child 
<5 years in the household. The largest aPAFs were seen for exposure by the infant: 
18.5% (95%CI 0.1-33.4) of acquisitions in mothers and 31.2% (95%CI 5.8-49.8) of 
acquisitions in other children <5 years were attributable to exposure by the infant. 
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Table 8.8 Acquisition of infants, mothers and other children <5yrs, stratified by exposure to other household members  
Acquiring category, Exposing 
category, and Exposurea 
No. with 
events 
No. without 
events 
Total no.b cRR  aRRc 
 
95%CI cPAF (%) aPAFb (%) 95%CI 
Infant          
 Mother          
  Yes 11 38 49 18.55 9.53 4.51, 20.11 16.8 8.8 0.3, 16.6 
  No 51 4163 4214       
Infant          
 Other child          
  Yes 15 89 104 13.49 8.24 4.22, 16.09 23.54 15.3 4.1, 25.2 
  No 44 4071 4115       
Mother          
 Infant          
  Yes 6 52 58 21.45 18.14 7.22, 45.58 19.7 18.5 0.1, 33.4 
  No 23 4746 4769       
Mother          
 Other child          
  Yes 5 122 127 9.09 5.83  2.20,15.45 18.5 11.7 0, 25.3 
  No 19 4366 4385       
Other child          
 Infant          
  Yes 9 45 54 8.43 11.00 4.51, 26.80 20.9 31.2 5.8, 49.8 
  No 29 1438 1467       
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Table 8.8 Acquisition of infants, mothers and other children <5yrs, stratified by exposure to other household members  
Acquiring category, Exposing 
category, and Exposurea 
No. with 
events 
No. without 
events 
Total no.b cRR  aRRc 
 
95%CI cPAF (%) aPAFb (%) 95%CI 
Other child          
 Mother          
  Yes 2 5 7 15.8 3.23 0.88, 11.88 5.1 1.3 0, 6.8 
  No 35 1903 1938       
Other child          
 Other child          
  Yes 4 18 22 8.74 4.87 1.44, 16.40 7.2 4.1 0,12.9 
  No 45 2118 2163       
Abbreviations: aRR, adjusted rate ratio; aPAF, adjusted population attributable fraction; CI, confidence interval; cRR, crude rate ratio; cPAF, crude population 
attributable fraction.a Exposure was defined as carriage by another household member at any of the previous two sample times. Analysis was limited to those 
samples for which exposure data for at least one of the two previous sample times was available. b Adjusted analysis for exposure by index child, exposure by 
children <5 yrs, exposure by mother. 
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8.4 Results: HIV-positive adults on ART 
8.4.1 Study participants and samples 
In 2008-10 545 participants (contributing 1248 samples) were recruited, in 2014 199 
participants were recruited. Individuals participating in the post-vaccination period were 
on average older than individuals participating in the pre-vaccination period, more likely 
to be female, and less likely to live with one or more children <5 years in the household 
(Table 8.9). The study conducted in 2008-2010 recruited only individuals newly 
attending the ART clinic, whereas in the study conducted in 2014 all individuals 
attending the ART clinic were included, resulting in a difference in time on ART 
treatment. Also a difference in cotrimoxazole prophylactic treatment and tuberculosis 
treatment was observed between the two time periods.   
  
Table 8.9 Characteristics of participants in the pre- and post-vaccination period 
 Pre-vaccination Post-vaccination p-value 
Female sex 326/545 (59.8%) 136/199 (68.3%) 0.04 
Age in years (mean, sd) 39.1, sd=10.9 45.3, sd = 10.2 <0.001 
Number of children 
<5 years in the household 
0: 232 (47.6%) 
1: 180 (37.0%) 
2: 62 (12.7%) 
3-4: 13 (2.7%) 
0: 111 (69.8%) 
1: 40 (25.2%) 
2: 7 (4.4%) 
3: 1 (0.6%) 
<0.001 
Years on ART 0-2: 545/545 
(100%) 
0-2: 38 (19.1%) 
3-6: 99 (49.7%) 
7+: 62 (31.2%) 
<0.001 
Received cotrimoxazole 
prophylactic treatment1 
307/545 (56.3%) 199/199 (100%) <0.001  
Received tuberculosis1 
treatment 
11/545 (2.0%) 0/193 (0%) 0.10 
1For pre-vaccination period: received treatment at least once during the study period 
 
8.4.2 Pneumococcal carriage amongst HIV-positive adults in the pre and post-
vaccination period  
 
Pneumococcal carriage prevalence amongst HIV-positive adults attending the local 
ART clinic was 10.1% (20/199) in the post-vaccination period. A vaccine serotype was 
detected in only one sample (0.5%). There was some evidence that carriage of any 
serotype was higher in females (aPR 2.18, 95%CI 0.76-6.23) and individuals living with 
children <5 years (aPR 2.19, 95%CI 0.98-4.91) (Table 8.10).  
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Table 8.10. Risk factors associated with pneumococcal carriage in HIV-positive adults sampled in the post-vaccination period. 
Risk factor n 
Carriage Crude  
PR  
95%CI  P 
Adjusted 
PR 
95%CI  P 
n % 
Sex          
 Male 63 4 6.4% -   -   
 Female 136 16 11.8% 1.85   0.65, 5.32 0.25 2.18   0.76, 6.23 0.15 
Age (years)          
 <40 59 6 10.2% -      
 ≥40 140 14 10.0% 0.98 0.40, 2.43 0.97 1.23  0.49, 3.10 0.66 
Years on ART          
 0-2.5 38 5 13.2% -      
 >2.5 161 15 9.3% 0.71 0.27, 1.83 0.48 0.54   0.22, 1.32 0.18 
Children <5 years in householdb          
 No 111 11 9.9% -      
 Yes 48 9 18.8% 1.89 0.84, 4.27 0.12 2.19   0.98, 4.91 0.06 
Number of household membersb          
 0-2 29 4 13.8% -      
 3-6 106 13 12.3% 0.89 0.31, 2.52 0.83 0.65   0.23, 1.88  0.43 
 7-11 24 3 12.5% 0.91 0.22, 3.66 0.89 0.52 0.11, 2.42 0.40 
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Table 8.11 Carriage prevalence and prevalence ratio for pneumococcal carriage 
amongst HIV-positive adults on ART 
 Carriage 
prevalence  
pre-vaccination 
Carriage 
prevalence post-
vaccination 
Crude prevalence 
ratio (95%CI) 
Adjusted 
prevalence ratio 
(95%CI)1 
Any serotype 
 
284/1248 (22.8%) 20/199 (10.1%) 0.44 (0.29-0.68) 0.79 (0.36-1.74) 
VT 130/1248 (10.4%) 1/199 (0.5%) 0.05 (0.01-0.34) 0.06 (0.01-0.40) 
NVT 154/1248 (12.3%) 19/199 (9.6%) 0.77 (0.49-1.22) 1.17 (0.46-2.95) 
1 Adjusted for sex, number of children <5 years in the household, month of sampling and ART 
duration (any serotypes and NVT only) 
 
Pneumococcal carriage prevalence in 2014 was lower than in 2008-2010 for VT, NVT 
and any serotype (Table 8.11), although in the adjusted analysis only the prevalence 
ratio for VT carriage remained significant (aPR 0.06, 95%CI 0.01-0.40).  
 
Table 8.12 shows the different comparisons done to investigate the association 
between pneumococcal carriage prevalence and ART duration in the pre- and post 
vaccination period. Carriage prevalence in individuals 0-2.5 years on ART in 2008-
2010 was 22.8% (284/1248) for any serotype. In 2014, carriage prevalence of any 
serotype was 13.2% (5/38) and 9.3% (15/161) for individuals 0-2.5 years and >2.5 
years on ART respectively (aPR 0.54, 95%CI 0.22-1.32). Combining both periods, the 
crude prevalence ratio was 0.41 (95%CI 0.25-0.68) for >2.5 vs. 0-2.5 years ART and 
the crude prevalence ratio was 0.44 (0.29-0.68) for the comparison between the pre- 
and post-vaccination period. In the multivariable model including month of sampling, 
sex and the presence of children <5 years in the household, the adjusted prevalence 
ratio for ART duration was 0.57 (95%CI 0.22-1.41) for >2.5 vs. 0-2.5 years of ART and 
the adjusted prevalence ratio for vaccination period was 0.79 (95%CI 0.36-1.74) for the 
post-vaccination vs. pre-vaccination period. No evidence was found for a difference in 
carriage by cotrimoxazole prophylactic treatment (aPR 1.03, 95%CI 0.84-1.28). Lower 
carriage was observed for individuals on tuberculosis treatment, but numbers were too 
small to draw any conclusions from this observation (aPR 0.47, 95%CI 0.08-2.87). 
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Table 8.12 Comparisons to assess the association with ART duration and 
vaccination period in HIV-positive adults on ART 
Comparison 
group 
n 
Carriage 
cPR  95%CI  aPR 95%CI  
n % 
Comparison between pre-and post vaccination period amongst individuals 0-2.5 years on ART 
Pre-vaccination  1248 248 22.8%     
Post-vaccination  38 5 13.2% 0.58 0.25, 1.32 0.78 0.35, 1.73 
Comparison between pre-and post vaccination period including all samples 
Pre-vaccination  1248 284 22.8%     
Post-vaccination  199 20 10.1% 0.44 0.29, 0.68 0.79 0.36, 1.74 
Comparison between 0-2.5 and >2.5 years ART within the post-vaccination period 
0-2.5 years on ART 38 5 13.2%     
>2.5 years on ART 161 15 9.3% 0.71 0.27, 1.83 0.54   0.22, 1.32 
Combining the pre- and post-vaccination period, assessing duration of ART 
0-2.5 years on ART 1286 253 19.7%      
> 2.5 years on ART 161 15 9.3% 0.41 0.25-0.68 0.57   0.23, 1.41 
 
8.4.3 Analyses tot assess survival bias 
The possibility of survival bias should be taken into account in our analysis on 
prolonged ART duration. Survival bias would occur if individuals on prolonged ART are 
different from those 0-2.5 years on ART because they have survived for >2.5 years: i.e. 
that pneumococcal carriage could be an indicator for adverse survival outcome and 
those that have died before 2.5 years on ART may have had higher carriage in 2008-
2010. To investigate this, we compared carriage from 2008-2010 by survivorship to 
2014. We found that pneumococcal carriage in 2008-2010 was higher in those who 
died in the next years: carriage was 27.4% (34/124 samples) in 68 individuals who died 
before August 2014 versus 23.0% (202/877 samples) in 346 individuals who were still 
alive in August 2014. Survivorship was unknown for 131 individuals because they 
moved out of the study area (n=99) or where lost to follow-up for other reasons (n=32). 
After adjusting for sex, ART use and CD4 count at time of sampling, the risk ratio for 
carriage associated with death in the following four years was 1.36 (95%CI 0.98-1.89). 
Another sub-analysis done to avoid survival bias was to only include those individuals 
who were sampled in both 2008-2010 and 2014. Amongst this subgroup of 65 
individuals, pneumococcal carriage of any serotype decreased from 24.9% (45/181 
samples) in 2008-2010 to 9.2% (6/65) in 2014.   
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8.5 Discussion 
 
We provide evidence for a reduction in carriage of VT pneumococcus three years after 
vaccine rollout in this rural Malawi population. Reductions in VT carriage in 
unvaccinated individuals yet no change in NVT carriage suggest herd protection is 
taking place. Six-week old infants and unvaccinated children <5 years continued to 
carry at a high rate. 
 
PCV is being rolled out worldwide: in December 2015 there were 125 countries with a 
nationwide pneumococcal infant vaccination policy (217). This is the first study on 
pneumococcal carriage prevalence after routine introduction of PCV-13 in a vaccine-
naive Sub-Saharan African country using a 3+0 schedule. Previous studies were 
conducted in Kenya, The Gambia and South Africa, but different vaccines and/or 
schedules were used (Table 8.12). In all three countries a decrease in VT carriage was 
observed in vaccinated age groups. In Kenya and South Africa, also a decrease in VT 
carriage was observed in unvaccinated age groups, suggesting an indirect vaccine 
effect. No decrease in carriage was observed in mothers in The Gambia. An increase 
in NVT carriage is observed in vaccinated age groups in Kenya and South Africa. In 
South Africa, a decrease in NVT carriage is also observed in unvaccinated age groups, 
suggesting that overall reduction of pneumococcal carriage may have occurred due to 
reasons other than PCV introduction. 
 
Cross-sectional carriage surveys are also being undertaken in Blantyre in Southern 
Malawi since June 2015, with nasopharyngeal samples being collected and analysed 
using the same techniques as in this study. Higher VT carriage was observed in 
Blantyre than in Karonga: VT carriage was 22.5% (95%CI 18.3-27.1), 25.7% (20.9-
31.1), 13.9% (9.8-18.8) in 476 vaccinated children 3-4 years, 375 unvaccinated 
children 5-10 years, and 318 adults receiving ART respectively. Serotype-1 was 
detected in 7.3%, 18.0% and 9.1% of VT carriage; a particularly worrying finding given 
serotype-1’s potential for outbreaks of invasive disease. No serotype-1 carriage was 
detected in this study in Karonga. NVT carriage was 62.2%, 41.3% and 28.6% in 
vaccinated children, unvaccinated children and adults, also higher than reported in this 
study.  
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Table 8.13 Studies comparing pneumococcal carriage pre- and post introduction of PCV in Sub-Saharan African countries  
Country Vaccine 
introduction 
Schedule Catch-up Comparison Number 
sampled 
Age 
group 
Result VT: adjusted 
prevalence or risk ratio  
(95%CI) 
Result NVT: 
adjusted prevalence 
or risk ratio (95%CI) 
Kenya (25) PCV-10: 2011 3+0 Kilifi Region:  
<5 years received 
up to two doses 
2009-2010 vs.  
2011-2012 
623 
1408 
<5 yrs 
≥5 yrs 
0.36 (0.26-0.51) 
0.34 (0.18-0.62) 
(estimates for PCV-10) 
1.37 (1.13-1.65) 
1.13 (0.92-1.38) 
South Africa 
(184) 
PCV-7: 2009 
PCV-13: 2011 
2+1  None 2009 vs. 2011  1307 
695 
794 
443 
1821 
609 
<2 yrs 
2-5 yrs 
6-12 yrs 
13-18 yrs 
19-45 yrs 
>45 yrs 
0.50 (0.42-0.59) 
0.79 (0.64-0.99) 
0.66 (0.48-0.92) 
0.49 (0.17-1.39) 
0.36 (0.18-0.74) 
0.63 (0.16-2.49) 
(estimates for PCV-7) 
1.35 (1.17-1.56) 
0.99 (0.84-1.18) 
0.87 (0.73-1.04) 
0.55 (0.34-0.89) 
0.46 (0.31-0.68) 
1.15 (0.48-2.72) 
The Gambia 
(218) 
PCV-7: 2009 
PCV-13: 2011 
3+0 No formal catch-up, 
but most <2 years 
received one dose 
PCV-7 
2011 vs. 2012 689 
 
689 
6-11 mo 
 
mothers 
0.52 (0.39-0.69) PCV-13 
0.52 (0.28-0.97) PCV-7  
1.14 (0.65-2.01) PCV-13 
0.85 (0.31-2.30) PCV-7 
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There is no clear explanation for the difference in carriage observed between Karonga 
and Blantyre. PCV-13 coverage is high (>85%) in both settings. It is possible that a 
difference in social mixing patterns between the rural community in Karonga and the 
urban community in Blantyre led to different pneumococcal transmission and hence a 
difference in indirect vaccine effect. It is also likely that seasonal and secular changes 
explain part of the variation in carriage prevalence observed. In Karonga we observed 
large variation of pneumococcal carriage by season and by year before the introduction 
of PCV-13. The results from the Blantyre study are from a different year and from the 
dry (peak) season. Surveillance of pneumococcal carriage prevalence in Blantyre and 
Karonga is ongoing and will be closely monitored to assess whether a change in 
vaccination schedule is required to obtain and sustain a direct and indirect vaccine 
effect.  
 
Using a 2-week sampling interval rather than a 4-6 week interval as was used before 
gave us a better understanding of the duration of carriage and household exposure. In 
40% of carriage episodes in infants, a pneumococcal serotype was only identified in a 
single sample, indicating that duration of carriage of 14 days or less is common. Using 
a shorter sampling interval also increased the proportion of carriage episodes that 
could be attributed to carriage in the household. Using a 4-6 week interval we found an 
aPAF of 1.9% (95%CI 0.0-4.3) for infant acquisition for exposure by the mother and an 
aPAF of 8.8% (95%CI 4.0-13.4) for exposure by children <5 years in the household 
(chapter 5). Using a 2-week interval we found an aPAF of 8.8% (95%CI 0.3-16.6) for 
exposure by the mother and an aPAF of 15.3% (95%CI 4.1-25.2) for exposure by 
children <5 years in the household. Our study also provided further evidence that 
infants themselves contribute to pneumococcal transmission in the household: 18.5% 
(95%CI 0.1-33.4) of carriage episodes in the mother and 31.2% (95%CI 5.8-49.8) of 
carriage episodes in other children <5 years could be attributed to exposure by the 
index infants. A limitation of the household exposure analysis is that results for which 
no serotyping result was available other than “NVT” had to be included. Most results 
from the household exposure analysis involved “NVT” acquisition and household 
exposure. It is likely that some “NVT” acquisitions were wrongly attributed to household 
exposure. In the pre-vaccination period we relied on serotype-specific results only: we 
had a large enough sample size and observed enough VT carriage to be able to 
include the five most carried serotypes.  
 
In the study on HIV-positive adults on ART a remarkable decrease in VT carriage was 
observed, with only one VT isolated in 2014. The reduction in VT carriage suggests an 
indirect effect of the vaccine, but should be considered with caution: although the 
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results from the household study also suggest an indirect vaccine effect, smaller 
reductions are seen in the household study. We hypothesised that a larger indirect 
effect would occur in the household study, where all unvaccinated participants are in 
contact with at least one vaccinated child. Also a decrease in carriage of any serotype 
was observed for HIV-positive adults on ART, mostly attributable to the decrease in 
VT. Thus it is difficult to fully reconcile these findings. We provide some evidence that 
pneumococcal carriage prevalence is lower in HIV-positive adults on prolonged ART. It 
is likely that the combination of prolonged duration of ART and PCV-13 introduction 
both attributed to the decrease in any serotype and VT pneumococcal carriage in HIV-
positive adults. Our results need to be considered with caution: no difference in 
pneumococcal carriage by ART duration was observed in the cross-sectional 
conducted study in Blantyre. Our study also suggests that pneumococcal dynamics are 
still driven by children <5 years: individuals living with children <5 years were more 
than two times as likely to carry a pneumococcus than individuals living without 
children <5 years. No evidence for this association was found in the study conducted in 
2008-2010 (aRR 1.05, 95%CI 0.81-1.37); we previously had assumed that the 
increased risk of carriage in women was attributable to universal child contact and not 
determined by household contact only.  
 
Several limitations can be identified for this study. Firstly, we recruited mother-infant 
pairs at the local hospital, thus missing infants born at home. During the study period, 
97% of infants were born in a health centre, indicating that our recruitment strategy 
included most infants. We also recruited HIV-positive adults from the ART clinic only, 
potentially missing HIV-positive adults not attending the clinic. A cross-sectional 
analysis conducted in 2007-2008 showed that of 837 HIV-positive adults, 788 (94%) 
knew their status, but only 209 (25%) completed screening for ART. Of 202 eligible for 
ART, 194 (96%) received ART at time of the study. Delays between HIV-diagnosis and 
ART screening were shorter in men and decreased with increasing age (219). 
Secondly, we did not perform HIV-testing on participating mothers, but relied on the 
HIV-status in their health passport or verbal report. Documented HIV status was 
available for the majority of mothers and 98% of mothers were HIV-tested within the 
last year, making HIV testing for the purpose of this study unnecessary. Thirdly, adult 
household members other than the mother were not included in this study and children 
5-15 years were included in the cross-sectional arm of the study only, prohibiting the 
investigation of their role in household dynamics. The cross-sectional analysis 
suggests that concordance of same serotype carriage does occur (2/7: 28.6%), but 
numbers are small and we cannot determine the direction of spread. Fourthly, the 
sample size calculations for the household study were based on including samples 
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from all months in the pre-vaccination period. Using only seasonality-matched samples 
was important for the comparison between the pre- and post-vaccination period in the 
household study, but this will have reduced the power to detect a difference between 
the two periods. Fifthly, our results suggest that some survival bias is occurring in our 
study on HIV-positive adults: we found that pneumococcal carriage in 2008-2010 was 
higher in those who died in the next years. However, because carriage in 2008-2010 
amongst those that survived is still higher than carriage in 2014 (23.0% vs. 10.1%), this 
does not change our conclusion on the association of reduced carriage with prolonged 
ART. Lastly, our laboratory procedures did not allow for detection of simultaneous 
colonization with multiple serotypes. A subset of samples from Blantyre was assessed 
for multiple serotype carriage using microarray technique. Multiple serotype carriage 
was found to be 54.1% in vaccinated and 59.3% in unvaccinated children. Serotyping 
using microarray increased detectable VT carriage by 35.6%. Our comparisons 
between the pre- and post-vaccination period are still valid, because multiple serotype 
assessment was performed in neither period, but will have decreased the accuracy of 
our estimates of carriage duration and household transmission. 
 
In conclusion, we provide evidence for a reduction in carriage of VT pneumococcus 
three years after vaccine rollout in this rural Malawi population. Reductions in VT 
carriage in unvaccinated individuals yet no change in non-VT carriage suggest herd 
protection is taking place. However, high VT carriage including carriage of serotype-1 
is observed in carriage prevalence surveys conducted in Blantyre, implicating that 
ongoing surveillance is required to evaluate whether a change in vaccination schedule 
is required to optimise the indirect vaccine effect from PCV-13. We also provide some 
evidence that pneumococcal carriage prevalence is lower in HIV-positive adults on 
prolonged ART. Ongoing work on HIV-positive adults on ART in Blantyre will be 
analysed to assess whether the same finding can be observed in this population. 
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9. A mathematical model to study pneumococcal 
transmission in the pre-vaccination period 
9.1 Introduction 
The longitudinal household studies conducted in the pre-vaccination and post-
vaccination period (chapter 5+8) showed that infant pneumococcal acquisition is 
associated with carriage in other children <5 years and mothers, but that this could only 
explain a limited proportion of acquisitions. With the results of the longitudinal studies, 
we could not study the transmission in the household as a whole, because of the low 
response rate from household members older than 5 years. Also, the results of the 
longitudinal studies did not allow for studying pneumococcal dynamics outside the 
household. Most importantly, the exact timing and direction of transmission events 
cannot be observed from longitudinal studies. Investigating transmission, including the 
inferring of unobserved transmission events, in the whole household, including older 
children and adults, and in the wider population, was possible with the use of a 
mathematical model parameterised with data established in the field studies.  
 
The study on HIV-positive adults attending an ART clinic (chapter 6) showed that 
pneumococcal carriage in HIV-positive adults remained high during the first two years 
of ART use and raised the question whether HIV-positive adults could remain a 
reservoir for pneumococcal carriage and diversity in the post-vaccination period. 
Understanding the dynamics of pneumococcal carriage in this group will help us 
understand their importance in pneumococcal transmission in the population. A 
mathematical model which allows for characteristics of carriage to differ between HIV-
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positive and HIV-negative adults would provide us with more information on the 
differences and similarities between the two groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
 
This chapter describes the mathematical model set up to study pneumococcal 
transmission in the pre-vaccination period. The model was fitted to pneumococcal 
carriage prevalence data collected in 2009-2011 (chapters 5+6). We developed a      
model based on the known household and population structure in the KHDSS with the 
aim of defining the importance of household versus community transmission of 
pneumococci in this population. The model included five different age/HIV groups 
(infants, children 1-4 years, children 5-15 years, HIV-positive and HIV-negative adults) 
to allow for further characterisation of pneumococcal dynamics for each age/HIV group. 
The model was then applied to investigate the impact of different vaccination 
strategies: results of the mathematical model for the post-vaccination period can be 
found in chapter 10. 
 
Figure 9.1 gives an overview of the different steps taken in the mathematical modelling 
process: 1. Design of the model (section 9.2-4), 2. Fit to dummy data (section 9.5), 3. 
Fit to observations from Karonga District (section 9.6) and 4. Simulate different 
vaccination scenarios (chapter 10). A glossary for mathematical modelling terms used 
in this chapter is provided in table 9.1.   
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Table 9.1 Glossary for mathematical modelling terms  
Term Explanation 
acceptance rate Proportion of particles accepted by applying a specific threshold. 
approximate Bayesian 
computation 
Computational method based on Bayesian statistics that bypasses the 
need for the calculation of a likelihood function by using summary 
statistics to assess the fit of a model to observations. 
force of infection (λ) Rate at which susceptible individuals become infected per unit of time. 
individual-based 
model 
Model which keeps track on the infection status of each individual in 
the population. 
likelihood Measurement of the support provided by the data for each possible 
value of the parameter. 
particle Set of parameter values, e.g. the combination of parameter values for 
duration of infection and transmission rate. 
particle filtering 
method (sequential 
Monte Carlo - SMC) 
Method to fit a model to observations. Assessing a set of parameter 
values (particle) in a step-wise approach. In each step the best fitting 
particles are kept and assigned a weight with which they are 
resampled in the next step.  
perturbation Randomly changing a particle along a particular distribution. 
prior distribution Probability distribution that expresses one's beliefs about a variable 
before some evidence is taken into account.  
posterior distribution Distribution of unobserved observations conditional on observed data. 
stochastic model Model allowing for random variation in one or more inputs. 
Susceptible-Infected-
Susceptible model 
Model in which individuals can belong to one of two states: susceptible 
or infected. After infection, the individual returns to a susceptible state. 
tolerance threshold Defined threshold, e.g. based on a statistical test value, that 
determines whether a particle gets accepted or not. 
Distributions  
beta distribution Continuous distribution with two positive parameters, α and β that 
determine its shape. Defined on interval [0,1]. 
gamma distribution Continuous distribution with shape parameter k and scale parameter 
θ. Defined on interval [0,]. 
log-normal distribution Continuous distribution in which the logarithm of a variable has a 
normal distribution. Contains parameters µ (mean) and σ (standard 
deviation). Defined on interval [0,]. 
logit-normal 
distribution 
Continuous distribution in which the logit (=log(p/1-p)) of a variable has 
a normal distribution. Contains parameters µ (mean) and σ (standard 
deviation). Defined on interval [0,1]. 
uniform distribution Continuous distribution with constant probability. Contains parameters 
a and b which are its minimum and maximum value. Defined on 
interval [-]. 
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Figure 9.1 Flowchart describing steps in mathematical modelling process 
Thesis chapters describing the steps in brackets.  
  
4. Use model 
to simulate 
different  
scenarios 
3. Fit to  
observations 
2. Fit to  
dummy  
data 
1. Design 
Design of model structure (9.2) 
Use posterior distribution of parameters to run 
simulations (9.6.4) 
Change model settings, e.g. include vaccination, 
to simulate different scenarios. (10) 
Select model fitting method (SMC ABC). Decide 
on summary statistics and threshold values (9.3) 
Selection of prior distributions for model 
parameters based on existing knowledge (9.4) 
Generate dummy data by running the model with 
known parameter settings (9.5.1) 
Fit model to dummy data to assess fitting method 
(9.5.2) 
Preparation of observed data (9.6.2)  
Fit model to observed data using SMC ABC 
method (9.6.3) 
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9.2 Description of the model 
 
Based on the literature review (chapter 4) we identified the following key characteristics 
for our model: 
 
• Susceptible-Infected-Susceptible (SIS) infection dynamics 
• Individual-based model 
• Stochastic infection and recovery transitions  
• Two levels of transmission: within-household and community (random mixing) 
• Explicit, dynamic household membership 
• Explicit, dynamic population structure  
 
We developed an individual-based stochastic transmission model, based on the model 
used by Melegaro et al. to describe pneumococcal transmission in the UK (220) 
(Figure 2). This is a Susceptible-Infected-Susceptible (SIS) type model: individuals can 
be non-carriers (S), carriers of vaccine serotype pneumococci (VT), carriers of non-
vaccine serotype pneumococci (NVT) or carriers of both (B). Carriers revert to the 
susceptible status when carriage is lost. The model includes the possibility of 
simultaneous VT and NVT carriage (B status) to reflect the findings of two studies 
conducted in Malawi which found that multiple serotype carriage was common 
amongst samples from both children and adults (47, 221) (see section 9.3.2 for 
details).  
 
Acquisition and loss of carriage occur as stochastic processes, with probability of 
acquisition determined by the force of infection and probability of loss determined by an 
age and HIV-infection status specific duration of carriage. Non-carriers (S) become 
infected according to the force of infection of vaccine type (!!") and non-vaccine type 
(!!"#) pneumococci, which consists of: 1) transmission in the household as determined 
by !!! and 2) transmission in the community as determined by !!"# . Individuals 
carrying vaccine type (VT) or non-vaccine type (NVT) pneumococci can become 
carriers of both (B) at the rate !! where ! is a competition parameter which defines how 
much carriage of one type (VT or NVT) protects against acquisition of the other type 
(VT or NVT) where 1 is no competition and 0 is complete competition. The model 
assumes there is no natural immunity following infection, as has been proposed by all 
but one modelling studies included in the literature review (chapter 4) (145-158, 222). 
To still reflect different susceptibilities by age and HIV group, parameter !!,!  was 
introduced. This parameter also distinguishes between susceptibility to VT and NVT 
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serotypes: it is a relative rate with susceptibility to VT serotypes in infants <1 year as 
the reference group (!!!"#,!"  =1). Individuals loose pneumococcal carriage at an 
age/HIV-specific recovery rate !!. Recovery rates do not differ between VT/NVT or B 
states, in accordance with a study from Denmark reporting that inhibition of 
colonization is the main mechanism of competition, and that the rate of clearance is not 
altered in multiple serotype carriage (147). Susceptibility !! and recovery !! were set 
for five different age/HIV groups: infants <1 year, children 1-4 years, children 5-15 
years, HIV-positive adults and HIV-negative adults.  
 
The transmission rates for our stochastic model are summarized in the following set of 
differential equations: 
 
 !"!" =  !" ! · !! +  !"# ! · !! −  ! ! ·  !!,!" · !!" ! −  ! ! ·  !!,!"# · !!"# !  
 
(1) 
 !"#!" =  ! ! · !! +   ! ! ·  !!,!" · !!" ! − !" ! · !!,!"# · ! · !!"#  !  
 
(2) 
 !"#$!" =  ! ! · !! +   ! ! ·  !!,!"# · !!"# ! − !"# ! · !!,!" · ! · !!"  !  
 
(3) 
 !"!" =   !" ! · ! ·  !!,!"# · !!"# ! +  !"# ! ·  ! ·  !!,!" · !!" ! − ! ! · !! 
 
(4) 
where !!,! is the age/HIV group and VT/NVT specific susceptibility parameter, !! is the 
age/HIV group specific recovery rate and !!" and !!"# are the force of infection for VT 
and NVT respectively.  
 
The force of infection is described by the following equations:  
 
 !!"# ! =  !!! ·  !"#!! ! + !!! !!!! ! − 1 + !!"# ·  !"#!"# ! + !!"# !!!"# ! − 1  (5) 
 !!" ! =  !!! ·  !"!! ! + !!! !!!! ! − 1 + !!"# !  ·  !"!"# ! + !!"# !!!"# ! − 1  (6) 
 
where !"!! ,!"#!! ,!!! ,!"!"# ,!"#!"# ,!!"# are the total number of individuals carrying 
VT, NVT or both within the household and the community at time t.  
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Figure 9.2. Model structure.  
Adapted from Melegaro et al, 2010 (220). Model describes the transmission to different 
states: S (susceptible), VT (carrier of vaccine type), NVT (carrier of non-vaccine type), 
B (carrier of both VT and NVT), where !!" and !!"# are the forces of infection for VT 
and NVT, !! is the age-specific recovery rate, ! is the competition parameter, and !!,! 
is the age/HIV and serotype-specific susceptibility parameter.  
 
 
S 
VT NVT 
B 
γa γa 
γa γa 
σa,vtλVT(t) σa,NVTλNVT(t) 
σa,NVTcλNVT(t) σa,VTcλVT(t) 
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9.3 Description of fitting process 
 
The model’s steady-state pneumococcal carriage prevalence for status VT, NVT and B 
by age group was fitted to the cross-sectional data available from nasopharyngeal 
swabs collected in the pre-vaccination period (see section 9.3.2). Sequential Monte 
Carlo approximate Bayesian computation (SMC ABC) was used for the fitting process 
(223). ABC combines a particle (see below) filtering method with summary statistics, 
allowing for the fitting of complex stochastic models such as ours for which the 
likelihood is difficult to define (224-226). The algorithm for ABC rejection sampling, the 
simplest form of ABC, is as follows: 
1. A candidate set of parameter values !∗, called a particle, is drawn from their 
respective prior distributions !(!).  
2. The model is run with the drawn parameter values, simulating a dataset !∗.  
3. The simulated dataset !∗ is compared to the observed data !! with summary 
statistics, creating distance function !(!!, !∗) 
4. If the distance function !(!!, !∗) is lower than a predefined tolerance threshold !, the parameter set is accepted, otherwise the parameter set is rejected. 
If ! is sufficiently small, the distribution of accepted particles will be a good 
approximation of the posterior distribution (223). The disadvantage of ABC rejection 
sampling is that the acceptance rate is very small if the prior distribution is different 
from the posterior distribution. To overcome this problem, SMC ABC is performed in 
multiple rounds !  to obtain intermediate distributions with decreasing tolerance 
thresholds (!! > !! > ⋯ >  !!) , until the target distribution is reached which will 
approximate the posterior distribution.  
 
In our fitting process, SMC ABC was performed in the following steps (223), depicted in 
figure 9.3: 
Preparation 
1. A pre-defined series of tolerance values was set with decreasing values for each 
round r: !! > !! > ⋯ >  !!. We used the step-wise linear series of ! = 
8000,6000,4000,2000,1000,800,600,400,200,100,80,60,40,20. 
Round 1 
2. Parameter values were sampled from their respective prior distributions !(!) (see 
9.2.5) to form a candidate parameter set !∗ (called a particle) (Fig. 9.2A). 
3. A simulation was run with the sampled parameter values until time !. We used one-
day time steps for a simulation period of two years (730 days). 
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4. The simulated steady-state pneumococcal carriage prevalence for status VT, NVT 
and B by age group was fitted to the cross-sectional data from nasopharyngeal 
swabs collected in the pre-vaccination period. We used the Chi-squared test on 
observed vs. model counts of individuals in age group ! with status VT, NVT and B 
as the summary statistic. 
5. If the z-value calculated by the Chi-square test was lower than the pre-defined 
tolerance value !!, the set of parameter values was accepted (Fig. 9.2B). 
6. Steps 1-5 were repeated until the number of accepted values reached the pre-
defined threshold ! when round 2 was started. We used !=200 in our fitting 
algorithm. 
Subsequent rounds  
7. A candidate particle was sampled from the accepted particles of the previous round 
with weights !!!! as defined in step 11 (Fig. 9.2C). Accepted particles of round 1 
were all given equal weight.  
8. The sampled particle was perturbed using a perturbation kernel (Fig 9.2D). For the 
parameter !!! log-normal perturbation was used to avoid negative parameter 
values. For all other parameters logit-normal perturbation was applied to restrain 
parameter values between 0 and 1. A standard deviation of 0.5 was used in all 
perturbations. 
9. A data set was simulated and evaluated as in step 4 described above. 
10. If the z-value calculated by the Chi-square test was lower than the pre-defined 
tolerance value !!, the set of parameter values was accepted. 
11. Accepted particles’ weight was calculated using the formula 
 !!(!) =  !(!!! )!!−1! !!!!=1 (!!−1! ,!!! ) )  
where the particle ! in round !, !!! , was assessed according to its prior distribution !(!) and to each of the particles ! accepted in the previous round ! − 1 by 
assessing it’s weight !!!!(!)  and perturbation kernel !!(!!!!! , !!! ).  
12. Steps 7-11 were repeated until the number of accepted values reached the pre-
defined threshold !=200. When threshold was reached, all weights for the round 
were normalized and the next round was started. 
13. Approximate posterior distribution was obtained after the final round (Fig 9.2E). The 
simulation was stopped when additional rounds only provide marginal changes in 
the distribution and when the acceptance rate was very low (<1%) causing an 
increase in the time to reach !. 
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Figure 9.3 Schematic overview of sequential Monte Carlo approximate Bayesian 
computation (SMC ABC) 
 
The main advantage of using ABC in contrast to more conventional optimization 
methods such as MCMC is that that the likelihood does not need to be theoretically 
derived (223-226). This allows for the fitting of more complex models. ABC is relatively 
simple and generalizable, and can be thus applied to deterministic and stochastic 
models (223). Moreover, by using different rounds in the fitting process, information on 
the sensitivity of the model to different parameters can be gathered from the shape of 
intermediate distributions (223). If the model is sensitive to a parameter, this parameter 
will be inferred in earlier rounds and have narrow credible intervals. If on the other 
hand the distribution for a parameter does not change much in subsequent SMC ABC 
rounds, it can be concluded that the parameters is not inferable given the available 
0.0 0.2 0.4 0.6 0.8 1.0
0.0 0.2 0.4 0.6 0.8 1.0
0.0 0.2 0.4 0.6 0.8 1.0
0.0 0.2 0.4 0.6 0.8 1.0
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parameter space
A. Particles are drawn from the 
prior distribution (uniform 
between 0 and 1 in this example) 
B. A dataset is simulated with 
each of the drawn particles. 
Summary statistic is calculated. 
If distance function < !, particle is 
accepted (shown in green). 
Intermediate distribution shown 
in dashed line. 
C. In the next round, the 
accepted particles from the 
previous round are resampled 
with replacement  
D. Each of sampled particles is 
perturbed using a perturbation 
kernel.  
E. A dataset is simulated with 
each of the perturbed particles. 
Summary statistic is calculated. 
If distance function < !, particle is 
accepted (shown in green). 
After final round is finished, the 
approximate posterior 
distribution can be obtained 
(shown in dashed line) 
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data. ABC methods can also be used to compare alternative model structures (223, 
225). Lastly, a major advantage of SMC ABC is that it is computationally efficient and 
can be run in parallel, allowing its application to complex models and large datasets 
without being too computationally demanding (225).  
 
The main drawback of using ABC is that it is a relatively new method and that does not 
yet have the statistical rigor of more conventional optimization methods. Studies have 
been published showing the competitiveness of ABC with full like-likelihood methods, 
but more studies are needed to better evaluate the degree of approximation (226). 
These studies, however, are restricted to models where explicit likelihoods functions 
are tractable. Another disadvantage of ABC methods is that they are reliant on the 
user-choice of appropriate summary statistics. Different summary statistics are found to 
influence how closely the posterior distribution is approximated (227). There are no 
well-defined rules as to which and how many summary statistics should be used (226), 
although the academic field is rapidly moving towards standardization of methods (227, 
228). The choice of the acceptance threshold is another area that similarly requires 
standardization (227). For the purpose of this PhD, the choice of summary statistics 
and the acceptance thresholds were set in advance and were not evaluated in a 
dynamic process. This is one area that could be improved in follow-up work.  
 
9.4 Selection of prior distributions 
We searched household modelling studies included in the systematic literature review 
(chapter 4) for estimates on which to base our prior distributions for each parameter 
requiring estimation. A summary of the prior distributions is shown in Table 9.6 at the 
end of this section. 
 
Transmission rates 
Table 9.2 shows household transmission parameters reported from mathematical 
studies in the literature. Some studies reported separate parameters by age group, but 
we decided to fit one parameter for within-household transmission only (!!!). For our 
model we chose a gamma prior distribution with a mean of 0.10 and a variance of 0.10. 
This mean is higher than the mean reported in the literature (table 9.2), because 
training simulations showed that a lower !!!  did not sustain transmission. 
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Table 9.2. Household transmission parameters and community force of infection reported in literature 
Setting (ref) Household transmission rate per day (95%CI) Community force of infection per day (95% CI) 
Bangladesh (153) family to child 0.0241 (0.0229-0.0258) community to child 0.0054 (0.0049–0.0059)  
Finland (154) family to child 0.012 (0.017-0.033) community to child 0.0002 (0.0001-0.0003)  
UK (157, 158, 220) adult to adult 0.048 (0.010-0.180) community to adult 0.004 (0.002-0.005)  
 adult to child 0.106 (0.020-0.450) community to child 0.012 (0.008-0.016)  
 child to adult 0.005 (0.000-0.018)   
 child to child 0.047 (0.008-0.200)   
South Africa (162) child to mother 0.0027 (0.0013-0.004) community to child 0.0051 (0.0044-0.0056)  
 mother to child 0.00044 (0.000-0.001) community to mother 0.0013 (0.0008-0.0019)  
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All studies identified in the literature reported the community force of infection as a 
constant, rather than a community transmission parameter which indicates the chance 
of effective transmission upon contact in the community. Because our model keeps 
track of individual infection status for the whole community, a community transmission 
parameter was used. We decided to use a uniform prior from 0 to 1 for the ratio of 
household and community transmission. This makes the assumption that !!"#  is 
smaller or identical to !!!: that the rate at which two individuals come into “effective” 
contact (contact sufficient to lead to infection if it occurs between a susceptive and 
infective person) is smaller in the community than amongst household members. 
Justification for this assumption is that household contact is more intimate and of 
longer duration than contact in the community. Support for our assumption comes from 
studies on influenza showing that susceptible individuals were more likely to be 
infected by their household members than by members of the community (229).  
 
Susceptibility 
Table 9.3. Susceptibility parameters reported in literature  
Setting (ref) Age groups 
comparison 
Susceptibility parameter (95% CI) 
Bangladesh (153) ≥5 vs. <5 yrs 0.46 (0.45-0.49) 
Finland (154) ≥7 vs. <7 yrs 0.41 (0.28-0.58) 
 
Two studies used a relative rate to estimate differences in susceptibility between age 
groups (Table 9.3). In our model, we used an age/HIV group and serotype (VT vs. 
NVT) specific parameter. We made the assumption that infants <1 year were most 
susceptible for pneumococcal acquisition, followed by children 1-4 years, 5-15 years 
and adults. We also assumed that infants <1 year were equally or more susceptible to 
VT than to NVT serotypes. The susceptibility parameter, defined as a relative rate of 
the force of infection, was set at 1 for infants <1 year for VT transmission (reference 
group). We used a prior beta distribution with a mean of 0.75 to describe susceptibility 
of infants <1 year for NVT as compared to VT serotypes. For age groups 1-4 years, 5-
15 years and adults a prior beta distribution was chosen for both VT and NVT 
transmission, with means of 0.75, 0.50 and 0.25 respectively. This is in line with the 
estimates from the studies in Table 9.3, which used a different age structure (our 
relative rate for ≥ 5 years vs. <5 years = 0.43). A wide variance (σ2 =0.03) was used on 
all susceptibility priors, allowing for parameter values on the whole range between 0 
and 1 to be selected. The priors for susceptibility of HIV-positive and HIV-negative 
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adults were set the same, but the parameter values were allowed to differ between 
HIV-positive and HIV-negative adults in the model.  
 
Competition 
Table 9.4. Competition parameters reported in literature  
Setting (ref) Parameter for VT (cv), NVT 
(cn) or both (c) 
Competition parameter (95% CI) 
Bangladesh (153) c 0.83 (0.73-0.93) 
UK / USA (157, 158, 
220) 
cv 0.5 
 cn 0.85 
Denmark (147) c 0.09 (0.05-0.15) 
Finland (154) c 0.68 (0.35-1.10) 
Norway (159) c 0.10 (0.06-0.14) 
Estimates of the competition parameter, defined as the relative rate of acquisition for 
non-carriers as compared to carriers of another serotype, differed in the literature with 
estimates ranging from 0.09 to 0.85 (Table 9.4). We therefore decided to use a uniform 
prior distribution from 0 to 1 for our model. 
 
Recovery rates 
Training simulations showed poor performance when both susceptibility parameters 
and recovery rates were fitted. We therefore decided to fix the recovery rates during 
our model fitting. Table 9.5 shows the estimated days of carriage reported from 
longitudinal or modelling studies in the literature. Four studies reported days of carriage 
for infants <1 years separately: a modelling study in the UK reported an average 
carriage duration of 71 days, a longitudinal study in Thailand-Myanmar reported 60 
days, a longitudinal study in Kenya reported 48.5 days and a modelling study in 
Sweden reported 30 days. For our model we choose carriage duration of 48.5 days, 
since we assumed that the situation in Kenya most closely resembled the situation in 
Malawi.  
 
For children 1-4 years, reported days of carriage ranged between 22 and 42.6 days. 
For our model we choose a mean duration of 31 days, again reflecting the Kenyan 
situation. Two studies included children 5-15 years, both reporting similar estimates of 
15 and 18 days. We used an estimate of 18 days for our model. For adults, studies 
reported carriage of 14 (Sweden), 17 (UK) or 31 (Thailand-Myanmar) days. The 
longitudinal study from Thailand-Myanmar used monthly swabbing intervals, however, 
and could therefore not detect carriage duration shorter than one month. We chose the 
UK estimate of 17 days for our model. 
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Table 9.5. Days of carriage by age group reported in literature  
Setting (ref) Age group Days carriage (95% CI*) 
Bangladesh (153) <5 yrs 42.6 (40.4 - 45.5) 
 ≥5 yrs 38  
Denmark (147) 1-3 yrs 24 
Finland (154) ≤7 yrs 44 (41-48) 
 >7 yrs 36 
France (149) 3-6 yrs 22 (20 - 24) 
Kenya (230) 6-11m 48.5 (30.8 - 76.4) 
 3-59m  31.3 (29.7 - 33.6) 
Sweden (231) <1 yrs 30 
 1-4 21 
 5-6 13 
 7-18 15 
 18+ 14 
Thailand-Myanmar (141) 0-2 yrs 60 (57.0 - 60.5) 
 Mothers  31 (31.0 - 31.5) 
UK (157, 158, 220) 0-1 yrs 71 
 2-4 yrs 28 
 5-17 yrs 18 
 18+ yrs 17 
*90% confidence intervals reported for study in Bangladesh. 
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Table 9.6. Prior distributions chosen for mathematical model in pre-vaccination 
period 
Parameter: meaning Prior / value Mean  Variance 
Fitted parameters 
   
βhh: transmission rate household Γ(0.1,1)   
 
0.10 0.10 
ratio βhh/βcom 
U(0,1) 
 
0.5 0.083 
σa: susceptibility 
age groups  
0 yr – VT 
0 yr - NVT 
1-4 yr (VT & NVT) 
5-15 yr (VT & NVT) 
16+ yr HIV+ (VT & NVT) 
16+ yr HIV- (VT & NVT) 
1 
B(3.9375, 1.3125) 
B(3.9375, 1.3125) 
B(3.6667, 3.6667) 
B(1.3125, 3.9375) 
B(1.3125, 3.9375)  
1 
0.75 
0.75 
0.5 
0.25 
0.25 
- 
0.03 
0.03 
0.03 
0.03 
0.03 
c: competition U(0,1)  0.5 0.083 
Fixed parameters 
   
γa: recovery rate 
(1/days carriage) 
0 yr 
1-4 yr 
5-15 yr 
16+ yr HIV+ 
16+ yr HIV- 
48.5 days 
31 days 
18 days 
17 days 
17 days  
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9.5 Assessment of fitting process 
9.5.1 Generating dummy data 
We assessed the fitting process by generating dummy data with known parameter 
settings. Fitting the model with prior settings as described in section 9.4 allowed us to 
assess how well the fitted parameters resembled the parameters set for this dummy 
data. The dummy data was fitted to an earlier version of the final model: the 
susceptibility parameter !! did not distinguish between VT and NVT serotypes in the 
dummy model.  
 
Parameter settings were defined as follows: !!!  and ! were fixed at 0.15 and 0.85 
respectively to ensure steady state transmission was achieved for all statuses (VT, 
NVT, B) in all age groups; for the ratio between !!! and !!"#  and !!  a random 
parameter was chosen between 0.5 and 2 times the mean of the prior as specified in 
Table 9.6; !! was fixed as described in section 9.3. The model was run with one-day 
time steps for a period of two years. Dummy data was generated by taking the mean 
values of 100 simulations. Table 9.8 shows the parameter settings for generating the 
dummy data and the results of the fitting process. 
9.5.2 Results of fitting to dummy data  
We fitted the model to dummy data using the SMC ABC algorithm described in section 
9.4.1. In the first round, in which particles were obtained from the prior distribution, the 
acceptance was 7.8% (Table 9.7). This was increased to 51.5% in round 2 and 
thereafter decreased with each round until we terminated the procedure after round 10, 
when the acceptance was 0.6%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.7 Acceptance for SMC ABC fitting to dummy data 
round tolerance ! acceptance  # simulations required to 
reach ! = 200 
1 8000 7.8% 2564 
2 6000 51.5% 388 
3 4000 35.5% 563 
4 2000 16.7% 1198 
5 1000 12.3% 1626 
6 800 9.6% 2083 
7 600 7.9% 2532 
8 400 4.9% 4082 
9 200 1.5% 13333 
10 100 0.6% 33333 
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Figure 9.4 shows the prior and (intermediate) posterior distributions for rounds 1, 4, 7 
and 10. Credible intervals were increasingly narrowing around the ‘true’ value with 
each round for all parameters, apart from the ratio !!! / !!"#. Table 9.8 shows the 
‘true’ value that the dummy data was fitted to and the weighted mean of the posterior 
after round 10.  
 
Table 9.8 Parameter settings for creating dummy data to assess fitting process 
and SMC ABC posterior distribution mean 
Parameter: meaning Value  Weighted mean posterior  
(95% credible interval) 
βhh: transmission rate household 0.150 0.172 (0.102-0.326) 
ratio βhh/βcom 0.602 0.535 (0.106-0.948) 
σa: susceptibility 
age groups  
0 yr 
1-4 yr 
5-15 yr 
16+ yr HIV+ 
16+ yr HIV- 
1 
0.782 
0.454 
0.167 
0.375 
- 
0.802 (0.591-0.963) 
0.468 (0.338-0.622) 
0.172 (0.091-0.266) 
0.380 (0.275-0.515) 
c: competition 0.850 0.828 (0.670-0.978) 
γa: recovery rate 
(1/days carriage) 
(fixed) 
0 yr 
1-4 yr 
5-15 yr 
16+ yr HIV+ 
16+ yr HIV- 
48.5 days 
31 days 
18 days 
17 days 
17 days 
- 
- 
- 
- 
- 
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Figure 9.4 Prior and posterior distribution of several rounds of SMC ABC fitting to dummy data 
 Round 1   Round 4            Round 7  Round 10 
 
 !!!: household 
transmission rate 
 
 
 
 
ratio !!!/!!"#  
 
 
 
 !!!! !"#: susceptibility 
 1-4 year olds compared 
to infants 
 
 !!!!" !"#: susceptibility  
5-14 year olds 
compared to infants 
 
 
prior
posterior
weighted mean posterior
dummy setting
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
0.0 0.2 0.4 0.6 0.8 1.0
0
2
4
6
8
1 0
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
4
0 .
8
1 .
2
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
3 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
2 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
3 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
220 | Chapter 9 
 
 
 !!"#!: susceptibility 
HIV-positive adults 
compared to infants 
 
 !!"#!: susceptibility 
HIV-negative adults 
compared to infants 
 
 
 ! : competition 
parameter 
  
 Round 1   Round 4            Round 7  Round 10 
prior
posterior
weighted mean posterior
dummy setting
Figure 9.4 cont. Prior and posterior distribution of several rounds of SMC ABC fitting to dummy data 
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
2 .
0
2 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
3 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
0.0 0.2 0.4 0.6 0.8 1.0
0
2
4
6
8
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
2 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
2 .
0
2 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
1 .
0
2 .
0
3 .
0
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
4
0 .
8
1 .
2
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
5
1 .
0
1 .
5
2 .
0
2 .
5
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
Mathematical model of the pre-vaccination period      221 	
 
 
 
Figure 9.5 Correlation between the posterior distribution of parameters fitted to 
dummy data.  
 
Figure 9.5 shows the correlation between the posterior distribution of parameters that 
were fitted to dummy data. A strong negative non-linear correlation was observed 
between !!! and the ratio !!! /!!"# , showing a trade-off between household and 
community transmission. Positive correlations were observed for the four susceptibility 
parameters. The susceptibility parameters were negatively correlated with !!! , 
especially those for children 5-14 years and HIV-negative adults. 
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9.6 Fitting the model to observed data from Karonga 
9.6.1 Population demography 
The model uses the known population and household structure in the KHDSS area, 
captured through the demographic surveillance system (54). The model uses census 
data from the population from 1st January 2009 to 30th June 2015. On 1st January 2009 
there were 34,111 individuals living in 7,742 households. There were 718 (2.1%) 
individuals living in more than one household (mostly polygamous heads of 
households); they were randomly assigned to one of the households they belong to for 
the purpose of this mathematical model. On 11th September 2015 there were 39,721 
individuals living in 9,602 households. There were 889 (2.2%) individuals who 
belonged to more than one household. HIV-status for individuals was obtained from the 
KHDSS records. There were 5,616 of 21,693 (25.9%) adults with unknown HIV-status. 
For individuals with unknown HIV-status, HIV-status was imputed according to their 
sex and age, based on HIV prevalence as reported for this population by Floyd et al. 
(56). We also imputed an HIV-status for older children who were included in the “5-15 
years” age group at the start of the simulation period, but matured into the adult age 
group during the simulation period. HIV-status for this group was missing for 5807 of 
8437 (68.8%) adolescents.    
 
9.6.2 Observed proportions of carriage  
The model was fit to observed prevalence of pneumococcal carriage in the pre-
vaccination period (2009-2011). In short, nasopharyngeal sample results were 
available from two longitudinal studies: a household study on pneumococcal carriage in 
HIV-exposed and HIV-unexposed infants (chapter 5), and a longitudinal study on HIV-
positive adults attending ART clinic (chapter 6). For the purpose of this modelling 
study, a cross-sectional estimate of pneumococcal carriage prevalence was taken from 
all samples collected in both longitudinal studies, for the five different age/HIV groups: 
infants <1 year, children 1-4 years, children 5-15 years, HIV-positive adults (16+ years) 
and HIV-negative adults (16+ years). The estimates for children 0-15 years were age-
standardized based on the census data from 2010.  
 
The laboratory methods used in both longitudinal studies conducted in the pre-
vaccination period allowed only for the detected of a single serotype per sample. 
Because the model involved the state “B” (carriers of both VT and NVT), we adjusted 
our prevalence estimates according to estimates from studies conducted in Malawi 
which used microarrays for serotyping, allowing the detection of multiple serotypes per 
sample (47, 221) (Table 9.9). Multiple serotype carriage was identified amongst 40% of 
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samples from children 0-13 years positive for Streptococcus pneumoniae, with 61% 
carrying a VT and NVT serotype simultaneously. Multiple serotype carriage was higher 
in children 0-2 years (48%) than in children 3-13 years (32%). Although this difference 
was not statistically significant (p=0.08) (221), we used these proportions for the age 
groups 0-1 years and 5-15 years in our modelling study. For the age group 1-4 years 
old we took the overall estimate (40%). Multiple serotype carriage was found to be 16% 
in HIV-negative adults and 20% in HIV-positive adults (232). In the study on adults no 
estimate was given on the proportion of samples with multiple carriage in with both a 
VT and NVT serotype was detected. For the purpose of this study we assumed this 
proportion of VT and NVT carriage to be the same as for the children (61%). For 
calculation of the proportion of samples with VT carriage, NVT carriage or carriage of 
both, we assumed that VT and NVT samples were misclassified as single carriage in 
equal proportions.  
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* age-standardized for children 0-15 years to 2010 KPS population 
 
Table 9.9 Observed proportion of VT and NVT carriage and estimated proportion of multiple carriage of VT and NVT by age group 
 Proportion multiple 
carriage amongst positive 
samples (47, 221) 
Observed carriage* (%) Estimated carriage (%) 
Age group VT and NVT VT NVT Total B VT NVT Total 
<1 years 0.48 · 0.61 = 0.293 23.9 18.4 42.3 0.293 · 42.3 = 12.4 23.9 – (12.4/2) = 17.7 18.4 – (12.4/2) = 12.2 42.3 
1-4 years 0.40 · 0.61 = 0.244 25.9 25.7 51.6 0.244 · 51.6 = 12.6 25.9 – (12.6/2) = 19.6 25.7 – (12.6/2) = 19.4 51.6 
5-15 years 0.32 · 0.61 = 0.195 14.9 22.0 36.9 0.195 · 36.9 = 7.2 14.9 – (7.2/2) = 11.3 22.0 – (7.2/2) = 18.4 36.9 
16+, HIV+ 0.20 · 0.61 = 0.122 10.0 12.6 22.6 0.122 · 22.6 = 2.8 10.0 – (2.8/2) = 8.6 12.6 – (2.8/2) = 11.2 22.6 
16+, HIV- 0.16 · 0.61 = 0.098 5.6 10.4 16.0 0.098 · 16.0 = 1.6 5.6 – (1.6/2) = 4.8  10.4 – (1.6/2) = 9.6 16.0 
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9.6.3 Results of fitting to observed data 
We fitted the model to the observed Karonga carriage prevalence data (section 9.3.2) 
using the SMC ABC algorithm described in section 9.4.1. In the first round, in which 
particles were obtained from the prior distribution, the acceptance was 2.6% (Table 
9.10). This was increased to 16.1% in round 2 and thereafter decreased with each 
round. We terminated the procedure after round 5, when the acceptance was 0.4%.  
 
Table 9.10 Acceptance for SMC ABC fitting to Karonga data 
round tolerance ! acceptance  # simulations required to reach ! = 200 
1 8000 2.6% 7745 
2 6000 16.1% 1244 
3 4000 10.7% 1878 
4 2000 1.9% 10300 
5 1000 0.4% 48500 
  
Figure 9.6 shows the observed carriage prevalence and the model carriage estimate 
for VT, NVT and B carriage in the five age/HIV groups. The 95% credible intervals for 
the observed and model estimate prevalence overlap for all carriage types (VT/NVT/B) 
and age/HIV groups, apart from NVT carriage in infants which is overestimated in the 
model.  
 
Figure 9.7 shows the prior and (intermediate) posterior distributions for rounds 1-5. For 
most parameters, credible intervals were increasingly narrowing with each fitting round. 
Round 5 was only marginally different from round 4, and saw the introduction of 
multimodal distributions. A narrow credible interval was observed for the household 
transmission rate !!!, and competition parameter !, identifying those two parameters 
as most important for the model fit. The peak of the distribution !!! lies around 0.1; this 
is higher than estimated from other studies (Table 9.2). The competition parameter 
defines how much carriage of one type (VT or NVT) protects against acquisition of the 
other type (VT or NVT) where 1 is no competition and 0 is complete competition. We 
estimate the competition parameter to be between 0.8 and 1, meaning that very little 
competition occurs in our setting.   
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Figure 9.6 Observed and model carriage prevalence for data of Karonga District. 
Model results from 200 simulations with parameters drawn from ABC SMC round 5 with 
weighted sampling. Model carriage prevalence was assessed at 2 years (730 days). 
 
For the susceptibility parameters, we made the assumption that infants were most 
susceptible for pneumococcal acquisition and that infants were equally or more 
susceptible to VT than to NVT serotypes. The susceptibility parameter, defined as a 
relative rate of the force of infection, was set at 1 for infants for VT transmission 
(reference group). Figure 9.7 shows that the model fit for !!!! !"#,!" tends to move 
towards 1, indicating that there is not much difference between the susceptibility of 
children 1-4 years for VT carriage as compared to infants. Also the model fit for !!! !"#,!"# tends to move towards 1, although the credible interval is wide. Poor fitting 
of this parameter is likely to have resulted in the overestimate of NVT carriage in 
infants in the model (Figure 9.6).   
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Figure 9.7 Prior and posterior distribution of several rounds of SMC ABC fitting to data from Karonga District 
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Figure 9.7 cont. Prior and posterior distribution of several rounds of SMC ABC fitting to data from Karonga District 
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Figure 9.7 cont. Prior and posterior distribution of several rounds of SMC ABC fitting to data from Karonga District 
 
Round 1         Round 2               Round 3          Round 4              Round 5 
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There is some evidence from the model fit that HIV-positive adults are more 
susceptible for VT carriage than HIV-negative adults, although the credible estimates 
of the model fit were wide. No convincing difference by HIV-status is observed for 
susceptibility of NVT carriage. Figure 9.8 shows the correlation between the posterior 
distributions of parameters that were fitted the data established in the field studies. 
Positive correlations were observed for the correlation between the VT and NVT 
parameters for !!!!" !"# and !!"#!; the susceptibility parameters for children 5-15 years 
and HIV-negative adults, respectively. This suggests that for those age/HIV-groups 
separate parameters for susceptibility of VT and NVT carriage were not required.  
 
A multimodal distribution is observed for the ratio !!!/!!"#. In round 5, a peak was 
observed around 0.35, which would indicate that !!"#  is approximately 0.035 given our 
estimate of !!!  of 0.10. Caution needs to be taken in reporting this finding, however, as 
smaller peaks are observed for estimates as small as 0.05 and as large as 0.7. The 
ratio !!! /!!"#  was also found to have the poorest fit in the fitting to dummy data, 
indicating that this parameter is difficult to fit with the current model structure. Figure 
9.8 shows that a strong negative non-linear correlation was observed between !!! and 
the ratio !!! / !!"# , indicating a trade-off between household and community 
transmission. This trade-off could have resulted in the poor fitting of the ratio !!!/!!"#. 
Fitting the ratio !!!/!!"# was also complicated by the uninformative uniform prior; it is 
possible that this parameter would have had a better fit with a more informative prior. 
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Figure 9.8 Correlation between the posterior distributions of parameters fitted to 
data from Karonga District.  
 
9.6.4 Simulations of pneumococcal carriage without vaccination strategy. 
Figure 9.9 shows the results from 200 simulations with parameters drawn from the 
posterior distribution (ABC SMC round 5) with weighted sampling. All simulations were 
started at the observed carriage prevalence by age/HIV group, in figure 9.9 depicted by 
the dashed horizontal line. The simulations were run from 1st January 2009 to 30th June 
2015 (2371 days). The vertical dashed line in figure 9.9 shows the date at which the 
model was assessed for the model fit (section 6.5.2): 1st January 2011, two years (730 
days) after the start of the simulation.  
 
Pneumococcal carriage prevalence decreases over the simulation time, particularly for 
VT and B carriage. Mean VT carriage prevalence in infants was highest at 23.8% at  
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Figure 9.9 Observed and model carriage 
prevalence for data of Karonga District 
Results from 200 simulations with parameters drawn from 
ABC SMC round 5 with weighted sampling.   
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day 35 after start of the simulation and lowest at 17.8% towards the end of the 
simulation. Mean carriage prevalence of both VT and NVT (“B status”) decreased in 
infants from 17.4% to 9.3% over the simulation period.  
 
9.7 Discussion 
 
Findings 
We developed a stochastic individual-based model with SIS infection dynamics and 
explicit, dynamic household and population structure, which allowed for the 
investigating of within-household and community transmission in five different age/HIV 
groups. We used SMC ABC to fit our model to observed data: a relatively new method 
for inference without the need of likelihood calculations, which was found to perform 
well in simulations using dummy data. Sequential ABC methodology has previously 
been used to estimate transmission dynamics of Streptococcus pneumoniae from 
strain prevalence data in a study on day-care centres in Finland (159).  
 
Whilst the model fitting to dummy data reached SMC ABC round 10 (! = z<100) before 
reaching the threshold of <1% acceptance, the model fitting to the observed carriage 
prevalence only reached SMC ABC round 5 (! = z<1000) before reaching the threshold 
of <1% acceptance. It was expected that the model fitting to dummy data performed 
better than the model fitting to observed data; in theory a ‘perfect fit’ is possible for the 
dummy data given it has been created using exactly the same model. A ‘perfect fit’ is 
almost impossible for the model fitting to observed data.  
 
The posterior distribution of the model fitted to observed data allows us to draw several 
conclusions. The peak of the distribution for household transmission (!!!) lies around 
0.1; this is higher than estimated from other studies (Table 9.2), indicating that 
household transmission frequently occurs in this population. We estimated the 
competition parameter to be between 0.8 and 1, meaning that very little competition 
occurs in our setting. Our competition parameter estimate is similar to the parameter fit 
from Bangladesh (!=0.83) (153). Low competition between VT and NVT is a likely 
reason for the high multiple serotype carriage estimates observed in children in this 
area. The latest study on multiple serotype carriage amongst carriers in Blantyre, 
Southern Malawi estimates that multiple serotype carriage occurs in 54.1% of 
vaccinated and 59.3% of unvaccinated children aged 5-6 years. These estimates 
(which only became available after model fitting had been completed) are higher than 
the 32% we used as an estimate for our model presented here. If we would have used 
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the latest estimate from Blantyre for our fitting, it is likely that we would have concluded 
that even less competition occurs between VT and NVT. There is some evidence from 
the model fit that HIV-positive adults are more susceptible for VT carriage than HIV-
negative adults, although the credible estimates of the model fit were wide. Increased 
susceptibility could explain the higher prevalence of carriage observed in HIV-positive 
as compared to HIV-negative adults. It is also possible that HIV-positive adults carry a 
pneumococcus for a longer period of time as hypothesized in chapter 6, but 
unfortunately we could not test this hypothesis in our model.  
 
When using a longer simulation time, a decreasing trend in pneumococcal carriage 
prevalence was observed. Most likely, a change in population structure is the result of 
this decreasing trend observed in the model; none of the model parameters were 
changed over the simulation period. When looking at the population dynamics over the 
simulation period, a decrease was observed for the proportion of infants and children 
<5 years in the population, whilst an increase was observed for the proportion of 
children 5-15 years and HIV-negative adults in the population. Also a decrease in the 
proportion of HIV-positive adults in the population is observed over the simulation 
period. This decrease in HIV-positive adults is a limitation of our model: we did not 
include HIV-transmission in the model, so no new HIV-infections in adults were 
included over the simulation period. Incidence of HIV decreased in Malawi in this 
period as a consequence of reduced transmission after introduction of ART (233), so 
although some new HIV-infections will have occurred, we do not expect our omission 
of implicit HIV-transmission will have had a large effect on the model. We did include 
an HIV-status for 5-15 year olds in the model: this (very low) HIV-prevalence was not 
taken into account for children 5-15 years, but did come into play when they aged to 
become HIV-positive or HIV-negative adults. Together, the shift in population structure 
will have affected the pneumococcal carriage prevalence dynamics over the simulation 
period. The decrease in carriage prevalence will need to be taken into account when 
using this model to predict the impact of different vaccination strategies in this 
population. 
 
Limitations and future improvements 
Several limitations can be identified for the model presented here which could be 
targets for future improvements. There are limitations related to the method used for 
model fitting, the design of the model, and the data used.  
 
We already highlighted the strengths and limitations of the ABC SMC method in 
section 9.4. The main drawback of using ABC is that it is a relatively new method and 
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that does not yet have the statistical rigor of more conventional optimization methods. 
Another disadvantage of ABC methods is that they are reliant on the user-choice of 
appropriate summary statistics and the choice of the acceptance threshold. In the 
current model we only used one summary statistic; the z-value calculated by the Chi-
square test performed on counts in the different VT/NVT/B statuses for the five 
age/HIV groups. Future work could explore using different summary statistics, e.g. the 
proportion of households infected. Similarly, the effect of using a dynamic process to 
set the acceptance threshold ! could be explored. We used a pre-defined step-wise 
linear series of acceptance thresholds, but a dynamic evaluation was used by 
Numminen et al. (159).  
 
There are three main limitations to the design of the model: related to the assumed 
mixing pattern, duration of carriage and assumptions about immunity. We assumed 
random mixing with the household and community, whereas in reality some degree of 
assortative mixing will take place, e.g. between children of the same age in schools. 
Similarly, mixing within the household can be expected to be non-random; for instance 
more contact can be expected to take place between infants and mothers than 
between infants and other adults in the household. Fitting the model using an 
assortative mixing matrix or using different transmission parameters for mother-infant 
contacts could be explored. SMC ABC can be applied to compare different model 
structures (223). We could apply this strategy to compare models with or without 
assortative mixing. The comparison could similarly be used on the current model: we 
use this to compare our current model with a model without explicit household 
transmission, or look at the difference between a model with or without separate 
characteristics for HIV-positive adults. Limitations regarding the duration of carriage 
stem from our decision to fix the recovery rates during our model fitting, because 
training simulations showed poor performance when both susceptibility parameters and 
recovery rates were fitted. Fixing the recovery rates in our model meant that we could 
not study differences in carriage duration between the different age/HIV groups. Also, 
under or overestimation of carriage duration could have influenced our model fit, and 
hence our conclusions regarding the other parameters fitted. Lastly, our model involves 
a simplification of the dynamics involved in pneumococcal carriage and transmission, a 
limitation inherent to mathematical modelling. We adopted Susceptible-Infected-
Susceptible dynamics for our model, consistent with other modelling studies in the 
literature (145-158, 222). Evidence is provided in the literature, however, for both 
serotype-specific (234) and serotype-independent (125) immunity. We did not include 
immunity as a result of previous carriage in the model. We did include a parameter 
reflecting different susceptibilities by age and HIV group.  
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Thirdly, there are limitations regarding the data we used to fit the model to and how this 
fitting was done. The data we used for the fitting of our model largely comes from 
households selected because they involved a newborn infant. We do not have any 
observations for HIV-negative adults living without young children. It is possible that 
this selection of data has led to an overestimation of carriage in HIV-negative adults. 
Our estimate for HIV-positive adults is generated from data collection within the 
household study (chapter 5) and the ART clinic (chapter 6): we expect this has given a 
good estimate of carriage among HIV-positive adults in the population. We fitted our 
model to the observed prevalence of pneumococcal carriage in the different age-HIV 
groups. More detailed use of the longitudinal household data from which the 
prevalence estimates were obtained could be used to study household transmission in 
more detail. Lastly, we did not include any variation in carriage by season in the model. 
Seasonality was found to be strongly associated with carriage in chapter 5 and 6. 
Including a parameter to model seasonality, fitted to carriage estimates by seasonality, 
would make the model more in line with reality.   
 
Conclusion 
In conclusion, we developed a stochastic individual-based model with SIS infection 
dynamics and explicit, dynamic household and population structure, which allowed for 
the investigating of within-household and community transmission in five different 
age/HIV groups. SMC ABC was found to perform well when fitting the model to dummy 
data. We used SMC ABC to fit the model to observed carriage prevalence in five 
age/HIV groups. From the model fit we can conclude that the household transmission 
rate is approximately 0.10 per effective contact. There was found to be little 
competition between VT and NVT serotype carriage, resulting in high prevalence of 
multiple serotype carriage in young children. There is some evidence from the model fit 
that HIV-positive adults are more susceptible for VT carriage than HIV-negative adults, 
although the credible estimates of the model fit were wide. Drawbacks of the current 
model fit are that the model overestimates the NVT carriage prevalence in infants, and 
that a decrease in VT and B carriage is observed in simulations without the 
implementation of a vaccination programme. Those two limitations will be taken into 
account when using this model to predict the impact of different vaccination strategies 
in this population (chapter 10). 
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10. A mathematical model to study 
pneumococcal transmission in the post-
vaccination period 
In chapter 9 we designed a stochastic individual-based mathematical model to 
describe pneumococcal carriage and transmission, and fitted this to the observed pre-
vaccination carriage prevalence in the pre-vaccination period (chapter 5+6). In this 
chapter we will use this fitted mathematical model to simulate the effect of PCV-13 
introduction in the population. We will validate our model with pneumococcal carriage 
prevalence data from the post-vaccination period (chapter 8). Using the observed 
carriage prevalence data and the known vaccination history of the population under 
surveillance in the KHDSS, we will run simulations with different assumptions about 
waning immunity, and report which duration for waning immunity fits best with the 
observed data. We will then use this finding to explore the effect of different vaccination 
schedules. 
 
10.1 Description of the model  
Figure 10.1 shows the adapted model including vaccination of the population. 
Vaccinated individuals gain partial protection against VT pneumococci acquisition by a 
degree of protection !, that ranges from !=1 (full protection) to !=0 (no protection) and 
increases with the number of doses of PCV-13 received. Vaccination does not affect 
acquisition of NVT pneumococci. Vaccine immunity wanes over time by waning rate ω, 
which is described by exponential decay: 
 ! ! =  !! (12) !!!! (1) 
where !! is the initial protection of the vaccine, ! !!  is the half-life of the vaccine 
protection (waning immunity), and !! is the vaccine protection after time !.  
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Figure 10.1 Model structure 
Adapted from Melegaro et al, 2010 (220). Model describes the transmission to different states: 
S (susceptible), VT (carrier of vaccine type), NVT (carrier of non-vaccine type), B (carrier of both 
VT and NVT), where !!" and !!"# are the forces of infection for VT and NVT, !! is the age-
specific recovery rate, ! is the competition parameter, and !! is the age-specific susceptibility 
parameter. In vaccinated individuals, acquisition of a VT pneumococcus is modified by vaccine 
protection ! . !  describes vaccination of susceptible individuals, !  waning of immunity in 
vaccinated individuals. 
 
The transmission states for our stochastic model are summarized in the following set of 
differential equations: !"!" =  !" ! · !! +  !!" ! · !! −  ! ! ·  !! · !!" ! −  ! ! ·  !! · !!"# ! − ! · !" ! + ! · !" (!) 
(2) 
!"#!" =  ! ! · !! +   ! ! ·  !! · !!" ! − !" ! · !! · ! · !!"#  ! − ! ·  !" ! + !· !"# (!) 
(3) 
!"#$!" =  ! ! · !! +   ! ! ·  !! · !!"# ! − !"# ! · !! · ! · !!"  ! − ! ·  !"# !+ ! · !"#$ (!) 
(4) 
! 
v 
S 
VT NVT 
B 
γa γa 
γa γa 
σa,vtλVT(t) σa,NVTλNVT(t) 
σa,NVTcλNVT(t) σa,VTcλVT(t) 
Unvaccinated individuals Vaccinated individuals 
Sv 
VTv NVTv 
Bv 
γa γa 
γa γa 
σa(1-π)λVT(t) σaλNVT(t) 
σacλNVT(t) σa(1-π)cλVT(t) 
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!"!" =   !" ! · ! ·  !! · !!"# ! +  !"# ! ·  ! ·  ! · !!" ! − ! ! · !! − ! ·  ! ! + !· !" (!) 
(5) 
!"#!" =  !"# ! · !! +  !"#$ ! · !! −  !" ! ·  !! · 1 − ! · !!" ! −  !" !·  !! · !!"# ! + ! · ! ! − ! · !"(!) 
(6) 
!"#$!" =  !" ! · !! +   !" ! ·  !! · 1 − ! · !!" ! − !"# ! · !! · ! · !!"#  ! + !·  !" ! − ! · !"# (!) 
(7) 
!"#$%!" =  !" ! · !! +   !" ! ·  !! · !!"# ! − !"#$ ! · !! · ! · 1 − ! · !!"  ! + !·  !"# ! − ! · !"#$ (!) 
(8) 
!"#!" =   !"# ! · ! ·  !! · !!"# ! +  !"#$ ! ·  ! ·  !! · 1 − ! · !!" ! − !" ! · !!+ ! ·  ! ! − ! · !"(!) 
(9) 
 
where !!,! is the age/HIV group and VT/NVT specific susceptibility parameter, !! is the 
age/HIV group specific recovery rate and !!" and !!"# are the force of infection for VT 
and NVT respectively (described in chapter 9). In vaccinated individuals, acquisition of 
a VT is modified by protection !. ! describes vaccination of susceptible individuals, ! 
waning of immunity in vaccinated individuals. 
 
10.2 Observed data  
10.2.1 Pneumococcal prevalence data in the post-vaccination period 
Table 10.1 shows the observed prevalence of VT and NVT carriage by age group, as 
well as the estimated proportion of VT, NVT and B carriage. To estimate the proportion 
of multiple carriage amongst carriers in the post-vaccination period, we assumed that 
VT carriage decreased equally within the VT and B groups post introduction of PCV-
13. We therefore decreased the proportion multiple carriage amongst positive samples 
observed in samples from Karonga (47, 221) (section 9.3.2) by the adjusted 
prevalence ratio reported in chapter 8 (Table 8.6).  
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1 Age-standardized to 2010 KPS population for children 1-4 years and 5-15 years  
2 Total observed and estimated carriage different due to rounding 
 
Table 10.1. Observed proportion of VT and NVT carriage and estimated proportion of multiple carriage of VT and NVT by age group 
 Proportion multiple 
carriage amongst positive 
samples (47, 221) 
Observed carriage1 (%) Estimated carriage (%) 
Age group VT and NVT VT NVT Total B VT NVT Total2 
<1 years 0.48 · 0.61 · 0.24 = 0.070 11.9 44.0 55.9 0.070 · 55.9 = 3.9 11.9 – (3.9/2) = 10.0 44.0 – (3.9/2) = 42.1 56.0 
1-4 years 0.40 · 0.61 · 0.63 = 0.154 19.7 50.1 69.8 0.154 · 69.8 = 10.7 19.7 – (10.7/2) = 14.4 50.1 – (10.7/2) = 44.8 69.9 
5-15 years 0.32 · 0.61 · 0.37 = 0.072 5.7 22.5 28.2 0.072 · 28.2= 2.0 5.7 – (2.0/2) = 4.7 22.5 – (2.0/2) = 21.5 28.2 
16+, HIV+ 0.20 · 0.61 · 0.06 = 0.007 0.5 9.6 10.1 0.007 · 10.1= 0.1 0.5 – (0.1/2) = 0.5 9.6 – (0.1/2) = 9.6 10.2 
16+, HIV- 0.16 · 0.61 · 0.34 = 0.033 2.4 12.9 15.3 0.033 · 15.3= 0.5 2.4 – (0.5/2) = 2.2 12.9 – (0.5/2) = 12.7 15.4 
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10.2.2 Vaccination uptake data  
 
To include vaccination in our stochastic individual-based models, we used the vaccine 
uptake data as recorded in the KHDSS annual census. Recorded vaccination dates 
were used to assign onset of vaccine protection: if the model reached the date 
associated with an individual’s vaccination date, this individual was assigned protection 
by vaccination ! (see section 10.3). 
 
Table 10.2 shows the vaccine uptake and the median age at vaccination amongst birth 
cohorts since introduction of PCV-13. This table includes any children born between 
10th November 2010 (oldest eligible for the PCV-13 catch-up campaign) and 30th June 
2015 (end of data included), including those that died and those that migrated in or out 
of the KHDSS area during this period. As described previously in chapter 7, PCV-13 
vaccination coverage increased since introduction of PCV-13, with 86.4% of age-
eligible infants receiving three doses of PCV-13 in 2011-2012, and 93.8% in 2013-
2014. Median age to vaccination decreased since introduction of PCV-13, with 20.2 
weeks in 2011-2012 and 18.4 weeks in 2013-2014. We included vaccine uptake data 
of measles vaccination (MV) in Table 10.2, because this data was used in simulations 
with vaccination strategies including a booster does: if a booster dose of PCV-13 were 
to be introduced, it is likely that it would be given at the same time as MV. 
 
A written or verbal history of dose 1 PCV-13 vaccination receipt was missing for 430 of 
6833 (6.3%) PCV-13 catch-up or birth cohort age-eligible children. Date of dose 1 
PCV-13 vaccination was missing for 1292 of 5991 (21.6%) age-eligible children who 
were recorded (written or by verbal history) to have received the first dose of PCV-13. 
In the model, explicit vaccination status and vaccination dates in case of vaccine 
receipt were required. Vaccination status and vaccination date were therefore imputed 
for individuals with missing status or dates, matched by month of birth, in four stages:  
1. Vaccination status for those who were interviewed before they were age-eligible 
was set to missing if the vaccine was not received at time of interview. This was 
done for all three doses of PCV-13 and MV.  
2. Each individual with missing vaccination status was randomly matched to an 
individual with recorded vaccination status (including written recorded and 
verbal history) by month of birth. The matched vaccination status was assigned 
to the individual with missing vaccination status.  
3. If vaccination date was available for two out of the three PCV-13 doses and the 
individual was said to have received all three doses (n=42), the third date was 
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estimated using the median time between PCV-13 dose 1 and PCV-13 dose 2 
in the population (35 days) or the median time between PCV-13 dose 2 and 
PCV-13 dose 3 (35 days). If only one date was available and the individual was 
said to have received all three doses (n=6), this date was disregarded and new 
dates were imputed (see step 4) 
4. Each individual with one or more missing vaccination dates was randomly 
matched to an individual with vaccination dates available. Matching was done 
by month of birth and number of vaccines received. Vaccination dates were 
calculated based on the age of vaccination of the matched individual. 
Imputation was done matched by month of birth, because time since introduction of 
PCV-13 was found to be strongly associated with PCV-13 receipt and vaccination age 
in chapter 7 and in Table 10.2.  
 
Table 10.2 Vaccine uptake and age at vaccination amongst birth cohorts since 
introduction of PCV-13 
 Birth cohorts1 
 2010-2011 
(catch-up) 
2011-2012 2012-2013 2013-2014 2014-20152 
Total 1447 1573 1386 1427 1000 
Vaccine uptake      
Vaccination 
status available3 
1387 
(95.9%) 
1490 
(94.7%) 
1325 
(95.6%) 
1336 
(93.6%) 
865 
(86.5%) 
Uptake4      
 PCV (6wk) 68.5% 92.5% 98.4% 99.2% 91.2% 
 PCV (10wk) 61.4% 91.2% 96.6% 97.4% 88.4% 
 PCV (14wk) 51.5% 87.4% 92.9% 94.5% 78.2% 
  MV (9mo) 96.5% 94.3% 93.0% 91.1% 68.6% 
Age at vaccination     
Vaccination date 
available5 
658  
(75.0%) 
1134 
(85.1%) 
1140 
(88.0%) 
1136 
(86.3%) 
631 
(85.3%) 
Median age at  
vaccination  
 PCV (6wk) 31.0 wks 8.7 wks 8.4 wks 7.9 wks 7.9 wks 
 PCV (10wk) 36.8 wks 14.3 wks 13.7 wks 13.0 wks 13.1 wks 
 PCV (14wk) 40.7 wks 20.2 wks 19.6 wks 18.4 wks 18.0 wks 
 MV (9mo) 9.7 mo 9.6 mo 9.6 mo 9.6 mo 9.4 mo 
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1 Birth cohorts from 29th November – 28th November to reflect time since introduction of PCV-13. 
Catch-up birth cohort = 10th November 2010 – 28th November 2011. Birth cohort 2014-2015 is 
29th November – 30th June 2015. 
2 Uptake in 2014-2015 is expected to be lower than in previous years, because this cohort will 
include children that received vaccination late and have been interviewed after vaccine-eligible 
age, but before receiving vaccination. 
3 Availability of PCV-13 dose 1 receipt by written documentation or verbal history. 
4 Uptake at any age amongst age-eligible children 
5 Availability of date PCV-13 dose 1 receipt amongst age-eligible children who are recorded 
(written or verbal history) to have received PCV-13 dose 1 
 
Including imputed data, vaccination coverage in all children <5 years (including age in-
eligible children) was 82.0% for one dose of PCV-13 and 70.9% for three doses of 
PCV-13 on 30th June 2015 (end of model simulations) (Fig 10.2). Vaccination coverage 
in all infants (including infants too young to be vaccinated) was 82.6% for one dose of 
PCV-13 and 56.4% for three doses of PCV-13.  
 
 
 
Figure 10.2 Vaccination coverage in infants and children <5 years (including age 
in-eligible children).  
Data includes imputation of vaccination dates for children with missing vaccination dates.  
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On 30th June 2015, 40.6% of all households included at least one fully vaccinated child 
(Fig 10.3). 
 
 
Figure 10.3 Vaccination coverage at household level 
Data includes imputation of vaccination dates for children with missing vaccination dates. A 
slight decrease in the proportion of households with at least one infant/at least one child <5 
years can be observed.  
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10.3 Models with different waning immunity rates 
 
Table 10.3 shows the parameter settings for modelled scenarios including vaccination. 
We set the degree of vaccine protection at 0.58 for dose 1, 0.67 for dose 2 and 0.89 for 
dose 3, to reflect the VE observed in the post-vaccination carriage study (chapter 
8.3.4). We ran simulations with four different levels of immunity half-life: 6 months, 1 
year, 2 years and 3 years. Each scenario was realised 200 times with parameters 
drawn from the posterior distribution as described in chapter 9: mean results are 
presented in figures 10.4-10.7.  
 
Table 10.3 Parameters describing vaccination  
Parameter Meaning Value ! vaccination rate observed vaccination in KHDSS  
(see paragraph 10.2.3) !   
 
degree of protection by vaccine 
dose against acquisition of a VT 
pneumococcus  
- dose 1: 0.58 
- dose 2: 0.67 
- dose 3: 0.89 ! waning immunity  
(half-life) 
models with different half-lives: 
- 6 months 
- 1 year 
- 2 years  
- 3 years  
 
Figure 10.4 shows the observed post-vaccination carriage prevalence and model 
estimates for simulations with different waning immunity half-lives. Models including a 
waning immunity of 6 months or 1 year provided a good fit to VT and B carriage for all 
age/HIV groups. NVT carriage in infants and children 1-4 years was underestimated 
using models with all different settings for waning immunity.  
 
Model fit to the observed post-vaccination carriage estimates was assessed by the Chi-
squared test on observed vs. model counts of individuals in the different age/HIV 
groups  with status VT, NVT and B at the mid-point of post-vaccination sample 
collection (5th May 2014). An immunity half-life of 1 year provided the best overall fit to 
the observed carriage data, taking into account VT, NVT and B carriage in all age/HIV 
groups. An immunity half-life of 6 months provided the fit to the observed carriage data 
for VT carriage in infants.  
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Figure 10.4 Observed post-vaccination carriage prevalence and model estimates 
for simulations with different waning immunity half-lives.  
Mean results and 95% credible intervals of 200 realisations.  
 
Figure 10.5 shows the different model simulations for VT carriage in the different 
age/HIV groups. A decrease in VT carriage was observed in all age/HIV groups, 
starting soon after introduction of PCV-13 on 12th November 2011 (indicated by an 
arrow in Figure 10.5). A large difference in carriage by the end of the model simulation 
(30th June 2015) was observed between models with waning immunity half-lives of 6 
months, 1 year or 2 years. Only a marginal difference was observed between models 
with waning immunity half-lives of 2 year or 3 years. Model simulations with different 
waning immunity half-lives for NVT and B carriage can be found in Figures 10.6 and 
10.7. NVT carriage was found to increase in all models simulations, with larger 
increases in NVT carriage observed in models with longer duration of protection 
against VT acquisition.    
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Figure 10.5 Simulated scenarios with different waning immunity half-lives: result 
for vaccine type carriage.  
Mean results of 200 realisations.  
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Figure 10.6 Simulations with different waning immunity half-lives: result for non-
vaccine type carriage.  
Mean results of 200 realisations.  
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Figure 10.7 Simulations with different waning immunity half-lives: result for 
multiple carriage of both vaccine and non-vaccine types.  
Mean results of 200 realisations.  
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10.4 Models with different vaccination strategies 
10.4.1 Description of vaccination strategies 
Table 10.4 describes the different vaccination strategies that were simulated. We 
simulated the currently implemented 3+0 vaccination schedule with a catch-up 
campaign for infants <1 year of age. The impact of a booster dose given at 9 months of 
age, at the same time as MW, was assessed in a 3+1 schedule and in a 2+1 schedule, 
with primary doses given at 6 and 14 weeks. All scenarios were run twice: with the 
parameter for waning immunity set to a half-life of 6 months or 1 year.  
 
We also looked at the impact of different catch-up campaigns. The status quo scenario 
includes a catch-up campaign with 3 doses offered 4 weeks apart in infants <1 year, as 
was implemented in Karonga District in November 2011. We ran the same scenario 
without catch-up campaign to assess the contribution the catch-up campaign has made 
to the post-vaccination pneumococcal carriage dynamics. We also modelled the impact 
of a more intense catch-up scenario, as was implemented in Kilifi Region in Kenya 
(25). In Kilifi, all infants were offered three doses of PCV-10 given 4 weeks apart. In 
addition, two doses of PCV-10 were given to children aged 12-59 months in two 1-2 
week outreach campaigns. For our model, we assumed that coverage of 80%, 75% 
and 70% would be reached with an enhanced 2-week catch-up campaign for the 
receipt of one, two and three doses PCV. In the catch-up campaign held in Karonga 
District in 2011, lower coverage was achieved, but this could be partially attributed to 
vaccine non-availability (chapter 7.3.2). We assumed that higher coverage could be 
achieved with enhanced outreach efforts and a better supply of vaccines. We assumed 
that vaccine protection in 12-59 month olds was better than in infants and that only two 
doses were required to reach the same level of protection. 
 
We also simulated vaccination of HIV-positive or all mothers, with one dose of PCV-13 
given at time of delivery. We assumed the same vaccine protection as in infants (0.58 
for dose 1, and 0.67 for dose 2 and 0.89 for dose 3 in the event of multiple births within 
the simulation period). We assumed an immunity half-life of one year in the mothers, 
regardless of HIV-status. Each scenario was realised 200 times with parameters drawn 
from the posterior distribution as described in chapter 9: mean results are presented in 
figures 10.8-10.12)  
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Table 10.4 Description of vaccination strategies 
Infant vaccination strategies 
# Description Schedule in  
birth-cohort 
Schedule in  
catch-up cohort 
0 3+0 (status quo) 6,10,14 wks 3 doses 4 weeks apart in infants <1 yr 
1 2+1 6,14 wks, 9 mo 3 doses 4 weeks apart in infants <1 yr 
2 3+1 6,10,14 wks, 9 mo 3 doses 4 weeks apart in infants <1 yr 
3 No catch-up 6,10,14 wks - 
4 Intense catch-up (Kilifi) 6,10,14 wks 3 doses 4 weeks apart in infants <1 yr 
2 doses 4 weeks apart in children 12-59 mo 
Adult vaccination strategies (simulated alongside current 3+0 infant schedule) 
# Description Schedule 
5 HIV-positive mothers only One dose at time of delivery 
6 All mothers One dose at time of delivery 
 
10.4.2 Model results 
Figure 10.8 shows the model results for VT carriage for simulations with different infant 
vaccination schedules. Only marginal differences were observed between the different 
vaccination schedules, with widely overlapping confidence intervals (not shown in 
Figure 10.8 for clarity). The 3+1 schedule was associated with lower carriage than the 
current schedule for all age/HIV groups. Adoption of a 2+1 schedule was initially 
associated with a less rapid decrease in VT carriage, but towards the end of the 
simulation time the gradient of VT carriage reduction was steeper in children 1-4 years 
than in simulations using the current 3+0 vaccination schedule, particularly when 
assuming an immunity half-life of 6 months (Figure 10.9). NVT carriage in infants and 
children 1-4 years increased after PCV-13 introduction in all simulations, but was not 
found to differ between the different vaccination schedules (Figure 10.10). 
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Figure 10.8 Simulated scenarios with different infant vaccination schedules: 
result for vaccine type carriage.  
Mean results of 200 realisations. Waning immunity of 1 year. Note different y-axis scale for 
infants and children 1-4 years, and for children 5-15 years and adults. 
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Figure 10.8 cont. Model results for simulations with different infant vaccination 
schedules: result for vaccine type carriage.  
Mean results of 200 realisations. Waning immunity of 1 year. Note different y-axis scale for 
infants and children 1-4 years, and for children 5-15 years and adults. 
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Figure 10.8 cont. Model results for simulations with different infant vaccination 
schedules: result for vaccine type carriage.  
Mean results of 200 realisations. Immunity half-life of 1 year. Note different y-axis scale for 
infants and children 1-4 years, and for children 5-15 years and adults. 
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Figure 10.9 Simulations with different infant vaccination schedules assuming an 
immunity half-life of 6 months: result for vaccine type carriage 
Mean results of 200 realisations. Results shown for infants and children 1-4 years only. 
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Figure 10.10 Simulations with different infant vaccination schedules: result for 
non-vaccine type carriage 
Mean results of 200 realisations. Assuming an immunity half-life of 6 months. Results shown for 
infants and children 1-4 years only. 
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Figure 10.11 shows the results for the scenarios with different catch-up campaigns: 
vaccination as currently implemented in Karonga District, with or without catch-up 
campaign, or with an enhanced outreach campaign as was implemented in Kilifi, 
Kenya. Beneficial effects of the catch-up campaigns could be seen for all age/HIV 
groups, particularly for children 1-4 years old, with a more rapid decline in VT carriage 
prevalence observed when a catch-up campaign was implemented. Fifty per cent 
reduction in VT carriage in children 1-4 years old (from 19.5% to 9.8%) was achieved 
approximately 6 months later without a catch-up campaign, as compared to the current 
immunisation implemented in Karonga District. At the end of the simulation time only 
minimal differences in VT carriage were observed between the 3+0 strategy with or 
without catch-up as currently implemented in Karonga District.  
 
An enhanced catch-up campaign with better coverage than currently achieved in 
Karonga District showed additional benefits: a very rapid decline in carriage was 
observed in all age/HIV groups. The enhanced catch-up campaign did not lead to a 
completed removal of VT carriage from the population: persistent low-level steady state 
VT carriage was observed in all age/HIV groups.    
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Figure 10.11 Simulations with and without catch-up campaign: result for vaccine 
type carriage. 
Mean results of 200 realisations. Assuming an immunity half-life of 1 year. 
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Models with vaccination in all HIV-positive mothers at time of delivery did not result in 
additional VT carriage reduction in the infant. Vaccination of all mothers led to minimal 
reductions in VT carriage in the infant only (Fig 10.12). 
 
 
 
Figure 10.12 Model results for simulations including vaccination of HIV-positive 
or all mothers: result for vaccine type carriage.  
Mean results of 200 realisations. Immunity half-life of 1 year in both mothers and infants. 
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10.5 Discussion 
 
We used the model described in chapter 9 to simulate the effect of PCV-13 introduction 
in the population, including different assumptions about the immunity half-life. We 
evaluated our model with pneumococcal carriage prevalence data from the post-
vaccination period and explored the effect of different vaccination schedules. 
 
PCV-13 introduction was found to have an immediate direct and indirect effect: the 
proportion of VT carriage reduced immediately after PCV-13 introduction in all age-HIV 
groups. This finding seems to be at odds with the simple threshold theory of herd 
immunity, which states that the incidence of infection would decline if the proportion 
immune in the population exceeds (1 − 1 / !!), with !! being the average number of 
individuals that get infected by one individual in a fully susceptible population (235, 
236). It is important to realise, however, that the simple threshold theory of herd 
immunity assumes vaccination delivered at random and random mixing in the 
population, whereas in reality targeted vaccination and non-random mixing occurs 
(235). Household transmission was explicitly included in our model, based on the real 
household structure observed in the KHDSS. At time of introduction of the vaccine, 
approximately 15% of households included at least one infant, and 55% of household 
included at least one child <5 years of age (Fig 10.3). At the end of the simulation 
period, 82% and 71% of all children <5 years had received one or three doses PCV-13, 
respectively. A large proportion of the population in contact with young children, 
together with good vaccine uptake, implied that a reduction in VT carriage in 
unvaccinated individuals could be observed before the herd immunity threshold was 
reached.  
 
Different assumptions about the duration of the vaccine protection had a large effect on 
the reduction in VT carriage, both for vaccinated and unvaccinated individuals. Models 
with an immunity half-life of 6 months were found to fit best to the observed VT 
carriage in infants. Models with an immunity half-life of 1 year were found to have the 
best overall fit (including VT, NVT and B carriage in all age/HIV groups). Increasing the 
immunity half-life to 2 years had a large impact on the reduction in VT carriage in all 
age/HIV groups. A meta-regression study performed on 22 carriage studies found an 
aggregate vaccine efficacy of 57% (95%CI 50-65%) 6 months after completion of the 
vaccination schedule (237). This finding is consistent with our estimate of an immunity 
half-life between 6 months and 1 year, given initial vaccine efficacy of 87% immediately 
after completion of the schedule. The meta-regression study also found evidence of 
sustained vaccine protection at 5 years, with an aggregate vaccine efficacy of 42%. 
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This is much higher than what would be expected after 5 years given our estimate of 
an immunity half-life between 6 months and 1 year. Our results are consistent with a 
study from South Africa and a study from the UK, which found no difference in VT 
carriage between PCV and placebo recipients 2-5 or 5 years after vaccination, 
respectively (238, 239).  
 
Unsurprisingly, a 3+1 schedule was found to have the largest reduction in VT carriage 
in all age/HIV groups. The 2+1 schedule yielded mixed results: reduction of VT 
carriage was found to be initially delayed as compared to the 3+0 schedule, but a 
steeper decline of VT carriage was observed towards the end of the observation time 
for children 1-4 years, particularly when assuming an immunity half-life of 6 months 
(Fig 10.9). A systematic literature review on the effect of PCV dosing schedules 
concluded that three-dose schedules are more effective in reducing VT carriage than 
two-dose schedules, but could not provide evidence on whether a 3+0 or 2+1 schedule 
reduced VT carriage more (240). Direct comparison between results from 3+0 and 2+1 
schedules reported in the literature proved difficult, because data from 2+1 schedules 
came from studies in Europe only, whereas data from 3+0 schedules can from clinical 
trials in middle income and developing countries. Our model provides an opportunity to 
evaluate different vaccination schedules within the same setting, and show the trade-
off between faster reduction of VT carriage after introduction (obtained in a 3+0 
schedule) and longer-term gains in further reduction of VT carriage in 1-4 year-olds 
(obtained in a 2+1 schedule). Vaccination of HIV-positive or even all mothers was 
found to have no additional benefit to the current infant immunisation schedule. Our 
model could only estimate the reduction in VT carriage in infants as a result of reduced 
transmission from the mothers: it did not include any possible reduction in VT carriage 
as a result of maternal antibody transfer. Despite moderate uptake of PCV-13 in the 
catch-up campaign with only 51.5% of age-eligible infants receiving three doses, the 
catch-up campaign implemented in Malawi was found to have an effect on VT carriage 
reduction in all age/HIV groups, with faster decline of VT carriage observed when a 
catch-up campaign was introduced. Towards the end of the simulation period, 
however, the same VT carriage prevalence was obtained in models with or without 
catch-up campaign. Further decreases in carriage in all age/HIV groups were observed 
with an enhanced catch-up campaign with better coverage in infants (70% receiving 
three doses) and a two-dose schedule offered to children 12-59 months. Despite a 
rapid fall in carriage, persistent low-level VT carriage was observed in all age/HIV-
groups. Carriage studies from Kilifi conducted 5 years after PCV-10 introduction, also 
show low-level persistence in VT carriage in all age groups (241), consistent with the 
findings from our models.  
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Strengths of the model are that it adequately predicted post-vaccination carriage 
prevalence in the VT and B groups. A unique feature of our model is that it includes 
observed vaccination data in combination with observed population data, including 
household structure. Other than in a model where the population and its vaccination is 
simulated, our model includes empiric data on vaccine uptake and timeliness. Also any 
‘hotspots’ of low or delayed vaccine receipt, e.g. amongst children in the same 
household, will be included in this model. Some vaccination data had to be imputed, 
but information on vaccination dates was available for the majority of children.  
 
A limitation of our model is that it did not provide a good fit to the observed NVT 
carriage. NVT carriage was already difficult to describe accurately when fitting to pre-
vaccination data (chapter 9) and this remains a drawback in the model including 
vaccination. Another limitation of our model is that the simulation time is limited, 
because it is dependent on the available population census data. We currently used 
data up to 30th June 2015, but it would be possible to extend this model to the current 
date in the future. Forecasting population dynamics beyond data availability will be 
difficult, because one would have to incorporate births, deaths, migration; and changes 
in household composition which are often driven by those key events. We relied on 
vaccination data from the KHDSS yearly census and imputed vaccination receipt and 
vaccination dates for those for whom no information was available. We included report 
of vaccination, regardless of whether written documentation was observed or not. In 
chapter 7 we could exclude infants without written documentation from our analysis on 
risk factors for low vaccine uptake, but in this model we had to explicitly state the 
vaccination status for each individual. We therefore chose to include all data available, 
and impute vaccination status where no record was available. It is possible that we 
have overestimated or underestimated vaccination coverage by also including verbal 
report.  
 
There are also limitations in the post-vaccination data collection that will have 
influenced the results of the validation of our model. We included the entire population 
in our model, but only have carriage prevalence estimates for particular sub-groups: 
children <15 years and mothers in households with a newborn infant, and HIV-positive 
adults attending the local ART clinic. In the post-vaccination period, we had no other 
estimate for HIV-negative adults than the carriage prevalence observed in mothers. It 
is likely that this estimate has been an overestimation of carriage prevalence in all HIV-
negative adults, given the mothers’ frequent contact with young children, including the 
index infant. Also sample collection from infants was sub-optimal for the purpose of this 
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model: we only collected samples from infants between 6 and 18 weeks of age, 
whereas the model includes infants at all ages. If the true prevalence of infants were 
lower or higher than estimated by our sample collection, this would have favoured an 
immunity half-life of 6 months or an immunity half-life of 1 year or more, respectively. 
We don’t know enough about carriage dynamics in the first year of life after vaccine 
receipt to make a definite conclusion about which of those conditions is correct, hence 
our cautious approach of including both possibilities whilst exploring vaccination 
strategies in this chapter.  
 
In conclusion, our model adequately simulated VT carriage in the post-vaccination 
period. The immunity half-life in infants is estimated to be between 6 months and 1 
year. Increasing the immunity half-life to 2 years would be associated with a large 
reduction in VT carriage in all age/HIV groups. An enhanced catch-up campaign was 
associated with a more rapid and greater fall in VT carriage, but persisting low-level VT 
carriage was observed. A 3+1 schedule was found to be most efficient in reducing VT 
carriage. In choosing between a 2+1 and 3+0 schedule, the trade-off between faster 
reduction of VT carriage after introduction (obtained in a 3+0 schedule) and longer-
term gains in further reduction of VT carriage in 1-4 year-olds (obtained in a 2+1 
schedule) needs to be carefully considered.  
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11. Discussion 
11.1 Summary of findings 
 
In this thesis we have combined epidemiogical and mathematical modelling studies to 
describe pneumococcal carriage and transmission in Karonga District, Malawi, a rural 
sub-Saharan setting, before and after introduction of PCV-13. Our studies had a main 
focus on infants and HIV-positive adults, both high-risk groups for developing IPD. The 
main findings from our work are:  
1) Pneumococcal acquisition did not differ between HIV-exposed and HIV-
unexposed infants, even though pneumococcal prevalence was higher in HIV-
positive mothers than in HIV-uninfected mothers. 
2) Pneumococcal acquisition in infants was associated more with carriage in other 
young children in the household than with carriage in the mother. 
3) Pneumococcal carriage in HIV-infected adults remained high despite two years 
of ART, with evidence of increased carriage of non-PCV-13 serotypes. 
4) Vaccine coverage was moderately high in Karonga District, but infants born to 
lower educated mothers or farming mothers and those living further away from 
the road or clinic were at greater risk of being not fully vaccinated and being 
vaccinated late. 
5) There is evidence for a direct and indirect vaccine effect with decreased VT 
carriage observed in vaccinated and unvaccinated older individuals, but no 
effect is observed in unvaccinated children <5 years. 
6) SMC ABC was found to be a useful and reliable method to estimate model 
parameters. 
7) Competition between VT and NVT pneumococci was estimated by our model to 
be limited 
8) There is evidence for waning immunity in vaccinated infants, our model 
suggests an immunity half-life between 6 months and 1 year. 
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9) Increasing the immunity half-life to 2 years or more would have a large impact 
on the reduction of VT carriage. 
10) An enhanced catch-up campaign including children up to 5 years of age would 
have resulted in a more rapid and greater decline in VT carriage, but would not 
have cleared all VT carriage in the population: a low-level steady-state of 
persistent VT carriage would have been observed. 
11) Changing the vaccination schedule from 3+0 to 2+1 is associated with a slower 
decline in VT carriage in infants initially, but seems to involve a steeper decline 
in VT carriage in 1-4 years old towards the end of the simulation period (4 
years).  
We will discuss the findings and implications for future work in this chapter.  
 
11.2 Pneumococcal carriage and transmission dynamics 
 
In our systematic literature review we found that most acquisition in children <5 years 
was explained by transmission from other children <5 years; in DCCs and amongst 
siblings within the household. Within the household, children <5 years transmit to both 
their siblings and parents or other adults. Household transmission from adults to 
children appears to account for less pneumococcal transmission dynamics, even 
amongst mother-infant pairs. Almost all studies report on some association between 
maternal and infant carriage, but its relative importance to sibling-to-sibling spread is 
doubted. The results from our studies provide evidence that acquisition of 
pneumococci in infants is more strongly associated with carriage in other children <5 
years in the household than with carriage in the mothers. No evidence was found for 
an effect of maternal HIV-status on pneumococcal acquisition in infants. If mother-to-
infant transmission were a main driver for pneumococcal acquisition in infants, we 
would have expected to see increased carriage in HIV-exposed infants as a result of 
the higher carriage prevalence in HIV-positive mothers. Also our mathematical 
modelling studies showed that vaccinating HIV-positive, or even all mothers at time of 
delivery, did not result in additional VT carriage reduction in the infant. Our model could 
only estimate the reduction in VT carriage in infants as a result of reduced transmission 
from the mothers: it did not include any possible reduction in VT carriage as a result of 
maternal antibody transfer. 
 
In the pre-vaccination period, a decrease in pneumococcal carriage prevalence was 
observed between 2009 and 2011. No parameter was included to reflect this decline in 
the mathematical models, yet a decreasing trend was also observed when simulating 
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pneumococcal carriage over a time period of five years. Looking more closely at the 
population dynamics provides us with a hypothesis to understand this decline: the 
proportion of children under five years within the whole population steadily declined 
over the study period. In 2009, 58.6% of all households included at least one child 
under five years old; in 2015 this had declined to 51.1%. Given the key influence of 
young children in transmitting pneumococci in the household, it is possible that the 
reduction in the proportion of children under five in the population led to a reduction in 
pneumococcal carriage. Conflicting with this hypothesis, however, is that no evidence 
was found for a sustained decrease in total carriage (including VT and NVT) in the 
post-vaccination period: total carriage levels in 2014 were similar to those observed in 
2009 and 2010. Carriage levels seem to fluctuate between years, for reasons not 
understood. A factor that could have influenced pneumococcal carriage is seasonal 
variation by year such as the time of rainy season onset. Historical meteorological data 
could be obtained to look into this relationship further. The occurrence of other 
seasonal respiratory infections such as influenza may also have influenced 
pneumococcal carriage differences by year. Concurrent increases in other respiratory 
viruses and pneumococcal activity have previously reported in other countries (242, 
243). The nasopharyngeal samples from our studies could be investigated for other 
bacterial and viral pathogens to give further insight into this relationship. Another 
hypothesis proposed to explain pneumococcal carriage differences by year is that 
nutrition and food availability fluctuates by year, and that poor nutritional status could 
lead to increased carriage. Although food security is a major problem in other parts of 
Malawi, this is less of a concern in the area under observation in the KHDSS: people in 
this area do not depend on one particular staple food, but produce maize, cassava and 
rice, which gave different harvesting times throughout the year. Fish from the lake is 
also available all year round. 
 
Pneumococcal carriage in HIV-infected adults in Malawi remained high despite two 
years of ART, with evidence of increased carriage of non-PCV-13 serotypes. Prior to 
conducting the post-vaccination studies, we hypothesised that HIV-infected adults 
could constitute a reservoir for persisting VT carriage and pneumococcal diversity post 
vaccine introduction. No evidence for this was found in the post-vaccination studies. VT 
carriage in HIV-positive adults on ART had decreased, and there was no evidence for 
a change in NVT carriage. There was some evidence that pneumococcal carriage 
prevalence is lower in HIV-positive adults on prolonged ART, even after taking survival 
bias into account. Survival bias occurred, because carriage in individuals surviving >2.5 
years after initiation of ART was lower as compared to carriage in those who died 
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within a couple of years after ART initiation. This finding suggests that pneumococcal 
carriage could be an indicator for adverse survival outcome in HIV-positive adults.  
 
11.3 Impact of PCV-13 introduction on pneumococcal carriage 
 
Malawi has achieved high coverage since the introduction of PCV-13 in November 
2011, even in our remote study setting. In June 2015 vaccination coverage in all 
children <5 years (including age ineligible children) was 82.0% for one dose of PCV-13 
and 70.9% for three doses of PCV-13. Vaccination coverage increased since 
introduction, from 87.4% in 2011-2012 to 94.5% in 2013-2014 for three doses of PCV-
13. Lower coverage was observed during the catch-up campaign (51.5%). Our results 
suggest that the initial lower coverage achieved was attributable to vaccine non-
availability. Despite the decision to provide catch-up vaccination to infants, the country 
was provided with doses adequate only for the birth cohort (211). Countries introducing 
new vaccines should ensure adequate stock and resources for planned catch-up 
campaigns and strengthen system required for rapid roll-out and delivery. Our model 
results show that a more rapid and greater fall in VT carriage could have been 
achieved with an enhanced catch-up campaign in children up to 5 years of age as was 
implemented in Kilifi, Kenya (25), but that the enhanced campaign would not clear VT 
carriage from the population: a low-level steady state of persistent VT carriage was 
observed in all age/HIV groups. 
 
We provide evidence for a reduction in carriage of VT pneumococcus three years after 
vaccine rollout in this rural Malawi population. Reduction in VT carriage in 
unvaccinated individuals without change in non-VT carriage suggests herd protection is 
taking place. Herd protection, however, is found to be lower than in other countries, 
and does not seem to extend to infants too young to be vaccinated. One hypothesis to 
explain why an indirect effect is seen in older unvaccinated individuals, but not in 
younger unvaccinated individuals, is that natural birth spacing decreases the likelihood 
that young infants are in household contact with newly vaccinated children. Assuming 
that household contact is most important to explain pneumococcal transmission, and 
assuming that immunity in vaccinated infants wanes substantially within the first year, 
we can expect that those benefitting most from an indirect effect are those in contact 
with newly vaccinated infants. If infants too young to be vaccinated have vaccinated 
household contacts, the contacts are most likely to be siblings who are at least 9 
months older and in whom immunity has already waned.  
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Surveillance of pneumococcal carriage is also undertaken in Blantyre, southern 
Malawi. High VT carriage was observed; 22.5% in vaccinated children aged 3-4 years, 
25.7% in unvaccinated children aged 5-10 years, and 13.9% in adults receiving ART. 
Serotype 1 represented respectively 7.3%, 18.0% and 9.1% of VT carriage. This is 
higher than in our study, where VT carriage was 16.5% in vaccinated children, 7.9% in 
unvaccinated children 5-15 years, and 0.5% in adults receiving ART. No carriage of 
serotype 1 was detected in our study. The difference in VT carriage is unlikely to be a 
result of lower vaccination coverage: uptake of vaccination in Blantyre is high, with 
>85% coverage amongst age-eligible children. It is possible that population structure 
including household composition is significantly different in urban Blantyre and rural 
Karonga and that this explains the difference in VT dynamics, but further studies would 
be required to investigate his. Estimates of VT carriage in the community are lacking 
from Blantyre for the pre-vaccination period: it is possible that VT carriage in Blantyre 
was higher than in Karonga in the pre-vaccination period, and that the current 
estimates reflect an equitable decrease as compared to the pre-vaccination period. 
The occurrence of serotype-1 is unnerving: this serotype is rarely detected in 
nasopharyngeal carriage worldwide, but is associated with clinical disease and has the 
potential to cause community-wide outbreaks of pneumococcal meningitis (219). 
Ongoing surveillance is required to monitor the presence of VT carriage, particularly 
serotype 1 in this vulnerable population.  
 
Immunity half-life in infants was modelled to be between 6 months and 1 year. 
Increasing the immunity half-life to 2 years would be associated with a large reduction 
in VT carriage in all age/HIV groups. A 3+1 schedule was found to be most efficient in 
reducing VT carriage, but the addition of an extra dose to the Malawi infant 
immunisation schedule is unlikely given the high costs of PCV-13. Countries newly 
introducing PCV need to decide between a 3+0 or a 2+1 schedule and carefully 
consider the trade-off between faster reduction of VT carriage after introduction 
(obtained in a 3+0 schedule) and longer-term gains in further reduction of VT carriage 
in 1-4 year-olds (obtained in a 2+1 schedule).  
 
We provided some evidence that pneumococcal carriage prevalence is lower in HIV-
positive adults on prolonged ART. It is likely that the combination of prolonged duration 
of ART and PCV-13 introduction both contributed to the decrease in any serotype and 
VT pneumococcal carriage in HIV-positive adults. Our results need to be considered 
with caution: no difference in pneumococcal carriage by ART duration was observed in 
the cross-sectional conducted study in Blantyre. Ongoing work on HIV-positive adults 
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on ART in Blantyre will be analysed to assess whether the same finding can be 
observed in this population. 
 
11.4 Limitations and strengths of the included studies  
 
The limitations of individual studies have been discussed in the discussion paragraphs 
of individual chapters. Some recurring themes can be identified, relating to the study 
designs, selection of participants, sample collection, and laboratory analysis.  
 
All epidemiological studies presented here are observational studies: no randomized 
controlled trials (RCTs) were conducted as part of this PhD thesis. Observational 
studies are more prone to bias than RCTs, because treatment is not provided at 
random. RCTs could have been used to give us a more robust estimate of the impact 
of PCV-13 vaccination or ART on pneumococcal carriage and transmission. For 
instance, a cluster-RCT design could have been implemented before national rollout of 
PCV-13 vaccination to study changes in pneumococcal carriage in vaccinated 
individuals and their unvaccinated households, including younger infant siblings. An 
RCT on ART initiation could have given us a more robust measure of change in 
pneumococcal carriage since ART onset, but of course this would not have been 
possible because of the ethical issues in delaying ART in eligible individuals.  
 
Selection of participants for our studies occurred in a non-random way. We recruited 
mother-infant pairs at the local hospital, thus missing infants born at home. During the 
study period, 97% of infants were born in a health centre, indicating that our 
recruitment strategy included most infants born in this population. Coverage of 
household members was incomplete, particularly for older children and adults other 
than the mother who were often absent during study visits or refused to participate in 
the pre-vaccination period, and were not included in the post-vaccination period. This 
precluded analyses on the role of older children and adults in household transmission. 
We recruited HIV-positive adults from the ART clinic only, thus missing HIV-positive 
adults not attending the clinic. A cross-sectional analysis conducted in 2007-2008 
showed only about 25% of HIV-positive adults completed screening for ART, 
suggesting that our sample at the ART clinic missed a large proportion of HIV-positive 
adults in the population.  
 
No formal assessment of the optimal sampling interval was made. We changed the 
sampling interval of 4-6 weeks in the pre-vaccination period to a 2-week sampling 
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interval in the post-vaccination period. We did not, however, calculate the likely optimal 
sampling interval for our studies based on estimates from other settings. Calculations 
on how our sampling interval would have likely impacted on our estimates for different 
serotypes and age groups would have helped us with the interpretation of our results.   
 
Our laboratory procedures did not allow for detection of simultaneous colonization with 
multiple serotypes. A subset of samples from Blantyre was assessed for multiple 
serotype carriage using microarray technique. Multiple serotype carriage was found to 
be 54.1% in vaccinated and 59.3% in unvaccinated children. Serotyping using 
microarray increased detectable VT carriage by 35.6%. Our comparisons between the 
pre- and post-vaccination period are still valid, because multiple serotype assessment 
was not performed in either period. Not allowing for detection of simultaneous 
colonization with multiple serotypes will have decreased the accuracy of our estimates 
of carriage duration and household transmission.  
 
Any limitations in our earlier studies will have had a ‘knock-on’ effect on the later 
studies and mathematical models. If our estimates of pneumococcal carriage in the 
pre-vaccination period were under- or overestimated, this will have influenced our 
conclusions in the before-after-comparison, and will have influenced the 
parameterization and inference of our mathematical models. In the pre-vaccination 
period, we observed a decreasing secular trend in pneumococcal carriage. The 
observed reducing carriage incidence was contemporaneous with decreasing rates of 
invasive disease in Malawi (40), suggesting long-term ecological trends in 
pneumococcal carriage and disease occur, possibly on the back of improved food 
security and nutrition in this population. However, we cannot rule out that the decrease 
in pneumococcal carriage was linked to inadvertent changes in sample collection and 
analysis over time. Enhanced quality control during the sample collection and analysis 
in the pre- and post-vaccination period would have given us more robust findings. In 
addition, sensitivity/specificity analyses on the different swabs (flocked vs. calcium 
alginate) and serotyping methods (Quellung vs. Latex agglutination) used would have 
provided us with a more robust comparison of samples collected before and after 
vaccine introduction.    
 
The major strength of this PhD thesis is its breadth: with the inclusion of pre-
vaccination carriage data, post-vaccination carriage data, vaccine uptake data, and 
mathematical modelling studies we provide an extensive overview of pneumococcal 
carriage during a time of vaccine introduction. Another strength of this PhD thesis is the 
extensive use of data from the Karonga HDSS. We used HDSS data in our 
272 Chapter 11 	
 
epidemiological studies to obtain information on an individual’s household status, 
vaccination status, HIV status and ART status. We also used HDSS data extensively in 
our mathematical model: a unique feature of our model is that it includes observed 
vaccination data in combination with observed population data, including household 
structure. Other than in a model where the population and its vaccination is simulated, 
our model included empiric data on vaccine uptake and timeliness. Also any ‘hotspots’ 
of low or delayed vaccine receipt, e.g. amongst children in the same household, will 
have been included in this model. The continued sampling in the same population is 
also a strength of our studies: some adults participating in the ART study in 2008-2010 
were sampled again in 2014, allowing for a comparison of pneumococcal carriage in 
the same study participants.  
 
11.5 Future directions 
 
Ongoing surveillance on pneumococcal carriage and disease is required to monitor the 
long-term impact of PCV-13 introduction. Further work is needed to confirm the 
existence of waning immunity in older vaccinated children, and how this impacts on 
herd immunity. A series of eight cross-sectional surveys conducted over four years is 
currently underway in Blantyre, southern Malawi. Recruitment includes PCV-13-
vaccinated and unvaccinated children aged 3-10 years, using stratified random 
sampling of households and schools; and adults receiving ART.  
 
An area that has not been explored in this PhD thesis is the impact of environmental 
factors on pneumococcal carriage and disease. Household air pollution from biomass 
fuel (animal or plant material) is known to be a risk factor for acute lower respiratory 
infection, with an estimated two-fold risk in exposed children (244). Very little is known 
about the impact of reducing household air pollution on reducing pneumococcal 
carriage. A study associated to this PhD thesis is underway to assess pneumococcal 
carriage in infants born into households taking part in a large randomized cluster trial 
on the impact of a Philips cookstove on pneumonia. Nasopharyngeal samples are 
collected at 6 weeks and 6 months of the infant’s age and will be serotyped using 
microarray. An estimate of air pollution exposure will be available from personal 
monitors are kept close to the infant for 48 hours. Results for this study are expected 
late 2016 and will, in addition to the analysis on air pollution, be used to assess 
pneumococcal carriage in infants five years after introduction of PCV-13.  
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Nasopharyngeal samples collected for this PhD thesis are being used in several 
collaborations with national and international partners. Whole genome sequencing was 
performed on samples collected in the pre- and post-vaccination. Using sequencing 
results was deemed to be outside the scope of this PhD thesis, but future analyses 
could be conducted to inform our studies on household transmission. Another area of 
molecular work following from this PhD thesis will be investigations into the 
nasopharyngeal microbiome. The cohort study design adapted in studies described in 
this PhD thesis will provide an opportunity to study the nasopharyngeal microbiome in 
young infants, before and after PCV-13 receipt, and to compare the nasopharyngeal 
micriobiota of household members.  
 
A review of vaccination schedules is required to determine whether the immunity half-
life can be extended in vaccinated children, and whether in a larger herd impact can be 
achieved, extending to infants too young to be vaccinated and unvaccinated children 
<5 years. Negotiations regarding a change in vaccination schedule are ongoing with 
the Malawi Ministry of Health and potential funders. If vaccination were to be changed 
to a ‘2+1’ schedule, a large cluster randomised controlled cluster trial design would be 
recommended to evaluate the impact of a booster dose on waning immunity in 
vaccinated children, and on herd immunity in unvaccinated individuals.  
 
11.6 Ongoing vaccine developments 
 
Global efforts are undertaken to develop new or enhanced conjugate vaccines, and to 
develop new generation pneumococcal vaccines. Current efforts to improve existing 
conjugate vaccines are focused on 1) decreasing the costs of PCVs, 2) increasing the 
number of serotypes included in the PCVs, and 3) increasing the effectiveness of 
PCVs.  
 
Decreasing the costs of PCVs is essential for their continued success in low- and 
middle-income countries. Many countries, including Malawi, are currently funded 
through GAVI, but are expected to increasingly contribute to the purchase of vaccines 
in the years after vaccine roll-out. The cost to GAVI per dose of PCV is approximately 
$3.10-$3.40 per dose, or $9.30-$10.20 per vaccinated child (245). The cost per dose in 
developed countries is much higher: around $120 per dose of PCV-13 in the USA 
(246), and £50 in the UK (247, 248). PCVs require a complicated manufacturing 
process, resulting in their relatively high price per dose. The difficulty of manufacturing 
also makes technology transfer to developing countries difficult. The most advanced 
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candidates in a developing country are 10- and 13-valent vaccines being developed by 
the Serum Institute of India and Panacea Biotech, another Indian pharmaceutical 
company (245). The candidate vaccines will have a different set of serotypes to the 
existing 10- and 13-valent vaccines to better represent the distribution of invasive 
serotypes in India. Another strategy to reduce costs of PCVs would be to develop 
multi-dose vials, thereby potentially reducing packaging and transport costs. Lastly, 
manufacturing processes are being optimised to become more efficient, resulting in 
reduced overall costs (245).  
 
The number of serotypes that can be included in conjugate vaccines is limited. The 
reason for this is two-fold: only a limited amount of serotypes can be conjugated to the 
carrier proteins currently in use, and the addition of extra serotypes seems to diminish 
the antibody response. Although protective levels (immunoglobulin type G (IgG) 
antibody concentration of >0.35 µg/l) were achieved by both vaccines for the seven 
common serotypes, lower geometric mean IgG antibody concentrations were obtained 
for the same serotypes when comparing PCV-13 with PCV-7 (249). In addition, 
diminishing results are expected with the inclusion of additional serotypes. After 
introduction of PCV-7, serotype-replacement disease was caused by a small number of 
serotypes, with serotype 19A in particular being a large contributor to NVT disease (18, 
250, 251). The switch from PCV-7 to PCV-13 led to significant further reductions in 
disease (26). Invasive disease caused by NVT serotypes in the post-PCV-13 era is 
more diverse, with multiple serotypes causing invasive disease (26). The addition of 
one or two extra serotypes to create a 14-valent or 15-valent vaccine will likely have a 
minor impact on the total burden of NVT disease. 
 
Also the efficacy and immune duration of PCVs could be improved. Our model 
suggests that increasing the immunity half-life has a large impact on the level of 
residual VT carriage in the population. A longer-lasting immune response could be 
achieved by the use of novel adjuvants. Adjuvants stimulating a toll-like receptor 
response on antigen-presenting cells have been found to enhance vaccine immune 
responses in vulnerable individuals, including preterm neonates (252) and HIV-infected 
adults (253). It is possible that a better immune response with an increased immunity 
half-life can be elicited with the use of adjuvants. In countries where the response to 
PCVs is suboptimal, adding an adjuvant to the vaccine, either as part of the vaccine 
formulation or as a stand-alone injection, could enhance its effect on carriage and 
disease. However, safety of newly developed adjuvants would need to be carefully 
monitored. Despite ongoing adjuvant research and development, there remain only a 
relatively small number of adjuvants used clinically as a result of safety concerns (254).  
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Numerous institutions worldwide are working on the development of a new serotype-
independent pneumococcal vaccine. Several strategies are investigated, including 
whole cell vaccines, protein-based vaccines, and live attenuated vaccines (245, 255). 
Also the possibility of adding serotype-independent proteins to the existing PCVs is 
being investigated (245). Common proteins that are a target of new generation 
vaccines are; pneumolysin, pneumococcal surface proteins A & C, pneumococcal 
surface antigen A, neuraminidase enzymes, and histidine-triad proteins. The 
omnipresence of those proteins should elicit a serotype-independent response. Mice 
studies have been promising, and the most advanced protein vaccine candidates are 
currently undergoing phase 2 clinical trials (245).  
 
New generation vaccines will face several challenges to licensure (245). PCV-13 was 
licensed based on non-inferiority immunogenicity studies, in which serotype-specific 
IgG antibody concentrations and functional antibody levels were measured (249). New 
PCVs in development, including those manufactured by Indian pharmaceuticals, may 
follow the same licensure pathway, but the requirements for new generation vaccines 
(whole-cell, live attenuated or protein-based vaccines) are unclear. Other than with 
serotype-specific vaccines, predictors of clinical outcome that can be used in 
immunogenicity studies for serotype-nonspecific are not yet well-defined (245). It is 
likely that large vaccine efficacy trials would be required to demonstrate efficacy of new 
generation vaccines. The outcome of those trials will also need to be defined: it is not 
yet clear whether a vaccine can be licensed based on its effect on nasopharyngeal 
carriage or otitis media, or whether a trial with pneumonia or IPD as outcome measure 
is required (245). It is also not clear what the role would be of a vaccine which protects 
against IPD, but has no or very little effect on carriage. It is possible that such a 
vaccine would be introduced alongside PCVs to allow for a reduction in serotype-
nonspecific disease, yet sustain the herd effect acquired by PCVs.  
 
This PhD thesis described the pneumococcal carriage and transmission in Karonga 
district, Malawi, before and after introduction of 13-valent pneumococcal conjugate 
vaccination. There is some evidence for a direct and indirect vaccine effect, but no 
effect was observed in unvaccinated children <5 years. VT carriage remains common 
in this population, and an increase in NVT carriage was observed in vaccinated 
individuals. It is yet unclear what the impact of new generation vaccines will be on 
pneumococcal carriage. Even if reduction of carriage with new vaccines is modest, an 
indirect vaccine effect could occur in this setting, given the high proportion of 
household contact with children <5 years. The shadow side of this dynamic is that if VT 
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carriage were to re-increase as a result of a future change from PCV-13 to serotype-
independent vaccines with lower impact of carriage, this could result in reintroduction 
of increased circulation of current VT carriage. If any change in vaccine were to be 
made, careful monitoring of carriage and disease is warranted.  
 
In conclusion, there is need for cheaper, more effective, serotype-independent 
pneumococcal vaccines. Potentially cheaper PCVs produced in India are in the 
pipeline, with results expected in the next couple of years. The pneumococcal research 
community is also eagerly awaiting the results from a couple of new generation 
vaccines that are currently in phase 2 clinical trials. The next decade is promising to be 
an exciting time for pneumococcal researchers and policy makers worldwide, as new 
vaccines will pose interesting possibilities to further decrease pneumococcal carriage 
and disease in settings worldwide. 
 
      277 	
 
 
References 
 
1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus 
pneumoniae in children younger than 5 years: global estimates. Lancet 
2009;374(9693):893-902. 
2. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 
240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease 
Study 2013. Lancet 2015;385(9963):117-71. 
3. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the 
most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin 
Infect Dis 2000;30(1):100-21. 
4. Watson DA, Musher DM, Jacobson JW, et al. A brief history of the pneumococcus in 
biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993;17(5):913-24. 
5. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key 
to pneumococcal disease. Lancet Infect Dis 2004;4(3):144-54. 
6. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive 
disease. Vaccine 2007;25(13):2406-12. 
7. Granat SM, Mia Z, Ollgren J, et al. Longitudinal study on pneumococcal carriage during 
the first year of life in Bangladesh. Pediatr Infect Dis J 2007;26(4):319-24. 
8. Tigoi CC, Gatakaa H, Karani A, et al. Rates of Acquisition of Pneumococcal Colonization 
and Transmission Probabilities, by Serotype, Among Newborn Infants in Kilifi District, 
Kenya. Clin Infect Dis 2012;55(2):180-8. 
9. Turner P, Turner C, Jankhot A, et al. A longitudinal study of streptococcus pneumoniae 
carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS 
ONE 2012;7(5). 
10. GlaxoSmithKline Inc. SYNFLORIX (product monograph). Date of Revision: February 9, 
2015. 
11. Pfizer Inc. Prevnar 13 (Medical Information. Last revision: 5/2015.; 2015. 
(https://www.pfizermedicalinformation.com/en-us/PREVNAR-13#Description). (Accessed 
15/06/2016). 
12. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 
2012;30(32):4717-8. 
278  	
 
13. Whitney CG, Goldblatt D, O'Brien KL. Dosing schedules for pneumococcal conjugate 
vaccine: considerations for policy makers. Pediatr Infect Dis J 2014;33 Suppl 2:S172-81. 
14. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate 
vaccine in children with and those without HIV infection. N Engl J Med 
2003;349(14):1341-8. 
15. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate 
pneumococcal vaccine in American Indian children: group randomised trial. Lancet 
2003;362(9381):355-61. 
16. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate 
vaccine against pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double-blind, placebo-controlled trial. Lancet 2005;365(9465):1139-46. 
17. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. 
Vaccine 2003;21(17-18):1815-25. 
18. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years 
after seven-valent pneumococcal conjugate vaccination in England and Wales: an 
observational cohort study. Lancet Infect Dis 2011;11(10):760-8. 
19. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on 
pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS 
Med 2011;8(10):e1001107-e. 
20. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after 
the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 
2003;348(18):1737-46. 
21. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult 
carriage of Streptococcus pneumoniae: an explanation of trends in invasive 
pneumococcal disease. J Infect Dis 2006;193(11):1487-94. 
22. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal 
conjugate vaccine on pneumococcal colonization among unvaccinated household 
members. Clin Infect Dis 2008;47(8):989-96. 
23. Vestrheim DF, Hoiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal 
vaccination in a 2+1 dose schedule. Vaccine 2010;28(10):2214-21. 
24. von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive 
pneumococcal disease in South Africa. N Engl J Med 2014;371(20):1889-99. 
25. Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal 
conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-
typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage 
studies. Lancet Glob Health 2014;2(7):e397-405. 
26. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after 
its introduction: an observational cohort study. Lancet Infect Dis 2015;15(5):535-43. 
27. Advisory Committee on Immunization Practices. Preventing pneumococcal disease 
among infants and young children. Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR 2000;49(RR-9):1. 
      279 	
 
28. Madhi SA, Cohen C, von Gottberg A. Introduction of pneumococcal conjugate vaccine 
into the public immunization program in South Africa: Translating research into policy. 
Vaccine 2012;30:C21-C7. 
29. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus 
influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 
1999;5(3):336-45. 
30. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to 
prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and 
Streptococcus pneumoniae. Vaccine 2008;26(35):4434-45. 
31. Pneumococcal vaccines WHO position paper—2012. Wkly Epidemiol Rec 
2012;87(14):129–44. 
32. Auranen K, Rinta-Kokko H, Goldblatt D, et al. Colonisation endpoints in Streptococcus 
pneumoniae vaccine trials. Vaccine 2013;32(1):153-8. 
33. Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial 
pneumonia in adults with HIV disease. Lancet Infect Dis 2004;4(7):445-55. 
34. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients 
infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect 
Dis 2004;38(11):1623-8. 
35. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive 
Streptococcus pneumoniae infections among persons with AIDS in an era of highly active 
antiretroviral therapy, 1995-2000. J Infect Dis 2005;191(12):2038-45. 
36. von Gottberg A, Cohen C, de Gouveia L, et al. Epidemiology of invasive pneumococcal 
disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine 
2013;31(38):4200-8. 
37. Nunes MC, von Gottberg A, de Gouveia L, et al. Persistent high burden of invasive 
pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral 
treatment program. PLoS One 2011;6(11):e27929. 
38. Wall EC, Cartwright K, Scarborough M, et al. High mortality amongst adolescents and 
adults with bacterial meningitis in sub-Saharan Africa: an analysis of 715 cases from 
Malawi. PLoS One 2013;8(7):e69783. 
39. Gordon SB, Chaponda M, Walsh AL, et al. Pneumococcal disease in HIV-infected 
Malawian adults: acute mortality and long-term survival. AIDS 2002;16(10):1409-17. 
40. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive 
Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole 
prophylaxis in Malawi. PLoS One 2011;6(3):e17765. 
41. Harries AD, Zachariah R, Jahn A, et al. Scaling up antiretroviral therapy in Malawi-
implications for managing other chronic diseases in resource-limited countries. J Acquir 
Immune Defic Syndr 2009;52 Suppl 1:S14-6. 
42. Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on 
the burden of invasive pneumococcal disease in South African children: a time series 
analysis. AIDS 2011;25(4):453-62. 
280  	
 
43. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate 
vaccine in HIV-infected adults. N Engl J Med 2010;362(9):812-22. 
44. British HIV Association. British HIV Association guidelines on the use of vaccines in HIV-
positive adults 2015.  November 2015. 
45. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal 
polysaccharide vaccine for adults with immunocompromising conditions: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
Morb Mortal Wkly Rep 2012;61(40):816-9. 
46. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide 
vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo 
controlled trial. Lancet 2000;355(9221):2106-11. 
47. Glennie SJ, Banda D, Gould K, et al. Defective pneumococcal-specific Th1 responses in 
HIV-infected adults precedes a loss of control of pneumococcal colonization. Clin Infect 
Dis 2013;56(2):291-9. 
48. Gill CJ, Mwanakasale V, Fox MP, et al. Impact of human immunodeficiency virus infection 
on Streptococcus pneumoniae colonization and seroepidemiology among Zambian 
women. J Infect Dis 2008;197(7):1000-5. 
49. Abdullahi O, Karani A, Tigoi CC, et al. The prevalence and risk factors for pneumococcal 
colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS One 
2012;7(2):e30787. 
50. The World Bank. Malawi - World Development Indicators 
(http://data.worldbank.org/country/malawi#cp_gep). (Accessed 20-05-2015). 
51. National Statistics Office Z, Malawi, . Malawi Demographic and Health Survey. 2010. 
52. O'Hare B, Makuta I, Bar-Zeev N, et al. The effect of illicit financial flows on time to reach 
the fourth Millennium Development Goal in Sub-Saharan Africa: a quantitative analysis. J 
R Soc Med 2014;107(4):148-56. 
53. Bar-Zeev N, Everett D, Alaerts M, et al. Is reduction in pneumococcal meningitis in non-
vaccinated age groups in Malawi attributable to the introduction of 13-valent 
pneumococcal conjugate vaccine? [ISPPD-0465]. pneumonia 2014;3:142, 2014. 
54. Crampin AC, Dube A, Mboma S, et al. Profile: the Karonga Health and Demographic 
Surveillance System. Int J Epidemiol 2012;41(3):676-85. 
55. Jahn A, Branson K, Crampin A, et al. Evaluation of a village-informant driven 
demographic surveillance system in Karonga, Northern Malawi. Demographic Research 
2007;16:217-48. 
56. Floyd S, Molesworth A, Dube A, et al. Underestimation of HIV prevalence in surveys 
when some people already know their status, and ways to reduce the bias. AIDS 
2013;27(2):233-42. 
57. O'Brien KL, Nohynek H. Report from a WHO Working Group: standard method for 
detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 
2003;22(2):e1-11. 
58. Slotved HC, Kaltoft M, Skovsted IC, et al. Simple, rapid latex agglutination test for 
serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol 2004;42(6):2518-22. 
      281 	
 
59. Gritzfeld JF, Cremers AJ, Ferwerda G, et al. Density and duration of experimental human 
pneumococcal carriage. Clin Microbiol Infect 2014;20(12):O1145-51. 
60. Carvalho Mda G, Pimenta FC, Moura I, et al. Non-pneumococcal mitis-group streptococci 
confound detection of pneumococcal capsular serotype-specific loci in upper respiratory 
tract. PeerJ 2013;1:e97. 
61. Greve T, Moller JK. Accuracy of using the lytA gene to distinguish Streptococcus 
pneumoniae from related species. J Med Microbiol 2012;61(Pt 4):478-82. 
62. Charalambous BM, Batt SL, Peek AC, et al. Quantitative validation of media for 
transportation and storage of Streptococcus pneumoniae. J Clin Microbiol 
2003;41(12):5551-6. 
63. Almeida ST, de Lencastre H, Sá-Leão R. Epidemiology and Population Structure of 
Serotypes 1, 5 and 7F Carried by Children in Portugal from 1996-2010 before 
Introduction of the 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines. PLoS 
One 2013;8(9). 
64. Bogaert D, Engelen MN, Timmers-Reker AJM, et al. Pneumococcal carriage in children in 
the Netherlands: A molecular epidemiological study. J Clin Microbiol 2001;39(9):3316-20. 
65. Boken DJ, Chartrand SA, Goering RV, et al. Colonization with penicillin-resistant 
Streptococcus-Pneumoniae in a child-care center Pediatr Infect Dis J 1995;14(10):879-
84. 
66. Borer A, Meirson H, Peled N, et al. Antibiotic-resistant pneumococci carried by young 
children do not appear to disseminate to adult members of a closed community. Clin 
Infect Dis 2001;33(4):436-44. 
67. Chen CJ, Huang YC, Su LH, et al. Nasal carriage of Streptococcus pneumoniae in 
healthy children and adults in northern Taiwan. Diagn Microbiol Infect Dis 
2007;59(3):265-9. 
68. Cheung YB, Zaman SMA, Nsekpong ED, et al. Nasopharyngeal carriage of streptococcus 
pneumoniae in gambian children who participated in a 9-valent pneumococcal conjugate 
vaccine trial and in their younger siblings. Pediatr Infect Dis J 2009;28(11):990-5. 
69. de Lencastre H, Kristinsson KG, Brito-Avo A, et al. Carriage of respiratory tract pathogens 
and molecular epidemiology of Streptococcus pneumoniae colonization in healthy 
children attending day care centers in Lisbon, Portugal. Microb Drug Resist 1999;5(1):19-
29. 
70. Gratten M, Young M, Smith D, et al. Nasal carriage of pathogenic bacteria in Kalauna 
Village, Goodenough Island. P N G Med J 1981;24(3):174-8. 
71. Gudnason T, Hrafnkelsson B, Laxdal B, et al. Risk factors for nasopharyngeal carriage of 
Streptococcus pneumoniae and effects of a hygiene intervention: repeated cross-
sectional cohort study at day care centres. Scand J Infect Dis 2014;46(7):493-501. 
72. Hoshino K, Watanabe H, Sugita R, et al. High rate of transmission of penicillin-resistant 
Streptococcus pneumoniae between parents and children. J Clin Microbiol 
2002;40(11):4357-9. 
282  	
 
73. Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 
Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediat Adol 
Med 1999;153(5):495-502. 
74. Medina MJ, Greene CM, Gertz RE, et al. Novel antibiotic-resistant pneumococcal strains 
recovered from the upper respiratory tracts of HIV-infected adults and their children in 
Kisumu, Kenya. Microb Drug Resist 2005;11(1):9-17. 
75. Nunes S, Sá-Leão R, Pereira LC, et al. Emergence of a serotype 1 Streptococcus 
pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate 
vaccination era. Clin Microbiol Infect 2008;14(1):82-4. 
76. Perçin D, Bozdoǧan B, Ayangil D, et al. Molecular epidemiology and antibacterial 
susceptibility of streptococci isolated from healthy children attending day care units. 
Balkan Med J 2011;28(4):414-9. 
77. Petrosillo N, Pantosti A, Bordi E, et al. Prevalence, determinants, and molecular 
epidemiology of Streptococcus pneumoniae isolates colonizing the nasopharynx of 
healthy children in Rome. Eur J Clin Microbiol Infect Dis 2002;21(3):181-8. 
78. Pickering H, Rose G. Nasal and hand carriage of Streptococcus pneumoniae in children 
and mothers in the Tari Basin of Papua New Guinea. T Roy Soc Trop Med H 
1988;82(6):911-3. 
79. Porat N, Amit U, Givon-Lavi N, et al. Increasing importance of multidrug-resistant 
serotype 6A Streptococcus pneumoniae clones in acute otitis media in southern Israel. 
Pediatr Infect Dis J 2010;29(2):126-30. 
80. Porat N, Leibovitz E, Dagan R, et al. Molecular typing of Streptococcus pneumoniae in 
northeastern Romania: Unique clones of S-pneumoniae isolated from children 
hospitalized for infections and from healthy and human immunodeficiency virus-infected 
children in the community. J Infect Dis 2000;181(3):966-74. 
81. Porat N, Park IH, Nahm MH, et al. Differential circulation of Streptococcus pneumoniae 
serotype 6C clones in two Israeli pediatric populations. J Clin Microbiol 
2010;48(12):4649-51. 
82. Regev-Yochay G, Abullaish I, Malley R, et al. Streptococcus pneumoniae carriage in the 
Gaza strip. PLoS One 2012;7(4):e35061. 
83. Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus 
pneumoniae by adults and children in community and family settings. Clin Infect Dis 
2004;38(5):632-9. 
84. Reis JN, Palma T, Ribeiro GS, et al. Transmission of Streptococcus pneumoniae in an 
urban slum community. J Infect 2008;57(3):204-13. 
85. Rivera-Olivero IA, Bogaert D, Bello T, et al. Pneumococcal carriage among indigenous 
Warao children in Venezuela: Serotypes, susceptibility patterns, and molecular 
epidemiology. Clin Infect Dis 2007;45(11):1427-34. 
86. Rusen ID, FraserRoberts L, Slaney L, et al. Nasopharyngeal pneumococcal colonization 
among Kenyan children: antibiotic resistance, strain types and associations with human 
immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1997;16(7):656-62. 
      283 	
 
87. Sa-Leao R, Tomasz A, Sanches IS, et al. Carriage of internationally spread clones of 
Streptococcus pneumoniae with unusual drug resistance patterns in children attending 
day care centers in Lisbon, Portugal. J Infect Dis 2000;182(4):1153-60. 
88. Sa-Leao R, Tomasz A, Sanches IS, et al. Genetic diversity and clonal patterns among 
antibiotic-susceptible and -resistant Streptococcus pneumoniae colonizing children: Day 
care centers as autonomous epidemiological units. J Clin Microbiol 2000;38(11):4137-44. 
89. Samore MH, Magill MK, Alder SC, et al. High rates of multiple antibiotic resistance in 
Streptococcus pneumoniae from healthy children living in isolated rural communities: 
Association with cephalosporin use and intrafamilial transmission. Pediatrics 
2001;108(4):856-65. 
90. Smith-Vaughan H, Marsh R, Mackenzie G, et al. Age-specific cluster of cases of serotype 
1 Streptococcus pneumoniae carriage in remote indigenous communities in Australia. 
Clin Vaccine Immunol 2009;16(2):218-21. 
91. Souli M, Volonakis K, Kapaskelis A, et al. Characterisation of macrolide-non-susceptible 
Streptococcus pneumoniae colonising children attending day-care centres in Athens, 
Greece during 2000 and 2003. Clin Microbiol Infect 2007;13(1):70-7. 
92. Syrogiannopoulos GA, Grivea IN, Beratis NG, et al. Resistance patterns of Streptococcus 
pneumoniae from carriers attending day-care centers in Southwestern Greece. Clin Infect 
Dis 1997;25(2):188-94. 
93. Tsolia M, Kouppari G, Zaphiropoulou A, et al. Prevalence and patterns of resistance of 
Streptococcus pneumoniae strains isolated from carriers attending day care centers in 
the area of athens. Microb Drug Resist 1999;5(4):271-8. 
94. Vestrheim DF, Hoiby EA, Aaberge IS, et al. Phenotypic and genotypic characterization of 
Streptococcus pneumoniae strains colonizing children attending day-care centers in 
Norway. J Clin Microbiol 2008;46(8):2508-18. 
95. Watanabe H, Batuwanthudawe R, Thevanesam V, et al. Possible prevalence and 
transmission of acute respiratory tract infections caused by Streptococcus pneumoniae 
and Haemophilus influenzae among the internally displaced persons in tsunami disaster 
evacuation camps of Sri Lanka. Internal Med 2007;46(17):1395-402. 
96. Cane A, Capelli C, Casanueva E, et al. Streptococcus Pneumoniae sepsis in newborns 
associated with vertical transmission: description of two cases. ISPPD-9. Hyderabad, 
India, 2014. 
97. Centers for Disease Control and Prevention (CDC). Hemorrhage and shock associated 
with invasive pneumococcal infection in healthy infants and children--New Mexico, 1993-
1994.[Erratum appears in MMWR Morb Mortal Wkly Rep 1995 Feb 10;44(5):97]. MMWR 
1995;43(51-52):949-52. 
98. Centers for Disease Control and Prevention (CDC). Multidrug-resistant Streptococcus 
pneumoniae in a child care center - southwest Georgia, December 2000. MMWR 
2002;50(51-52):1156-8. 
99. Cherian T, Steinhoff MC, Harrison LH, et al. A cluster of invasive pneumococcal disease 
in young children in child care. JAMA 1994;271(9):695-7. 
284  	
 
100. Christenson B, Sylvan SP, Noreen B. Drug-resistant Streptococcus pneumoniae in day-
care centres in Stockholm County. J Infect 1998;37(1):9-14. 
101. Ekdahl K, Hansson HB, Mölstad S, et al. Limiting the spread of penicillin-resistant 
Streptococcus pneumoniae: Experiences from the south Swedish pneumococcal 
intervention project. Microb Drug Resist 1998;4(2):99-105. 
102. Gupta A, Khaw FM, Stokle EL, et al. Outbreak of Streptococcus pneumoniae serotype 1 
pneumonia in a United Kingdom school. BMJ 2008;337. 
103. Henriqus Normark B, Christensson B, Sandgren A, et al. Clonal analysis of Streptococcus 
pneumoniae nonsusceptible to penicillin at day-care centers with index cases, in a region 
with low incidence of resistance: emergence of an invasive type 35B clone among 
carriers. Microb Drug Resist 2003;9(4):337-44. 
104. Högberg L, Normark BH, Ringberg H, et al. The impact of active intervention on the 
spread of penicillin-resistant Streptococcus pneumoniae in Swedish day-care centres. 
Scand J Infect Dis 2004;36(9):629-35. 
105. Klugman KP, Coffey TJ, Smith A, et al. Cluster of an erythromycin-resistant variant of the 
Spanish multiply resistant 23F clone of Streptococcus pneumoniae in South Africa. Eur J 
Clin Microbiol Infect Dis 1994;13(2):171-4. 
106. Lamaro-Cardoso J, de Lemos APS, da Glória Carvalho M, et al. Molecular 
epidemiological investigation to determine the source of a fatal case of serotype 22F 
pneumococcal meningitis. J Med Microbiol 2012;61(5):686-92. 
107. Lauderdale TL, Lee Y, Cheng MF, et al. High carriage rate of high-level penicillin-resistant 
Streptococcus pneumoniae in a Taiwan kindergarten associated with a case of 
pneumococcal meningitis. BMC Infect Dis 2005;5. 
108. Melander E, Ekdahl K, Hansson HB, et al. Introduction and clonal spread of penicillin- 
and trimethoprim/sulfamethoxazole-resistant streptococcus pneumoniae, serotype 9V, in 
Southern Sweden. Microb Drug Resist 1998;4(1):71-8. 
109. Melander E, Hansson HB, Mölstad S, et al. Limited spread of penicillin-nonsusceptible 
pneumococci, Skåne County, Sweden. Emerg Infect Dis 2004;10(6):1082-7. 
110. Melander E, Mölstad S, Persson K, et al. Previous antibiotic consumption and other risk 
factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur J 
Clin Microbiol Infect Dis 1998;17(12):834-8. 
111. Nilsson P, Laurell MH. Carriage of penicillin-resistant Streptococcus pneumoniae by 
children in day-care centers during an intervention program in Malmo, Sweden. Pediatr 
Infect Dis J 2001;20(12):1144-9. 
112. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant 
Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166(6):1346-
53. 
113. Shouval DS, Porat N, Dagan R, et al. Bacteremia caused by a highly-resistant 
Streptococcus pneumoniae serotype 19A circulating in a daycare center. Int J Infect Dis 
2010;14 Suppl 3:e253-5. 
114. Simpson JM, Patel JS, Ispahani P. Streptococcus pneumoniae invasive disease in the 
neonatal period: an increasing problem? Eur J Pediatr 1995;154(7):563-6. 
      285 	
 
115. Zulz T, Wenger JD, Rudolph K, et al. Molecular characterization of Streptococcus 
pneumoniae serotype 12F isolates associated with rural community outbreaks in Alaska. 
J Clin Microbiol 2013;51(5):1402-7. 
116. LloydEvans N, Odempsey TJD, Baldeh I, et al. Nasopharyngeal carriage of pneumococci 
in Gambian children and in their families. Pediatr Infect Dis J 1996;15(10):866-71. 
117. Barnes DM, Whittier S, Gilligan PH, et al. Transmission of multidrug-resistant serotype 
23F Streptococcus pneumoniae in group day care: evidence suggesting capsular 
transformation of the resistant strain in vivo. J Infect Dis 1995;171(4):890-6. 
118. Chidekel AS, Steele-Moore L, Padman R, et al. Nasopharyngeal colonization in children 
with cystic fibrosis: Antibiotic resistance and intrafamilial spread. Infect Dis Clin Prac 
2000;9(8):333-6. 
119. Darboe MK, Fulford AJC, Secka O, et al. The dynamics of nasopharyngeal streptococcus 
pneumoniae carriage among rural Gambian mother-infant pairs. BMC Infect Dis 
2010;10:195. 
120. Dowling JN, Sheehe PR, Feldman HA. Pharyngeal pneumococcal acquisitions in 
"normal" families: a longitudinal study. J Infect Dis 1971;124(1):9-17. 
121. Francis JP, Richmond PC, Pomat WS, et al. Maternal antibodies to pneumolysin but not 
to pneumococcal surface protein a delay early pneumococcal carriage in high-risk Papua 
New Guinean infants. Clin Vaccine Immunol 2009;16(11):1633-8. 
122. Gill CJ, Mwanakasale V, Fox MP, et al. Effect of presumptive co-trimoxazole prophylaxis 
on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in 
Zambian infants: A longitudinal cohort study. B World Health Organ 2008;86(12):929-38. 
123. Givon-Lavi N, Dagan R, Fraser D, et al. Marked differences in pneumococcal carriage 
and resistance patterns between day care centers located within a small area. Clin Infect 
Dis 1999;29(5):1274-80. 
124. Givon-Lavi N, Fraser D, Porat N, et al. Spread of Streptococcus pneumoniae and 
antibiotic-resistant S. pneumoniae from day-care center attendees to their younger 
siblings. J Infect Dis 2002;186(11):1608-14. 
125. Granat SM, Ollgren J, Herva E, et al. Epidemiological evidence for serotype-independent 
acquired immunity to pneumococcal carriage. J Infect Dis 2009;200(1):99-106. 
126. Gwaltney Jr JM, Sande MA, Austrian R, et al. Spread of Streptococcus pneumoniae in 
families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum 
antibody. J Infect Dis 1975;132(1):62-8. 
127. Hill PC, Townend J, Antonio M, et al. Transmission of Streptococcus pneumoniae in rural 
gambian villages: A longitudinal study. Clin Infect Dis 2010;50(11):1468-76. 
128. Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of 
Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 
2005;133(5):891-8. 
129. Leino T, Auranen K, Jokinen J, et al. Pneumococcal carriage in children during their first 
two years: Important role of family exposure. Pediatr Infect Dis J 2001;20(11):1022-7. 
130. Leino T, Hoti F, Syrjänen R, et al. Clustering of serotypes in a longitudinal study of 
Streptococcus pneumoniae carriage in three day care centres. BMC Infect Dis 2008;8. 
286  	
 
131. Kinabo GD, van der Ven A, Msuya LJ, et al. Dynamics of nasopharyngeal bacterial 
colonisation in HIV-exposed young infants in Tanzania. Trop Med Int Health 
2013;18(3):286-95. 
132. Mosser JF, Grant LR, Millar EV, et al. Nasopharyngeal carriage and transmission of 
Streptococcus pneumoniae in American Indian households after a decade of 
pneumococcal conjugate vaccine use. PLoS One 2014;9(1):e79578. 
133. Nunes MC, Shiri T, van Niekerk N, et al. Acquisition of Streptococcus pneumoniae in 
Pneumococcal Conjugate Vaccine-Naive South African Children and Their Mothers. 
Pediatr Infect Dis J 2013;32(5):e192-205. 
134. Ogundare O, Bojang A, Odutola A, et al. Comparison of nasopharyngeal bacterial 
isolates from mother-infant pairs during the first 12 weeks after birth in The Gambia. 
ISPPD-8. Iguaçu Falls, Brazil, 2012. 
135. Pebody RG, Morgan O, Choi Y, et al. Use of antibiotics and risk factors for carriage of 
Streptococcus pneumoniae: A longitudinal household study in the United Kingdom. 
Epidemiol Infect 2009;137(4):555-61. 
136. Pons JL, Mandement MN, Martin E, et al. Clonal and temporal patterns of 
nasopharyngeal penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae 
strains in children attending a day care center. J Clin Microbiol 1996;34(12):3218-22. 
137. Raymond J, Le Thomas I, Moulin F, et al. Sequential colonization by Streptococcus 
pneumoniae of healthy children living in an orphanage. J Infect Dis 2000;181(6):1983-8. 
138. Rosen C, Christensen P, Hovelius B, et al. A longitudinal study of the nasopharyngeal 
carriage of pneumococci as related to pneumococcal vaccination in children attending 
day-care centres. Acta Oto-Laryngol 1984;98(5-6):524-32. 
139. Sá-Leão R, Nunes S, Brito-Avô A, et al. High rates of transmission of and colonization by 
Streptococcus pneumoniae and Haemophilus influenzae within a day care center 
revealed in a longitudinal study. J Clin Microbiol 2008;46(1):225-34. 
140. Scott JR, Millar EV, Lipsitch M, et al. Impact of more than a decade of pneumococcal 
conjugate vaccine use on carriage and invasive potential in native American 
communities. J Infect Dis 2012;205(2):280-8. 
141. Turner P, Turner C, Jankhot A, et al. A longitudinal study of Streptococcus pneumoniae 
carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS 
One 2012;7(5):e38271. 
142. Vives M, Garcia ME, Saenz P, et al. Nasopharyngeal colonization in Costa Rican children 
during the first year of life. Pediatr Infect Dis J 1997;16(9):852-8. 
143. Yagupsky P, Porat N, Fraser D, et al. Acquisition, carriage, and transmission of 
pneumococci with decreased antibiotic susceptibility in young children attending a day 
care facility in southern Israel. J Infect Dis 1998;177(4):1003-12. 
144. Yano H, Suetake M, Kuga A, et al. Pulsed-field gel electrophoresis analysis of 
nasopharyngeal flora in children attending a day care center. J Clin Microbiol 
2000;38(2):625-9. 
      287 	
 
145. Andersson M, Ekdahl K, Mölstad S, et al. Modelling the spread of penicillin-resistant 
Streptococcus pneumoniae in day-care and evaluation of intervention. Stat Med 
2005;24(23):3593-607. 
146. Auranen K, Arjas E, Leino T, et al. Transmission of Pneumococcal Carriage in Families: A 
Latent Markov Process Model for Binary Longitudinal Data. JASA 2000;95(452):1044-53. 
147. Auranen K, Mehtälä J, Tanskanen A, et al. Between-strain competition in acquisition and 
clearance of pneumococcal carriage epidemiologic evidence from a longitudinal study of 
day-care children. Am J Epidemiol 2010;171(2):169-76. 
148. Cauchemez S, Temime L, Guillemot D, et al. Investigating heterogeneity in 
pneumococcal transmission: A bayesian MCMC approach applied to a follow-up of 
schools. JASA 2006;101(475):946-58. 
149. Cauchemez S, Temime L, Valleron AJ, et al. S. pneumoniae transmission according to 
inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools. 
BMC Infect Dis 2006;6. 
150. De Cellès MD, Opatowski L, Salomon J, et al. Intrinsic epidemicity of Streptococcus 
pneumoniae depends on strain serotype and antibiotic susceptibility pattern. Antimicrob 
Agents Chemother 2011;55(11):5255-61. 
151. Ekholm A, Jokinen J, Kilpi T. Combining regression and association modelling for 
longitudinal data on bacterial carriage. Stat Med 2002;21(5):773-91. 
152. Erästö P, Hoti F, Auranen K. Modeling transmission of multitype infectious agents: 
Application to carriage of Streptococcus pneumoniae. Stat Med 2012;31(14):1450-63. 
153. Erästö P, Hoti F, Granat SM, et al. Modelling multi-type transmission of pneumococcal 
carriage in Bangladeshi families. Epidemiol Infect 2010;138(6):861-72. 
154. Hoti F, Erästö P, Leino T, et al. Outbreaks of Streptococcus pneumoniae carriage in day 
care cohorts in Finland - Implications for elimination of transmission. BMC Infect Dis 
2009;9. 
155. Huang SS, Finkelstein JA, Lipsitch M. Modeling community- and individual-level effects of 
child-care center attendance on pneumococcal carriage. Clin Infect Dis 2005;40(9):1215-
22. 
156. Karlsson D, Jansson A, Normark BH, et al. An individual-based network model to 
evaluate interventions for controlling pneumococcal transmission. BMC Infect Dis 2008;8. 
157. Melegaro A, Choi Y, Pebody R, et al. Pneumococcal carriage in United Kingdom families: 
Estimating serotype-specific transmission parameters from longitudinal data. Am J 
Epidemiol 2007;166(2):228-35. 
158. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of 
pneumococcal carriage in households. Epidemiol Infect 2004;132(3):433-41. 
159. Numminen E, Cheng L, Gyllenberg M, et al. Estimating the transmission dynamics of 
Streptococcus pneumoniae from strain prevalence data. Biometrics 2013;69(3):748-57. 
160. Pessoa D, Hoti F, Syrjanen R, et al. Comparative analysis of Streptococcus pneumoniae 
transmission in Portuguese and Finnish day-care centres. BMC Infect Dis 2013;13:180. 
161. Sheehe PR, Feldman HA. Exposure model analysis of streptococcal acquisitions. J Infect 
Dis 1969;119(2):172-81. 
288  	
 
162. Shiri T, Auranen K, Nunes MC, et al. Dynamics of pneumococcal transmission in vaccine-
naive children and their HIV-infected or HIV-uninfected mothers during the first 2 years of 
life. Am J Epidemiol 2013;178(11):1629-37. 
163. Nunes S, Sá-Leão R, De Lencastre H. Optochin resistance among Streptococcus 
pneumoniae strains colonizing healthy children in Portugal. Journal of Clinical 
Microbiology 2008;46(1):321-4. 
164. Koyanagi A, Humphrey JH, Ntozini R, et al. Morbidity among human immunodeficiency 
virus-exposed but uninfected, human immunodeficiency virus-infected, and human 
immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly 
active antiretroviral therapy. Pediatr Infect Dis J 2011;30(1):45-51. 
165. von Mollendorf C, von Gottberg A, Tempia S, et al. Increased Risk for and Mortality From 
Invasive Pneumococcal Disease in HIV-Exposed but Uninfected Infants Aged <1 Year in 
South Africa, 2009-2013. Clin Infect Dis 2015;60(9):1346-56. 
166. Gupta A, Mathad JS, Yang WT, et al. Maternal pneumococcal capsular IgG antibodies 
and transplacental transfer are low in South Asian HIV-infected mother-infant pairs. 
Vaccine 2014;32(13):1466-72. 
167. R Core Team. R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria, 2012. 
168. Therneau T. A Package for Survival Analysis in S. R package version 2.37-7. 
http://CRAN.R-project.org/package=survival. Published January 22, 2014. Accessed May 
14, 2015. 
169. Knol MJ, Le Cessie S, Algra A, et al. Overestimation of risk ratios by odds ratios in trials 
and cohort studies: alternatives to logistic regression. Can Med Assoc J 2012;184(8):895-
9. 
170. Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with 
discontinuous risk intervals. An example of a longitudinal study of functional disability 
among older persons. Methods Inf Med 2008;47(2):107-16. 
171. Bates D, Maechler M, Bolker B. lme4: Linear mixed-effects models using Eigen and S4. R 
package version 1.1-7. http://CRAN.R-project.org/package=lme4. Published July 19, 
2014. Accessed May 14, 2015  
172. Wood S. gamm4: Generalized additive mixed models using mgcv and lme4. R package 
version 0.2-3. http://CRAN.R-project.org/package=gamm4. Published July 21, 2014. 
Accessed May 14, 2015. 
173. Sepako E, Glennie SJ, Jambo KC, et al. Incomplete recovery of pneumococcal CD4 T 
cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults. 
PLoS One 2014;9(6):e100640. 
174. Nicoletti C, Brandileone MC, Guerra ML, et al. Prevalence, serotypes, and risk factors for 
pneumococcal carriage among HIV-infected adults. Diagn Microbiol Infect Dis 
2007;57(3):259-65. 
175. Parrott FR, Mwafulirwa C, Ngwira B, et al. Combining qualitative and quantitative 
evidence to determine factors leading to late presentation for antiretroviral therapy in 
Malawi. PLoS One 2011;6(11):e27917. 
      289 	
 
176. Knol MJ, Le Cessie S, Algra A, et al. Overestimation of risk ratios by odds ratios in trials 
and cohort studies: alternatives to logistic regression. Can Med Assoc J 2012;184(8):895-
9. 
177. Costiniuk CT, Angel JB. Human immunodeficiency virus and the gastrointestinal immune 
system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol 
2012;5(6):596-604. 
178. Iwajomo OH, Moons P, Nkhata R, et al. Delayed reconstitution of B cell immunity to 
pneumococcus in HIV-infected Malawian children on antiretroviral therapy. The Journal of 
infection 2014. 
179. Neill DR, Coward WR, Gritzfeld JF, et al. Density and Duration of Pneumococcal Carriage 
Is Maintained by Transforming Growth Factor beta1 and T Regulatory Cells. Am J Respir 
Crit Care Med 2014;189(10):1250-9. 
180. Neill DR, Fernandes VE, Wisby L, et al. T regulatory cells control susceptibility to invasive 
pneumococcal pneumonia in mice. PLoS pathogens 2012;8(4):e1002660. 
181. Davis SM, Deloria-Knoll M, Kassa HT, et al. Impact of pneumococcal conjugate vaccines 
on nasopharyngeal carriage and invasive disease among unvaccinated people: review of 
evidence on indirect effects. Vaccine 2013;32(1):133-45. 
182. Egere U, Townend J, Roca A, et al. Indirect effect of 7-valent pneumococcal conjugate 
vaccine on pneumococcal carriage in newborns in rural Gambia: a randomised controlled 
trial. PLoS One 2012;7(11):e49143. 
183. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on 
pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS 
Med 2011;8(10):e1001107. 
184. Nzenze SA, Shiri T, Nunes MC, et al. Temporal changes in pneumococcal colonization in 
a rural African community with high HIV prevalence following routine infant pneumococcal 
immunization. Pediatr Infect Dis J 2013;32(11):1270-8. 
185. WHO, UNICEF, World Bank. State of the world’s vaccines and immunization, 3rd ed. 
Geneva, World Health Organization, 2009. Accessed on 11/05/2015 at 
http://whqlibdoc.who.int/publications/2009/9789241563864_eng.pdf  
186. Gram L, Soremekun S, ten Asbroek A, et al. Socio-economic determinants and inequities 
in coverage and timeliness of early childhood immunisation in rural Ghana. Trop Med Int 
Health 2014;19(7):802-11. 
187. Fadnes LT, Nankabirwa V, Sommerfelt H, et al. Is vaccination coverage a good indicator 
of age-appropriate vaccination? A prospective study from Uganda. Vaccine 
2011;29(19):3564-70. 
188. Jahn A, Floyd S, Mwinuka V, et al. Ascertainment of childhood vaccination histories in 
northern Malawi. Trop Med Int Health 2008;13(1):129-38. 
189. Government of Malawi. Comprehensive EPI Multi-Year Plan 2012-2016. Accessed on 
08/07/2015 at 
http://www.nationalplanningcycles.org/sites/default/files/country_docs/Malawi/document_
no.pdf.  2011. 
290  	
 
190. Huber P. The behavior of maximum likelihood estimates under non-standard conditions. 
Proc Fifth Berkeley Symp Math Statist and Prob 1967:221-33. 
191. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for 
heteroskedasticity. Econometrica 1980;48:817-30. 
192. Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size 
undermines the reliability of neuroscience. Nat Rev Neurosci 2013;14(5):365-76. 
193. Abadura SA, Lerebo WT, Kulkarni U, et al. Individual and community level determinants 
of childhood full immunization in Ethiopia: a multilevel analysis. BMC Public Health 
2015;15(1):972. 
194. Babalola S. Determinants of the uptake of the full dose of diphtheria-pertussis-tetanus 
vaccines (DPT3) in Northern Nigeria: a multilevel analysis. Matern Child Health J 
2009;13(4):550-8. 
195. Babirye JN, Engebretsen IM, Makumbi F, et al. Timeliness of childhood vaccinations in 
Kampala Uganda: a community-based cross-sectional study. PLoS One 
2012;7(4):e35432. 
196. Bosch-Capblanch X, Banerjee K, Burton A. Unvaccinated children in years of increasing 
coverage: how many and who are they? Evidence from 96 low- and middle-income 
countries. Trop Med Int Health 2012;17(6):697-710. 
197. Canavan ME, Sipsma HL, Kassie GM, et al. Correlates of complete childhood vaccination 
in East African countries. PLoS One 2014;9(4):e95709. 
198. Fadnes LT, Jackson D, Engebretsen IM, et al. Vaccination coverage and timeliness in 
three South African areas: a prospective study. BMC Public Health 2011;11:404. 
199. Favin M, Steinglass R, Fields R, et al. Why children are not vaccinated: a review of the 
grey literature. Int Health 2012;4(4):229-38. 
200. Glatman-Freedman A, Nichols K. The effect of social determinants on immunization 
programs. Hum Vaccin Immunother 2012;8(3):293-301. 
201. Jani JV, De Schacht C, Jani IV, et al. Risk factors for incomplete vaccination and missed 
opportunity for immunization in rural Mozambique. BMC Public Health 2008;8:161. 
202. Le Polain de Waroux O, Schellenberg JR, Manzi F, et al. Timeliness and completeness of 
vaccination and risk factors for low and late vaccine uptake in young children living in 
rural southern Tanzania. Int Health 2013;5(2):139-47. 
203. Munthali AC. Determinants of vaccination coverage in Malawi: evidence from the 
demographic and health surveys. Malawi Med J 2007;19(2):79-82. 
204. National Statistical Office (NSO) and ICF Macro. Malawi Demographic and Health Survey 
2010. Zomba, Malawi, and Calverton, Maryland, USA: NSO and ICF Macro.  2011. 
205. Odutola A, Afolabi MO, Ogundare EO, et al. Risk factors for delay in age-appropriate 
vaccinations among Gambian children. BMC Health Serv Res 2015;15:346. 
206. Payne S, Townend J, Jasseh M, et al. Achieving comprehensive childhood immunization: 
an analysis of obstacles and opportunities in The Gambia. Health Policy Plan 
2014;29(2):193-203. 
      291 	
 
207. Rainey JJ, Watkins M, Ryman TK, et al. Reasons related to non-vaccination and under-
vaccination of children in low and middle income countries: findings from a systematic 
review of the published literature, 1999-2009. Vaccine 2011;29(46):8215-21. 
208. Schoeps A, Ouedraogo N, Kagone M, et al. Socio-demographic determinants of timely 
adherence to BCG, Penta3, measles, and complete vaccination schedule in Burkina 
Faso. Vaccine 2013;32(1):96-102. 
209. Wiysonge CS, Uthman OA, Ndumbe PM, et al. Individual and contextual factors 
associated with low childhood immunisation coverage in sub-Saharan Africa: a multilevel 
analysis. PLoS One 2012;7(5):e37905. 
210. Bar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in 
infants in Malawi after programmatic roll-out: an observational and case-control study. 
Lancet Infect Dis 2015;15(4):422-8. 
211. Clinton Health Access Initiative. Annual Report 2013. p. 1-24. Accessed on 17 March 
2015 at www.clintonhealthaccess.org/files/CHAI_Annual_Report_3.pdf. 
212. Scott JA, Ojal J, Ashton L, et al. Pneumococcal conjugate vaccine given shortly after birth 
stimulates effective antibody concentrations and primes immunological memory for 
sustained infant protection. Clin Infect Dis 2011;53(7):663-70. 
213. Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent 
pneumococcal conjugate vaccine administered according to 4 different primary 
immunization schedules in infants: a randomized clinical trial. JAMA 2013;310(9):930-7. 
214. Bar-Zeev N, Kapanda L, King C, et al. Methods and challenges in measuring the impact 
of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in 
Malawi. Vaccine 2015;33(23):2637-45. 
215. Champely S. pwr: Basic functions for power analysis. R package version 1.1.1. 
http://CRAN.R-project.org/package=pwr. 2009. (Accessed 15/06/2016). 
216. Wolak M, Fairbairn D, Paulsen Y. Guidelines for Estimating Repeatability. Methods Ecol 
Evol 2012;3(1):129-37. 
217. International Vaccine Assess Center (IVAC). VIMS report: global vaccine introduction. 
December 2015. (http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/IVAC-
VIMS-Report-2015Dec.pdf). (Accessed 18th February 2016). 
218. Roca A, Bojang A, Bottomley C, et al. Effect on nasopharyngeal pneumococcal carriage 
of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The 
Gambia. Vaccine 2015;33(51):7144-51. 
219. Wringe A, Floyd S, Kazooba P, et al. Antiretroviral therapy uptake and coverage in four 
HIV community cohort studies in sub-Saharan Africa. Trop Med Int Health 
2012;17(8):e38-48. 
220. Melegaro A, Choi YH, George R, et al. Dynamic models of pneumococcal carriage and 
the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive 
pneumococcal disease. BMC Infect Dis 2010;10:90. 
221. Kamng'ona AW, Hinds J, Bar-Zeev N, et al. High multiple carriage and emergence of 
Streptococcus pneumoniae vaccine serotype variants in Malawian children. BMC Infect 
Dis 2015;15:234. 
292  	
 
222. Lipsitch M, Abdullahi O, D'Amour A, et al. Estimating rates of carriage acquisition and 
clearance and competitive ability for pneumococcal serotypes in kenya with a markov 
transition model. Epidemiology 2012;23(4):510-9. 
223. Toni T, Welch D, Strelkowa N, et al. Approximate Bayesian computation scheme for 
parameter inference and model selection in dynamical systems. J R Soc Interface 
2009;6(31):187-202. 
224. Brooks-Pollock E, Roberts GO, Keeling MJ. A dynamic model of bovine tuberculosis 
spread and control in Great Britain. Nature 2014;511(7508):228-31. 
225. Lopes JS, Beaumont MA. ABC: a useful Bayesian tool for the analysis of population data. 
Infect Genet Evol 2010;10(6):826-33. 
226. Bertorelle G, Benazzo A, Mona S. ABC as a flexible framework to estimate demography 
over space and time: some cons, many pros. Mol Ecol 2010;19(13):2609-25. 
227. Burr T, Skurikhin A. Selecting summary statistics in approximate Bayesian computation 
for calibrating stochastic models. Biomed Res Int 2013;2013:210646. 
228. Prangle D, Fearnhead P, Cox MP, et al. Semi-automatic selection of summary statistics 
for ABC model choice. Stat Appl Genet Mol Biol 2014;13(1):67-82. 
229. Longini IM, Jr., Koopman JS, Haber M, et al. Statistical inference for infectious diseases. 
Risk-specific household and community transmission parameters. Am J Epidemiol 
1988;128(4):845-59. 
230. Abdullahi O, Karani A, Tigoi CC, et al. Rates of acquisition and clearance of 
pneumococcal serotypes in the nasopharynges of children in Kilifi District, Kenya. J infect 
Dis 2012;206(7):1020-9. 
231. Ekdahl K, Ahlinder I, Hansson HB, et al. Duration of nasopharyngeal carriage of penicillin-
resistant Streptococcus pneumoniae: experiences from the South Swedish 
Pneumococcal Intervention Project. Clin Infect Dis 1997;25(5):1113-7. 
232. Kamng'ona AW. Understanding the Nasopharyngeal Carriage Dynamic of Streptococcus 
pneumoniae and Other Microbiota in Malawian Children and Adults PhD thesis, 
University of Liverpool 2014. 
233. Liotta G, Chimbwandira F, Wouters K, et al. Impact of Extended Combination 
Antiretroviral Therapy on the Decline of HIV Prevalence in Pregnant Women in Malawi. J 
Int Assoc Provid AIDS Care 2016;15(2):172-7. 
234. Weinberger DM, Dagan R, Givon-Lavi N, et al. Epidemiologic evidence for serotype-
specific acquired immunity to pneumococcal carriage. J Infect Dis 2008;197(11):1511-8. 
235. Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis 
2011;52(7):911-6. 
236. Smith CE. Prospects for the control of infectious disease. Proc R Soc Med 1970;63(11 
Part 2):1181-90. 
237. Le Polain De Waroux O, Flasche S, Prieto-Merino D, et al. The Efficacy and Duration of 
Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A 
Meta-regression Model. Pediatr Infect Dis J 2015;34(8):858-64. 
238. Madhi SA, Adrian P, Kuwanda L, et al. Long-term effect of pneumococcal conjugate 
vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated 
      293 	
 
interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in 
HIV-Infected and HIV-uninfected children. J Infect Dis 2007;196(11):1662-6. 
239. Lakshman R, Murdoch C, Race G, et al. Pneumococcal nasopharyngeal carriage in 
children following heptavalent pneumococcal conjugate vaccination in infancy. Arch Dis 
Child 2003;88(3):211-4. 
240. Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of 
pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal 
carriage. Pediatr Infect Dis J 2014;33 Suppl 2:S152-60. 
241. Hammitt LL, Akech DO, Morpeth SC, et al. Population impact of 10-valent pneumococcal 
conjugate vaccine (PCV) on nasopharyngeal carrige of Streptococcus Pneumoniae in 
Kilifi, Kenya. ISPPD-10. Glasgow, UK, 2016. 
242. Zakikhany K, Degail MA, Lamagni T, et al. Increase in invasive Streptococcus pyogenes 
and Streptococcus pneumoniae infections in England, December 2010 to January 2011. 
Euro Surveill 2011;16(5). 
243. Weinberger DM, Grant LR, Steiner CA, et al. Seasonal drivers of pneumococcal disease 
incidence: impact of bacterial carriage and viral activity. Clin Infect Dis 2014;58(2):188-94. 
244. Dherani M, Pope D, Mascarenhas M, et al. Indoor air pollution from unprocessed solid 
fuel use and pneumonia risk in children aged under five years: a systematic review and 
meta-analysis. Bull World Health Organ 2008;86(5):390-8C. 
245. Alderson MR. Status of research and development of pediatric vaccines for 
Streptococcus pneumoniae. Vaccine 2016;34(26):2959-61. 
246. Centers for Disease Control and Prevention (CDC). CDC Vaccine Price List. 2016. 
(Accessed July 10, 2016). 
247. van Hoek AJ, Choi YH, Trotter C, et al. The cost-effectiveness of a 13-valent 
pneumococcal conjugate vaccination for infants in England. Vaccine 2012;30(50):7205-
13. 
248. van Hoek AJ, Miller E. Cost-Effectiveness of Vaccinating Immunocompetent >/=65 Year 
Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. PLoS One 
2016;11(2):e0149540. 
249. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent 
pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal 
conjugate vaccine given as a three-dose series with routine vaccines in healthy infants 
and toddlers. Clin Vaccine Immunol 2010;17(6):1017-26. 
250. Moore MR, Gertz RE, Jr., Woodbury RL, et al. Population snapshot of emergent 
Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 
2008;197(7):1016-27. 
251. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive 
pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled 
analysis of multiple surveillance sites. PLoS Med 2013;10(9):e1001517. 
252. Schuller S, Wisgrill L, Sadeghi K, et al. The TLR-specific adjuvants R-848 and CpG-B 
endorse the immunological reaction of neonatal antigen-presenting cells. Pediatr Res 
2016. 
294  	
 
253. Offersen R, Melchjorsen J, Paludan SR, et al. TLR9-adjuvanted pneumococcal conjugate 
vaccine induces antibody-independent memory responses in HIV-infected adults. Hum 
Vaccin Immunother 2012;8(8):1042-7. 
254. Sogaard OS. The clinical use of adjuvants in pneumococcal vaccination: current status 
and future perspectives. Hum Vaccin 2011;7(2):276-80. 
255. Rosch JW, Iverson AR, Humann J, et al. A live-attenuated pneumococcal vaccine elicits 
CD4+ T-cell dependent class switching and provides serotype independent protection 
against acute otitis media. EMBO Mol Med 2014;6(1):141-54. 
 
 
Appendix      295 	
 
Appendix 
Ethical approval - National Health Sciences Research Committee 
 
 
 
 
Telephone: + 265 789 400 
Facsimile: + 265 789 431 
e-mail doccentre@malawi.net 
All Communications should be addressed to: 
The Secretary for Health 
In reply please quote No. MED/4/36c 
MINISTRY OF HEALTH 
P.O. BOX 30377 
LILONGWE 3 
MALAWI 
14*^  February 2014 
Neil French 
Karonga Prevention Study 
Dear Sir/Madam, 
R E : Protocol # 1232: Pneumococcal carriage and transmission in Karonga district, Malawi two years 
after the introduction of pneumococcal conjugate vaccine into the infant immunization programme 
Thank you for the above titled proposal that you submitted to the National Health Sciences Research 
Committee (NHSRC) for review. Please be advised that the NHSRC has reviewed and approved your 
application to conduct the above titled study. 
• APPROVAL NUMBER : NHSRC # 1226 
The above details should be used on all correspondence, consent forms and documents as appropriate. 
• APPROVAL DATE : 14/02/2014 
• EXPIRATION DATE :This approval expires on 14/02/2015 
After this date, this project may only continue upon renewal. For purposes of renewal, a progress report on 
a standard form obtainable from the NHSRC secretariat should be submitted one month before the 
expiration date for continuing review. 
• SERIOUS ADVERSE EVENT REPORTING :A11 serious problems having to do with subject safety 
must be reported to the National Health Sciences Research Committee within 10 working days using 
standard forms obtainable from the NHSRC Secretariat. 
• MODIFICATIONS: Prior NHSRC approval using standard forms obtainable from the NHSRC 
Secretariat is required before implementing any changes in the Protocol (including changes in the consent 
documents). You may not use any other consent documents besides those approved by the NHSRC. 
• TERMINATION OF STUDY: On termination of a study, a report has to be submitted to the NHSRC 
using standard forms obtainable from the NHSRC Secretariat. 
• QUESTIONS: Please contact the NHSRC on Telephone No. (01) 724418, 0888344443 or by e-mail on 
mohdocentre@gmail.com 
• Other: 
Please be reminded to send in copies of your final research results for our records as well as for the Health 
Research Database. 
PROMOTING THE ETHICAL CONDUCT OF RESEARCH 
Executive Committee: Dr.C.Mwansambo (Chairman), Prof. E. Molynuex (Vice Chairperson) 
Registered with the USA Office for Human Research Protections (OHRP) as an International IRB 
aRB Number IRB00003905 FWA00005976) 
296  	
 
Ethical approval - University of Liverpool 
 
 
 
From: Ethics ethics@liverpool.ac.uk
Subject: RE: RETH000670 application for ethical approval
Date: February 27, 2014 at 8:55
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Data collection tools 
 
Data collection tools specific to this study were used in conjunction with generic data 
tools, used for e.g. birth registration, specimen collection, and HIV/AIDS status 
confirmation. 
 
  white       PVCR    02/04/14 
 
Version 2a 02/04/2014  
PVCR – registration form (round 3)  
 
Fill this form if willing to receive follow-up visit for consent   
  
1 Date   intdate 
2 Name of Mother   ident 
3 Date of birth 
 Birth decade estimate 
1950-59 1960-69 1970-79 1980-89 1990-99 
 
birthest 
birthmm 
birthyear G H I J K 
4 Village of birth   bvil 
5 Name of mother   idmoth 
6 if alive elsewhere, name head of HH and village 
HH: vge.: Alive Died mothvita 
7 Name of father   idfath 
8 if alive elsewhere, name head of HH and village 
HH: vge.: Alive Died fathvita 
9 Have you been known by any other names in the past?  
10 Name HH & village or HC where last seen:   
 
 Household and Residence   
11 Current household   idhdhse 
12 Current village   curvil 
 
13 List siblings alive in Karonga 
If no siblings are known alive in Kga.: List other members of the HH where last seen  
tick if 
same: 
mother father 
14 (1)    
15 (2)    
16 (3)    
 
 Included in Longitudinal (samples 1, 6,8,10,12,14,18, wks) or Cross-sectional study (1 sample at 6 wks) L            C longcross 
 
17 Interviewer   rcdr 
18 Coder  Checker  codr chkr 
 
This section does not need to be entered in the data office 
 Date of birth infant   
 Firstborn or are there other children? What are their ages?    
 Residence after delivery  
 Where will you go in the weeks after delivery?  Current  /  Mother’s  /  Other  household 
  
 
     If mother’s/other: How many weeks do you plan to stay there?   
    If current / mother’s: check details above are complete and correct   
    If other: head of household   
    If other: village   
 Instructions to find the house / other comments: 
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                                                                                                                                         Version 5 (11/02/2014) 
 
PVCF   
PVCF - follow-up pre-printed ticket – Post-vaccination (Round 3) 
 
1 Week  Village  Week 
2 CRSHSE  Head of house  repgp, 
cluster, 
hhlistno 
3 ID headhse  idhdhse 
4 Mothers STID   
 
mstid 
5 Childs STID    cstid 
If child no longer present fill exit form 
 
6 Date of visit                                                                                         (DD/MM/YYYY)  intdate 
7 Household Seen    If N then go to Q 24 staffcode Y    N hseseen 
8 Does the child currently receive cotrimoxazole?  Y    N cotricurr 
9 Has the child received cotrimoxazole in the last 4 weeks? Y   N cotripast 
10      If yes, how long was/is the treatment?   Less / More than 2 weeks L  M  
  
 If this is a 6,10 or 14 week visit vaccine is due 
11  Vaccine visit Y    N  
12  If yes, vaccine given? Y    N vacc 
13  If no, reason: Unwell     Refusal       Already given     Other N    R     A    O novacc 
14  If other describe 
 
 
 
 
15 Any change in household members Y    N members 
Mother,child and siblings <15 years old (cross-sectional) or < 5 (longitudinal) 
 Ident Name Sex Bthyr Status* Swab STID CNO  
16     P M D Y N R  orange label  
17  
 
  P M D Y N R 
 
orange label  
18     P M D Y N R  orange label  
19     P M D Y N R  orange label  
20     P M D Y N R  orange label  
21     P M D Y N R  orange label  
22     P M D Y N R  orange label  
23     P M D Y N R  orange label  
24     P M D Y N R  orange label  
25     P M D Y N R  orange label  
 
* for status Present, Missing, Died    for swab Yes No Refused 
 
26 Staffcode  rcdr 
 
27 Level 2 Checker   chkr             
 
Appendix      299 	
 
 
 
                                                                                                                   Version 1a (27/05/2014) 
 
PVCA – Pneumococcal Carriage in ART clinic 
 
 
1 Date   intdate 
2 ART number (hand copy from card)  artno 
3 
ART STID and CNO hand-copy register orange label 
stid,cno 
 
4 Consent given – if NO finish Y          N con 
 
5 Currently taking cotrimoxazole prophylaxis? Y          N 
cotrim 
6 
      If yes, cotrimoxazole started at the same time as ART? 
Y          N 
cotrst 
  
            If no, since when? (dd/mm/yyyy or descriptive) 
 
cotrdd 
cotrmm 
cotryr 
 
 
Comments  
  
  
 
9 Interviewer staffcode  rcdr 
 
 
  
 
 
 
 
 
PVCA  21/05/2014 
 
